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Abstract
Given the guidelines such as the Q8 document published by the International
Conference on Harmonization (ICH), that describe the “Quality by Design” paradigm
for the Pharmaceutical Development, the aim of this work is to provide a complete
methodology addressing this problematic. As a result, various Design Spaces were
obtained for different analytical methods and a manufacturing process.
In Q8, Design Space has been defined as the “the multidimensional combination
and interaction of input variables (e.g., material attributes) and process parameters
that have been demonstrated to provide assurance of quality” for the analytical
outputs or processes involved in Pharmaceutical Development. Q8 is thus clearly
devoted to optimization strategies and robustness studies.
In the beginning of this work, it was noted that existing statistical methodolo-
gies in optimization context were limited as the predictive framework is based on
mean response predictions. In such situations, the data and model uncertainties are
generally completely ignored. This often leads to increase the risks of taking wrong
decision or obtaining unreliable manufactured product. The reasons why it happens
are also unidentified. The “assurance of quality” is clearly not addressed in this
case.
To improve the predictive nature of statistical models, the Bayesian statistical
framework was used to facilitate the identification of the predictive distribution of
new outputs, using numerical simulations or mathematical derivations when possi-
ble.
By use of the improved models in a risk-based environment, separation analytical
methods such as the high performance liquid chromatography were studied. First,
optimal solutions of separation of several compounds in mixtures were identified.
Second, the robustness of the methods was simultaneously assessed thanks to the
risk-based Design Space identification. The usefulness of the methodology was also
demonstrated in the optimization of the separation of subsets of relevant compounds,
without additional experiments.
The high guarantee of quality of the optimized methods allowed easing their
use for their very purpose, i.e., the tracing of compounds and their quantification.
Transfer of robust methods to high-end equipments was also simplified.
In parallel, one sub-objective was the total automation of analytical method de-
velopment and validation. Some data treatments including the Independent Com-
ponent Analysis and clustering methodologies were found more than promising to
provide accurate automated results.
Next, the Design Space methodology was applied to a small-scale spray-dryer
manufacturing process. It also allowed the expression of guarantees about the quality
of the obtained powder.
Finally, other predictive models including mixed-effects models were used for the
validation of analytical and bio-analytical quantitative methods.
i
Résumé
Afin de répondre aux exigences dictées par les documents traitant de la prob-
lématique du “Quality by Design”, tels ICH Q8 publié par la Conférence Interna-
tionale d’Harmonisation (ICH), l’objectif de ce travail est de fournir une méthodolo-
gie adéquate permettant le calcul du Design Space pour les différentes méthodes
analytiques et procédés de fabrication liés au développement de médicaments.
Le Design Space (ou Espace de Conception) a été défini comme l’ensemble des
conditions opératoires d’une méthode ou d’un procédé qui permettent de garantir
une haute qualité du résultat ainsi optimisé, que ce soit une réponse analytique, un
produit fini ou intermédiaire dans le processus de fabrication.
En analysant les méthodologies existantes permettant une telle optimisation, il
a été noté que l’aspect prédictif des modèles statistiques, utilisés notamment en
planification expérimentale, était généralement basé sur la prédiction de réponses
moyennes. L’analyse de l’incertitude présente dans les données et les modèles n’est
malheureusement pas souvent faite. Cela a pour conséquence l’obtention de résultats
peu fiables dont les causes sont méconnues. Les “garanties de qualité” ne sont
clairement pas considérées dans ces conditions.
Dans cette optique, la statistique Bayésienne a été utilisée afin de fournir un cadre
de travail dans lequel l’analyse de l’incertitude prédictive est facilitée. Différents
modèles statistiques ont ainsi été définis et la distribution de leurs prédictions a été
dérivée mathématiquement, ou en utilisant des méthodes de simulations numériques.
En combinant ces modèles statistiques prédictifs avec une approche basée sur
l’analyse du risque, les méthodes analytiques séparatives –telle la chromatographie
liquide à haute performance– ont fait l’objet de différentes études. D’une part, il a
ainsi été possible d’optimiser les conditions de séparation de composés de plusieurs
mélanges. D’autres part, l’analyse de la robustesse de ces méthodes a pu être faite
simultanément grâce à l’analyse du risque dans le Design Space. L’utilisation de
sous-ensembles de données comprenant des composés particuliers a également per-
mis l’optimisation de nouvelles méthodes rapides et robustes sans réaliser aucune
expérience supplémentaire.
A terme, cela a permis l’application de ces méthodes analytiques pour analyser
de nombreux composés, tout en simplifiant considérablement l’utilisation de ces
méthodes pour leur quantification. Le transfert de méthode vers des équipements
plus performants a également été abordé et largement simplifié grâce à la robustesse
prédite et observée lors de l’étape d’optimisation basée sur l’analyse du risque.
Parallèlement, la problématique de l’automatisation du développement des méth-
odes séparatives a pu être envisagée grâce à l’utilisation de l’Analyse en Composantes
Indépendantes, combinées à divers algorithmes de partitionnement de données.
Par ailleurs, le calcul du Design Space a pu être appliqué à un procédé pilote de
fabrication de poudre pharmaceutique au moyen d’un équipement de laboratoire.
Ceci a permis d’exprimer des garanties sur la qualité future du produit fini.
Finalement, les modèles prédictifs ont également été utilisés dans le contexte de
la validation de méthodes analytiques et bio-analytiques quantitatives.
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Introduction
During the development and manufacturing of drug or the quality control of
pharmaceutical formulations registered on the market, analytical methods play a
prominent role. To understand the context of the present work, it is worth to give
some hints about the drug development process and the drug analysis context.
Drug discovery and clinical phases
During the drug development process, analytical and bio-analytical methods are
used intensively to obtain a thorough knowledge about the development and follow
up of the involved molecules, vaccines, antibodies, genes, stem cells, hormones, etc.
The aims are multiple and include the understanding of the biological mechanisms
in action during a treatment, the analysis of the effect of the dosing of the drug on
its efficacy and its safety, and the ability to prove that a drug is compliant with
the regulatory texts given by authorities. Indeed, regulatory bodies such as the US
Food and Drug Administration (FDA), the European Medicines Agency (EMA),
the Ministry of Health, Labour and Welfare (in Japan), etc. strongly regulates the
development of drugs. The drug development process is schematized on Figure 1,
which illustrates the different phases and time needed to bring a new drug on the
market.
Figure 1: Drug development process. (Chang, 2011; DiMasi et al., 2003).
1
2 Drug discovery and preclinical phase
The results generated by analytical methods are directly used to make the critical
decisions during all the phases of the drug development process (drug discovery,
preclinical phase, clinical trials phases, etc.), or to provide useful working material in
this direction. For instance, the kind of information and decision based on analytical
methods are:
• the conformity of the drug, i.e. the precise dosage of its active pharmaceutical
ingredients (API), as well as the determination of impurities,
• the establishment of the biodisponibility and of the pharmacokynetic (PK)
and pharmacodynamic (PD) parameters and models, by dosing the drug in
biological samples
• some clinical laboratory measures to determine safety during preclinical and
clinical developments,
• the optimization of a dose and the concentration-effect modeling, usually using
a biomarker to be quantified,
• the optimization of the dosage form,
• the release of a production batch,
• the stability studies to determine shelf life and the determination of potentially
toxic impurities,
• the optimization and quality control (QC) of a manufacturing process based
on quantitative and qualitative measurements of the outputs,
• etc.
The use of these analytical results can lead to the premature ending of preclinical
or clinical studies, due to safety or lack of efficacy issues, or due to unstable produc-
tion processes. On the other side, it could lead to continue a trial whereas hidden
problems could threaten the safety of the subjects. Considering the time and the
costs needed for the drug development process, the experimenters want the involved
analytical methods to be as reliable as possible to avoid the risks to take wrong
decisions. From the many drugs candidates that can be identified and/or created
by research and development (R&D) laboratories, only a very small proportion will
succeed to pass the successive and laborious steps (1/5000, Figure 1) allowing them
to be commercial drugs. More information about drug development phases can be
found in the references. See ICH E8 Expert Working Group (1998); Food and Drugs
Administration (2006); Pocock (2004); Chang (2011).
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Drug analysis
Analytical methods are also developed to control drugs on the market. Manu-
facturers or governments often asks independent laboratories to analyze drugs. The
aim is generally to obtain independent results in order to assess the drug quality.
In some cases, the analytical method to carry out the analysis is known (e.g. the
pharmacopeia or international publications) or provided by the manufacturer. In
other cases, no analytical method exists and the development of precise and rapid
methods is mandatory. This second case is mainly explored in this manuscript.
A particular case of drug analysis concerns the fake detection in which more
and more laboratories are involved. Counterfeit and fake drugs have adverse con-
sequences for public health (Panusa et al., 2007). The World Health Organization
(WHO) reported 6% of drugs worldwide are counterfeit and the Food and Drug
Administration (FDA, USA) estimated this proportion to be 10% (Mazières, 2007).
This proportion varies from one country to another. In some African countries,
Marini et al. (2010a) confirmed that up to 80% of medical products are poor quality
medicines. To ensure the quality of drugs and to help battle fake and counterfeit
medicines, the development of analytical methods, that can simultaneously trace
many of the most commonly used molecules in various therapeutic classes, is an
important effort.
Different forms of frauds are observed. One of the most frequent is the low dosage
of the drug’s API compared to the nominal amount stated by the manufacturer. Of
course, the drug might simply not contain the API that treats the disease. Another
form of fraud occurs when a malicious manufacturer provides a fake drug in the
box of another manufacturer. This is referred as counterfeit. Often, even the visual
aspect of the counterfeit drug looks similar to the real drug, and precise analytical
methods remain the only tools able to try to fight against these illegalities.
Logically, it is expected that the malicious manufacturer is selling the drugs
without complete analysis to detect non-compliances such as impurities, with the
objective to drastically reduce costs. Unfortunately, the worldwide market of fraud-
ulent medicines is one of the most profitable, with lower risks for the counterfeiters
than other drug crimes (Marini et al., 2010a).
A last type of fraud is related to poor storage conditions, such as incorrect tem-
perature or direct sunlight on drugs. This might also cause potentially dangerous
impurities to appear, even if the drug shelf life is respected.
To protect the consumer and to provide effective treatment against widespread
diseases, the need for accurate method to analyze concurrently many compounds
is high. During this work, innovative screening and quantitative methods for the
analysis of various anti-paludic drugs (Debrus et al., 2011c) and non-steroidal anti-
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inflammatory drugs (NSAIDS) (Krier et al., 2011; Mbinze Kindenge et al., 2011)
have been developed. Some results are presented in Chapters 7 and 8. The proposed
analytical methods are illustrated with some excursions in drug quality, that may
potentially help to combat fraud and counterfeit.
A last field where analytical methods are decisive is the analysis of forbidden
products such as narcotics and doping product in biological samples. See for instance
the joint works with De Backer et al. (2009) and Debrus et al. (2011a).
Analytical methods
In order to browse a majority of the existing analytical methods, a small sur-
vey is shown in Figure 2. The data represents the proportion of talks and posters
concerning specific analytical methods, that have been presented during a recent
and important symposium (Drug Analysis, 2010). It illustrates, among others, the
prominence of the separation techniques, including the liquid chromatography (LC),
the capillary electrophoresis (CE), and the gaz chromatography (GC). The pro-
portion of the communications given during all the symposium is 50% for the LC
methods only. This proportion is also representative of the place of the LC in the
pharmaceutical industry.
The separation techniques are generally coupled with performant detectors such
as ultra-violet diode-array detector (UV-DAD) or mass spectroscopy detector (MS).
Other methods such as the spectroscopy (including near infrared, infrared and
Raman spectroscopy), or the nuclear magnetic resonance (NMR) are also wide areas
of research and this survey should only be taken as a quick snapshot of these rapidly
evolving fields.
Concerning separation techniques, they generally share the same objectives : to be
able to separate the relevant compounds of various matrices in the shortest analysis
time. These matrices includes pharmaceutical formulations, plant extracts, plasma
samples, etc. This separation allows further quantitative and qualitative analysis.
The next section briefly introduces the liquid chromatography separation technique.
High performance liquid chromatography
The birth of chromatography is attributed to the first works of Tswett (1906).
Subsequent development of techniques by Martin and Synge (1941) during the 1940s
and 1950s allowed the definitions of the basic principles of partition chromatography.
This work led them to receive the Nobel prize in Chemistry as it permitted the
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Figure 2: Proportion of talks and posters for several analytical techniques, as ob-
served at the International Symposium of Drug Analyis (2010). (Courtesy of B.
Debrus)
rapid development of several separation techniques, including the high performance
liquid chromatography (HPLC) developed in the 1960s. Since these inventions,
impressive technological advances have been performed. For instance, the ultra
HPLC (UHPLC) is able to perform analysis in a very short run time while gaining
in efficiency.
Nowadays, one of the most common chromatography technique is the HPLC,
schematically presented on Figure 3. Within the device, the sample (or mixture)
is driven by a liquid mobile phase (solvents and buffer) through a stationary phase
(analytical column), and the physico-chemical interactions between both phases and
the sample allow or not the separation of the compounds of the sample. This sepa-
ration can be observed thanks to a detector that generates and records a plot called
a chromatogram. Each peak within the chromatogram corresponds to a detected
compound during the analysis time. The ability to detect low-concentrated or low-
detectable compounds from background noise is referred as the sensitivity. The
terms high performance were added to differentiate from older devices that were not
able to deliver high pressure in a constant flow rate.
The affinities of the compounds to remain in the mobile or stationary phases make
a separation possible. Indeed, given the nature of both phases, certain compounds
will move through the stationary phase quicker or slower, before reaching the detec-
tor. With regards to this separation, the selectivity factor describes the ability of the
separation of the compounds by the mobile and stationary phases. This selectivity
provides the specificity of the method, which is its capability to deliver the observed
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Figure 3: Schematic view of a HPLC system.
signals of the compounds with no interference of other compounds or artifacts.
The nature of the stationary phase (or analytical column) is generally chosen by
the analyst. It is a complex task regarding the number of existing columns, that
have different physico-chemical ways of action. For certain new and experimental
columns, there is a limited knowledge about the compounds-columns interactions.
However, information on the compounds and use of standard or generic columns
can help this arduous process. Of course, the nature of a stationary phase can
be included in a designed experiment to select an optimal one during a screening
process.
Several factors interacting with the column are known to have significant impact
on the separation: the temperature, the pressure given by the pump, etc. Fur-
thermore, the nature of the mobile phase (the solvents and buffer) provides a very
flexible way to improve separation, and many different operating conditions can be
set. For instance, the pH, the percentage of the organic modifier (that may be
changed during run time), the nature of the organic modifier, the nature of acid, the
flow rate, etc., can generally be considered as having an influence on the separation
and on the total run time of the method. More details about HPLC and similar
analytical methods can be found in Snyder et al. (1997, 2010); Meyer (2004).
Design of experiments 7
As previously mentioned, the output of the HPLC is named a chromatogram,
which is a plot recorded by the detector during the run time, as shown on Figure
4. A bad results occurs when peaks are overlapping, or in chromatographic terms,
when they are coeluted (peaks 1-4 and 5-6 on Figure 4, A). As stated previously, a
quality output will show well separated peak in a reasonable analysis time (Figure
4, B).
Specific problems such as the method calibration for quantitative measurements,
the inverse prediction and the validation of the analytical methods, are presented in
the application sections (Part II).
While it is observed that the diversity and the quality of analytical methods
have evolved exponentially allowing substantial gains in selectivity, sensitivity, and
repeatability of the results, there is still a lack for a rationale towards the develop-
ment of robust separation methods in a systematic way.
Figure 4: Example of HPLC outputs. (A) Typical results of a non optimal method
with coeluting peaks. (B) Example of chromatograms showing nice properties of
separation.
Design of experiments
Given that number of possible combinations of operating conditions is consider-
ably high, it is natural to envisage design of experiments (DoE) when optimizing an
analytical separation method. However, despite the fact that DoE methodologies
exist and are successfully applied in many fields since more than 40 years, their
generalization in pharmaceutical sciences, and especially in analytical chemistry, is
far from being achieved.
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The reasons are linked to the complexity of the processes under investigation.
Indeed, the multivariate nature of experiments and responses that are encountered
leads to complex designs and statistical models, slowing down the adoption of any
structured statistical methodology. Also, the strong believe that years of practical
experience can not be “replaced” by mathematics is still very common in pharma-
ceutical laboratories. Finally, many analysts see the statistical methodologies as
black boxes and are not comfortable with the interpretation of the results.
In this text, statistical methodologies are proposed, extending more conventionnal
DoE methodologies. They are not envisaged to “replace” the analytical skills and
expertise, but rather to help and enhance the understanding and mastering of the
processes and methods involved.
Notice that several softwares already exist for the optimization of HPLC condi-
tions. The most known are Drylab,1 Chromsword,2 ACD/LC simulator3, Osiris,4
and Fusion AE.5 These softwares are based on solvophobic and linear solvent strength
theories (Horváth et al., 1976; Snyder et al., 1979, 1989; Molnar, 2002; Snyder et al.,
2010) and generally allow for drastically reduced number of experiments to perform.
However, they all have two major limitations. First, they only allow the optimiza-
tion of two or three HPLC factors simultaneously. These factors are often the most
prominent to achieve a separation but they are chosen by the softwares developers.
Unfortunately, flexibility is not left to the analysts to choose other relevant factors.
This can be problematic in many specific cases. The second reason is more criti-
cal as these softwares generally rely on mean response optimization, which will be
explained as non sufficient in the next chapter. As the uncertainty of prediction is
not taken into account, dissimilarities between the softwares’ predictions and the
experimental observations do occur, without clear explanation nor understanding.
Notice however that some software developers tend to give more importance to un-
certainty, as it is the case with Fusion AE which now relies on some Monte-Carlo
simulations to assess the robustness.
Quality by Design
Improving and providing guarantees about the overall quality of a process is at the
heart of Quality by Design (QbD). QbD has been first applied in processes within the
industries such as the automotive industry, see for instance Deming (1986); Juran
(1992). The aim was to improve the quality of the products by understanding as
best as possible the products and the processes setup to build it. If quality controls
1http://www.molnar-institute.com
2http://www.chromsword.de
3http://acdlabs.eu/products/com_iden/meth_dev/lc_sim
4http://www.datalys.net/index.htm
5http://www.smatrix.com
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(QC) remain mandatory, the improvements provided by QbD should lead to the
production of less “bad products” since the mechanisms leading to this quality are
known.
In the pharmaceutical industry, the International Conference on Harmonization of
Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH),
that regroups experts from the pharmaceutical field and regulatory authorities from
Europe, Japan and United States, has clearly understood the gains of such ap-
proaches when applied to pharmaceutical processes, in which analytical methods
are obviously involved. The ICH releases regulatory documents that are adopted
by countries as laws or guidelines. The work of ICH is classified in four topics: the
quality (Q), the safety (S), the efficiency (E), and some multidisciplinary (M) topics.
In the present work, the focus is put on the first topic, the quality, with the
objective to facilitate the analytical method development in a QbD environment.
It will be shown how the ICH requirements can be applied for several applications
involving analytical methods.
In particular, the document Q8 presents the concept of Design Space (DS) as
a tool to achieve QbD. Quoting the website of ICH (2010) “[...] the document Q8
shows how concepts and tools (e.g., design space) [...] could be put into practice by
the applicant for all dosage forms. Where a company chooses to apply quality by
design and quality risk management (Q9), linked to an appropriate pharmaceutical
quality system, then opportunities arise to enhance science- and risk-based regulatory
approaches (Q10)". This underlines how the topics Q8, Q9 and Q10 – development,
risk and quality – are written to provide ways to improve knowledge. These doc-
uments have been subject to questions and answers and the US Food and Drug
Administration (2011) has now provided the procedures to effectively apply the
guidances. This indicates it is a growing and important field within the pharmaceu-
tical companies. However, given the broad nature of their applications, ICH Q8, Q9
and Q10 do not propose any detailed solution to apply QbD. Instead, it gives clearly
the principles with some questionable examples of the proposed tools based on mean
responses. Thus, there is a clear need from the industries to have methodologies to
answer the overall QbD problematic.
In summary, Quality by Design should allow to design products and processes
to ensure they meet specific objectives, in contrast to the classical Quality by Test-
ing, where some batches or runs are tested to observe their performance post-hoc.
Following the Food and Drugs Administration (2009), QbD is two-fold:
1. it must increase the scientific understanding of products and processes,
2. it must include a risk-based assessment of the quality of products and pro-
cesses.
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Design Space
ICH Q8 (2009) introduces the DS as “the multidimensional combination and
interaction of input variables (e.g., material attributes) and process parameters that
have been demonstrated to provide assurance of quality”. In other words, QbD for
ICH aims at understanding and gaining knowledge about a process or a method to
find a parametric region of reliable robustness for its future performance.
Figure 5 illustrates the DS concept. The DS is the region formed by the oper-
ating conditions x, where the corresponding predicted outputs Y = f(x) will show
acceptable quality level. The operating conditions can obviously be explored with a
designed experiments strategy. The concept of acceptance on the outputs of the pro-
cess is defined with specifications, namely, some acceptance limits (λ’s) that are used
to give some values of minimal acceptable quality. The critical step is to quantify the
assurance of this quality, i.e. the guarantee to have outputs within specifications, or
the risk to be out of specifications. This is the risk-based assessment as defined by
Food and Drugs Administration (2009).
x 
Specs 
Y (CQAs) 
Predictive 
Model f 
!L1 <Y1 < !U1 
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DS 
Designed experiments 
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Output 
!"#$%&'()
P(Y?!) ? 
Figure 5: Illustration of the Design Space (DS) as the region of the operating condi-
tions x for which there is guarantee that the related responses Y = f(x) are within
acceptance limits (in red).
The guideline states that “Working within the Design Space is not considered as
a change. Movement out of the Design Space is considered to be a change and would
normally initiate a regulatory post approval change process. (...)”. An interpretation
of this is the following : if the DS is large with respect to operating conditions,
the solution or the process can be considered as robust. This makes sense in the
context of analytical method development, where robustness is mandatory since the
variability of the inputs and of the analytical process can be important for a given
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time period. Robustness is also desired to ease the transfer of the method from an
R&D department to a manufacturing site.
The overall aim is to provide “assurance of quality” to the management or to
regulatory authorities. Regarding manufacturing, the producer must be confident
that high quality products will, in the future, be obtained by reliable processes, i.e.
that are designed proactively to become reliable. Regarding quantitative methods,
the analyst want to be confident in the results that will be provided to take important
decisions.
The “quality” is expressed in terms of quality criteria or responses (namely, the
critical quality attributes, CQAs) that must lie within acceptance limits that are
specified a priori and that reflect the minimal desired settings (e.g. yield > 95% and
processing time ≤ 5 min.). Those specifications are, or at least should, be driven
by the customer of the product or the results. As an example, safety considerations
from phase I clinical studies should be used to define specifications for the maximum
tolerated dose, i.e. the maximum limit to the quantity of an active pharmaceutical
ingredient (API) that can be found in a drug. The processes must be precise enough
to ensure this specification is never exceeded, and the analytical methods must be
accurate enough in order to detect a poorly manufactured drug.
The concept of “assurance” refers to the ways to provide guarantees that, given
uncertainty of processes and measurements, it is very likely that the quality will
be met in the future as long as specific operating conditions are satisfied. In that
perspective, to give the necessary assurance of quality, the manufacturer may try
to demonstrate that tight operating conditions are fully under control, e.g. using
Statistical Process Control (SPC), i.e., Quality by Testing. Unfortunately, the prac-
ticalities make this option difficult and expensive to achieve. This approach also
fails to give indications about the optimality or robustness of the process.
Another option is the one dictated by ICH Q8: the manufacturer must show
evidence that the quality of the outcome or the product remains within acceptable
limits (λ’s), even in presence of changes in operating conditions occurring within
identified limits (i.e. operating conditions lying within the DS). This second option,
referred as Quality by Design, is more efficient because it integrates the unavoidable
variability of the process or method, which may more or less impact on the quality.
It is then the ideal way to cope with uncertainty and to become less sensitive to
normal range of disturbances in the operating conditions. It could also provide a
broader set of conditions that allows achieving the intended quality, if robustness is
demonstrated. Both producers and customers would benefit from this approach. As
previously explained, QC remains mandatory but improved quality would ensure a
lower rejection rate.
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Objectives
It has been shown that several guidelines explain the ways to apply Quality by De-
sign in estimating the guarantee to achieve the objectives of processes or analytical
methods. However, when this work has begun no practical methodology yet existed
with the ability to provide an answer for this problematic within the pharmaceutical
industry. The general objective is then to translate the requirements of
the regulatory documents into statistical terms and to develop a com-
plete methodology addressing Quality by Design for analytical methods and
processes.
Liquid chromatography is one of the most widespread analytical technique. While
the chromatographic technologies have evolved permitting higher quality outputs in
terms of selectivity and sensitivity, no generic way exists for the rapid development
of complex analytical methods in a QbD environment. One identified reason was
the complex nature of multivariate experiments and outputs. Several softwares
for chromatographic optimization exist but they have some limitations that does
not allow them to be as generic, flexible and QbD compliant, as needed. The
first objective is then to define a complete methodology, specific for the
development of analytical separation methods, compliant with the Quality by
Design movement and allowing the achievement of separation for complex mixtures
of possibly unknown compounds.
To provide guarantee of quality, this methodology must take into account the
error from the models, the processes their measurements. One way to achieve this
is to work with statistical models accounting for the multivariate error of prediction
of every future result. Parallel to the development of the methodology, the second
objective consists in building predictive statistical models and to review
the multi-criteria optimization strategies accordingly.
To obtain a rapid and robust framework for method development, automation is
added to the list of requirements. The third objective is to use multivariate
deconvolution techniques and automated identification of compounds to
automatically read the analytical method outputs, which is a time consum-
ing and non-error-free manual process. This should allow for a fully automated
development of analytical methods, from the very optimization to the method
validation and routine analysis.
The three previous objectives are intended to show that the development of rapid
and robust analytical methods is a reality for the pharmaceutical industry and for
the laboratories involved in the drug analysis.
A fourth and final objective is to transpose and apply the developed
Structure of the manuscript 13
methodology to small-scale manufacturing processes and other steps of
the analytical method life cycle, such as the validation of the quantitative
results. The idea is then to use the developed statistical models and optimization
strategies in different contexts to illustrate their applicability and confirm their
generic nature.
Structure of the manuscript
Part I
Chapter 1 underlines the statistical needs for the application and the computation
of Design Space, based on the ICH guidelines. Particularly, the objective is to point
out several concerns arising when using classical tools for prediction. In this chapter,
it is shown that neglecting the uncertainty and dependencies during the predictions
is an obstacle to the QbD application.
These statistical needs are mainly centered about the predictions of future runs of
the process or the methods. Chapter 2 generically introduces the Bayesian frame-
work to derive the distribution of such predictions. This framework is then used
to obtain the predictive distribution of the standard multivariate regression (Chap-
ter 3), that is flexible enough to model the behavior of the liquid chromatographic
methods. An application of this model to a small-scale manufacturing process is
also envisaged in Part II. This multivariate model is helpful to optimize the quality
of the outputs and to assess the uncertainty of the predictions. Next, Chapter 4
presents a Markov chain Monte Carlo (MCMC) sampling perspective to obtain the
predictive distributions of several univariate mixed models including the random
ANOVA, the hierarchical linear regression and the mixed-effects four-parameters
logistic (4PL) regression with a heteroskedastic variance proportional to a power of
the mean. These models are used for the validation of analytical methods and for
the calibration and validation of analytical and bio-analytical methods, using the
uncertainty of the back-calculated prediction.
Chapter 5 presents the concepts of multi-criteria optimization (MCO) and multi-
criteria decision methods (MCDM) in the predictive context. This is useful when
several CQAs must be optimized jointly in presence of competing responses. It
is shown how a risk-based approach can be combined with MCDM, using joint
posterior probabilities of acceptance or predictive desirability methodologies.
Finally, the Chapter 6 introduces the independent component analysis (ICA),
that separates a matrix-like signal into a sum of independent sources. In many
circumstances, the ICA can be used to help and to fasten the analysis of UV-DAD
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chromatograms. The objective of the proposed methodology is to automatically find
and identify the peaks, and possibly to remove much of the noise and disturbances
that are often observed. Innovative criteria are developed to assess if a source
is relevant or not. A last step is the identification and clustering of the relevant
sources (“which chromatographic peak corresponds to which compound?”), on the
basis of their reconstructed spectral signature.
Part II
The second part of the manuscript illustrates the use of the methodologies with
real laboratory applications. All examples except one are based on real data.
Chapter 7 introduces the development of a HPLC method to screen anti-paludic
drugs in the QbD context while explaining the different steps of the methodology.
Chapter 8 illustrates the power of a unique design of experiments to optimize several
methods aiming at screening and quantifying an exhaustive list of non steroidal anti-
inflammatory drugs (NSAIDS). The predicted robustness of the developed methods
allowed for a transfer to a high-end equipment and eased the validation of quan-
titative methods. These excursions in drugs quality show the potentialities of the
developed analytical methods to identify substandard drugs and potentially to com-
bat fake and poor quality medicines.
Next, the transposition of the methodologies is made from analytical methods to
a small-scale manufacturing process. An application of QbD and DS computation is
shown for the optimization of a spray-dryer in Chapter 9. It allowed quantifying the
guarantees about the quality of the future products manufactured by the optimized
process.
The last chapters discuss the analysis and validation of quantitative methods
using predictive methodologies. First, Chapter 10 explains how the ICA can be
used to fully automate the treatment of chromatograms in order to obtain data
for method validation. Automatic computations to derive calibration curves and
validation results are also carried out. To assess the performance of ICA, the data
have been created in such way it is nearly impossible to obtain any relevant results
manually. Finally, Chapter 11 treats the problem of bio-analytical methods such as
ligand-binding assays, where calibration curves are non-linear. It allows providing
Critical Quality Attributes about the assay future performance.
Part I
Theory
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Chapter 1
General context
1.1 Quality by Design
The concept of Quality by Design (QbD) is currently one of the most recurrent
idea in the pharmaceutical literature. It mainly touches the drug discovery, method
development and production areas. However, this concept is not new.
It has been emphasized by Deming (1986) and Juran (1992) in the end of the
80s, but the roots are older. For instance, Juran (1951) had worked on quality
management from the beginning of the 50s. His idea was that the quality of a prod-
uct can be rigorously planned in the ways this product is built. If each production
processes can demonstrate great quality achievements, most problems related to the
manufacturing of the product could be avoided. A common successful application
of this idea was done with the automotive industry in Japan. It is well recognized
that the overall quality of the production chains has allowed Japanese industries to
manufacture low-cost and high quality cars. The same applies for high technologies
such as the design and miniaturization of microprocessors, cellphones, etc. Due to
its success, the QbD concept has naturally propagated around the world and the
various industries.
More recently, the Food and Drug Administration (FDA) and the International
Conference for Harmonization (ICH) have seen the opportunity to apply QbD to
gain knowledge and understanding about the products and processes of the pharma-
ceutical industry (see the following regulatory document and guidelines: Food and
Drugs Administration, 2007, 2009; ICH Q8, 2009; ICH Q9, 2005; ICH Q10, 2008).
These guidelines rely on the use of information and prior knowledges gathered dur-
ing pharmaceutical development studies to provide a scientific rationale about the
manufacturing process of a product (Yu, 2008).
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A risk-based approach. QbD emphases on the products (API and excipients),
on the process understanding and on the process control. It advocates a systematic
approach for their development based on clear and predefined objectives. Particu-
larly, the risks that a product or a process will not fulfill the quality requirements
must be assessed. Regulatory actions now begin to go in this risk-based direction and
the pharmaceutical industries will have to be fully compliant with these guidelines in
order to prove they are able to provide high quality medicines. See for instance the
recent manual of policies and procedures (MaPP) published by the Food and Drug
Administration (2011). Of course, the interest of the industries is high as QbD could
finally allow more success in quality control (QC). Indeed, as the minimal required
quality is proved during all the production steps, the QCs will be easier to fulfill,
although still mandatory. Less products will be rejected, which is a noticeable gain
for both the consumers and the producers, in terms of risk management (ICH Q9,
2005).
1.2 Method development
Let envisage how QbD can be implemented in order to achieve the quality for
a general method to be developed. The reader will notice that the very general
following explanations apply for analytical methods as well as any process that can
be encountered in production, and also in other areas than the pharmaceutical field.
Figure 1.1 describes a generic scheme for a method or a process. It represents the
knowledge available even if any experiment is carried out, and without any math-
ematical and statistical consideration. Generally, an operating condition defined
by various input variables x = (x1, x2, x3, ...) must be assigned to Critical Process
Parameters (CPP) for the process to run. CPPs are the factors whose variation has
an impact on the output. They should then be monitored or controlled to ensure
that the process or method runs appropriately.
x
x
x
x
...
1
4
3
2
Method / Process Output
CQA CQA CQA ...1 2 3
Specifications :    λ   λ  λ      ...1 2 3
Measures :
Figure 1.1: Schematic representation of an analytical method or a process.
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What matters is the output of the method, as it is used to make important deci-
sions, such as the release of a production batch, a stability study, the optimization of
the dose of a drug based on some biomarker information, etc. Thus, the analytical
method must provide quality outputs. Otherwise, the risks to take a wrong decision
will be high.
An output is analyzed through its Critical Quality Attributes (CQAs). According
to ICH Q8, “a CQA is a physical, chemical, biological, or microbiological property
or characteristic that should be within an appropriate limit, range, or distribution to
ensure the desired product quality”. A CQA can thus be the output of the method,
or any properties that can be observed on this output. For a chromatographic sepa-
ration method, the output is a chromatogram, and the CQAs can be the separation
or/and the resolution between two or all peaks, or the total run time of the method.
For a quantitative method, this can be its dosing range, its accuracy within this
dosing range, etc. For a process, it can be the yield, the solidity, the taste of the
product, etc. Clearly, CQAs must be measurable quantities. What is important is
to define and choose the CQAs in accordance to the decisions that will be taken.
The ICH Q8 definition focuses also on appropriate limits. Equivalents of “appro-
priate limits” are “acceptance limits” or simply ‘specifications” (the λ’s, on Figure
1.1). These specifications are set up by the domain experts in order to define specif-
ically what is a (minimal) satisfactory quality. For instance, in the chromatographic
world, a separation of at least 0 min between two peaks means they are non coelut-
ing (overlapping). For a quantitative method, one may want to have a dosing range
of at least 0.1-500 mg/mL for a compound of interest, with a lower limit of detec-
tion of 0.05 mg/mL. For a process, it can be mandatory to have a yield higher than
95%, to be profitable enough. Usually, those specification should largely be driven
by customer needs, or derived from customers requirements. Some could also be
defined for efficacy purpose or good science practice.
Difficulties are sometimes encountered about the definition of these specifications.
In most cases however, the inability to properly define these limits is a consequence
that the method or process is not well understood. In this case it is clearly harder
to give guarantees and risks about the quality of the outputs. By experience, little
discussions are mandatory but generally sufficient to have a clearer view.
1.3 Design of experiments
Classically, the CQAs of a method are (or can be) optimized. The setting of
the operating conditions is chosen so that the method has the best CQAs, pos-
sibly jointly, using multi-criteria approaches. Statistical tools such as Design of
Experiments (DoE), including screening and response surface models, and multi-
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criteria decision methods (MCDM) are possible choices to achieve this objectives
(Cox and Cochran, 1957; Harrington, 1965; Montgomery, 2009). The advantages of
DoE methodology against other optimization strategies (e.g. one-factor-at-a-time
optimization) are well known. Briefly, DoE is a tool to obtain the maximum informa-
tion with the minimum number of experiments. It also allows providing knowledge
about a whole well-defined multivariate experimental domain for the operating con-
ditions.
Let us define the very general model (Yj | x) = fj(x;θj) + εj, for each of the
m pertinent responses Yj, with j = 1, ...,m. The measured responses can be some
descriptions of the output or directly the CQAs. They are observed at different
operating conditions x belonging to an experimental domain denoted χ. A common
assumption is that the error follows a Normal distribution, εij ∼ N(0, σ2j ).
The responses must be well chosen to allow good model fitting properties. In
parallel, the identification of the most relevant model(s) to be used can be done.
These most relevant models fj represent the assumed but unknown links between
the CPPs and the responses. Finally, if the responses are not directly the CQAs,
they must allow the computation of the CQAs.
The parameters θj and σ2j are unknown and are estimated using the data gathered
through experiments using e.g. the ordinary least-square, maximum likelihood or
maximum a posteriori estimate. The point estimate value of the parameters is
noted θˆj and the mean predicted responses are obtained on every points x using
these estimates: yˆj|x = Eˆ[Yj | x] = fj(x; θˆj). The plan defined by yˆj|x, ∀x ∈ χ, is
called a response surface.
1.3.1 Mean responses optimization
Let assume the univariate response Yj ought to be optimized (e.g. maximized)
over χ, as it is one CQA of interest. Classically, this optimization is carried out using
the mean predicted response (i.e. the response surface) at new points x˜ included in
the experimental domain. One will look after the operating condition x∗ such that
x∗ = argmax
x˜∈χ
Eˆ[Yj | x˜] = argmax
x˜∈χ
fj(x˜; θˆj).
Graphically, the results of such optimization process can be nicely represented if the
dimensionality is moderated, as illustrated on Figure 1.2. Notice the data used to
create all the graphs hereafter are artificial.
The majority of statistical packages are able to provide such optimization results.
However, there is no clue that using the operating condition x∗ will produce a
satisfactory output. Indeed, at optimum, the result will be on average better than
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Figure 1.2: Illustration of a response surface model with an optimal solution x∗.
with any other operating condition (in the explored domain χ). But this does not
imply a high quality. Also, if the result is subject to noise, caution should be taken
regarding the optimum. The analysis of the model parameters and classical tools
such as residuals analysis, Q-Q plots, etc. associated with statistics such as R2 or
RMSEP, etc. may prevent the analyst to use the (mean) results provided by the
model.
When envisaging multiple response optimization, the desirability methodology
are appealing to aggregate the various (mean) responses into one index representing
the quality of the solution, as proposed by Harrington (1965); Derringer and Suich
(1980). More details on this subject are given in Chapter 5.
1.3.2 Sweet Spot
A better answer to assess the quality is to define some specification(s), say Λ =
(Λ1, ...,Λm), for the m responses or CQAs envisaged. In this context, not only the
optimal solution is of interest, but instead the set of operating conditions giving
outputs with mean CQAs Eˆ[Yj | x˜] within the specifications Λj. This is the concept
of Sweet Spot (Anderson and Whitcomb, 1998; Peterson and Lief, 2010). Formally,
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for an univariate problem with one CQA Yj, it is defined as:
Sweet Spot =
{
x˜ ∈ χ | Eˆ[Yj | x˜] ∈ Λj
}
,
=
{
x˜ ∈ χ | fj(x˜; θˆj) ∈ Λj
}
. (1.1)
It is possible to represent graphically the sweet spot when dimensionality is limited,
as shown in Figure 1.3. In this example, the assumed specification Λj is to obtain
Yj ≥ λ, i.e. the jth CQA must be higher than a specified value. The zone of the
experimental domain where the mean response surface is higher than λ defines the
Sweet Spot (in red). The interpretation is as follows: in this zone, the response
is, on average, within specifications. Of course, an optimal solution may still have
sense to define exactly the operating condition to use.
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Figure 1.3: Illustration of a univariate Sweet Spot. In red is the subpart of χ
providing an expected CQA better than λ (dashed plan).
When considering a multivariate responses process, Sweet Spot methodology is
generally used on the overlapping mean response surfaces. The idea is then to find
a subpart of χ where every mean response is located within its specifications. This
can be written as follows:
Sweet Spot =
{
x˜ ∈ χ | Eˆ[Y | x˜] ∈ Λ
}
(1.2)
=
{
x˜ ∈ χ | yˆ1|x ∈ Λ1
⋂
...
⋂
yˆm|x ∈ Λm
}
,
where Eˆ[Y | x˜] is the multivariate mean response surface and Λ is the set of speci-
fications for the responses.
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The sad news about Sweet Spot is that the provided solution gives limited guar-
antees that the quality will be observed in the future use of the method, under
the presence of inevitable uncertainties (Peterson, 2009; Peterson and Lief, 2010;
Schofield, 2010). Indeed, in the Sweet Spot, considering a symmetric distribution
for Yj, and εj being an additive error, the mere interpretation is that there is at
least 50% of chance to observe the univariate response within specification, that is,
P (Yj ≥ λj | x˜, θˆj) ≥ 0.5. At the border of the Sweet Spot, there is one chance out
of 2 to be out of specification when dealing with an univariate problem, if the model
can be assumed correct.
Finally, correlation structures that might exist between the simultaneous re-
sponses are completely ignored, which further increases the risk to take wrong de-
cision. As an example, considering two responses Y1 and Y2, assumed independent
and predicted at an operating conditions x˜, situated at the border of each univariate
Sweet Spot, such that P (Y1 ≥ λ1 | x˜, θˆ) = 0.5 and P (Y2 ≥ λ2 | x˜, θˆ) = 0.5. The
only guarantee about the joint acceptance of both specifications is then, using the
rule of product for independent variables, P (Y1 ≥ λ1, Y2 ≥ λ2 | x˜, θˆ) = 0.52 = 0.25.
In other words, there is 1 − 0.25 = 0.75 probability that the actual outputs are
not within both specifications, although the solution lies within the Sweet Spot. If
correlations were present and taken into account, this result would be different.
Because the responses/CQAs dependencies are not taken into account, the use
of (overlapping) mean responses and Sweet Spot may certainly give unexpected and
unexplained results for the future use of the method or process.1
1.4 Design Space
As explained in the previous sections, the basic use of DoE for optimization is
generally not sufficient to achieve the risk-based perspective advocated for the QbD
approach. The issue comes from the use of mean responses (CQAs) derived from
the statistical model. Hereafter are summarized the flaws of mean responses.
Mean responses does not provide sufficient clues about the method re-
liability. Assuming a statistical model is appropriate to describe data, the only
interpretation of an univariate mean response is that the results are at least as good
as the predicted one in about 50% of the runs (i.e., on average). Conversely, one can
expect 50% of future results to be not that good ! The obvious solution is to work on
1Notice the examples in the appendix of ICH Q8 (2009) are all about Sweet Spot, which is
believed non compliant with a fully QbD strategy. However, the document states that proven
(univariate) acceptable ranges continue to be acceptable from the regulatory perspective but are
not considered as a design space (Section 2.4.5 and Question and Answers B.1.Q8.)
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the complete distribution of the responses instead of point estimates. Uncertainty
and dependencies between responses are the keys to assess reliability. The previous
section has also explained the problem when comparing mean responses to minimal
specifications.
Mean responses give limited information on the future performance. The
purpose of optimizing or validating a method is to give evidences that it will per-
form appropriately in its future use, i.e. most of the time, the outcome will meet
quality criteria. The use of prediction intervals can be thought as a nice tool for
this. Indeed, intervals are practical to express the uncertainty of the responses in
a comprehensive way. But unfortunately, they do not quantify the guarantees or
risks to be within or outside specifications, respectively. Intervals are then less ap-
propriate when envisaging a risk-based approach, even if they integrate the various
sources of uncertainty.
1.4.1 Definition
To explain the QbD practice, ICH Q8 guideline defines the important concept
of Design Space (DS), central in this manuscript. The DS is “the multidimensional
combination and interaction of input variables (e.g., material attributes) and pro-
cess parameters that have been demonstrated to provide assurance of quality”. The
objective of ICH Q8 is to improve the way to understand and gain knowledge about
a process or method to find a parametric region of robustness for future performance
of this process or method, in order to provide the guarantees of quality. To compute
these guarantees, the idea is to replace the expectations in Equations (1.2) with a
probability measure to obtain the results within specifications (Chiao and Hamada,
2001). Mathematically, a simplistic but pragmatic DS definition is as follows, for a
univariate or a multivariate response:
Design Space =
{
x˜ ∈ χ | P (Yj ∈ Λj | x˜, θˆ) ≥ pij, j = 1, ...,m
}
,
=
{
x˜ ∈ χ | P (Y ∈ Λ | x˜, θˆ) ≥ pi
}
. (1.3)
The main differences between Equations (1.2) and (1.3) is that the latter is about an
acceptance probability that is compared to a minimal quality level pij (marginally)
or pi (jointly). In the frequentist statistical framework, a common solution to ob-
tain this probability estimate is to use the assumed distribution of the error εj in
repeated sampling, with the parameters assumed known (Normal distribution) or
estimated using the available data (Student’s distribution). Obviously, the joint
distribution of the responses must be considered when envisaging the computation
of joint probabilities.
Figure 1.4 illustrates the results of such computations. First, Subfigure A depicts
an hypothetical univariate distribution of a response Yj for a given x∗, assumed
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Figure 1.4: (A) Density at optimal condition. Shaded zone: Probability that Yj ≥
λj. (B-C-D) Surface of the probability that Yj ≥ λj for every operating conditions,
and Design Space (in red) at various quality levels. (B) Quality level of pij = 50%.
Similar results than Sweet Spot. (C) Quality level of pij = 70%. (D) Quality level
of pij = 90%, no Design Space is identified.
optimal. On this basis, the proportion of this distribution that is higher than a
value λj can be computed (blue). It expresses the guarantee (i.e. the probability)
to observe Y ∈ Λ. In this example, let’s assume we are interested in Yj ≥ λj.
Repeating the operation on every point x˜ ∈ χ, it is then possible to draw a map
of these probabilities, as illustrated on the Subfigures B,C and D. The difference
between these three images is the level of pij. On Figure 1.4 (B), the minimal quality
level pij is set to 50% (shaded grey plan), and the operating conditions satisfying
this quality level are said to belong to the Design Space (red) with pij = 50%. As it
could be expected with a symmetrical distribution, choosing pij =50% leads to the
same set of operating conditions as the Sweet Spot (see Figure 1.3). However, when
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the desired quality level is higher (i.e. lower risks), such as pij = 70% (C), the DS is
becoming smaller and may potentially not exist anymore, as in Figure 1.4 (D) that
illustrates pij = 90%. Indeed, in this example, the probability P (Yj ≥ λj | x∗, θˆ)
at optimal condition x∗ is merely 0.86, so it is not possible to achieve 90% quality
level.
As with the Sweet Spot, an optimum still makes sense. Thus, one will look after
the operating condition x∗ such that
x∗ = argmax
x˜∈χ
P (Yj ≥ λ | x˜, θˆ).
If the DS is able to provide a set of satisfying operating conditions, the optimum
still defines the best quality within χ, which a customer or a producer will definitely
benefits. If high quality level is observed, this optimum could become the future
working operating condition.
Figure 1.5 summarizes the concept of DS. This flowchart can be compared to
Figure 1.1. The use of an acceptance probability is the major advance of DS against
the classical use of Sweet Spot that is based on mean responses. As the joint
distribution of responses is used, this method relies on the data covariance structure
to improve results. However, to obtain results that are valid for the prediction of
individual future outcomes, the DS definition must finally be based on a predictive
distribution, as presented in the next subsection. To do so, the idea is to take into
account the uncertainty of the model parameters instead of their point estimates
(Peterson, 2004).
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Figure 1.5: Flow chart representing the concept of Design Space.
1.4.2 Risk-based predictive approach - a Bayesian choice
From the previous explanations, it is enviable to obtain a general solution for
multivariate problems, with a risk-based emphasis that is based on a predictive dis-
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tribution of new outcome. In this context, the Bayesian framework is well adapted to
obtain it. Among other qualities, the Bayesian analysis allows obtaining the predic-
tive distribution for any problem, by means of simulations or analytical derivation.
In the Bayesian predictive context, Equation 1.3 can be restated as (Peterson, 2004):
Design Space = {x˜ ∈ χ | P (Y ∈ Λ | x˜, data) ≥ pi} . (1.4)
The parameters and CQAs uncertainties and their dependencies are fully taken
into account in the predictive distribution of Y , allowing computing the (posterior)
predictive probability to observe Y within specifications Λ. In this sense, even a
poor model is able to provide some results: a large model uncertainty will result in
a wide predictive distribution. This however still allows deriving an expression of
the guarantees of future quality, or the risks not to meet the specifications, without
relying on mean and univariate responses, and without ignoring the dependencies.
An analysis of the model performance using the predictive distribution is finally
possible (Gelman et al., 2004). This can lead to the identification of problems such
as poor sample size or noisy process or parameters. This may give hints on the
direction to tackle the problems.
The Bayesian predictive distributions is described for several types of statistical
models in the Chapters 2, 3 and 4. The Chapter 5 introduces the multi-criteria
decision methodology using such predictive distribution. Applications are then given
in the Part II.
1.5 Conclusion
DoE has been stressed as an appropriate tool to achieve QbD. However, it is clear
that DoE, as classically understood, is not inherently QbD. It is used to explore
an experimental domain efficiently and to provide some statistics of interest. One
important step in the QbD initiative is to understand the impact of the parameters
(CPP) on the outputs quality (CQA). DoE and classical statistics are an empirical
ways to gather this understanding.
However, when it comes to prediction using statistical models, handling the un-
certainty is necessary to appropriately assess the risk not observing the outputs
within well-defined specifications. In summary, a QbD approach should answer the
following questions:
- Are there parameters with strong or poor influence on the CQAs?
- What are the sources of uncertainties? Is there dependencies between the
parameters and/or between CQAs?
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- Which parameter settings will provide satisfactory outputs? What are the
guarantees and risks?
- What are the possible improvements?
A predictive approach was shown to be the way to obtain acceptable process
or method parameter ranges, i.e. a risk-based Design Space, in which there are
guarantees that it will perform appropriately.
If no Design Space is found, two options are possible. Either the statistical
models are not able to explain the behavior of the process precisely; or the process
or method is not able to provide quality with high assurance. Both options will
result in a large predictive uncertainty that can however help understanding why
one run of the process or method does differ from others. This can give insights on
the reasons of poor quality and be the starting point for improvements.
Chapter 2
Bayesian methodologies
From the publication of the initial formulation of the Bayes’ theorem by Thomas
Bayes (1763), there have been various opinions regarding its use. However, it has
now become clear that the underlying statistical methodologies are more than a
simple alternative to classical (frequentist) statistics.
These lasts decades, some factors has led to the increased application of Bayesian
statistics. Probably the most important is the discovery of the Markov-chain Monte-
Carlo method (MCMC) that allows overcoming many of mathematical problems by
means of computer intensive simulations (Metropolis et al., 1953). The gain in power
of computers explains the very recent explosion of Bayesian statistics, as the time
needed to get results is now generally reasonable, even with complex models.
In the context of prediction, frequentist statistics suffers from various issues, as
pointed out by Aitchison (1964) : “in the theory of statistical tolerance regions, as
usually presented in Frequentist terms, there are inherent difficulties of formulation,
development and interpretation”. These issues are essentially related to predictions.
The core of the problem lies in the definition of the probability in frequentist statis-
tics that is the frequency of an event. When departing from asymptotic or other
assumptions (e.g. Normality, independence of errors), the frequentist solutions often
become rather intricate. This definition of a probability as a frequency of observed
event is also clearly not adapted to some problems, when there is no data available
yet today (e.g. stock exchanges, etc. ). In Bayesian statistics, the probability is seen
as a degree of plausibility that an event will occur. It provides a general framework
for every statistical problem, using the Bayes’ theorem as a central point.
The ability of Bayesian statistics to propose a general framework to obtain the
(posterior) predictive distribution of the data is very practical as this distribution
contains the necessary information about the future new data and their uncertainty
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(Guttman, 1988).
The first sections of this chapter describes the basis of Bayesian analysis in very
general terms. Chapters 3 and 4 illustrate some applications of Bayesian methodolo-
gies to get a predictive distribution for the examples that are used in this manuscript:
the standard multivariate regression, the one-way random ANOVA, the hierarchi-
cal linear regression and the mixed-effect non-linear regression with model for the
variance.
2.1 Bayes’ theorem
In the Bayesian framework, the quantities of interest are assumed to be random
values that follow a probability distribution. If y = (y1, ..., yn) is the vector of
n observations of the random value Y , that depends upon some parameters θ =
(θ1, ..., θp), then it has a probability density function p(y | θ, I). I represents any
pertinent information included, translated into assumptions about the distribution.
For simplicity, I might be ignored in the notations to shorten equations.
The uncertainty about the unknown parameters θ is also expressed using a dis-
tribution p(θ | I). Applying the rule of products:
p(y | θ) . p(θ) = p(y,θ) = p(θ | y) . p(y). (2.1)
Isolating the distribution of θ conditional to the data y, the following result is
obtained:
p(θ | y) = p(y | θ) p(θ)
p(y)
= p(y | θ) p(θ)∫
θ p(y | θ) p(θ) dθ
Posterior = Likelihood × PriorMarginal likelihood . (2.2)
This is the well-known Bayes’ theorem. p(θ | y) is called the posterior density of θ,
expressing how θ is distributed given the data. It is often written p(θ | data). p(θ)
is referred as its prior density. It expresses what is known about θ before any look
on the data.
p(y | θ) is the likelihood function and is also written L(θ | y). p(y) is the
marginal likelihood and is a normalizing constant depending only on the data. Its
main utility is to ensure the posterior density integrates to 1. p(y) being a constant,
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Equation (2.2) is often simplified into
p(θ | y) ∝ L(θ | y) . p(θ)
Posterior ∝ Likelihood × Prior, (2.3)
where ∝ stands for “equals up to a constant”. The posterior density of θ is the prior
knowledge of θ that is updated through the likelihood function.
The prior distribution of θ can be the expression of ignorance about θ. In this
case, a non-informative prior distribution, or vague prior distribution, is used. This
distribution is generally very flat over the domain of θ (notice that giving a vague a
priori is considered as a pertinent information I about θ). On the opposite, if pre-
vious experiments give clues about θ, or if general knowledge about the application
domain provides useful information (i.e. location, spread), it can be incorporated in
the definition of p(θ) as an informative a priori.
The use of a prior distribution for the parameters is what makes the difference
with the frequentist approach, and is sometimes viewed as a strong argument against
the Bayesian approach, because it is mandatory to set these prior values. This
argument can however be reverted as it would be harmful not incorporating any
useful and valid information about θ. In addition, when non-informative a priori are
used, this leads to results similar to frequentist statistics: the posterior distribution
has the same form than the likelihood.
The difficulty to set up priors increases with the dimensionality of parameters
(Gelman et al., 2008; Kerman, 2011). This is a common problem for the Bayesian
analysis that can be addressed through some sensitivity studies of the effect that
the prior information has on the posterior distribution.
2.2 Posterior distribution of the parameters
In Bayesian statistics, the Equations (2.2) and (2.3) must be solved. This can be
done analytically or using numerical methods. The most desirable situation arises
when it is possible to find the analytical form of p(θ | y), and to identify its under-
lying distribution. This option is realistic when working on simple problems (small
dimension, linearity, classical distribution assumptions, simple priors etc.) but of-
ten, the full joint posterior distribution of the parameters remains unidentified. In
that case, numerical solutions based on sampling methodologies might be envisaged.
The reasons why the posterior distribution can remain unidentified are of various
natures.
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Reason 1. The distributions of the parameters are too different in nature. Regard-
ing the various forms of parameters, it might be simpler to identify the conditional
or marginal distribution of each of them, or of several subsets of them. For instance,
assuming the joint posterior density of two parameters p(θ | y) = p(θ1, θ2 | y) is non
identifiable as a standard distribution, one may rather try to identify the conditional
p(θ1 | θ2,y) and the marginal p(θ2 | y). Using the rule of product, one still gets the
joint posterior density:
p(θ | y) = p(θ1, θ2 | y) = p(θ1 | θ2,y) p(θ2 | y). (2.4)
Slicing the problem this way can obviously be easier. Regarding p(θ1 | θ2,y) alone,
θ2 is simply considered as a constant. This constant may be dropped out of the
computations. For the second term, p(θ2 | y), θ1 must be integrated out of the joint
posterior density:
p(θ2 | y) =
∫
θ1
p(θ1, θ2 | y)dθ1. (2.5)
This is feasible on various class of densities. Of course, it is possible to reverse the
problem to search for the identification of p(θ2 | θ1,y) and p(θ1 | y), that also fully
describes the joint posterior density by rule of product.
Reason 2. The joint posterior density may not be integrable w.r.t. one, some or
all the parameters. The solution proposed in the previous paragraph is then not
usable. However, if a full set of conditional posterior distributions can be identified
(in the previous example, p(θ2 | θ1,y) and p(θ1 | θ2,y)), Gibbs sampling algorithm
may be used to draw samples from the joint posterior (Geman and Geman, 1984;
Gelfand and Smith, 1990). This is presented in Appendix C.4.
Reason 3. Sometimes, very little can be done to identify the conditional or
marginal distributions of the parameters. An elegant solution to obtain samples
that follows any (joint posterior) density is the Markov-chains Monte-Carlo (MCMC)
sampling algorithm due to Metropolis et al. (1953). It works with a random walk
that runs on the unidentified joint posterior density of the parameters. Basis of
MCMC sampling algorithms are presented in Appendix C.2 and C.3.
2.2.1 Credible interval and region
When the posterior distribution of parameters has been identified or when sam-
ples have been drawn from the posterior distribution, credible intervals or regions
can be derived. Inspecting the (marginal) posterior distribution of an univariate
parameter θ, any interval [δ1, δ2] that contains β.(100)% of the distribution define
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a credible interval at level β (Edwards et al., 1963). For two-sided intervals, it is
common to look for the shortest interval [δ1, δ2]. Under the assumption that θ is not
uniform, the interval can be formally defined as
δ1, δ2 such as
∫ δ2
δ1
p(θ | y)dθ = β, with p(δ1 | y) = p(δ2 | y) (2.6)
It is also named the highest posterior density (HPD) interval (Box and Tiao, 1973).
It is the bayesian equivalent of the classical confidence interval, but the interpretation
is fairly different. A β.(100)% credible interval for the random variable θ means that
the probability that θ lies in the interval [δ1, δ2] is β. On the opposite, a frequentist
β.(100)% confidence interval [δ1, δ2] about an unknown but fixed θ means that with
a large number of repeated sampling from the original population, β.(100)% of
the calculated confidence intervals would include the true value of the parameter
(De Gryze et al., 2007). In this case β is a level of confidence and not a coverage
nor a probability.
In most cases, the credible and confidence intervals are different. The common
frequentist assumption that error parameters have a value assumed known, leads
to a different ways to manage the uncertainty, directly impacting the interval. The
incorporation of prior information can also lead to obvious differences.
Notice that for a multivariate density, the credible interval is named the credible
region.
2.3 Predictive distribution of new responses
Prediction in a risk-based environment is a major statistical problem since all the
uncertainties that may impact on the outcome must be included to assess what will
happen in the future. One of the strength of the Bayesian paradigm is to be able
to provide the predictive distribution of some random values of interest, in many
situations. This predictive distribution is at the heart of the Design Space definition.
The density of a future observation y˜ of Y is denoted p(y˜ | y). Its predictive
density is formally defined as
p(y˜ | y) =
∫
θ
p(y˜,θ | y) dθ,
=
∫
θ
p(y˜ | y,θ) p(θ | y) dθ.
Assuming y˜ and y are conditionally independent given θ, the predictive density can
be written as
p(y˜ | y) =
∫
θ
p(y˜ | θ) p(θ | y) dθ, (2.7)
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where p(y˜ | θ) is given by the model for given values of the parameters and p(θ | y)
is the posterior density of these parameters given the data.
Different options are available to solve Equation (2.7). The ideal case is to carry
out the integral and identify a known distribution for the prediction of y˜. When
this is possible, inference about the future behavior of y˜ is made simple.
However, this integral might not be analytically tractable. In this case, Monte-
Carlo simulations are a way to propagate the posterior uncertainty of the parameters
to the model responses. To obtain samples from the predictive distribution, Equa-
tion (2.7) suggests to do the following:
• draw θ(s) from the joint posterior density p(θ | y),
• draw y˜(s) from the model p(y˜ | θ(s)),
with s = 1, ..., n∗ is the number of samples to draw.
Apart from its direct implication in Design Space computations, the predictive
density can be used to check the model quality, as suggested firstly by Rubin (1981,
1984) and discussed by Gelman et al. (2004). Basically, a good model should obvi-
ously have a good fit that can be assessed through the use of classical displays of the
observed and mean predicted data in graphs (fit, residuals, etc.). Furthermore, the
predictive uncertainty should be as limited as possible. The data should naturally
be compliant with the predictive distribution (i.e. the model), and conversely.
2.3.1 Predictive interval and region
Similarly to the credible interval, the predictive interval is defined as the shortest
interval [δ1, δ2] that contains β(100)% of the predictive density. It identifies the
values of y˜ that have the highest (predictive) density support. They can formally
be defined as
δ1, δ2 such as
∫ δ2
δ1
p(y˜ | y)dy˜ = β, with p(δ1 | y) = p(δ2 | y) (2.8)
The Bayesian predictive interval is not the equivalent of the classical prediction
interval, but is directly related to the β-expectation tolerance interval (Guttman,
1988). It is expected that a specified proportion (or coverage) β of y˜ will fall within
[δ1, δ2].
This gives clue that, at least from a simulation point of view, the β-expectation
tolerance intervals are simple to obtain in the Bayesian framework, while they are
often complicated to derive in the frequentist framework, even for simple models.
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For a multivariate predictive density, the predictive interval becomes the predic-
tive region.
2.4 Risk-based approach
This last decade, it has been observed that the use of probabilities (e.g. p-values)
has been progressively replaced by the use of statistical intervals (Bland, 2010).
They provide a simpler interpretation, with values that are in the domain of the
statistical variable of interest. They are particularly informative when analyzing
univariate variables. For multivariate variables, they are less practical to describe
as the intervals become ellipsoids or more complex regions.
Moreover, intervals or regions are not appropriate to provide risk-based infor-
mation about the responses or some critical quality attributes (CQAs), i.e. when
comparing their distribution with some values of interest. The risk-based approach
might be summarized with the two following questions.
1. What is the guarantee to have my CQA(s) within some specification(s) ?
2. What is the risk to have my CQA(s) out of specification(s) ?
A probabilistic approach using the predictive distribution is the answer to these
questions. Consider the following example with two specifications Λ : Y ≥ λ1 and
Y ≤ λ2. It is possible to estimate the guarantee to observe a future realization y˜ of
Y within specifications:
PΛ = P (Y ∈ Λ | y)
= P (λ1 ≤ Y ≤ λ2 | y)
=
∫ λ2
λ1
p(y˜ | y)dy˜. (2.9)
PΛ is an expression of the guarantee of quality, and is then a probability measure
to obtain y˜ within specifications. A one-sided computation is achieved defining
λ1 = −∞ or λ2 = +∞. The risk to fall outside Λ is expressed as 1− PΛ. Equation
(2.9) can also be easily extended to deal with multivariate variables or CQAs (see
Chapter 5). It is particularly elegant when the joint predictive distribution of the
multivariate CQAs is available.
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2.5 Conclusion
The Bayesian framework is able to provide the posterior and predictive densities
of a (set of) variable(s) of interest. Either these densities can be identified as known
distributions, so it is easy to work on; either the densities remain unidentified.
In that case, sampling procedures such as Gibbs sampling, Markov-chains Monte-
Carlo methods or Monte-Carlo simulations theoretically allow obtaining samples
that follow any densities.
The predictive distribution can then be used to find Bayesian predictive intervals,
known as β-expectation tolerance intervals in frequentist statistics, through the
use of the probability density function or through Monte-Carlo simulations. The
predictive distribution can also be used for a risk-based approach, i.e. to provide
the guarantee that the variable(s)/CQA(s) will be within some specification(s) in
the future.
The following chapters describe the Bayesian methodologies for the standard
multivariate regression, the random one-way ANOVA model, the hierarchical simple
linear regression and the mixed-effects non-linear regression using a four parameters
logistic regression with model for the variance.
Chapter 3
Bayesian standard multivariate
regression
This chapter presents the Bayesian solution for the distributions of a multivariate
variable and the associated parameters in the linear regression context. Suppose that
realizations of the multivariate variable Y = (y1, ...,yj, ...,ym) have been observed n
times. Each yj is then a vector of size n containing observations made on a response
Yj when some operating conditions are changed. Each of the n operating conditions
is defined by k adjusted critical process parameters (CPP, also referred as factors
or input variables) that are common for each response. Changing the values of the
CPPs induces changes in the responses.
It is generally assumed that n  k. A response surface model in the form of a
polynomial with p explanatory variables is envisaged for all the responses. Then,
X = (x1, ...,xp) is the n × p model matrix that specifies a polynomial model that
may be estimated over the k factors (p ≥ k). The p columns of X generally consist
of a constant term (intercept), main (qualitative and quantitative) factor effects,
quadratic or higher order effect terms for quantitative factors and interactions. Be-
cause they are defined over the CPPs, these p effects are supposed to describe the
main variations observed in the responses. Quantitative factors are usually cen-
tered and scaled in the [−1, 1] interval before being included in X, to facilitate the
interpretation of the effects. Qualitative factors are coded into dummy variables.
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A set of m multiple linear regression equations is then developed,
y1 = Xβ1 + ε1,
...
yj = Xβj + εj, (3.1)
...
ym = Xβm + εm,
where βj are the (p × 1) model parameters for the jth responses and elements of
εj = (ε1j, ..., εij, ..., εnj)′ are independent and identically distributed (i.i.d.) as a
Normal. As the model matrix X is common for each response, it is possible to write
the multivariate model in matrix form:
Y
(n×m)
= X
(n×p)
B
(p×m)
+ E
(n×m)
, (3.2)
where E is the (n×m) matrix for the errors, with 0-mean and semi-definite positive
covariance matrix Σ. B is the (p×m) matrix containing the regression parameters
of the multivariate model.
3.1 Likelihood
From Equation 3.2 and assumptions about the error, each of the n observed
response vector yi, of size m, i = 1, ..., n, is also i.i.d. and assumed to follow a
multivariate Normal distribution given the parameters B and Σ. Then,
yi ∼ Nm (xiB,Σ) , i = 1, ..., n, (3.3)
where xi is the line i of X. The joint density of the n vectors of error εi = yi−xiB
defines the likelihood function and is
L (B,Σ | Y) = (2pi)−mn2 |Σ|−n2 . exp
(
−12
n∑
i=1
[
(yi − xiB) Σ−1 (yi − xiB)′
])
,
or, more conveniently,
L (B,Σ | Y) ∝ |Σ|−n2 . exp
(
−12tr
[
Σ−1 (Y −XB)′ (Y −XB)
])
(3.4)
The next two sections present the posterior distributions and the predictive distri-
butions of new responses obtained when using different prior distributions. Section
3.2 gives the well known solutions for these distributions when a non-informative
prior distribution is chosen for the parameters. In Section 3.3 a solution is proposed
when using proper informative and conjugate prior distributions for the parameters.
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3.2 Solution with non-informative priors
With non-informative priors, the posterior density of the parameters has been
well described by Geisser and Cornfield (1963), Geisser (1965) and Box and Tiao
(1973). In the same non-informative context, the predictive distribution of a new (or
several) response vector(s) has been described as a multivariate Student distribution
by Zellner and Chetty (1965), Johnson (1987) or Press (2003). In the Design Space
context, the benefits to use such a predictive distribution have already been shown
by Miró-Quesada et al. (2004) and Peterson (2004).
3.2.1 Prior distributions
The following joint non-informative prior distribution has been proposed by
Geisser and Cornfield (1963) to express ignorance about the parameters:
p (B,Σ) ∝ |Σ|− 12 (m+1) . (3.5)
Notice this assumes the independence of the parameters B and Σ a priori, which has
been advocated by Jeffreys (1961) and Savage (1962) when little is known about both
parameters. This distribution has the advantage to be invariant under parameter
transformation.
3.2.2 Posterior distributions
Combining the prior distribution of Equation (3.5) with the likelihood using
Bayes’ theorem yields the joint posterior distribution p (B,Σ | data) ∝ L (B,Σ | Y).
p (B,Σ). However, the joint posterior density is unpractical to work with so the
marginal and conditional distributions of the parameters have been derived as de-
scribed in the beginning of Section 2.2, page 31.
Conditional distribution of B given Σ
The conditional posterior distribution of B given Σ is expressed as the following
matrix-variate Normal distribution (see Appendix D.4 for the distribution defini-
tion):
B | Σ, data ∼ Np×m
(
Bˆ,Σ, (X′X)−1
)
, (3.6)
or, equivalently,
vec(B | Σ, data) ∼ Npm
(
vec(Bˆ),Σ⊗ (X′X)−1
)
. (3.7)
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The operator vec, applied on a (p ×m) matrix, stacks its columns into a vector of
length pm. This is rather useful for implementation purpose as the matrix-variate
Normal is usually not available in softwares. The matrix-variate Normal has location
parameter Bˆ of dimension (p ×m) and covariance matrices Σ and (X′X)−1. Bˆ is
the least-square estimator of B:
Bˆ = (X′X)−1 X′Y.
Marginal distribution of B
When envisaging linear modeling, it is often interesting to focus on the analy-
sis of the effects of the input variables and their interpretation. For instance, in a
screening experimental design, the distribution of the regression parameters is cen-
tral. Integrating Σ out of the joint posterior, the marginal posterior distribution of
B is given by:
B | data ∼ Tp×m
(
Bˆ,A,
(
X′X
)−1
, ν
)
, (3.8)
i.e. a matrix-variate Student’s distribution with location Bˆ, scale matrices A and(
X′X
)−1
and ν = n − (m + p) + 1 degrees of freedom (See Appendix D.6). The
A matrix is the (m ×m) symmetric semi positive definite scale matrix defined as
(Y−XBˆ)′(Y−XBˆ). A is proportional to the estimated sample covariance matrix
Σ.
Marginal distribution of Σ
The marginal posterior distribution of Σ is obtained by integrating B out of the
joint posterior, and is:
Σ | data ∼ W−11 (A, ν), ν > 0, (3.9)
This is an m-dimensional inverse-Wishart with ν degrees of freedom (see Appendix
D.2). Notice that the analytical form of the inverse-Wishart distribution W−11 used
by Geisser (1965) or Box and Tiao (1973) is slightly different than the one that may
be found in more recent works or that is usually implemented in softwares such as
R, WinBUGS or SAS (Dawid, 1981). The inverse-Wishart distribution W−11 has,
say, ν d.f. (ν > 0), while the one in R or WinBUGS, noted W−12 , has an equivalent
of ν+m− 1 d.f. with ν > m− 1 (e.g. package MCMCpack, Martin et al., 2010). This
is of particular importance to compare results with the ones that may be found in
the references. In summary,
Σ | data ∼ W−11 (A, ν) = W−12 (A, ν +m− 1). (3.10)
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Still for implementation purpose, as the inverse-Wishart distribution is sometimes
unavailable, one can use the following equivalence:
Σ | data ∼ W−11 (A, ν) ⇔ Σ−1 | data ∼ W1(A−1, ν), (3.11)
A more detailed presentation of the Wishart and inverse-Wishart distributions is
available in Appendix D.1 and D.2.
It is then possible to draw samples from the joint posterior distribution of the
parameters using Equations (3.9), (3.10) or (3.11) followed by (3.6). When analysing
the regression effects, Equation (3.8) provides an easier way to obtain samples or
statistics from B | data.
3.2.3 Predictive distribution of a new response vector
A new response vector y˜ at one new point x˜ included in the experimental domain
is obtained from the predictive distribution, defined as,
p (y˜ | x˜, data) =
∫
Σ
∫
B
p (y˜ | x˜,B,Σ) .p (B,Σ | data) .dB.dΣ (3.12)
In the particular case of standard multivariate regression, this can be solved
and the predictive distribution of y˜ | x˜ is identified as a multivariate Student’s
distribution (Press, 1972; Kibria, 2006):
y˜ | x˜, data ∼ Tm
(
x˜Bˆ,
(
1 + x˜′(X′X)−1x˜
)
A, ν
)
, (3.13)
where
(
1 + x˜′(X′X)−1x˜
)
A/ν is the estimated scale or spread matrix of the multi-
variate distribution, with ν degrees of freedom (ν > 0). For more information about
the multivariate Student’s distribution, refer to Appendix D.5.
3.3 Solution with informative priors
There is little literature existing on the use of informative prior distribution in
multivariate regression problem. Concerning univariate multiple linear regression,
Marriott and Spencer (2001) have shown the methodology to derive the posterior
distribution of the parameters and the predictive distribution of a new responses.
They used conjugate informative priors and illustrated the simplicity of updating
prior information. In this section, only the solutions are presented. Detailed deriva-
tions can be found in Appendix A.
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3.3.1 Prior distributions
For multivariate (multiple linear) regression, a classical conjugate joint prior for
(B,Σ−1) is the Normal-Wishart distribution. In this case, Guttman (1988); Press
(2003) showed that the posterior distribution of (B,Σ−1) also follows a Normal-
Wishart. Similarly, it is possible to use the following decomposition of the prior
distribution: p(B,Σ) = p(B | Σ)p(Σ) (Press, 1972). This is a simplified form for
the Normal-inverse-Wishart as in Aitchison and Dunsmore (1975). One can see
the similarity of such prior construction with the posterior distributions defined in
Equations (3.6) and (3.9).
Conjugate prior distributions for both p(B | Σ) and p(Σ) can be given. First,
the prior distribution of B | Σ is defined as the (p×m)-dimensional matrix-variate
Normal distribution with mean B0 (same dimension than B) and covariance matrices
Σ and Σ0, for the columns and the rows of B, respectively. That is,
B | Σ ∼ Np×m (B0,Σ,Σ0) . (3.14)
The dependency on Σ leads to the restriction that the (p × p) prior matrix Σ0 is
common for every m responses, i.e. all the corresponding regressors β1,...,j,...,m have
a similar prior covariance. Nevertheless, this restriction eases the identification of
the posterior and predictive distributions.
Second, the prior distribution for Σ is chosen as an inverse-Wishart distribution
(defined as in Box and Tiao, 1973):
Σ ∼ W−11 (Ω, ν0), (3.15)
where Ω is the a priori responses scale matrix, that has the same interpretation as
a sum of squared errors. For instance, it might be Ω = Σprior.ν0, where Σprior is
a covariance matrix estimated over previous experiments. ν0 > 0 is the number of
degrees of freedom of the prior distribution. The value of ν0 indicates the certainty
that one may have in Ω. For a simple interpretation of the prior distribution, we
define ν0 in the same form than ν. That is, ν0 = n0 − (m + p) + 1. It is advised
to keep ν0 (or n0) as low as possible to moderate the prior subjectivity. Sensitivity
analysis can be done as well. n0 can be seen as the number of virtual observations
of the prior distribution.
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3.3.2 Posterior distributions
Given the likelihood and the prior distributions (Equations (3.14) and (3.15)),
and applying Bayes’ theorem, the joint posterior density of the parameters is
p (B,Σ | data) ∝L (B,Σ | Y) .p (B | Σ) .p (Σ) (3.16)
∝ |Σ|−n2 . exp
(
−12tr
[
Σ−1 (Y −XB)′ (Y −XB)
])
. |Σ|−p2 . exp
(
−12tr
[
Σ−1(B−B0)′Σ−10 (B−B0)
])
. |Σ|−ν0−2m2 . exp
(
−12tr
(
ΩΣ−1
))
.
A metropolis-hasting algorithm can be implemented to explore this posterior dis-
tribution. However, to avoid efficacy trouble when dimensionality is moderate or
high, it advised to use a built-in sampler such as WinBUGS (Lunn et al., 2000).
Unfortunately, WinBUGS cannot be used directly to sample from the proposed joint
posterior distribution. First, to be able to carry the computations, the matrix of
regression parameters B must be converted into its vector form (see the equivalence
in Equation (3.7)). Second, the dependence between Σ and B would imply a Kro-
necker product in the multivariate Normal prior for vec(B). WinBUGS has been
found unable to deal with such operation.
To permit the computation, the WinBUGS code then slightly departs from the
assumptions in that it forces the prior for Σ and B to be independent (i.e. p(B,Σ) =
p(B).p(Σ)). This has a direct implication on the degrees of freedom (d.f.). Indeed,
p(B) no longer depends on Σ. As a result, |Σ|−p2 would then be missing in the prior
density p(B) (see the third line of Equation (3.16)). For this reason, p d.f. are lost
due to the independent prior. To compare results, one may simply add these p d.f.
to the prior p(Σ) in WinBUGS, as shown in listing 3.1.
To use this code with a non-informative a priori on B, "InvSigxSig0" is defined as
a low precision (pm× pm) matrix. For the regression part (function inprod(...)), the
elements of vec(B) that corresponds to each response are selected, which translates
the matrix product XB. Finally, the Wishart distribution (function dwish(...)) is
adapted to be in accordance with Box and Tiao (1973) (see comment on page 40).
The degrees of freedom are then (ν0 + p) + m − 1. Finally, notice the different
implementation of the Wishart distribution in Winbugs, that uses Ω instead of
Ω−1.
The sampler performs well when the dimensionality of the problem is low to
moderate, but the computational burden remains high when the number of responses
and parameters increases. Convergence can also be slow to achieve. Thus, it is
preferable to identify the posterior distribution of the parameters. Fortunately, in
this case, it is possible to identify them.
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Listing 3.1: BUGS code for the multivariate regression.
model
{
#For each obse rva t i on
for ( i in 1 : n) {
Y[ i , 1 :m] ~ dmnorm(mu.Y[ i , 1 :m] , invSigma [ , ] ) #l i k e l i h o o d
#For each response
for ( j in 1 :m){
mu.Y[ i , j ] <− inprod ( vecB [ ( ( p∗( j −1))+1):( j ∗p ) ] , X[ i , 1 : p ] )
}
}
#pr ior d i s t r i b u t i o n
vecB [ 1 : (m∗p ) ] ~ dmnorm( vecB0 [ 1 : (m∗p ) ] , InvS igxS ig0 [ , ] )
invSigma [ 1 :m, 1 :m] ~ dwish (Omega [ , ] , nu0 + p + m −1)
#conver t p r e c i s i on matrix in to covar iance matrix
Sigma [ 1 :m, 1 :m] <− i n v e r s e ( invSigma [ , ] )
}
Conditional distribution of B given Σ
The conditional posterior distribution of B given Σ can be identified as the
following matrix-variate Normal:
B | Σ, data ∼Np×m
(
MBpost,Σ,
(
X′X + Σ−10
)−1)
(3.17)
where
MBpost =
(
X′X + Σ−10
)−1 (
X′XBˆ + Σ−10 B0
)
.
One can see that the posterior mean MBpost is a linear combination of the least-
square estimation of B (Bˆ = (X′X)−1 X′Y) and its prior mean B0, weighted by their
respective precision matrix (inverse of covariances). The posterior row covariance is
the inverse of the sum of the matrix (X′X) and of the prior row precision matrix
Σ−10 .
Marginal distribution of B
It is possible to integrate Σ out of the joint posterior distribution in order to
identify a simple form for the marginal posterior distribution of B. It follows a
matrix-variate Student’s distribution.
B | data ∼ Tp×m
(
MBpost,Ω + A∗,
(
X′X + Σ−10
)−1
, ν + n0
)
(3.18)
with A∗ = Y′Y + B′0Σ−10 B0− (X′XBˆ + Σ−10 B0)′(X′X + Σ−10 )−1(X′XBˆ + Σ−10 B0).
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When the prior distributions are uniform, A∗ is reduced to A = (Y−XBˆ)′(Y−
XBˆ), which is the matrix presented by Geisser (1965) and Box and Tiao (1973) for
the non-informative case.
The posterior d.f. is the sum of the d.f. coming from the likelihood (ν), plus the
number of virtual observations n0, coming from the prior parameter distributions.
Marginal distribution of Σ
Integrating B out of (3.16) gives the marginal density of Σ, identified as the
following inverse-Wishart distribution:
(Σ | data) ∼ W−11 (Ω + A∗, ν + n0) = W−12 (Ω + A∗, ν + n0 +m− 1) , (3.19)
Samples from the joint posterior (B,Σ | data) can be obtained by using Equation
(3.19) followed by Equation (3.17).
3.3.3 Predictive distributions of a new response vector
In the informative case, the predictive distribution becomes:
y˜ | x˜, data ∼ Tm
(
x˜MBpost,
(
1 + x˜′(X′X + Σ−10 )−1x˜
)
(Ω + A∗), ν + n0
)
. (3.20)
That is, in the informative case, the multivariate Student’s distribution is centered
around the posterior mean regression surface, instead of its least-square estimates.
With uniform prior distributions, Equation (3.20) naturally reduces to Equation
(3.13).
Notice that for a joint prediction of a set of n˜ input conditions x˜1, ..., x˜n˜, the
predictive distribution nicely extends to a matrix-variate Student’s distribution, as
presented in Appendix A.
With such results, Gibbs sampling or MCMC techniques are not required and
predictions can be obtained directly from this predictive distribution. This allows
a potentially immediate computation of Design Space when the modeled responses
are the Critical Quality Attributes of interest.
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3.4 Equivalence between sampling algorithms, a
small simulation study
A small simulation study has been conducted. It involved a set of m = 3, 5, 10
responses modeled jointly, each with p = 4, 6 regression parameters. The aim was
to assess the equivalence between different sampling schemes for the posterior and
the predictive distributions. For each scenario, the number of virtual observations
envisaged for the inverse-Wishart prior distribution were n0 = 3, 8, 17.
Simulated data
The simulated responses were created as if they were recorded during a designed
set of experiments. The design consisted of a 32 full factorial design with the two
factors normalized between -1 and 1, with 3 repetitions added randomly on different
points of the design, so that it is not always balanced. The model contained an
intercept, two main effects, one interaction and two quadratic effects (for p = 6).
In this example, X is then a (12 × 4) or a (12 × 6) matrix. The true parameters
were randomly generated following an Uniform distribution between -40 and 40.
A multivariate error vector of size m was then generated following a multivariate
Normal N(0,Σtrue) for each of the 12 observations. Different variances and covari-
ance structure were given for Σtrue, to simulate correlated and uncorrelated data
(matrices not presented).
Only vague prior distributions (Ω,Σ−10 ,B0 = 0) are used in order to make the
comparisons possible when using Winbugs. Indeed, the structure of the prior used
in Winbugs are different and it is difficult to provide a similar information using
p(B,Σ) = p(B | Σ).p(Σ) or p(B,Σ) = p(B).p(Σ).
18 simulations were carried out for each assessed covariance matrices Σtrue. Some
simulations were not possible when n0 was too low, as the inverse-Wishart distribu-
tions must have its d.f. strictly higher thanm−1. In this case, n0 has been increased
so that the prior and posterior inverse-Wishart distributions are always identified.
In each simulation and each sampling scheme, 200.000 samples were drawn, allowing
to fit kernel densities and to record credible or predictive intervals.
Posterior distribution of the regression parameters
The envisaged sampling schemes to obtain samples from the marginal posterior
p(B | data) are the following (see explanations in the previous sections for d.f.
assignment):
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1. Winbugs (MCMC sampling) is used to draw samples from the unidentified
joint posterior p(B,Σ | data), the d.f. of the prior Wishart distribution W2
for Σ−1 being (ν0 + p) + m− 1 = n0 (Equation (3.16)). Σ−1 is then inverted
to obtain Σ.
2. The identified p(B | Σ, data) and p(Σ | data) are used to draw the samples,
the d.f. of the posterior inverse-Wishart distributionW−12 being ν+n0+m−1
(Equations (3.17) and (3.19));
3. The marginal posterior p(B | data) is used to draw the samples with ν + n0
d.f. (Equation (3.18)).
Figure 3.1 illustrates the comparison of the kernel densities of the marginal poste-
rior distribution of B for m = 5, p = 4, n0 = 5 (A) and m = 2, p = 6, n0 = 30 (B). In
blue, the curves are the densities obtained with scheme 1 (Winbugs sampling). The
red densities are obtained using scheme 2 (sampling from the identified posterior
distributions). The black densities are obtained with the scheme 3 (direct sampling
from the marginal posterior distribution of B). For each parameters, the 99% cred-
ible interval are graphically provided. They are in total agreement whatever the
sampling scheme.
Predictive distribution of the responses
The next simulations aimed at exploring the predictive distribution of a new
response vector, from which samples are obtained using three different sampling
schemes.
The two firsts assume that n∗ samples of the joint posterior distribution p(B,Σ |
data) are available. To predict a new response vectors from the posterior samples,
the following equation isapplied, that numerically solve Equation (3.12) to obtain
samples from the predictive distribution.
(y˜(s) | Y,x0, data) ∼ N(x0B(s),Σ(s)), (3.21)
with (B(s),Σ(s)) ∼ p(B,Σ | data), s = 1, ..., n∗.
Finally, the third sampling perspective is the draw of samples from the predictive
distribution directly. In summary, the three sampling schemes envisaged are:
1. The joint posterior p(B,Σ | data) from Winbugs (Equation (3.16)) is used,
followed by Equation (3.21);
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Figure 3.1: Marginal posterior distributions of the parameters in two sampling sim-
ulations. The results of 3 different sampling schemes are superimposed.
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2. The joint posterior obtained as a draw from the identified p(Σ | data), then a
draw from p(B | Σ, data), is used (Equations (3.19) and (3.17)), followed by
Equation (3.21);
3. The identified predictive distribution (with ν+n0 d.f.) is directly used (Equa-
tion (3.20)).
Figure 3.2 illustrates the comparison of the kernel densities of the marginal pre-
dictive distribution for m = 10, p = 6, n0 = 10 (A) and m = 5, p = 4, n0 = 5 (B).
The blue curves are the marginal densities obtained with scheme 1 (Winbugs). The
red densities are obtained from the sampling scheme 2 (identified posterior distri-
butions). The green densities are obtained using scheme 3 (predictive distribution).
For each response, the 99% predictive interval are graphically provided. They are
also in agreement whatever the sampling scheme.
3.5 Linear constraint on the responses
Assume that some constraints apply on the responses. For instance, in the chro-
matographic models presented in Chapters 7 and 8, the responses representing one
peak (kB, kA and kE) must be well-ordered. Indeed, it is physically mandatory to
have kB < kA < kE. Not only mean responses must satisfy the linear constraints,
but the whole (joint) distribution as well (i.e., every joint sample). Notice that
a strong correlation between the responses does not ensure the constraints to be
fulfilled.
Naive rejection sampling can be employed: samples of the distribution not achiev-
ing the constraints are discarded. However, in complex cases, the ratio of rejected
to accepted samples can be very high. In this case, response transformations might
be preferred, as described in Chapter 7.
Another possibility is to use a truncated version of the multivariate Student’s
distribution to directly generate samples that include the constraints as proposed
by Geweke (1991). This technique is briefly presented in Appendix E.3.
The constraints must be explicitly given on the form of a matrix C and two
vectors a and b, giving the structure of the linear constraints and the limiting
values, respectively. Formally, if the m-sized vector Y , distributed as a Tm(µ,Σ, ν),
must satisfy a ≤ CY ≤ b, it is possible to define C as a full-rank m ×m matrix
expressing the linear constraints, and the elements of a and b can be any reals
between −∞ and +∞ (aj < bj, j= 1,...,m). Using this notation, a maximum of
m linear restrictions can be applied on Y , which is generally sufficient for many
problems.
50 3. Bayesian standard multivariate regression
(A)
−6 −4 −2 0
0.
0
0.
3
0.
6
Density of response 1 + 99% predictive intervals
D
en
si
ty
−2 0 2 4 6 8 10
0.
00
0.
20
Density of response 2 + 99% predictive intervals
D
en
si
ty
−5 0 5
0.
00
0.
20
Density of response 3 + 99% predictive intervals
D
en
si
ty
−10 −5 0 5
0.
00
0.
15
Density of response 4 + 99% predictive intervals
D
en
si
ty
−5 0 5 10
0.
00
0.
15
Density of response 5 + 99% predictive intervals
D
en
si
ty
37 38 39 40 41 42
0.
0
0.
4
0.
8 Density of response 6 + 99% predictive intervals
D
en
si
ty
−8 −6 −4 −2 0 2 4
0.
00
0.
20
Density of response 7 + 99% predictive intervals
D
en
si
ty
1.5 2.0 2.5 3.0
0.
0
1.
5
Density of response 8 + 99% predictive intervals
D
en
si
ty
−40 −20 0 20 40
0.
00
0.
03
Density of response 9 + 99% predictive intervals
D
en
si
ty
−10 −5 0
0.
00
0.
15
Density of response 10 + 99% predictive intervals
D
en
si
ty
(B)
−8 −6 −4 −2 0
0.
0
0.
3
Density of response 1 + 99% predictive intervals
D
en
si
ty
−2 0 2 4 6 8
0.
0
0.
2
Density of response 2 + 99% predictive intervals
D
en
si
ty
−15 −10 −5 0
0.
00
0.
15
Density of response 3 + 99% predictive intervals
D
en
si
ty
−4 −3 −2 −1
0.
0
0.
6
Density of response 4 + 99% predictive intervals
D
en
si
ty
−30 −25 −20 −15 −10
0.
00
0.
15
Density of response 5 + 99% predictive intervals
D
en
si
ty
Figure 3.2: Marginal predictive distributions in two sampling simulations. The
results of 3 different sampling schemes are superimposed.
Chapter 4
Bayesian Hierarchical models
4.1 Introduction
An univariate response Y is observed n times as y = (y1, ...., yn), at different
combinations of k factors (input variables). This allows defining a model matrix
specifying p variables explaining the effects of the k factors on the response. X =
(x1, ...,xp) is this n × p model matrix. In many situations, the relation between y
and X is well explained by a linear model of the form
y = Xβ + ε.
In this simple expression of linear model, ε is assumed to be the main source of
error.
However, when the data are collected in such way that different observations are
taken on related individuals (e.g. same person, same batch), clustered into some
series, slight differences will be observed on the parameters of the linear model,
for each of the different series of data. Then, the data are nested or hierarchically
structured. In this case, the assumptions on the error ε (Gaussian, i.i.d.) are too
simple to analyze the different source of variations that occur in the model.
This is customary when an analytical or biological quantitative method is vali-
dated to prove that its results will be accurate in its future routine use. For this
purpose, the data are recorded in series that may represent different changes such
as operator, batches of samples or analytical devices. The aim of this sampling
scheme is to reproduce the real life of the analytical method. In practice, these
different changes induce an additional source of error that will affect the results of
the methods.
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A mixed-effects modeling allows including this type of series effect as one or sev-
eral additional random parameters, that are well suited to account for the modeling
of such nested data. The general form of the model becomes:
y = Xβ + Zα+ ε, (4.1)
where β is the vector of the so-called fixed effects and α is the vector of random
effects parameters. Z is a known design matrix for the random effects parameters.
The role of α is to extend the way the error is described by the model. For instance,
correlations between measurements can be estimated. For a general approach of
mixed models, see for instance Henderson (1990); Searle et al. (1992); Verbeke and
Molenberghs (1997); Demidenko (2004).
Further assumptions are that both  and α are 0-centered and they are mutually
independent. In the Normal case, the covariance structure of α is G and the one of
ε is Σ.
Chapter structure
First, in Section 4.2, the one-way ANOVA random model for repeated measure-
ments is presented as a special case of Equation (4.1). X specifies an intercept
and Z contains dummy variables that code one categorical variable of interest (the
series). G describes the variances in a diagonal structure, and Σ contains the clas-
sical error assumption Σ = σ2εIn, In being a (n × n) identity matrix. Generally,
the interest is to analyze the variances and covariances in the model, see e.g. Box
and Tiao (1973); Hill (1965); Krishnamoorthy and Mathew (2010). However, in this
work, the Bayesian predictive distribution remains the main interest. This distribu-
tion describes the predictive uncertainty of every single new data. This uncertainty
comes from both the measurements and the series-to-series variation.
Second, Section 4.3 illustrates the problem of simple hierarchical linear regression
in linear calibration problems. In this hierarchical univariate regression problem, the
matrices X = Z are identical and allow the estimation of an intercept and a parame-
ter corresponding to a slope coefficients for one input variable. Both parameters are
estimated for the fixed and random effects. The Bayesian predictive distributions
of the response (y˜ | x˜, data) and of the back-calculated input variable (x˜ | y˜, data)
will be the main result of this section as they are useful to assess the uncertainty of
a linear calibration.
Finally, the last section introduces non-linear mixed-effects models in a similar
calibration problem. These models are useful when a linear model is not able to
fit the analytical data properly. In this case, a non-linear model is often appropri-
ate to fit the calibration curve of ligand-binding assays with serial dilutions (e.g.
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ELISA test). Typically, a 4-parameters logistic regression with a variance modeled
as proportional to a power of the mean is used as a calibration curve. Some fixed
parameters might have a random counterpart while others might be assumed fixed.
4.2 Bayesian one-way ANOVA random model
Assume that the observations of Y are repeated in m different experimental units
such as series (either batches, individuals, days, devices, etc.) with nj observations
per series. The data yj observed on the jth serie will present a certain correlation,
as they come from the same or experimental unit (j = 1, ...,m). The complete data
set may be written y = (y1, ...,ym).
A wide review of classical and Bayesian methodologies to estimate variance com-
ponents can be found in Khuri and Sahai (1985), that particularly address the
one-way ANOVA random model. For the frequentist results addressing predictions,
the approximation developed by Mee (1984) is a reference in this domain.
To remain as general as possible and to be concise, the posterior and predictive
distributions will be presented in a sampling perspective, although it is possible to
obtain closed-forms for the posterior distributions in specific cases (see for instance
the chapter 5 of Box and Tiao, 1973).
4.2.1 Model
To capture the correlation between the data of the same series, the series effect
are modeled by a random effect parameter αj. Assuming for the sake of generality
that the data are unbalanced, the one-way ANOVA random model can be written
as:
yij = µ+ αj + εij, with εij ∼ N(0, σ2ε) and αj ∼ N(0, σ2α) (4.2)
j = 1, ...,m, i = 1, ..., nj, n =
m∑
j=1
nj.
In this equation, µ is the overall mean. The aim is to estimate the variance compo-
nents that quantify the between-series variability (σ2α = 1/τα) and the within-series
variability (σ2ε = 1/τε)1 in order to find the total variability of the response (referred
as the intermediate precision, i.p.). The two variance components are assumed in-
dependent so that vari.p.(Y ) = σ2α + σ2 .
1τα and τε are called precisions, i.e. the inverse of the variances.
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An alternative notation can be used to simplify the description of the model:
yij ∼ N(αj, σ2ε), with αj ∼ N(µ, σ2α). (4.3)
Notice that when n1 = nj = nm, the design is balanced. The vector of parameters
is then (µ, σ2α, σ2ε), or equivalently, (µ, τα, τε).
4.2.2 Likelihood
The likelihood L(µ, σ2α, σ2ε | y) can be expressed as the following density (see Hill
(1965); Box and Tiao (1973))
L(µ, σ2α, σ2ε | y) =
m∏
j=1
∫
αj
p(y | αj, σ2ε).p(αj | µ, σ2α).dαj (4.4)
∝ (σ2ε)−
n−m
2 . exp
−
∑
i,j
(yij − y¯j)2
2σ2ε

m∏
j=1
(σ2ε + njσ2α)−
1
2 exp
−12
m∑
j=1
nj(y¯j − µ)2
σ2ε + njσ2α
 ,
(4.5)
with σ2α > 0 and σ2ε > 0. Equivalently, in terms of precisions, the likelihood becomes:
L(µ, τα, τε | y) ∝ τ
n−m
2
ε exp
−τε2 ∑i,j (yij − y¯j)2

.
m∏
j=1
(τα + njτε)−
1
2 (τετα)
1
2 exp
−12
m∑
j=1
τετα
τα + njτε
nj(y¯j − µ)2
 (4.6)
The first line of (4.6) expresses the information concerning yij. The second line
represents the information concerning the random parameters αj.
The complexity of this density (mixture of Normal densities) gives clue on the
difficulty one may have to work analytically on its basis. This also gives little
information on the way to find conjugate prior distribution.
4.2.3 Prior distribution of the parameters
Independent prior distributions are assumed for the parameters µ, τε and τα. To
avoid negative variance estimations, that is a major concern in the mixed model
estimation, Culver (1971) examined the prior distribution of the within-series and
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between-series variance components. He proposed to use two independent inverted-
Gamma prior distributions for the variance components and one uniform prior dis-
tribution for the location parameter µ. Similarly, when being non-informative, it is
also possible to use uniform prior distributions on the domain [0, c], with c being a
large positive value. The sampling approach described by Wolfinger (1998) is devel-
oped in the following sections. It extends the one of Culver by replacing the uniform
distribution of the location with a Normal.
In term of precision, a possible prior distribution for τε is then a Gamma distri-
bution, that corresponds to the choice of an inverted-Gamma for σ2ε .
p(τε) = Gamma(k0ε , δ0ε). (4.7)
For a distribution representing a diffuse information, k0ε and δ0ε are chosen being
very small positive values, such as 10−5. In this case, the Gamma is very flat in the
domain [0,+∞).
For the parameters µ and τα, the prior distributions can be chosen as Normal
and Gamma distributions, respectively.
p(µ) = N(µ0, σ20) = N(µ0, 1/τ0) (4.8)
p(τα) = Gamma(k0α, δ0α), (4.9)
Diffuse a priori for µ can be set up with a very low precision τ0 = 10−5. Notice
that if the precision is very low, the particular value of µ0 is non significant. An
usual choice is to give a value of µ0 = 0. With this Normal prior, flexibility is left
to define an informative prior distribution if desired, with µ0 and τ0 being values
that might be estimated over previous experimental data, for instance. For p(τα),
diffuse knowledge can be given fixing k0α and δ0α to very small positive values, e.g.
10−5. Informative prior knowledge can be used as well, choosing different values.
When possible, a direct implication of the use of informative prior information
in analytical method validation and calibration is to be able to provide the results
with limited experiments. In this case, the validity of the prior information must be
guaranteed to avoid harmful biases.
4.2.4 (Sampled) posterior distribution of the parameters
Applying Bayesian rule, the joint posterior density of the parameters is expressed
as
p(µ, τα, τ | data) ∝ L(µ, τα, τε | y).p(τε).p(µ).p(τα). (4.10)
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MCMC sampling is used to draw samples from the joint posterior distribution of
(4.10), with the prior distribution defined in Equations (4.7)-(4.9), provided that it
is easy to have enough samples in a short computation time. In this context, Ra-
jagopalan and Broemeling (1983), Harville and Zimmermann (1996) and Gamerman
(1997) illustrated the use of MCMC methods to characterize the posterior distri-
bution of parameters for the mixed-effect model. The classical MCMC methods
presented in the Appendix C can be used to carry out such a work. Specialized
softwares such as WinBUGS (Lunn et al. (2000)) and the MCMC procedure from
SAS software’s (SAS/STAT® 9.2.1 User’s Guide, SAS Institute Inc. (2010)) provide
nice interfaces to MCMC methods. An example of BUGS code for the unbalanced
random one-way ANOVA is given in listing 4.1.
Listing 4.1: BUGS code for unbalanced random one-way ANOVA.
model{
for ( j in 1 :m){
for ( i in n [ j ] : ( n [ j +1]−1)){
y [ i ] ~ dnorm( a [ j ] , tau . e ) #l i k e l i h o o d
}
a [ j ] ~ dnorm(mu, tau . a )
}
#f l a t p r io r d i s t r i b u t i o n s
mu ~ dnorm(0 , 0 .0001)
tau . a ~ dgamma(0 . 0001 , 0 . 0 001 )
tau . e ~ dgamma(0 . 0001 , 0 . 0 001 )
#conver t p r e c i s i on in to var iance
sigma2 . e <− 1/ tau . e
sigma2 . a <− 1/ tau . a
}
In the previous piece of code, the observations are stacked in one vector y and n[j] is
a value of some offsets that indicates the series for each observation.
Notice that WinBUGS uses Normal distribution (dnorm()) whose dispersion is
parametrized with a precision instead of a variance. The location of the posterior
distributions of σ2α and σ2ε are useful to identify the major source of variance. Their
spread may be used to assess the quality of these variance estimates.
The focus is now put on the sampled predictive distribution of a new observation
of Y , that includes within-series and between-series sources of variability.
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4.2.5 (Sampled) predictive distribution of one new response
In the frequentist predictive approach, the main works about prediction have
been done on the computation of tolerance intervals (Wilks, 1941; Wald and Wol-
fowitz, 1946; Wallis, 1951; Ellison, 1964; Mee, 1984; De Gryze et al., 2007). Many
complications arise when sufficient statistics for the model can not be analytically
described. This is mostly the case when departing from Normality assumptions and
when the data are unbalanced (Krishnamoorthy and Mathew, 2010).
From a Bayesian perspective, the link between the predictive distribution and
tolerance intervals is direct, as pointed out by Guttman (1970). Following his idea,
the β.(100)% HPD quantiles of a predictive distribution of a new response are simply
the β-expectation tolerance intervals (see also Guttman, 1988; Hamada et al., 2004).
Tolerance intervals can then be computed from the predictive distribution using
simulations (see Aitchison, 1964; Wolfinger, 1998; Krishnamoorthy and Mathew,
2010).
The predictive density of a new observation y˜ is computed as
p(y˜ | data) =
∫
µ
∫
τα
∫
τε
p(y˜ | µ, τα, τε).p(µ, τα, τε | data).dτε.dτα.dµ. (4.11)
Difficulties arises in the analytical identification of the predictive distribution of y˜.
Instead, a simple simulation procedure can be used to draw samples from (y˜ | data).
First, following the model, the random effect parameter αj is distributed as a Normal
with a posteriori location (µ |data) and precision (τα |data) (Wolfinger, 1998). This
allows drawing samples of new random parameters α˜(1), . . . , α˜(s), . . . , α˜(n∗). Each
α˜(s) then represents the effect of a new predicted serie that follows the observed
between-series variance component. Second, this series effect is included in the
model, to draw a new response. As stated by the model, it also follows a Normal
distribution with posterior location α˜(s) and estimated within-series precision (τε |
data): y˜(s) ∼ N(α˜(s), τε | data). This gives the following algorithm:
For s = 1 to n∗
1. sample (µ(s), τ (s)α , τ (s)ε ) from p(µ, τα, τ | data), see Eq. (4.10)
2. sample α˜(s) from N(µ(s), σ2(s)α ), or from N(µ(s), 1/τ (s)α ),
3. sample y˜(s) from N(α˜(s), σ2(s)ε ), or from N(α˜(s), 1/τ (s)ε ).
End
At the end, samples y˜(1), ..., y˜(s), ..., y˜(n∗) following p(y˜ | data) are obtained. A sim-
plification of the sampling process is possible, replacing step 2 and 3 of the algorithm
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by the sampling of y˜(s) directly from N(µ(s), σ2(s)α + σ2(s)ε ). The same predictive dis-
tribution is obtained, due to the independence assumption between the variance
components.
4.2.6 Simulation results
When prior distributions tends to be uniform, one normally gets the same pre-
dictive distribution that the one that can be obtained (approximately) in the Fre-
quentist framework. In this section, the β-expectation tolerance interval presented
by Mee (1984) and applied in Hubert et al. (2007) is used and compared to the
β-expectation tolerance interval obtained from the Bayesian predictive distribution.
The simulation set up is as follows: m = 3, ..., 200 series of data were created.
For each serie, nj = 3 or 10 replicates (e.g. measurements of the same batch) were
available, following the generating model:
yij = µ+ αj + εij, with εij ∼ N(0, σ2ε) and αj ∼ N(0, σ2α) (4.12)
j = 1, ...,m, i = 1, ..., nj, n =
m∑
j=1
nj.
µ was set to 100; the between variance σ2α was assumed to be 5 and the within
variance was defined from the ratio σ2ε = σ2α/R, where R was 1 or 20. When R was
20, the effect of the series is considerably higher than the residual error. To obtain
unbalanced data, 3 observations were removed at random in different series, except
when m = 3 and nj = 3 (j = 1, 2, 3), as the data set was already limited in this
situation.
The β−expectation tolerance interval of Mee at β = 95% states that, on average,
the proportion of future results that would be found within the interval is β. After
being adapted for unbalanced data and expressed in relative scale, it can be defined
as: bias(%)−t 1+β
2
(ν)
√
1 + 1
n.B2
RSDIP ;
bias(%) + t 1+β
2
(ν)
√
1 + 1
n.B2
RSDIP
, (4.13)
where
• bias(%) = µˆ−µ
µ
× 100,
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• µ is known from simulation set up (in practice, it may be assumed known from
averaged measurements with negligible error); µˆ is estimated from the data
(grand mean),
• RSDIP = σˆIPµ ×100, the relative standard deviation of intermediate precision,
with
• σˆ2IP = σˆ2α + σˆ2ε , the estimate of the variance of the intermediate precision, i.e.
the sum of the estimated within and between series variances, and
• B =
√
Rˆ+1
n
m
Rˆ+1 , with Rˆ =
σˆ2α
σˆ2ε
,
• ν = (Rˆ+1)2(Rˆ+m
n
)2/(m−1)+(1−m
n
)/n , (known as Satterthwaite (1941) approximation),
• t 1+β
2
(ν), the 1+β2 quantile of the Student distribution with ν degrees of freedom.
In the Bayesian framework, samples y˜(s) of the predictive distribution can directly
be used. According to Guttman (1970), the β-expectation tolerance interval is the
95% HPD quantiles of the predictive distribution. To compare to Equation (4.13)
the samples from the predictive distribution were also put in relative scale:
y˜(s)r =
y˜(s) − µ
µ
× 100.
The HPD quantiles were then compute on y˜(s)r . µ was known from simulation set
up.
Using the sampler presented in Section 4.2.4 with non-informative flat prior dis-
tributions, 10000 samples were recorded, after a burnin period of 5000 samples.
Samples of the predictive distribution were then obtained as in Section 4.2.5. No
convergency issue was detected in the simulations, using autocorrelation plots and
Gelman-Rubin-Brooks test/plots provided by the coda R package (Brooks and Gel-
man, 1998; Plummer et al., 2010).
Results of the simulations are presented in Figure 4.1. It presents the β-expectation
tolerance interval at 95% versus the number of series. The interval derived from Mee
is presented in blue whereas the one obtained from the predictive distribution is
shown in green. In the four cases (A, B, C and D), both intervals were very similar,
particularly when the number of series was increased. When the number of series
was at least m = 30, the total uncertainty remains stable, even if the number of
repetition was low. With these scenarii, it seems more profitable to envisage enough
series while limiting the number of repetitions.
In this manuscript, the β-expectation tolerance interval for the one-way ANOVA
random model is applied to validate the results of a quantitative method. An ex-
ample of application is given in Chapter 10.
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Figure 4.1: Evolution of the β-expectation tolerance interval when the number of
series m is increased from 3 to 200. (Red) Reference total relative error specification
fixed at + or - 5%. (Green) 95% HPD interval of the predictive distribution. (Blue)
Frequentist tolerance interval as in Equation (4.13). (A) The ratio of the between
and within variances, R, is 1 and the targeted number of repetitions, nj, is 3. (B)
R = 1, nj = 10. (C) R = 20, nj = 3. (D) R = 20, nj = 10.
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4.3 Bayesian hierarchical linear regression
The hierarchical regression is introduced in the context of the calibration of an
analytical method. A comprehensive review of frequentist and Bayesian models for
calibration is given in Osborne (1991).
In calibration problem, at a concentration of an analyte xi corresponds a signal
Y | xi. The standards x = (x1, ..., xi, ..., xn) are assumed known as they are deter-
mined by a supposed extremely accurate standard method. The error on x is then
negligible. However, this standard method may also have some inconveniences such
as running time or cost. The analytical method providing y, the observations of
Y , is generally more flexible, quicker and less expensive than the standard method.
Nevertheless, this analytical method requires this calibration process.
After the calibration process, the analytical method is run (e.g. routine): a
new signal is observed, and an inverse prediction is used to find the corresponding
concentration. To mimic the real application of the method, different series of
data may be used to create the calibration curve. Series effect can be included in
the regression using random effect parameters. These series can represent different
operators, different batches of samples, different devices carrying out the analytical
method, etc. When the calibration curves are assumed linear, this model is useful
to analyze the uncertainty one can expect for future runs.
4.3.1 Model
The proposed approach enriches the one described by Hunter and Lamboy (1981)
through a mixed-effect modeling.
Assume that each measure of Y is repeated in m series, for different known
concentration level x. The general linear mixed-effect model equation is:
y = Xβ + Zα+ ε.
In the simple linear case, this last equation can be written as:
yij = β0 + β1xi + α0j + α1jzi + εij, with j = 1, ...,m. (4.14)
With hierarchical models, it is further assumed that xi = zi, and Equation (4.14)
can be rewritten:
yij = (β0 + α0j) + (β1 + α1j)xi + εij, (4.15)
The classical assumptions are εij ∼ N(0, σ2ε), α0j ∼ N(0, σ20) and α1j ∼ N(0, σ21).
As in the previous section, alternative notations can be used, in terms of variances
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or precisions:
yij ∼ N(α0j + α1jxi, σ2ε), with α0j ∼ N(β0, σ20) and α1j ∼ N(β1, σ21), or ,
yij ∼ N(α0j + α1jxi, 1/τε), with α0j ∼ N(β0, 1/τ0) and α1j ∼ N(β1, 1/τ1). (4.16)
Notice that α0j and α1j are supposed independent. This is a simplistic assumption
that can be improved using a multivariate Normal for their joint distribution, with
a covariance matrix expressing their dependency.
For the non-balanced case, the total number of observations is the sum of all the
data of each serie, n = ∑mj=1 nj.
4.3.2 Likelihood
With Normally distributed data in a mixed-effect model, the likelihood is decom-
posed as follows:
L(β0, β1, τ0, τ1, τε | y)
=
m∏
j=1
∫
α0j ,α1j
nj∏
i=1
p(yij | α0j, α1j, τε)p(α0j, α1j | β0, τ0, β1, τ1)d(α0j, α1j),
=
m∏
j=1
∫
α0j ,α1j
p(y | α0j, α1j, τε) p(α0j | β0, τ0)p(α1j | β1, τ1)dα0jdα1j.
(4.17)
The likelihood is then averaged over the possible values of the random parameters.
This is complex to resolve analytically, but it is simple to code with the BUGS
language as it will be shown later.
4.3.3 Prior distribution of the parameters
The following prior distributions p(β0, β1, τ0, τ1, τε) can be defined, assuming the
parameters are independent a priori:
p(τε) = p(1/σ2ε) = Gamma(k0ε , δ0ε),
p(β0) = N(µβ0 , 1/τβ0),
p(τ0) = p(1/σ20) = Gamma(k00, δ00),
p(β1) = N(µβ1 , 1/τβ1),
p(τ1) = p(1/σ21) = Gamma(k01, δ01). (4.18)
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Vague information can be defined using small values for the hyper-parameters, for
example:
k0ε , δ
0
ε , k
0
0, δ
0
0, k
0
1, δ
0
1 = 10−5,
τβ0 , τβ1 = 10−5,
and with µβ0 , µβ1 = 0. (4.19)
Informative prior distributions can be given in the same way, using estimates that
come from previous experiments, if any.
4.3.4 (Sampled) posterior distribution of the parameters
Applying Bayesian rule, one obtains:
p(β0, β1, τ0, τ1, τε | data) ∝ L(β0, β1, τ0, τ1, τε | y).p(β0, β1, τ0, τ1, τε). (4.20)
This formula shares similarities with the one-way ANOVA random model of the
previous section. The following BUGS code (listing 4.2) allows drawing samples
from p(β0, β1, τ0, τ1, τε | data).
Listing 4.2: BUGS code for unbalanced hierarchical linear regression.
model{
for ( j in 1 :m){
for ( i in n [ j ] : ( n [ j +1]−1)){
y [ i ] ~ dnorm( yj , tau . e ) #l i k e l i h o o d
yj <− alpha0 [ j ]+ alpha1 [ j ]∗ x
}
alpha0 [ j ] ~ dnorm( beta0 , tau . 0 )
alpha1 [ j ] ~ dnorm( beta1 , tau . 1 )
}
#hyper−p r i o r s #
beta0 ~ dnorm(0 , 0 .0001) #non−in format i ve
beta1 ~ dnorm(0 , 0 .0001) #non−in format i ve
tau . 0 ~ dgamma(0 . 0001 , 0 . 0 001 ) #non−in format i ve
tau . 1 ~ dgamma(0 . 0001 , 0 . 0 001 ) #non−in format i ve
tau . e ~ dgamma(0 . 0001 , 0 . 0 001 ) #non−in format i ve
#conver t p r e c i s i on in to var iance
sigma2 . e <− 1/ tau . e
sigma2 . 0 <− 1/ tau . 0
sigma2 . 1 <− 1/ tau . 1
}
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4.3.5 (Sampled) predictive distribution of one new response
Given a new concentration x˜, the predictive distribution of a new observation y˜
is computed as
p(y˜ | x˜, data) =∫
β0,β1,τb0 ,τb1 ,τε
p(y˜ | x˜, β0, β1, τb0 , τb1 , τε).p(β0, β1, τb0 , τb1 , τε | data).d(β0, β1, τb0 , τb1 , τε).
(4.21)
It is possible to numerically solve this integral by doing the following computations
(Wolfinger, 1998). First, obtain samples from the posterior distribution of the pa-
rameters. These samples are used to compute the values of regression parameters
α˜
(s)
0 and α˜
(s)
1 that represent their future possible values for new predicted series
(s = 1, ..., n∗). Next, using these samples in the regression model, the residual un-
certainty can be added to obtain samples from the predictive distribution of a new
observation y˜, using Monte-Carlo simulations:
For s = 1 to n∗
1. sample (β(s)0 , β
(s)
1 , τ
(s)
0 , τ
(s)
1 , τ
(s)
ε ) from p(β0, β1, τ0, τ1, τε | data),
2. sample α˜(s)0 from N(β
(s)
0 , 1/τ
(s)
0 ),
3. sample α˜(s)1 from N(β
(s)
1 , 1/τ
(s)
1 ),
4. sample y˜(s) | x˜ from N(α˜(s)0 + α˜(s)1 x˜, 1/τ (s)ε ).
End
As the variance parameters are assumed independent, it is also possible to sample
directly as follows:
For s = 1 to n∗
1. sample (β(s)0 , β
(s)
1 , τ
(s)
0 , τ
(s)
1 , τ
(s)
ε ) from p(β0, β1, τ0, τ1, τε | data),
2. sample y˜(s) | x˜ from N(β(s)0 + β(s)1 x˜, 1/τ (s)ε + 1/τ (s)0 + 1/τ (s)1 ),
= N(β(s)0 + β
(s)
1 x˜, σ
2(s)
ε + σ
2(s)
0 + σ
2(s)
1 ).
End
4. Bayesian Hierarchical models 65
4.3.6 (Sampled) distribution of the inverse prediction of one
new result
When using the calibration line in practice, the interest is generally centered on
the x values, i.e. the concentration of an analyte, given a observed signal y˜ provided
by the analytical method.
In the bayesian framework, there is an opportunity to easily obtain samples from
the predictive distribution of these concentrations given a new signal, using the
(sampled) posterior distribution of the parameters obtained as in section 4.3.4. The
idea is to use use the inverse of the linear calibration line (Hunter and Lamboy,
1981):
x˜ = y˜ − α0
α1
, (4.22)
Noticing that α0 and α1 are unknown, their posterior distributions must be used.
The following algorithm shows how to proceed:
For s = 1 to n∗
1. sample (β(s)0 , β
(s)
1 , τ
(s)
0 , τ
(s)
1 , τ
(s)
ε ) from p(β0, β1, τ0, τ1, τε | data),
2. sample α˜(s)0 from N(β
(s)
0 , 1/τ
(s)
0 ),
3. sample α˜(s)1 from N(β
(s)
1 , 1/τ
(s)
1 ),
4. sample x˜(s) | y˜ from N( y˜−α˜
(s)
0
α˜
(s)
1
, 1/τ (s)ε ).
End
This predictive distribution can then be used to assess the calibration quality in a
predictive fashion that takes into account the additional variability due to the series.
Some examples of applications are the following: the derivation of the dosing range
of the analytical method (the concentration for which the method will perform in
a satisfactory manner), the illustration of the predictive uncertainty using precision
profiles of the method, or the illustration of the risk not being within some predefined
specifications. This is illustrated in Chapter 10.
4.4 Bayesian mixed-effects non-linear regression
When departing from the linearity of the calibration curve, two options are avail-
able. The first one is to reduce the concentration range so that the data looks locally
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linear, and apply the theory of Section 4.3. The second one is to select a model able
to account for this non-linearity. The first option is of course rather disappointing
due to the non ability to use all the possible data, i.e. every concentration level that
could be recorded by the method. Fortunately, there is generally simple non-linear
structures that can be adopted to model such data.
In this section, the focus is put on a particular bio-analytical method, the ligand-
binding assay with serial dilution, used to quantify products such as proteins by the
mean of biological properties. Without going into details, a heterogenous variance
is common. In this case, Davidian and Giltinan (1995) proposed to use a model that
accounts for this heterogeneity through a variance that is proportional to a power
of the expected predicted responses, often referred as power of the mean (POM)
variance.
With the problem of (inverse) prediction, some constraints will apply on the
prior distribution of the parameters to obtain a predictive density of the signals (the
concentration) that shares enviable properties, such as positivity and computability
of the POM variance.
As an example, a mixed-effects four parameters logistic regression model with a
POM variance is described, with some effects assumed fixed and some other that
are random. As in the previous sections, the data are organized in m series.
4.4.1 Model
In the condition of assumed known concentrations x = (x1, ..., xi, ..., xn), let the
response Y be explained by the following logistic model:
yij = αj1 +
β2 − αj1
1 + ( xi
αj4
)αj3 + εij with j = 1, ...,m. (4.23)
The error is modeled as εij ∼ N(0, 1/τY ), with the following model for the variance,
expressed in term of precision:
τY =
τ
E[yi]θ
.
Let define the set of fixed parameters β = (β2, τ, θ) and the set of random parameters
αj = (αj1, αj3, αj4). For the interpretation, αj1 and β2 are the top (for the jth serie)
and bottom asymptotes. The bottom asymptote has been chosen as fixed as its
value should not depend upon the series. It is then estimated for all the series. This
assumption states that a zero concentration sample should always result in a zero
signal, whatever the series. Next, αj3 is the slope of the curve at the inflection point
(C50) and C50 is modeled by αj4. τ can be seen as an averaged precision, observed
for the possible values of yi. θ is used to inflate or deflate the precision with respect
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to the expected values of yi. The choice to fit a parameter as random or fixed can
also be driven by some predictive indices such as the Deviance Information Criterion
(DIC) or other predictive checks.
As in the previous section, the number of observations for the jth serie is nj, and
the total number of observations is n = ∑mj=1 nj.
The model also supposes the following independent distributions for the random
variable of the calibration curve:
αj1 ∼ logN(β1, 1/τ1),
αj3 ∼ N(β3, 1/τ3),
αj4 ∼ logN(β4, 1/τ4) (4.24)
Finally, let’s define ζ = (β1, τ1, β3, τ3, β4, τ4). ζ is often referred as the set of hyper-
parameters for the random parameters. These hyper-parameters explain how the
series affect the values of α. p(α | ζ) is then the conditional density of the mixed
variables.
4.4.2 Likelihood
Summarizing the model in a general form, one gets:
yij = m(xi;β,αj | ζ) + εij, with εij ∼ N(0, 1/τY ) and j = 1, ...,m. (4.25)
Conditionally to the parameters, each observation is distributed as:
yij | xi,β,αj, ζ ∼ N(m(xi,β,αj | ζ), 1/τY ), (4.26)
Assuming the observations identically distributed, the likelihood is the product of
the marginal densities of the observations conditional to the parameters. It can
then be written similarly to the likelihood of the hierarchical model of the previous
section.
L(β, ζ | y) =
m∏
j=1
∫
αj
p(y | β,αj, ζ).p(αj | ζ).dαj. (4.27)
In this application, p(αj | ζ) is the product of the densities of Equation (4.24).
4.4.3 Prior distribution of the parameters
The regression parameters (α1j, β2, α3j, α3j) of the logistic curve and the variance
parameters are assumed independent a priori. This restriction is rather useful as all
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the proposed distributions are not Normal nor identical so it is difficult to extend
them to multivariate distributions. The parameters for the bottom asymptote, top
asymptotes and for the C50 (i.e. αj1, β2, αj4) are assumed log-Normal to ensure their
positivity. The support domain of the slope parameter (βj3) is assumed to be R.
This may be controversial (see the discussion of Hill in Hunter and Lamboy, 1981),
but it provides a more general model, for instance to be able to fit some data that
shows a decreasing curve. In this case, βj3 could be negative.
The prior distribution of the fixed parameters β are as follows:
p(β2) = logN(b2, τ2)
p(τ) = Gamma(a, b),
p(θ) = Gamma(c, d), (4.28)
then, p(β) = p(β2).p(τ).p(θ). (4.29)
With these prior assumptions, τ and θ are restricted to positive value due to their
Gamma prior. For vague a priori, the following values have been chosen:
b2 = 0,
τ2 = 0.00001,
a, b, c, d = 0.00001.
For the random parametersα, second-stage priors are defined for the hyper-parameters
ζ. They describe the distributions for their locations and scales, and are assumed
independent.
p(β1) = N(µβ1 , τβ1),
p(τ1) = Gamma(a1, b1),
p(β3) = N(µβ3 , τβ3),
p(τ3) = Gamma(a3, b3),
p(β4) = N(µβ4 , τβ4),
p(τ4) = Gamma(a4, b4), (4.30)
then p(ζ) = p(β1).p(τ1).p(β3).p(τ3).p(β4).p(τ4).
Vague priors can be given as follows:
µβ1 , µβ3 , µβ4 = 0,
τβ1 , τβ3 , τβ4 = 0.00001,
a1, b1, a3, b3, a4, b4 = 0.00001.
Informative prior distributions can be given in the same way, using estimates that
come from previous experiments, if any.
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4.4.4 (Sampled) posterior distribution of the parameters
The posterior density of the parameters (β, ζ) is obtained using Bayes’ theorem
p(β, ζ | data) ∝ L(β, ζ | y).p(β).p(ζ) (4.31)
Unfortunately, there is no analytical solutions to solve Equation 4.31. Instead of
relying on complex approximations, MCMC simulations are used to obtain samples
from the joint posterior distribution of the parameters. Listing 4.3 is a BUGS code
implementing the model.
To implement the likelihood, BUGS coding allows making use of the variables αj.
This allows easily defining the likelihood without having to solve the multiple integral
in (4.27). WinBUGS carries out the involved product of the marginal likelihood over
the series.
Listing 4.3: Winbugs code for the mixed four parameters logistic regression with a
variance proportional to a power of the mean (unbalanced case).
model{
for ( i in 1 : n){
re sponse [ i ] ~ dnorm( expect [ i ] , powertau [ i ] )
#POM variance
powertau [ i ] <− 1/( exp ( theta ∗ l og ( expect [ i ] ) ) ∗ sigma2 . y )
#mean
expect [ i ]<−alpha1 [ s e r i e s [ i ] ] +
( ( beta2−alpha1 [ s e r i e s [ i ] ] ) /
(1+exp ( ( l og (x [ i ] / alpha4 [ s e r i e s [ i ] ] ) ) ∗ alpha3 [ s e r i e s [ i ] ] ) ) )
}
for ( j in 1 :m){
alpha1 [ j ] ~ dlnorm ( beta1 , tau1 )
alpha3 [ j ] ~ dnorm( beta3 , tau3 )
alpha4 [ j ] ~ dlnorm ( beta4 , tau4 )
}
#conver t p r e c i s i on in to var
sigma2 . y <− 1/ tau .Y
#pr io r s on f i x e d parameters
tau .Y ~ dgamma(a , b)
theta ~ dgamma( c , d)
beta2 ~ dlnorm (b2 , tau2 )
#hyper−p r i o r s on mixed parameters
beta1 ~ dnorm(mubeta1 , taubeta1 )
tau1 ~ dgamma( a1 , b1 )
beta3 ~ dnorm(mubeta3 , taubeta3 )
tau3 ~ dgamma( a3 , b2 )
beta4 ~ dnorm(mubeta4 , taubeta4 )
tau4 ~ dgamma( a4 , b4 )
}
During MCMC simulations, the independence assumption might give poor sam-
pling acceptance (high rejection of samples) with the Metropolis-Hasting algorithm
as it will not be able to adapt the proposal to account for the dependencies. As a
consequence, the sampler might slowly explore the posterior density, and can get
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stuck into local sub-optimal zones. The obtained chains of samples might also be
strongly autocorrelated. A common solution, though computationally intensive, is
to draw (many) more samples and to thin them.
In the listing, the unbalanced data are handled in a different way than in the
previous sections. A vector series of size n was defined to identify the series for every
observation i. This vector provides the index of the series for the variables that
incorporate the series effect (αj).
It must be noticed that all the exponents including random variables were equiv-
alently rewritten using the canceling exponentials property (i.e. exp(log(x)) = x).
WinBUGS has been found unable to handle them properly. This permits using the
power rule of the log operator, log(xd) = d log(x), to get rid of the exponents that
include variables.
This notation makes also clear why positiveness is essential for certain parameters
under log operator. The POM variance constraints the mean sampled predicted
values (expect[i]) to R+ such that the log operator is properly defined. The same fact
is observed about the concentrations x[i] and the parameter alpha4[j]. To observe the
positivity of the mean predicted, alpha1[j] must also be strictly higher than beta2, i.e.
the calibration curve must be increasing. If expect[i] was defined over R, one could
use its absolute value when computing the POM variance, or use another model for
the variance.
4.4.5 (Sampled) predictive distribution of one new response
Given a new concentration x˜, the predictive distribution of the signal is computed
as
p(y˜ | x˜, data)
=
∫
(β,ζ)
p(y˜ | x˜,β, ζ).p(β, ζ | data).d(β, ζ)
=
∫
(β,α,ζ)
p(y˜ | x˜,β,α, ζ).p(α | ζ).p(β, ζ | data).d(β,α, ζ). (4.32)
Using simulations, samples can be drawn from the predictive distribution of Y using
the following algorithm.
s = 1 to n∗
1. Sample hyper-parameters ζ(s) from p(ζ | data),
2. Sample random parameters α(s) | ζ(s) = (α˜(s)1 , α˜(s)3 , α˜(s)4 ) from p(α | ζ(s)),
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3. Sample fixed parameters β(s) = (β(s)2 , τ (s), θ(s)) from p(β | data),
4. Compute mean µ˜(s)y = α˜
(s)
1 +
β
(s)
2 −α˜
(s)
1
1+( x˜
α˜
(s)
4
)α˜
(s)
3
and precision τ (s)µ˜Y =
τ (s)
(µ˜(s)y )θ
(s) ,
5. Sample (y˜(s) | x˜, data) from N(µ˜(s)y , τ (s)µ˜Y ).
end
In step 1 and 3, the sampling from the posterior distribution of the parameters
is done. Practically, these two steps are carried out in the same time as a draw from
the joint posterior distribution.
4.4.6 (Sampled) distribution of the inverse prediction of one
new result
When using the bio-analytical method during routine, the inverse calibration
curve is used to translate an observed signal y˜ into the concentration of the cor-
responding sample. Assuming the parameters known, the equation of the inverse
curve can be obtained from Equation (4.23) and is
x˜ = α4(
β2 − y˜
y˜ − α1 )
1
α3 . (4.33)
As the parameters are not known, their (joint) posterior distribution is used to
propagate their uncertainty to the inverse prediction. The following algorithm can
be used to draw samples from the distribution of the inverse prediction.
s = 1 to n∗
1. Sample hyper-parameters ζ(s) from p(ζ | data),
2. Sample random parameters α(s) | ζ(s) = (α˜(s)1 , α˜(s)3 , α˜(s)4 ) from p(α | ζ(s)),
3. Sample fixed parameters β(s) = (β(s)2 , τ (s), θ(s)) from p(β | data),
4. Compute precision τ (s)µ˜Y =
τ (s)
y˜θ
(s) ,
5. Sample y˜(s) from N(y˜, τ (s)µ˜Y ),
6. Compute the inverse prediction (x˜(s) | y˜(s), data) = α˜(s)4 (β
(s)
2 −y˜(s)
y˜(s)−α˜(s)1
)
1
α˜
(s)
3 .
end
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4.5 Conclusion
In this chapter, different types of mixed models have been reviewed. The Bayesian
analysis has been shown useful to easily obtain a predictive distribution for the
response of interest. The simulation approach is rather systematic and can be used
with small or complex models. In that simulation perspective, enough samples
must be available to compute statistics such as a mean, an interval, a probability
of acceptance, etc. The sampling size and the considerations of Appendix B for
Monte-Carlo simulations then apply. Fortunately, modern computers are able to
deal with long simulations and complex models within reasonable run time.
The distributions of the prediction and inverse prediction are of particular interest
as often, the parameters estimates and their distribution give poor information about
the model and the method quality. Instead, the predictive distribution provides a
better insight on such qualities. It provides the necessary information towards the
objective of the method, i.e. to know if it is capable to perform accurately, within
known and well-defined specifications.
Chapter 5
Bayesian predictive multicriteria
decision method
Introduction
Design Space (DS) is directly related to multi-criteria optimization (MCO) and
multi-criteria decision making (MCDM). Regarding the factors influencing a process
or a method, several Critical Process Parameters (CPP) are selected to analyze their
concurrent effects on several outputs. Regarding the outputs, they are summarized
by Critical Quality Attributes (CQA) that should show satisfactory properties con-
currently. Design of Experiments (DoE) methodologies provide powerful tools to
carry out such tasks.
In Chapter 1, the DS was presented as a risk-based tool that is built over DoE
to jointly assess various CQAs in a predictive fashion. Chapters 2 – 4 showed some
developments to obtain predictive solutions for various classes of statistical models.
In classical DoE context, the CQAs are random variables Y = (Y1, ..., Yj, ..., Ym) ∈
Rm that are the responses of a designed experiment defined over the domains of some
CPPs, noted x = (x1, ..., xk). Changing these CPPs induces changes to each Yj | x
following a model fj whose parameters θj are estimated using the experimental
data.
Yj = fj(x;θj) + εj (5.1)
Classically, the CQAs are considered independent and are often modeled sepa-
rately. In addition, the jth estimated model fj is often assumed to be the true link
function between the jth CQA and the CPPs. The very basic optimization pro-
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cess looks for the CPP setting x∗ such that the mean predicted responses Eˆ[Yj |
x∗] = fj(x∗, θˆj) are optimal jointly. Of course, it is unlikely that a unique condition
would be optimal for every CQA. MCO methodologies should then be envisaged.
The flaws of using mean responses have been presented in Chapter 1 but will be
explained again hereafter.
In this chapter, the particular statistical models fj are of limited interest. To
be as general as possible, the CQAs are assumed to be either the multivariate re-
sponse vector Y , either transformations of these responses, say Y ∗ = O(Y ). Simple
transformations include log, logit or identity functions. More complex transforma-
tions include various combinations of responses, possibly with non continuous or non
derivable operator such as min or max. In the chromatographic field, the resolution
or the separation of the critical pair of peaks are good examples of combinations
with discontinuities (see Chapter 7, page 120). To simplify, Y is assumed to be the
vector containing the (possibly transformed) CQAs.
Structure of the chapter
First, Section 5.1 briefly explains some problems encountered with classical ap-
proaches based on mean responses. The issues are related to the uncertainty of
the statistical models that is generally not taken into account, providing limited
evidences about the predictions.
Next, Section 5.2 presents the classical solution for MCO in case where the CQAs
are not optimal jointly at a unique operating condition. This is known as the compet-
ing responses problem. To answer this problem, methodologies have been developed
to optimize one unitless index. It aggregates the different CQAs and indicates if the
process performs well or not at a given operating condition, according to predefined
targets to achieve. This is the well-known desirability concept: basically, each CQA
is first transformed into a desirability index using a desirability function (DF). After,
the indexes are aggregated into a global desirability index, reflecting how close the
output is from the ideal objective.
However, the desirability approach can’t be used directly for deriving a DS. The
reasons are the following : first, it has been recognized that the use of mean predicted
responses to compute a mean global desirability index often gives biased results
(Steuer, 2000). Second, as with the Sweet Spot, using mean predictions does not
provide any clue about the reliability of the solution. Recent developments of MCO
tends to give a more important role to the uncertainty that is encountered in the
statistical models, since uncertainty is crucial to assess risk. Some of them are
presented in Section 5.3.
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In Section 5.4, the desirability methodologies are linked to the risk-based ap-
proach presented in Chapter 1. It is shown how the risk-based DS approach is a
particular case of the more flexible method based on desirability functions.
5.1 Classical vs. Bayesian methodologies
For years, the standard analysis of data coming from DoE has been done using the
mean predicted CQAs, Eˆ[Yj | x]. One reason is that most of the available statistical
softwares having an MCO module (SAS/JMP, Statistica, Design Expert, Minitab,
etc.) rely on mean responses only. To allow for a certain compliance with Quality
by Design (QbD) approaches, the most sophisticated of them are able to compare
the overlapped mean responses to some specifications, allowing the construction of
some Sweet Spots or to compute a global optimum based on desirability functions
(Harrington, 1965). Generally, the study of CQAs stops at this point.
In Chapter 1, Sweet Spot computation has been described as non sufficient: it
does not take into account the model uncertainties and CQAs dependencies. As
a consequence, it does not provide any indication about how well and how often
the process or method can meet the specifications with respect to the investigated
CQAs (Peterson, 2008). Thus solutions within the Sweet Spot are subject to give
disappointing results for the future use of the process or method. In the context of
the ICH Q8 (2009) guideline, this represents a major drawback since it is clearly
asking to analyze the guarantees of quality, and not only a quality that would be
observed on average. Clearly, desirability approaches based on mean responses suffer
from the same problems.
Contrasting with the overlapped mean response approach, a Bayesian predictive
approach to define the DS is able to take into account the parameters and CQAs
uncertainties and their dependencies (Castagnoli et al., 2010; Lebrun et al., 2012b).
This approach integrates these variabilities using the predictive multivariate error
associated to the responses predictions. As the data and model parameters uncer-
tainties are accounted, the Bayesian predictive approach may significantly improve
the ability of models to provide predictions. This is certainly one of the most ef-
ficient way for “demonstrating assurance of quality” as requested by the ICH Q8
definition of the DS.
For the next parts of this chapter, a new observation of the CQAs Y observed at
a CPP setting x˜ will be noted y˜. y˜ is then a sample of (Y | x˜, data).
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5.2 Classical multi-criteria methodologies using
desirability functions
A flexible methodology for MCO has been proposed by Harrington (1965) to
optimize only one value that aggregates together the relevant CQAs. In this way, the
MCO is simplified in an univariate problem. Harrington based his methodology on
two steps. First, the CQAs are scaled into a unitless value between 0 and 1, namely
the desirability indices, using desirability functions that are parametrized according
to each CQA and its specifications. A CQA with a desirability of 1 has the perfect
achievement of quality. A desirability of 0 indicates a totally undesirable value for
the CQA. Second, Harrington proposed to aggregate together the desirability indices
into a global desirability index using a weighted geometric mean.
5.2.1 Desirability functions
Definition. For a CQA Y , let any function d : R→ [0, 1], Y 7→ d(Y ), be a desir-
ability function (DF). A desirability of d(Y ) = 0 is considered a totally undesirable
value for Y while a desirability of d(Y ) = 1 represents a perfectly desirable value.
Three types of DFs are generally encountered, for the cases where Y must be max-
imized, minimized or must reach a target value. In the literature, various authors
have proposed different implementations of the DFs, with the objective to provide
functions that are flexible, understandable, or mathematically “well-behaved” (Har-
rington, 1965; Derringer and Suich, 1980; Gibb et al., 2001; Le Bailly de Tilleghem
and Govaerts, 2005b).
5.2.2 Global desirability index
To reduce the MCO problem into a simpler univariate problem, the individual
DFs, d1(Y1), ..., dm(Ym), are aggregated into a global desirability index noted D(Y ).
In general, a weighted geometric mean is used to accomplish the task, although a
(weighted) arithmetic mean, a (weighted) harmonic mean or the minimum value
between all individual DFs could also be envisaged. For m CQAs combined with a
weighted geometric mean, D(Y ) is computed as:
D(Y ) = D(d1(Y1), ..., dm(Ym)) =
m∏
j=1
(dj(Yj))wj with
m∑
j=1
wj = 1, (5.2)
where wj values are fixed by an expert according to the relative importance he
wants to give to each CQA in the global desirability index. Flexibility is the main
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advantage of this approach, while the loss of interpretation of each CQA within
D(Y ) is the corresponding drawback.
5.2.3 Optimization
Classically, the optimization is done using the mean predicted values of the CQAs
Eˆ[Y | x0]. Then, the optimal operating condition x∗ is defined as:
x∗ = argmax
x˜∈χ
D(Eˆ[Y | x˜]) = argmax
x˜∈χ
m∏
j=1
(dj(Eˆ[Yj | x0]))wj
= argmax
x˜∈χ
m∏
j=1
(dj(fj(x0; θˆj)))wj , (5.3)
where χ is the experimental domain covered by the experiments.
As for any optimization problem, several algorithms exist. Grid search is advo-
cated when dimensionality is small and when local optima might prevent to obtain
the best solution. It also gives a global map of the evolution of the global desirability
index over the experimental domain. Other methods might be used as well, such as
gradient descend, simplex algorithm, or simulated annealing.
5.3 Improvements of the global desirability index
When optimal conditions are derived from statistical model predictions, it is
fundamental to study the impact of the model prediction error on the reliability of
the solution found. Unfortunately, this is rarely underlined in the literature. It has
been discussed firstly by Steuer (2000). The obvious but hardly applied conclusion
of this study is that the global desirability index must be taken as a random variable,
and its full distribution must be used to find its expected value and other statistics.
Steuer also noted that the classical use of mean predicted DFs gives biased results as
most implementations of DFs are non linear. The technique of Steuer is to propagate
the uncertainty of each predicted CQA (assumed known and Normally distributed,
εj ∼ N(0, σ2j )) using Monte-Carlo simulations. Thus, the maximization problem is
modified to:
x∗ = argmax
x˜∈χ
Eˆ[D(Y | x˜)] = argmax
x˜∈χ
Eˆ[
m∏
j=1
dj(fj(x˜; θˆj) + εj)wj ] (5.4)
The optimum is the one that maximize Eˆ[D(Y )], instead of the one that maxi-
mize the global desirability index computed from expected (mean predicted) CQAs:
D(Eˆ[Y ]).
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To avoid the use of intensive Monte-Carlo simulations, further works have been
done by Weber and Weihs (2003) and Trautmann and Weihs (2004, 2006), that
discussed the impact of the model prediction error on the reliability of the optimal
solution. They derived an approximation of the cumulative distribution function of
D(Y ) in a bi-variate MCO (two responses to optimize jointly). The complexity of
the density function of D(Y ) is however already high in this simple case. These im-
provements showed the way to better understand and use the desirability methods.
Still, they do not provide a solution for correlated CQAs.
Le Bailly de Tilleghem and Govaerts (2005a,b); Le Bailly de Tilleghem (2007)
also made progress in this field, firstly defining a new class of DFs, based on the
Normal cumulative distribution function. As the DFs are continuous and strictly
increasing/decreasing over their domain (R), the Pareto optimality is guaranteed,
unlike with other types of DFs. Their great flexibility and mathematical properties
allow propagating analytically the uncertainty of regression parameters and the
experimental error to D(Y ). This gave the way to define the classical prediction
intervals for D(Y ) and an indistinguishable optimal zone in the space of factors,
where one can not say it is significantly different than its optimal level. This work
has also been extended to correlated models residuals.
Two gaps are identified on these improved approaches. First, when uncertainty
is assessed, it is not based on the joint predictive distribution of y˜. For instance,
Le Bailly de Tilleghem and Govaerts (2005b) analyzed the variability of the global
desirability index prediction using the 95% classical prediction intervals. However, to
predict the behavior of individual new observations, Aitchison (1964) and Aitchison
and Dunsmore (1975) advocated the generalization of the use of tolerance intervals.
In this complex situation implying desirability functions, it is probably hopeless to
succeed in deriving such intervals. The second gap is that none of the proposed
solutions are risk-based.
In the next sections, the solution proposed by Steuer is envisaged using a more
realistic distributional assumption on the CQAs. This would allow extending the
methodology so that it is compliant with the ICH Q8 guideline and the Quality
by Design concept. In this setting, Peterson (2004) successfully illustrated the use
of the joint predictive distribution of CQAs to compute the predictive distribution
of the Derringer’s DFs and the global desirability index using Monte-Carlo simu-
lations. However, the decision on the optimal solution is based on rather artificial
specifications given on the global desirability index. Specifications are only used to
define the parameters of the DFs, as proposed by Harrington (1965) and later by
Derringer and Suich (1980).
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5.4 Monte-Carlo simulations for MCDM
When envisaging the computation of a Design Space, Monte-Carlo simulations
provide a generic framework to provide estimations of the guarantee to observe
some CQAs within specifications. The next subsections illustrate the problem with
a classical approach based on joint probabilities and with the desirability method.
The distribution of the improved global desirability index could be analytically
obtained in some cases, with or without some approximations. However, Monte-
Carlo (MC) simulations represent a great alternative as the solution is applicable in
any situations, e.g. when CQAs are some discontinuous functions of some combina-
tions of the responses.
Given that it is possible to obtain samples from the joint posterior predictive
distribution of the CQAs, MCO can be simply envisaged using MC simulations.
See Chapters 2–4 and Appendices A–C for generic and applied derivations of such
predictive distribution.
Without a desirability function
For the classical risk-based approach not relying on desirability functions, the DS
was defined as follows:
Design Space = {x˜ ∈ χ | P (Y ∈ Λ | x˜, data) ≥ pi} . (5.5)
In other words, the DS is a region of the experimental domain χ where the
posterior probability that the CQAs are within specifications Λ, is higher than a
specified quality level pi. This posterior probability includes the uncertainty of the
responses and of the parameters θ and is defined conditionally to the observed data
and prior knowledge. The expected posterior probability can be estimated through
MC simulations. If y˜(s) is a sample from (Y | x˜, data), it is:
P (Y ∈ Λ | x˜, data) ≈ 1
n∗
n∗∑
s=1
I(y˜(s) ∈ Λ), (5.6)
where I(A) is 1 if A is true, 0 otherwise; Λ is the set of specifications, e.g. {y |
λjl ≤ yj ≤ λju, j = 1, ...,m}. Provided that n∗ is high enough, this MC simulation
can provide an accurate estimate of the acceptance probability. One-sided decision
is obtained with λjl or λju set to −∞ or +∞, respectively. More information about
MC simulations can be find in Appendix B.
Figure 5.1 illustrates an example of distribution from the chromatographic world.
Two CQAs are analyzed: the chromatographic run time (Y1) and the minimal sepa-
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CQA space
Figure 5.1: Predictive distribution of the CQAs Y = (Y1, Y2) at CPPs=x˜ , with λ1
and λ2, some specifications. The proportion of blue points is the MC estimate of
the expected probability.
ration (Y2), when predicted at CPPs=x˜. A clear positive correlation was observed.
Logically, when the run time is increased, there is more room to observe an higher
separation between analytes. In blue are two one-sided specifications λ1u and λ2l.
Specifications are Λ = {y | y1 ≤ λ1u = 7, y2 ≥ λ2l = 0}. An MC simulation on
n∗ = 20000 samples drawn from the joint posterior predictive distribution of the
two CQAs was envisaged.
The proportion of blue points is the MC estimate of P ((Y1, Y2) ∈ Λ | x˜, data).
The joint predictive probability to achieve simultaneously both limits is computed
using Equation (5.6):
P ((Y1, Y2) ∈ Λ | x˜, data) ≈ 0.42. (5.7)
The marginal expected posterior probabilities were also computed for both specifica-
tions separately and were P (Y1 ≤ 7 | x˜, data) = 0.92 and P (Y2 ≥ 0 | x˜, data) = 0.49.
The joint probability is lower than the marginal ones because logically, two spec-
ifications are always harder to achieve than one, and also because the correlation
structure between the CQAs is not favorable.
Applying the MC simulations on every points of a grid created over χ would
allow recording, for every operating condition, the expected posterior probability of
achievement of the specifications. Eventually, over this grid, the operating conditions
where the probability is higher than the minimal quality level pi could be identified.
This set of operating conditions is the risk-based DS. It is also possible to make a
complete optimization of the process and to chose the optimal operating condition
x∗:
x∗ = argmax
x˜∈χ
P (Y ∈ Λ | x˜, data). (5.8)
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With desirability functions
From the predictive distribution, it is easy to transform each sample y˜(s) =
(y˜(s)1 , ..., y˜
(s)
j , ..., y˜
(s)
m ) into the desirability space using m DFs dj(y˜
(s)
j ). After, the de-
sirability indices are usually aggregated into a global desirability index D(y˜(s)) using
the classical weighted geometric mean. Thus, obtaining samples from the predictive
distribution of D(Y | x˜, data) is straightforward using Monte-Carlo simulations.
The approach presented in the next paragraphs extends the Normal error propa-
gation method of Steuer (2000) or the more convincing posterior predictive approach
of Peterson (2004). In this last reference, it has been noted that a rather artificial
specification for the global desirability index was used. It was either propose to base
the decision process on the recommendations of Harrington (1965) on the expected
(mean) global desirability index, and to identify the DS using a percent change from
optimal global desirability index. Here, it is proposed to use the real specifications
Λ that apply on the CQAs to provide a risk-based approach more similar to the one
presented in the previous section.
For the continuation of the example, the DFs of Le Bailly de Tilleghem and
Govaerts (2005a) have been chosen. Other DFs’ definitions might be used as well
without restriction. These DFs are presented in Figure 5.2.
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Figure 5.2: Desirability function of Le Bailly de Tilleghem and Govaerts (2005a). λ
is a specification used to set up the desirability functions used in maximization and
minimization problems.
.
The proposed methodology is explained for one-sided specification, as follows: for
each CQA Yj, the DF is centered on an acceptance limit λj (i.e., λjl for a CQA to
maximize and λju for a CQA to minimize). Next, the predictive distributions of the
CQAs and the specifications are rescaled to the desirability space. Suppose that Y1
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ought to be minimized and Y2 to be maximized. This gives:
d1(y˜(s)1 ) = 1− Φ(
y˜
(s)
1 − λ1
s1
) and d1(λ1) = 1− Φ(λ1 − λ1
s1
) = 0.5
d2(y˜(s)2 ) = Φ(
y˜
(s)
1 − λ2
s2
) and d2(λ2) = Φ(
λ2 − λ2
s2
) = 0.5 (5.9)
where s1 and s2 are parameters that allow changing the stiffness of the DF curves,
and Φ is the cumulative distribution function of the standard Normal variable defined
as:
Φ(x) = 1√
2pi
∫ x
−∞
exp(−t
2
2 )dt. (5.10)
Preferably, the parameters (λj, sj) should depend on the objectives, and not on
the data. For instance, Le Bailly de Tilleghem and Govaerts (2005a) proposed a
computation based on lower and upper limits of interest for the CQAs. A manual
tuning (related to the process to optimize) is also possible. In the example, λj were
defined to be the objectives (j = 1, 2). Thus, if a (mean) CQA barely achieves
its specification so that Eˆ[Yj] = λj, its desirability would be 0.5. However, sj was
set up as the standard deviation of the observation of the CQA j, which may be
non recommendable. For both CQAs, a desirability lower than 0.5 signifies a non
achievement of the specification and a desirability higher than 0.5 represents a better
achievement of quality.
Figure 5.3 continues the example of previous section. The sampled predictive
distribution of the CQAs is presented on (A). Distribution and specifications were
the same as in Figure 5.1. If the specifications are not too strict, a certain trade-
off between the CQA quality is possible and the desirability methodology may be
envisaged.
The joint distribution of (d1(y˜1), d2(y˜2)) is illustrated in Figure 5.3(B) with the
univariate specifications d1(λ1) = 0.5 and d2(λ2) = 0.5 in the desirability space
(blue). In the desirability space, every CQA has to be maximized. The red curve
and red points are explained in the next paragraphs.
Next, the global desirability index is computed using the geometric mean with
equal weights wj = 0.5. It is done both on the CQA and on their specifications :
D(y˜(s)) = d1(y˜(s)1 )0.5. d2(y˜
(s)
2 )0.5 and D(Λ) = d1(λ1)0.5. d2(λ2)0.5 (5.11)
A fitted density computed from the samples D(y˜(s)) of D(Y | x˜, data) is shown in
Figure 5.3(C). The two specifications transformed into the global desirability space
provide the univariate specification D(Λ) (red line). In this case, D(Λ) = 0.5. The
portion of the density of D(Y | x˜, data) higher than D(Λ) is also depicted in red.
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Figure 5.3: (A) : Predictive distribution of two CQAs ; (blue) samples within speci-
fications. (B) predictive distribution scaled into the desirability space ; (blue) scaled
specifications ; (red) samples with a global desirability index D(Y | x˜, data) higher
than D(Λ). (C) density of the D(Y | x˜, data) ; (red) proportion of sampled points
such that D(Y | x˜, data) ≥ D(Λ). (D) predictive distribution of the two CQAs in
their original space ; (red) points such that D(Y | x˜, data) ≥ D(Λ).
This portion is an expected probability of acceptance and may be computed via MC
simulations:
P (D(Y ) ≥ D(Λ) | x˜, data) = 1
n∗
n∗∑
s=1
I
(
D(y˜)(s) ≥ D(Λ)
)
= 0.71. (5.12)
The higher predicted probability (0.71, compared to 0.42 in the previous section)
is the result of the modification of the marginal univariate specifications into an
acceptance border that integrates the trade-off between the CQAs.
This is illustrated in Figure 5.3(B). The red line is the iso-desirability curve
corresponding to D(Λ). The global desirability index computed on each point of
this curve is the same than D(Λ). Its equation is obtained from Equation 5.11
(right), writing d(λ2) as a function of d(λ1). The red points are the samples with
a global desirability index higher than D(Λ). The proportion of red points is also
84 5. Bayesian predictive multicriteria decision method
obtained using Equation 5.12.
Finally, it is possible to retrieve the iso-desirability curve in the CQAs space, using
the inverse desirability functions (i.e. in this case, the Normal quantile functions
Φ−1). If the iso-desirability curve is represented by the set of points (d1(y∗1), d2(y∗2))
such that the global desirability index is exactly 0.5, the following set of points
(y∗1,y∗2) is the iso-desirability curve in the CQAs space:
y∗1 = λ1 + s1.Φ−1(1− d1(y∗1))
y∗2 = λ2 + s2.Φ−1(d2(y∗2))
(5.13)
The untransformed iso-desirability curve is shown on Figure 5.3(D, red), and il-
lustrates the flexibility left for the specifications. Blue points corresponded to sam-
ples fulfilling jointly the specifications, while red points now correspond to samples
providing a desirability better than D(Λ).
Finally, regarding risk-based MCO, the expected probability to have both specifi-
cations flexibly accepted can be chosen as the univariate criteria to optimize. Thus,
in this case, the optimal condition x∗ is:
x∗ = argmax
x˜∈χ
P (D(Y ) ≥ D(Λ) | x˜, data) . (5.14)
With or without desirability functions - link between both approaches
The desirability approach simply extends the approach based on joint probability.
To show how it happens, the parametrization of the desirability functions will be
changed progressively, with the stiffness parameters (sj) approaching to 0. Doing so
makes the cumulative Normal distribution a step function. This process is possible
for the other forms of DFs.
When sj tends to 0, the desirability function has a discrete form with the ordinate
that can only be 0 or 1. The impact on the iso-desirability curves is illustrated on
Figure 5.4. As previously, the DFs are kept centered on the specifications (i.e. the
“steps” of the DFs are the specifications λj). In (A), sj is as in the previous section.
In (B), it has been divided by 6. Eventually, when the stiffness parameter comes
very close to 0, as in (C), the DF tends to be a step function (in practice, sj has
been divided by 1000). The marginal desirability of a sampled point for the jth
CQA tends to 1 if it achieves the specification λj, 0 otherwise.
When each sj takes a 0 value, no trade-off is allowed any longer. Samples from
the distribution of the global desirability index will take value 0 when only one CQA
has a desirability of 0. Conversely, it will be 1 only if every CQA has desirability 1.
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Figure 5.4: Behavior of the GDI when sz tends towards 0.
Thus, the global desirability index is also discrete. Moreover, the results using this
discrete global desirability index coincide with the results obtained using Equation
(5.6), the global desirability values becoming the results of the indicator function
I() in Equation (5.6). This similarity is observed comparing the third plot of Figure
5.4 (C) with Figure 5.1).
5.5 Conclusions
In this chapter, the ways to compute the expected probability to observe a process
or an analytical method running within specifications have been explained. Such
predicted probability is at the heart of the Design Space computation.
A short review of multi-criteria decision method has been made to understand
why it is important to base the decisions on the joint posterior predictive distribution
of the Critical Quality Attributes.
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When it is possible to envisage some trade-off between the critical quality at-
tributes, desirability functions can be used as a flexible optimization tool. In this
context, the decision must also be made on the basis of the predictive distribution
of the global desirability index. Furthermore, it was shown it is possible to remain
in the risk-based framework when using desirability indices.
Finally, it was illustrated how the desirability methodology simply extends the
approach based on joint probability to be within specification.
Chapter 6
Independent component analysis
and clustering methods to track
chromatographic peaks in DoE
context
6.1 Introduction
In the context of the development of separation methods such as the high perfor-
mance liquid chromatography (HPLC), a matter of particular interest is to automate
the data treatment of chromatograms. Indeed, when envisaging the computation
of a Design Space for a separation method, or when obtaining the data for the
validation of a chromatographic method, the identification of the peaks and their
integration are generally tedious and time consuming.
This data treatment can be decomposed in two successive steps. The first step
consists in the extraction of the peaks from the noise that is observed in the chro-
matograms. This process is referred as peak picking. The second step aims at
discovering the compounds behind the identified peaks, and to track them on the
different chromatograms. This is referred as peak tracking.
When envisaging design of experiments (DoE) for chromatographic method de-
velopment, the manual peak picking and tracking can be very problematic as the
amount of collected data might be large and the order of the apparition of the
peaks (the elution order or the selectivity) changes from one chromatogram to an-
other. A classical issue is the observation of several peaks at the same time. This
phenomenon is known as coelution. All these facts make tedious the extraction of
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relevant information in complex chromatograms.
Fortunately, mathematical and statistical methodologies exist to improve knowl-
edge from large arrays of data (Vivó-Truyols and al., 2005a,b; Hu et al., 2005; de
Juan and Tauler, 2007). In the last decade, the independent component analysis
(ICA) proposed by Hyvärinen and Oja (1997) has been found powerful to separate
many types of signals. See also Hyvärinen (1999); Hyvärinen and Oja (2000); De-
lorme et al. (2007); Yamamoto et al. (2006). In analytical chemistry, the ICA even
becomed a classical tool for data analysis. Recent reviews by Wang et al. (2008)
and Parastar et al. (2011) show several applications and some limitations of the
algorithm in this field.
In the domain of chromatographic method development, the usefulness of ICA
has been demonstrated in Debrus et al. (2009, 2011b) and parts from these works
and data are used in the present chapter. When human expertise is not sufficient to
properly pick and track the peaks with diode array-detected (DAD) chromatograms,
ICA may significantly improve the knowledge about the retention times of the peaks.
It is aso able to reconstruct the UV-signatures of the compounds, useful for their
identification.
Basically, ICA has the ability to separate signals recorded by different moni-
tors, by demixing them in a number of independent sources. Considering a DAD-
chromatogram (see Figure 6.1, left), the monitors are the recorded wavelengths
obtained by the diode array detector. At each time point, a vector of information
is provided. It consists in the absorbance of the UV light projected through the
mobile phase to contains the mixture. Each change of absorbance corresponds to
exogenous phenomenon such as compounds (observed as peaks), changes of mobile
phase composition (e.g. baseline drift, dead-time perturbation), etc.
Figure 6.1: Recording of a DAD chromatogram.
6. Independent component analysis to track chromatographic peaks 89
From our previous works, ICA decomposition allowed the picking and manual
identification of peaks, based on their reconstructed UV-signature (Debrus et al.,
2009, 2011b). Nevertheless, the automated tracking of the peaks among various
chromatograms has not been addressed so far. Various methods also exist to improve
the peak matching.
Lankmayr et al. (1989) described a methodology based on fuzzy theory, that is
applied on some criteria such as the area and the elution order of the peaks. Molnar
et al. (1989) proposed tools based on the normalized band area of the peaks, allowing
the matching of peaks between different runs where the HPLC gradient steepness
is changed. See also Molnar (2002). Bogolomov and McBrien (2003) developed the
mutual peak matching (MAP) approach. It uses abstract factor analysis (AFA) and
iterative key set factor analysis (IKSFA) to detect the unknown number of peaks
in a mixture. This last methodology also aims at providing the basis to develop an
automated peak matching system. However, it is observed that these tools succeed
to match peaks only for some specific cases, but they might fail the recognition with
real or complex data.
Objectives, notations and structure of the chapter
Assume that the data consists in n DAD-chromatograms that were recorded on
the same mixture at n different chromatographic conditions. Changes in
these conditions includes modifications of selected factors such as the pH of the
buffer, the temperature, or the time to modify linearly the proportion of organic
modifier in the mobile phase from a low level to a higher level, known as gradient
time. In this context, DOE is an efficient way to plan the way the chromatographic
conditions are explored. Each DAD-chromatograms is an (m × ttot) matrix con-
taining m values of absorbance recorded over a certain time period ttot indexed as
1, ..., t, ..., ttot.
The objectives of this study are multiple. They are listed below:
• find the (assumed unknown) number of compounds in the mixture, copt,
• optimize the number of ICA sources fi used to separate the nDAD-chromatograms
(i = 1, ..., n),
• extract the copt compounds in the n DAD-chromatograms from the noise (peak
picking),
• rebuild n ICA estimated DAD-chromatograms, cleaned from the noise,
• match the peaks among the n DAD-chromatograms (peak tracking),
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• determine peaks parameters such as their elution times, their area under the
curve (AUC), etc.
A general objective finally consists in the automation of the previous objectives.
To simplify the notation, ttot must be understood as the total time of one specific
DAD-chromatogram. However, ttot is generally different from one DAD-chromatogram
to another. Similarly, when studying one DAD-chromatogram, the number of ICA
sources will be noted f .
To achieve the objectives, an innovative methodology is presented, based on clas-
sical tools of classification to cluster together the peaks corresponding to relevant
compounds. Classification criteria are based on the peak UV-signatures that are re-
constructed using ICA. Section 6.3 focuses on the ICA applied to chromatographic
data, to provide a theoretical background. Section 6.4 describes how the number of
sources fi used to unmix the n original chromatograms can be chosen. The aim is
to obtain the best results for peak picking. Section 6.5 proposes a methodology to
classify together different peaks coming from different DAD-chromatograms, solving
the problem of automated peak tracking. Additional results are discussed in Section
6.6.
6.2 Data
To illustrate the application of the methodology, an example of data is provided.
It consists in n = 17 DAD-chromatograms realized on a blinded mixture provided
by Eli Lilly & Company. In a DoE used to optimize the separation of the mixture,
the chromatographic conditions were changed. This resulted in very different DAD-
chromatograms. Data and optimization results are fully presented in Debrus et al.
(2009). Figure 6.2 (top) illustrates two DAD-chromatograms. Several peaks in
each chromatogram are observed. Some of them are very small, and their visibility
may depend on the particular wavelength of observation (bottom chromatograms
are observed at 240 nm). Furthermore, some peaks are mixtures of two (or more)
peaks. Mixed signals are typical in DoE context, leading to a complex identification
of the compounds and of their attributes (e.g. time of beginning, apex and end of
the peaks, UV-signatures, etc.).
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Figure 6.2: (top) Examples of DAD-chromatograms recorded at pH 2.6, gradient
time 10 min (left), and pH 10, gradient time 20 min (right). (bottom) Chro-
matograms extracted at wavelength 240 nm. (left, insert) UV-signature of the peak
observed at 19.75 min. (right, insert) UV-signature of the peak observed at 12.5
min. This spectrum is a mixture of the signatures of two coeluted compounds.
6.3 Sources extraction
6.3.1 Independent Component Analysis
ICA is a non supervised technique that is applicable to blind source separation
problems. Different definitions can be given for ICA. Hereafter is presented the
noise-free ICA, developed by Hyvärinen and Oja (1997).
The ICA of an (m× ttot) matrix X of m signals observed at ttot different times,
(x1, ...,xm)′, consists of estimating the following generative model for the data:
X = AS (6.1)
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where A is a constant (m× f) mixing matrix. f is the main parameter of ICA and
requires fine tuning (f ≤ m). S = (s1, ..., sf )′ is a (f × ttot) matrix containing the f
independent sources of the signals. Both A and S must be estimated.
Before applying ICA, a preprocessing step is applied. It consists in centering
and whitening the data. The concept of whitening is to transform the matrix X
such that its lines are uncorrelated and unit variance. These two transformations
provide a matrix Xw of dimension (m× ttot). A principal component analysis (PCA)
is common to carry out this task. This can also allow for a first dimension reduction
by selecting only the f most informative components.
Other possible pretreatments of the DAD-chromatograms can be envisaged be-
fore applying ICA. On one hand, useless data points can be removed, such as the
beginning and the end of the chromatograms, if no peak is observed. On the other
hand, some smoothing using low-pass filter can be done, using e.g. the algorithm
of Savitzky and Golay (1964). This filter is particularly good at preserving origi-
nal chromatographic shape while removing noise with high frequencies (R package
signal, Short, 2011).
To accomplish the blind source separation, the ICA algorithm iteratively esti-
mates an unmixing matrix Aˆ′−1w from Xw, in such way that the lines of Sˆw are as
statistically independent as possible. On the basis of Aˆ′−1w , the independent sources
are estimated as follows.
Sˆw = Aˆ
′−1
w Xw (6.2)
A consequence of the preprocessing step with PCA is that ICA works on or-
thogonal and standardized data. However, most algorithms are able to retrieve the
matrices Aˆ−1 and Sˆ in their original scale, from Aˆ−1w and Sˆw. To apply the ICA,
the package fastICA for R has been used (Marchini et al., 2010). The algorithm
is based on the fact that a way to find independent sources is to search for an un-
mixing matrix Aˆ−1w that maximizes the non-gaussianity of the sources, as proposed
by Hyvärinen and Oja (1997). Finally, notice that the pseudo-inverse of Aˆ−1w is
computed to retrieve Aˆw.
Mixing
matrix
Source
matrix
Reconstructed
DAD signal
Figure 6.3: Illustration of the signal reconstruction after ICA.
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After estimating the independent sources and their mixing process, it is possible
to reconstruct the complete original data (assuming f = m), as illustrated on Figure
6.3. Furthermore, the gth component Xˆg of size (m × ttot) is defined as the matrix
product between the gth column of Aˆ and the gth line of Sˆ:
Aˆ,gSˆg, = Xˆg and
f∑
g=1
Xˆg = AˆSˆ = Xˆ. (6.3)
At this stage, a selection can be done on the f estimated components. It is possible
to discard the components containing noise (Bugli, 2006) or irrelevant artifacts from
the summation. In this way, a cleaned version of Xˆ can be obtained.
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Figure 6.4: Components computed by ICA with f = 16, plotted at the wavelength
of 240nm. Components 1–5, 7, 8, 10–13 are visually identified as peaks. Other
components correspond to noise or irrelevant artifacts.
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To illustrate the source separation, ICA was applied on a DAD-chromatogram
from the data set (presented in Figure 6.2, left). On this example, f was manually
tuned and a value of f = 16 was chosen. Figure 6.4 illustrates the estimated
components Xˆg,240nm, observed at 240nm (i.e., each graph shows one line of each
Xˆg, g = 1, ..., f). Unlike the results that can be obtained with PCA, the components
are unordered. However, the ten components indexed as 1–5, 7, 8, 10–13 can be
visually identified as chromatographic peaks. The other components seem to contain
noise and non-relevant artifacts such as baseline drift (component 14). A possible
way to manually assess the relevance of a component is to look at the scale (y-axis)
of the plots.
Obviously, this process is non systematic and is subject to error of judgement.
Furthermore, nothing indicates that the value of f = 16 is optimal and will be a good
candidate for the other DAD-chromatograms under study. In the same way, there is
low assurance that copt = 10 compounds are effectively present in the mixture. A last
issue consists in the application of ICA for each of the n DAD-chromatograms, with
the tedious and time-consuming selection of the appropriate number of sources fi
(i = 1, ...n), and followed by the manual peak picking. A methodology to automate
this process is desirable and is the subject of the next section.
Finally, Figure 6.5 shows the corresponding chromatogram (observed at 240nm)
that was reconstructed using only the ten selected components following Equation
(6.3). The vertical grey lines show the result of the peak picking and are placed
at the elution times of the apexes of the peaks that were identified in the 10 se-
lected components. As the original data observed at 240nm did not show significant
baseline drift or noise, the reconstructed DAD-chromatogram observed at the same
wavelength is very similar to the one presented in Figure 6.2, left (bottom).
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Figure 6.5: Chromatogram reconstructed with the ten selected components and
observed at 240nm. (Grey) results of the peak picking.
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6.4 Automated selection of relevant sources
This section details an automated methodology to optimize the number of sources
fi used to separate the n DAD-chromatograms (i = 1, ..., n), and to identify the
unknown number of compounds copt in the mixture. The general idea is to de-
rive some characteristics of the ICA components, computed on each of the DAD-
chromatograms separately. These characteristics are then used to differentiate the
peaks from noise and irrelevant artifacts. Next, the results obtained for all the
DAD-chromatograms are analyzed concurrently to identify the optimal fi and copt.
6.4.1 k-means algorithm to identify sources containing rel-
evant information
Assuming that noise follows a Normal distribution (Gaussian white noise), the in-
dependent components given by ICA are investigated in order to find which one may
be considered as relevant or contains only noise. It has been discussed that the kur-
tosis or other high-order statistics of a distribution are good criteria to characterize
artifacts and noise (see McKeown et al., 1998; Delorme et al., 2007).
Thus, different statistics or moments can be used to check the normality of the
distribution of each source. If normality is not observed, it should imply that the
component is unlikely to be noise and therefore likely corresponds to an exogenous
phenomenon such as a compound present in the mixture. In summary, (lines of the)
components of interest are assumed to have a non-normal distribution, and will be
identified as peaks or other relevant artifacts. The following statistics were found
useful for this purpose : the kurtosis and the Shapiro-Wilks statistics
Kurtosis
The kurtosis is the fourth standardized moment of a random variable and is a
measurement of the peakedness (or the flattening) of the distribution of this vari-
able. It may be estimated on the components at a particular wavelength or simply
on the sources provided by ICA. When computed on the gth source of one DAD-
chromatogram, it is defined as:
Kˆg =
mˆg,4
mˆ2g,2
− 3 =
1
ttot
ttot∑
t=1
(Sg,t − S¯g)4(
1
ttot
ttot∑
t=1
(Sg,t − S¯g)2
)2 − 3. (6.4)
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mˆgk represents the estimated moment of order k (about the mean) for source g, and
S¯g is the mean of source g. The kurtosis of the Normal distribution is zero. Lets
also define Kˆi,fi , the vector of fi estimated kurtosis for the DAD-chromatogram i.
Shapiro–Wilk statistic
The non-parametric Shapiro–Wilk (S–W) test examines the null hypothesis that
a sample Sg,1, ..., Sg,t, ..., Sg,ttot comes from a Normally distributed population. This
hypothesis is rejected if the test statistic is too small. This test statistic can be
used to characterize the distribution (or equivalently, the associated p-value). More
details about this test can be found in Shapiro and Wilk (1965). S-W statistics
can be computed on the components or on the corresponding sources as well. It
is carried out on the sources for this application. Lets define ŜWi,fi , the vector
containing the fi S-W statistics computed on the DAD-chromatogram i.
Kurtosis and S–W statistics can then be used to describe the degree of nor-
mality of a distribution and, hence, to identify sources containing noise. However,
these are not the only possible criteria and other simple or complex statistics can
also be used in this context, such as skewness of the distribution of the source,
Kolmogorov–Smirnov Normality test, etc. Simple decision based on peak’s height,
range and variance of the source, area under the curve, etc. are also possible. It can
allows discarding some identified peaks that are smaller than a certain threshold.
k-means clustering
The objective is to use the characteristics of the sources (or components) to
discriminate relevant and irrelevant artifacts. k-means is a non-supervised method
to cluster objects into k partitions on the basis of their attributes. For the DAD-
chromatogram i, the objects are the fi sources computed by ICA and the attributes
are the estimated statistics computed on these sources, namely the kurtosis and
Shapiro–Wilk statistic.
Before applying clustering, attributes are divided by their standard deviation
computed from the fi sources in order to give each attribute the same weight in the
clustering decision process.
k-means works by comparing the Euclidian distance between the objects. A short
distance (slight difference in the computed attributes) is a sign of closeness between
objects. The closest objects are put together in the same cluster. Different imple-
mentations exist for k-means clustering. The Hartigan and Wong (1979) algorithm
was used here (R package stats, R Development Core Team, 2010).
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As the purpose is to separate the sources between two classes (relevant or noisy),
k-means is set up with k = 2. The ideal situation arises when the clusters are as
follows: the first with sources having a high Kurtosis and low S–W values, corre-
sponding to the relevant cluster (cr), and the second with low Kurtosis and high
S–W value, corresponding to noise and irrelevant artifacts. The outcome of the
k-means clustering algorithm may vary from one run to another because the k cen-
ters are randomly placed at the start of the algorithm. To avoid this dependency
to initial conditions, it is a good practice to run the algorithm one hundred times.
This is done for each of the n DAD-chromatograms, while changing initial values.
For each DAD-chromatogram i, the clusters occurring with the highest frequency
are selected.
Figure 6.6 (top) illustrates the results of the k-means algorithm applied on the
chromatogram presented in Figure 6.2 (left), on the 16 sources computed by ICA.
The cluster identified by the red cross contains the relevant artifacts. On the bottom,
the apexes of the peaks in the sources identified as relevant are juxtaposed (sources
1–5, 7, 8, 10–13, grey lines) with the original chromatogram. The corresponding
source numbers are given in red. The coelution between the peaks present in sources
13 and 5, and sources 2 and 4 have been resolved. Small peaks were also properly
picked, such as the one observed in source 3. Notably, these automated results are
the same than the one obtained previously with manual peak picking.
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Figure 6.6: Results of k-means clustering. (top) Ten sources are clustered together
as relevant artifacts (red). (bottom) Original chromatogram with the automatically
identified apexes (grey lines).
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6.4.2 Number of sources to identify the unknown number
of peaks
In this section, the automated optimization of the number of sources fi and
automated identification of the unknown number of compounds copt are detailed,
using the results of the k-means algorithm. The idea is to run ICA on the n
DAD-chromatograms several times, while slowly increasing fi until finding some
convergency in the identified number of peaks. The treatment is the following :
1. Set fi to a low value (e.g. fi = 3)
2. For i = 1, ..., n
- Compute ICA on the DAD-chromatogram i, with fi sources
- Compute the Kurtosis and S-W statistics of the fi sources
- Apply k-means algorithm on the Kurtosis and S–W cloud of points
- Record cr(i, fi), the number of sources found in the relevant cluster
End
3. Define c∗r(fi), the mode of the cr(i, fi) distribution (for i = 1, ..., n), corresponding
to the most probable number of compounds in the mixture, for a given fi
4. fi <– fi + 1
5. Repeat steps 2–4 until c∗r(fi) stabilizes
6. If c∗r(fi) is stabilized, define f∗ = fi.
Thus, cr(i, fi) is assumed to be the number of detected peak for the DAD-
chromatogram i, for a given fi. As previously stated, the same mixture is injected
several times using different analytical conditions. Thus, each DAD-chromatogram
should contain the same information, i.e., the same number of relevant peaks. The
algorithm makes clear that finding an optimal value for fi is thus similar to identi-
fying the most plausible number of sources counted in the relevant clusters for all
DAD-chromatograms. The number of iterations to declare that c∗r(fi) is stabilized
is still subject to subjectivity. In our various applications of the algorithm, adding
10 iterations after the first stable value was generally sufficient. Lets define fmax,
the maximum number of sources used for ICA.
Figure 6.7 illustrates the process on the complete set of data. The value of c∗r(fi),
computed from the n = 17 chromatograms, is plotted against fi, ranging from 3 to
25. A stabilization of c∗r(fi) to a value of 10 is observed when fi = 16,∀i. It allowed
defining copt = 10, the number of relevant sources present in the mixture.
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Figure 6.7: Optimization of f . Plot of the variation of c∗r(f) versus f .
Unfortunately, when fixing f ∗, it is unlikely that the number of sources identified
as relevant will be copt for every chromatogram. A solution is to use the recorded
cr(i, fi) to identify a value of fi that can be used to obtain copt relevant sources for
the chromatogram i (i = 1, ..., n; fi = 3, ..., fmax)1.
For chromatograms where it is not possible to find copt sources for any fi, another
option is to use a ranking provided by the Kurtosis/S-W ratio and to chose the copt
sources that have the highest ratio, keeping fi = f ∗. If the problem occurs for the
DAD-chromatogram i, the ranking is then provided as the order of the following
values: Kˆi,f∗/ŜWi,f∗ .
For the chromatogram of Figure 6.2 (left) decomposed in f ∗ = 16 sources as in
Figure 6.4, the ranking was the following:
Kurtosis/S-W 26.6 22.7 21.9 21.9 21.8 20.0 19.8 19.4 13.9 4.7 0.4 0.0 0.0 0.0 0.0 0.0
Source Index 8 2 13 7 12 11 5 4 3 1 14 10 9 16 15 6
For this example, the peak picking results were then unchanged when identifying
the first copt sources with the highest ratio as relevant (copt=10).
After a comparison of the automated treatment and data that were treated man-
ually, every peak of interest seemed to be automatically found among the 17 chro-
matograms, except one. Among the 17*10-1 = 169 sources identified as relevant, one
source contained a baseline drift and 16 other sources contained artifacts around one
compound (see sources 6 and 10 of Figure 6.6 (bottom)). In Debrus et al. (2009),
these artifacts were deleted before further analysis, leading to a solution where 9
compounds were found in each chromatogram. For the next steps of this study, all
the 169 relevant artifacts were intentionally kept to study how the automated peak
1To avoid non-deterministic execution of ICA, the random number generator seed must be fixed.
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tracking can help to detect problems.
6.5 Peak tracking - classification
In the previous section, stot = 169 ICA sources and corresponding components
were identified as relevant in the DAD-chromatograms of the experimental plan.
The aim of this section is to develop a methodology to match which peak in one
chromatogram corresponds to the same peak in the others. The stot reconstructed
UV-signatures (i.e. one column of each independent components) are used to assess
the similarity between peaks among the DAD-chromatograms.
To solve this problem, agglomerative clustering is proposed to create sets of ob-
jects (the components), that aims at finding groups that are the most homogeneous
with regard to some predefined criteria computed on the UV-signatures recovered
by ICA. A conventional and efficient method to find these sets is the hierarchical
clustering algorithm developed by Ward (1963). The idea is to build a dendrogram
representing a sequence of partitions, from the leaves (where stot clusters contain
the components of every chromatogram), to the trunk (where 1 cluster contains stot
components). At each iteration of the procedure, one cluster is nested within an-
other based on a symmetrical (stot×stot) dissimilarity (or distance) matrix computed
from attributes of the objects.
Usually, an Euclidian distance matrix is provided to the Ward’s algorithm to
avoid local optima (and to preserve the interpretation of distance throughout the
algorithm). However, it is possible to extend the application of the algorithm using
dissimilarity matrices, although the strict order of “distances” among clusters will
not be preserved (Duda et al., 2001). This is not a problem as these dissimilarities
are not used as a metric for further analysis and the local optima generally does not
prevent the algorithm to finish. The next section details how to compute several
dissimilarity matrices that can be combined together to obtained the desired peak
matching.
6.5.1 Distances and dissimilarities between objects
For each (m × ttot) component Xˆs, (s = 1, ..., stot) identified as relevant in the
complete set of DAD-chromatograms, the lines are vectors containing an unmixed
signal of a chromatogram, observed at specific wavelengths. Remember that this
information was used to identify the components/sources as relevant or noisy. On
the other hand, the columns of the Xˆs are assumed to be the reconstructed UV-
signature of a compound. It is further assumed that two components that have the
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same UV-signature represent the same compound. Hence, they should be grouped
together. Usually, the elution time of the compounds does not influence the UV-
signature.
Lets define u(s), the column of Xˆs that contains the UV-signature of the com-
ponent s, observed at the time of the apex (maximum over the time) of the peak.
Below are listed some interesting distances or dissimilarities that can be computed
between two UV-signature vectors u(s1) and u(s2) (s1, s2 = 1, ..., stot).
Euclidean distance
The distance between the two points defined by the vectors u(s1) and u(s2) in the
m-dimensional Euclidean space is defined as:
dE(s1, s2) =
√√√√ m∑
j=1
(u(s1)j − u(s2)j )2. (6.5)
The Euclidean distance between identical spectra is then 0.
Cosine of the angle between vectors
A classical method used to compare two vectors is the cosine of the angle formed
between them in the m-dimensional space. It is computed as follow:
cosφ(s1, s2) =
m∑
j=1
(u(s1)j .u
(s2)
j )√√√√ m∑
j=1
(u(s1)j )2.
m∑
j=1
(u(s2)j )2
. (6.6)
When u(s1) and u(s2) are similar, the angle between them is equal to 0. cosφ(s1, s2)
is then equals to 1. − | cosφ(s1, s2) | can be chosen as a distance between the two
vectors.
Correlation coefficient
The cloud of points created by plotting one UV-signature vector against one
other will lay on a straight line if the vectors are similar. In this case the correlation
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coefficient is about 1. The Pearson correlation is computed as:
r(s1, s2) =
m∑
j=1
(
u
(s1)
j − u¯(s1)
) (
u
(s2)
j − u¯(s2)
)
(m− 1)su(s1)su(s2)
, (6.7)
where u¯(s) and su(s) are the estimated mean and standard deviation of u(s), respec-
tively. − | r(s1, s2) | can be chosen as a distance between the two vectors.
Mutual information
In information theory, the mutual information quantifies the mutual dependence
between two random variables. It is then a measure of the information shared by
u(s1) and u(s2). It can be defined as:
MI(s1, s2) =
∫
u(s1)
∫
u(s2)
p(u(s1),u(s2)) log
(
p(u(s1),u(s2))
p(u(s1)) p(u(s2))
)
du(s1) du(s2), (6.8)
where p(x, y) is the joint density function of x and y, and p(x) and p(y) are the
marginal density functions of x and y. If u(s1) and u(s2) are independent (dissimilar),
MI(s1, s2) = 0. Specialized packages can compute the mutual information efficiently
(e.g. R package minet, Meyer et al., 2008).
Length of correlation line
An innovative yet simple criterion is the length of the correlation line that is
created by plotting one UV-signature vector against another one. The idea is then
related to the correlation coefficient. This dissimilarity is computed as follows:
dcl(s1, s2) =
m−1∑
j=1
√
(u(s1)j+1 − u(s1)j )2 + (u(s2)j+1 − u(s2)j )2 (6.9)
This criterion makes a better use of the particular shape of the UV-signatures
and is not too sensitive to their scales. It has been created to attempt to solve the
fact that other criteria generally attribute too high similarities between vectors that
are obviously different (e.g. it is too “easy” to obtain a correlation coefficient of
0.99).
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Other criteria
It is difficult to be exhaustive in the definition of interesting criteria to quantify
the closeness of agreement between UV-signatures. Among others, the difference
between area under the curve (AUC) of two peaks, or the difference between the
values of absorbance at apex (i.e. peak’s height) for a specific wavelength, are at-
tractive criteria if the injected solution keep identical the quantities of compounds.
However, this might not be the case during validation experiments where the con-
centrations of compounds are generally changed. This results in changes of peak’s
AUC and height.
Usually, once a HPLC method is well developed so that all the compounds are
separated, there is no reason to modify the input parameters. In this case, the times
at which the peaks are observed will not change (except a small natural noise),
and a last relevant criterion can be derived from the time of apexes of each peak
observed in the relevant components. The elution order would also be an appealing
criterion in this case. See Chapter 10 for an application of such criteria in a method
validation context.
6.5.2 Artificial penalty distance
To avoid the possibility to match together several components coming from the
same chromatogram, a special artificial distance is given between these objects. It
is simply defined as:
if u(s1) and u(s2) ∈ ith DAD-chromatogram : dart(s1, s2) = c, i = 1, ..., n,
else : dart(s1, s2) = 1, (6.10)
where c is a large number (e.g. 100).
To create an appropriate dissimilarity matrix for the Ward’s algorithm, the
penalty distance is combined with one or several other distance matrices using a
matrix sum or a matrix dot product.
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6.5.3 Example
Further data treatments
It is known that the pH or changes of organic modifier may have an impact on
DAD-chromatogram for the lowest wavelengths around 220nm. The UV-signatures
of the compounds are affected by these changes. Unfortunately, the ICA is generally
not able to perfectly remove these disturbance. To avoid problem when tracking the
peaks, a good practice is to remove low wavelengths when computing the dissimi-
larities, i.e. cutting in the matrices of components. Hereafter, the data from 210 to
240 nm were removed. Notice this preprocessing can also be done before applying
ICA.
Clustering
The application of the agglomerative clustering is carried out on the stot = 169
relevant components found after ICA. In this example, the following dissimilarity
matrix D was used, combining the artificial penalty distance and the length of the
correlation line–distance with a sum:
D ≡ {ds1,s2} = dart(s1, s2) + dcl(s1, s2).
The corresponding dendrogram obtained with Ward’s algorithm is presented in Fig-
ure 6.8. The leaves of the tree are the components (characterized by their UV-
signature) while the branch represents the merging of the components into clusters.
A low grouping height stands for similar components (peaks) while higher heights
identify dissimilar components.
In order to terminate the tracking of peaks, the cutting height of the dendro-
gram must be chosen. As copt = 10 relevant components were found in each chro-
matogram, it would be logical to cut the dendrogram at a height where 10 clusters
are found.
However, in this example, it was decided to cut it at a height where only 9 clusters
are found. Indeed, Figure 6.8 suggests that the components grouped in the cluster
3 share some similarities, although the artificial penalty distance should put away
the components belonging to the same DAD-chromatogram. The UV-signatures
were then assumed similar for these compounds. As explained, the reason is that
cluster 3 corresponds to a compound that was erroneously split in two sources by
ICA in most (15 out of 17) chromatograms. The reasons of this poor results are
unidentified. An option to overcome this problem is to sum the components found
in the same cluster and belonging to the same chromatogram. This would simply
reconstruct the peak that was split.
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Figure 6.8: Dendrogram of the matching of peaks. The leaves are the objects (the
components). Red rectangles are the clusters. Group 3 is bigger than the others as
it contains the information of an ICA-duplicated peak.
Figure 6.9 (A-D) shows the UV-signatures of the compounds placed in the clus-
ters 1, 3, 6 and 8, respectively. From the n =17 chromatograms, 17 components were
properly classified in the cluster 1 (A), in spite of the clear perturbations observed
at wavelengths 210-250 nm (note these wavelength were removed prior to computa-
tions). As explained, it was due to the pH changes across the experiments. Next,
cluster 3 (B) contains the components of the peak (naproxen) that has been split by
ICA. Fortunately, the matching allowed easily retrieving all the sources. Among the
33 components present in this cluster, one also corresponded to a wrongly matched
peak (box). Next, 17 components were properly classified in cluster 6 (C). Finally,
Clusters 8 (D) contained only 16 components. The missing peak was not picked as
a relevant component after the ICA. This peak could be easily retrieved manually.
All the other clusters tracked perfectly the peaks except cluster 9 where one
supplementary component was found. Based on the UV-signature, it was easy to
identify it as a solvent artifact.
Finally, the compounds composing the unknown mixture were revealed and ana-
lytical expertise was used to match the real compound names and the clusters. Table
6.1 shows the correspondence between the cluster numbers and the real names of the
compounds. The compounds that was erroneously split by ICA was the Naproxen.
No other compound had a similar UV-signature.
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Figure 6.9: Example of matching of peaks based on the UV-signature of the ICA-
reconstructed components. x-axis: wavelength; y-axis: absorbance. (A) cluster 1;
(B) cluster 3; (C) cluster 6; (D) cluster 8.
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Cluster number Compound
1 Retinoic acid
2 Warfarin
3 Naproxen
4 Atenolol
5 Pindolol
6 Indoprofen
7 Impurity of retinoic acid
8 Unknown impurity
9 Propanolol
Table 6.1: Correspondence between cluster numbers and real compounds.
6.6 Additional results: accurate recording of re-
tention times and other attributes
When peaks are severely coeluted, the manual recording of their time attributes
is often intricate. The statistical models created to optimize and find Design Space
of chromatographic method rely on these times and an accurate determination is
mandatory. In several of our applications including the ones presented in the two
next chapters, the models and their predictions were found better with the data
processed by ICA.
Figure 6.10 compares the recording process on the first peak at 12 min. in Figure
6.2 (left) and on the chromatogram decomposed by ICA. Actual chromatographic
management softwares generally proceed as follow when a coelution is detected: the
retention times of the apexes (A1,A2) of the peaks are accurately recorded (top)
but the times of beginning and end of the peaks are not. Generally, these times
are assumed similar for peak 1 and 2. Thus, they are recorded here as B12 and
E12. Thus, they are recorded as if they were part of only one peak. Sometimes, if
a valley is visible between the peaks, the time of this valley could be taken for the
end of the first peak (E1) and the beginning of the second (B2). The problem of
such practice is that the separation (Scrit = B2 − E1) computed from these times
will be 0, although peaks are not separated. Furthermore, other information such
as the area under the curve (AUC) of both peaks is simply not computable.
The solution provided by ICA is definitively better as it allows recording prop-
erly the retention times (bottom). As the peaks are numerically separated (atenolol
(blue), warfarin (red)), one can work on the components to easily identify the be-
ginning, apex and end of each peak.
Finally, it is noted that ICA may results in a slight change of the shape of the
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Figure 6.10: Example of recording of retention times (observed at 240 nm). (top) In-
accurate manual recording made on the raw chromatogram. (bottom) Improvement
of the recording after ICA decomposition of the chromatogram. Black thick line:
original chromatogram; blue: ICA-reconstructed peak corresponding to atenolol
(peak 1); red: ICA-reconstructed peak corresponding to warfarin (peak 2).
sources corresponding to coeluted compounds. Indeed, in Figure 6.10 (bottom) the
negative absorbance at the extremities of the peaks is not present in the real signals
and is due to a perfectible unmixing. This has fortunately little importance on the
better identification of the retention times, but could be more or less problematic
when computing an AUC (see Chapter 10).
6.7 Conclusions
The automated peak picking is a very crucial step in the automated development
of analytical methods. A new and original approach combining ICA, high-order
statistics and clustering methodologies was successfully used for the data treatment
of a real and blinded test mixture of pharmaceutical compounds in the framework of
a DOEmethodology. The present approach can also be envisaged in high throughput
screening experiments consisting in the analysis of complex matrices with numerous
and unknown compounds, which is often problematic. Moreover, it does not require
expensive equipment to detect the compounds, such as a mass spectrometer, as long
as the compounds absorb in the UV and have different UV-signatures.
The first clustering method allows the efficient separation of the noise compo-
6. Independent component analysis to track chromatographic peaks 109
nents from the relevant ones, using adequate summary statistics. The technique to
find an optimal number of sources is very convenient although time consuming. For-
tunately, the time needed for the numerical data treatments is much smaller than
the mixture analysis time. Therefore, this gives the opportunity to easily imple-
ment the numerical data treatments in a semi-concurrent mode, i.e. just after each
chromatogram recording.
On the other hand, this process can also be performed only on sub-parts of a
complex DAD-chromatogram. For instance, searching for coeluted impurities only
around peaks of interest would allow for a significant reduction in the time devoted
to the computational process. ICA can also be used as a simple noise removal
algorithm. Rebuilding the DAD-chromatogram using only the relevant components
allows the improvement of the signal-to-noise ratio and the cleaning of artifacts such
as the baseline drift.
Finally, a strategy was proposed to automatically identify the peaks in unknown
mixtures (peak tracking), solely based on the ICA rebuilt UV-signature of the com-
pounds. Again, clustering methodologies carried out on some similarities/dissimilar-
ities were found helpful to automatically and accurately group together the similar
peaks.
Eventually, the combination of the original aforesaid strategies described in this
chapter provides a powerful tool and opens new perspective for the automated de-
velopment of LC–UV-DAD methods. Chromatographic management softwares and
analysts would definitely improve their skills and capacities using such methodology,
even in using this methodology in a semi-automatic way.
The only restriction to use this methodology is the following: the different com-
pounds must have different UV-signatures to allow the tracking to work properly.
Improvement can be obtained if a low number of UV-signatures are identical (e.g.
enantiomeric compounds). This requires a different post-processing of the compo-
nents that contains two or several peaks.

Part II
Applications
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Chapter 7
Generic optimization of
chromatographic methods to
separate anti-paludic drugs
Parts of this chapter have been issued as an original publication by Debrus,
Lebrun et al. (2011c). This chapter introduces the chromatographic method devel-
opment with simple statistical models to illustrate the main concepts.
7.1 Introduction
Malaria remains one of the most extended illnesses worldwide. According to the
World Health Organization (2010), almost 3.3 billion peoples scattered across hun-
dreds of countries (mostly in the inter-tropical belt) are at risk of various species of
plasmodium. Despite numerous active antimalarial molecules, several reasons are
behind malaria resurgence. First, over past decades, the improper use of antimalar-
ial drugs contributed to widen resistance against malaria parasite to several drugs
(see Laufer and Plowe, 2004; Cowman and Foote, 1990). Nevertheless, artemisinin-
based combination therapies (ACT) bring new hopes in the fight against malaria
(Mutabingwa, 2005; Obonyo et al., 2007; Valecha et al., 2009; Singh et al., 2011).
The second reason is the counterfeit of medecines. Marini et al. (2010a) observed
that, in some African countries, up to 80% of medical products are counterfeit. In
this context, analytical chemistry and especially chromatographic methods can help
to fight this problem.
Screening analytical methods are usually used for several purposes. They can be
used to confirm if a targeted active antimalarial ingredient (AAI) is present or ab-
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Compounds pKa logP
Most acidic Most Basic
Amodiaquine 9.43±0.50 5.62±0.50 3.126±0.840
Arteether NA NA 3.330±0.864
Artemether NA NA 2.820±0.864
Artemisinin NA NA 2.269±0.680
Artesunate 4.28±0.17 NA 3.291±0.883
Atovaquone 5.01±0.10 NA 6.465±0.729
Chloroquine NA 10.47±0.25 4.412±0.758
Cinchonine 12.98±0.20 9.33±0.70 2.788±0.415
Dihydroartemisinin 12.61±0.70 NA 2.190±0.859
Halofantrine 13.57±0.20 9.44±0.50 8.902±1.302
Lumefantrine 13.44±0.20 8.71±0.50 8.671±0.405
Mefloquine 12.81±0.20 9.24±0.10 2.197±1.149
Piperaquine NA 8.92±0.50 6.796±1.413
Primaquine NA 10.38±0.10 2.740±0.255
Proguanil NA 11.15±0.10 2.485±0.263
Pyrimethamine NA 7.18±0.10 2.750±0.328
Quinine 12.80±0.20 9.28±0.70 2.823±0.431
Sulfadoxine 6.16±0.50 2.18±0.10 0.460±0.419
Sulfalene 6.61±0.40 1.46±0.10 0.880±0.456
Table 7.1: Pka and logP (at 25 °C) found on SciFinder®, calculated using Advanced
Chemistry Development (ACD/Labs©) Software V11.02.
sent in a pharmaceutical formulation and to settle if an unappointed AAI is present
or absent in this formulation. In this perspective, a screening HPLC method could
be very helpful justifying the development of a generic method for the follow-up
of the various antimalarial drugs available on the market. The proposed HPLC-
UV method was thus developed for the screening of 19 active antimalarial ingre-
dients (AAI)s: amodiaquine (AQ), arteether (AE), artemether (AM), artemisinin
(ART), artesunate (AS), atovaquone (AT), chloroquine (CQ), cinchonine (CC), di-
hydroartemisinin (DHA), halofantrine (HF), lumefantrine (LF), mefloquine (MQ),
piperaquine (PPQ), primaquine (PQ), proguanil (PG), pyrimethamine (PM), qui-
nine (QN), sulfadoxine (SD) and sulfalene (SL). Chemical structures are presented
on Figure 7.1. Calculated pKa and logP are given in Table 7.1.
Nowadays, HPLC method development can be achieved using different method-
ologies. Some have already led to some commercial softwares (e.g. Drylab, ACD/LC
simulator, Chromsword, Osiris). These softwares make use of chromatography-based
theory such as solvophobic theory, linear solvent strength relationship, etc., to opti-
mize the separation of sample mixtures while maintaining the number of test exper-
iments to a minimum. See Horváth et al. (1976); Carr et al. (1993); Nagrath et al.
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Figure 7.1: Chemical structures of the 19 studied antimalarial drugs.
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(2011); Snyder et al. (1979, 1989); Nikitas and Pappa-Louisi (2009); Vivó-Truyols
et al. (2003). These strategies are generally fast and efficient. Nevertheless, in the
current trend of Quality by Design (QbD), these softwares do not provide the ability
to advisedly compute or estimate the robustness, also sometimes called ruggedness
in some regulatory documents. Consequently, Dejaegher and Vander Heyden (2007),
Ragonese et al. (2000) and Hund et al. (2000) proposed classical robustness tests
that have to be carried out at the end of the method validation phase to estimate the
method ability to remain unaffected by small, but deliberate variations in method
parameters.
In the present work, a distinct and innovative methodology combining design
of experiments (DoE), Independent Component Analysis (ICA) and ICH Q8 (2009)
Design Space (DS) was used to simultaneously optimize the separation and estimate
the method robustness over the whole experimental domain instead of around the
optima only. In the ICH pharmaceutical development guidelines Q8(R2), the DS
is defined as “the multidimensional combination and interaction of input variables
(e.g., material attributes) and process parameters that have been demonstrated to
provide assurance of quality”. Therefore, the multidimensional combination and in-
teraction of input variable should correspond to a subspace, the DS, where assurance
of quality has been proved. Thus, the DS is necessarily encompassed within the ex-
perimental domain which is the multidimensional space formed by the factor ranges
used during method development. The main concepts lying behind the ICH Q8(R2)
definition of DS are assurance of quality and quality risk management. Hence, a
HPLC method development process which do not take into account the errors from
the process, measurements and models in order to manage the risk cannot be con-
sidered as QbD compliant and will not allow the identification or computation of
the DS.
Even if ICH Q8 is the most appropriated guideline when discussing about QbD
and DS applied to pharmaceutical sciences, the given DS definition and the examples
shown in the Appendices of the document are divergent. From previous explanation,
the identification of the multidimensional zone where a (mean) predicted Critical
Quality Attribute (CQA) is within its specification does not define the DS which
have to provide assurance of quality. In other terms, in LC, to predict the multidi-
mensional region where the mean predicted resolution is acceptable (e.g. Rs ≥ 1.5),
does not define a DS as only quality is predicted but not assurance of quality. In-
deed, the risk assessment of not being within the specifications is not carried out.
On the other hand, using the posterior probability for a given or several CQA(s)
to be in specifications is a better way to define DS (e.g. P (Rs ≥ 1.5 | data)).
When computing such a probability, the quality risk management is carried out.
Interesting discussions about QbD and DS applied in LC and in pharmaceutical
development were already published in the scientific literature. See for instance the
works of Peterson (2004); Peterson et al. (2009); Peterson (2008); Stockdale and
Cheng (2009)). Some DoE-DS LC applications were also previously published by
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Lebrun et al. (2008); De Backer et al. (2009); Krier et al. (2011); Debrus et al.
(2011b).
The determination of the DS for a LC method development implies to consider the
error on the studied responses and CQAs in a predictive framework. The variability
of the retention times have to be taken into account during the development phase.
These considerations hold completely with the QbD definition. Furthermore, ICH
Q8 guideline states that “working within the Design Space is not considered as a
change. Movement out of the Design Space is considered to be a change and would
normally initiate a regulatory post approval change process”. Consequently, the DS
should define a zone of robustness as no significant changes in terms of separation
quality should be observed on the resulting chromatograms.
DoE strategy can be considered, by some pure chromatographists, as a “black-
box”. Indeed, fitted mathematical models are only an approximation of the “true”
chromatographic behavior of investigated compounds. Nevertheless, these models
are very useful to identify and study the chromatographic behavior of compounds
under investigation which can be unknown molecules. The most interesting advan-
tage is that the DoE strategy is an overall data-driven methodology which does not
necessarily imply preliminary knowledge of chromatographic behavior of compounds
under consideration and/or the understanding of their chromatographic parameters
before starting the optimization process. In some cases, the application of chromato-
graphic theories will lead to very good results. But when molecules are unknown
or when their chromatographic behaviors are hard to interpret, they can lead to
unpredicted and inoperable results.
In this work, an innovative methodology using DoE and ICA was used to optimize
the separation and identify the DS for the above mentioned AAIs. The present study
is a useful and relevant application of complementary strategies previously published
(Lebrun et al., 2008; Debrus et al., 2009). The first objective of the present work
was to demonstrate the ability of the DoE-ICA-DS methodology to provide optimal
and robust HPLC method. The second objective was to apply the methodology for
the development of a useful method for the screening of 19 antimalarial drugs. This
was also inscribed in the framework of the fight against counterfeit medicines.
7.2 Experimental
Sections “Chemicals and reagents”, “Standard samples preparation” and details
about “Experiments” can be found in Debrus et al. (2011c).
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7.2.1 Design of experiments
In order to model the chromatographic behavior of each peak, a full factorial
design was selected. It comprised three factors: pH of the aqueous part of the
mobile phase (pH), gradient time (tG) to linearly modify to proportion of methanol
from 5% to 95%, and column temperature (T ). Factors and their respective levels
are summarized in Table 7.2. A total of 45 experimental conditions (5 × 32) were
defined by this full factorial design. In the present case, a full factorial design was
used to simultaneously optimize the method, estimate its robustness and evaluate
the adequacy between chromatographic behaviors predicted by the theory of liquid
chromatography and those obtained by the mathematical models. On the other
hand, if method optimization is the unique objective, lighter DoE can be envisaged
(e.g. fractional factorial or central composite designs).
Factors Levels
pH 2.5 4 6 8 10
Gradient time (tG, min) 20 40 60
Temperature (T, °C) 25 30 35
Table 7.2: Factors and levels of the full factorial design
The temperature was investigated to assess the robustness of the developed meth-
ods w.r.t this factors. It is known to have a limited separation effect. The reason
is that the resulting screening HPLC method is intended to be used in different
laboratories that frequently have no column temperature control. Moreover, the
temperature should not be higher than 35 °C to avoid degradation of some unstable
molecules.
Gradient time and pH ranges were expanded as much as possible in order to widen
the experimental domain and to minimize the risk of not finding any separation
within it. XBridge C18 analytical columns can sustain pH from 1 to 12. pH range
was slightly narrowed from 2.5 to 10 in order to maintain suitable column lifetime.
Gradient time range was also wide (from 20 to 60 min). These factors were selected
to test out their effects on the selectivity and to shorten the time of analysis.
The experiments at a same pH were carried out in row for evident practical
reasons. Then, the within pH blocks experiments were conducted in a random
order. It is preferable to carry out the experiments in a totally random order to avoid
experimental biases. Nevertheless, the column equilibration and conditioning times
when constantly changing mobile phase pH drastically increase the time devoted to
achieve the DoE results. Furthermore, the pH measurement error can be assumed
to be equal to 0.1%. Other error sources (i.e. mobile phase composition during
gradient, temperature, etc.) generated higher response errors and the pH blocking
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did not lead to poor predictive errors. pH blocking effect was thus considered as
negligible in the present study.
The central point (i.e. pH = 6.0, tG = 40 min, T = 30 °C) was independently
run three times, including the preparation of new buffer and fresh mobile phase.
The central points for lower and higher temperatures (i.e. pH = 6.0, tG = 40 min,
T = 35 °C and pH = 6.0, tG = 40 min, T = 25 °C, respectively) were also carried
out twice.
7.2.2 Independent Component Analysis and retention times
recording
ICA is a statistical method allowing the numerical separation of sources maxi-
mizing the independence between them based on non-Gaussianity (Hyvärinen et al.,
2001). In chromatography, ICA was already used by Debrus et al. (2009, 2011b) to
numerically separate coeluting peaks in order to estimate their retention times (i.e.
the times at the beginning and end of a peak). See Chapter 6 for details about ICA.
Indeed, for coeluting peaks, when using a drop-line valley separator, the estimation
of integration limits is highly biased. Then, the modeling of responses based on these
biased times could lead to poor prediction accuracy. In order to avoid this situation,
ICA was used to numerically separate coeluting peaks of antimalarial drugs.
The retention times of non–coeluting peaks were obtained manually on the chro-
matograms, as illustrated on Figure 7.2. From each peak in each chromatogram,
three retention times can be extracted: the times at the beginning, at the apex and
at the end of the peaks at baseline-height (tB, tR and tE, respectively). T0 denotes
the dead time of the system, associated to the device and to the analytical column.
The retention times for the n chromatograms and the m compounds can be stored
in vectors tB,j, tR,j and tE,j of size n, j = 1, ...,m
Figure 7.2: example of (artificial) chromatogram with the positions of discretized
points: the retention times.
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7.2.3 Critical Quality Attributes
Various attributes may be used to assess the chromatographic quality of an output
of the method. tB,j, tR,j and tE,j denote the retention times of the m peaks of a
given chromatogram and tB,(j), tR,(j) and tE,(j), j = 1, ...,m the ordered ones (with
respect to the retention time of the apex). Each criterion cr can then be defined as
a function of these retention times:
cr1 = Analysis time = max(tR,j), j = 1, ...,m
cr2 = Scrit = min(tB,(j+1) − tE,(j)), j = 1, ...,m− 1
cr3 = max(tE,j − tB,j), j = 1, ...,m
cr4 = Rs,crit = min
(
2(tR,(j+1) − tR,(j))
(tE,(j+1) − tB,(j+1)) + (tE,(j) − tB,(j))
)
, j = 1, ...,m− 1
cr5 = max
( | tE,j + tB,j − 2tR,j |
tE,j + tB,j
)
, j = 1, ...,m (7.1)
Under these notations, the following interesting criteria are defined: cr1, the
longer elution time which should be minimum; cr2, the minimum separation be-
tween two subsequent peaks which should be maximum; cr3, the maximum peak
width which should be minimum; cr4, the minimum peak resolution which should
be maximum and cr5, the maximum peak asymmetry which should be minimum.
They are expressed as follows:
Thus, each global criterion is defined as the worst value of a calculated charac-
teristic in a given chromatogram. This ensures that all other computed values, for
other peaks or between other pairs of peaks, are at least better. Other criteria are
also possible. In the next parts, only cr1, cr2 and cr4 will be used.
7.2.4 Modeling and optimization methodology
Retention times modeling
Dewé et al. (2004) and Lebrun et al. (2008) provided a new approach for retention
times modeling and DS computation. In these works, they showed that the modeling
of the resolution can lead to poor prediction caused by its non-linear and non-
continuous behavior when selectivity drastically changes.
The studied responses were the logarithm of the retention factor and the loga-
rithms of both half-widths, computed as follows:
ktR,j = log
(tR,j − T0
T0
)
, wl,j = log (tR,j − tB,j) , wr,j = log (tE,j − tR,j)
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These 3m responses were modeled by individual multiple linear regressions using
a stepwise approach to maximize the adjusted coefficient of determination (R2adj).
The following model is then applied 3 ×m times. The reference to the particular
response has been removed to simplify the notation.
y = β0 + β1pH + β2pH2 + β3pH3 + β4tG + β5t2G + β6T + β7T 2+ (7.2)
β8pH tG + β9pH T + β10tG T + β11pH tG T + ε,
= Xβ + ε,
where y is either ktR,j , wl,j or wr,j. β0, . . . , β11 are the regression parameters and ε
are the residuals of the model, assumed Gaussian and i.i.d.. X is an n × p matrix
containing the effects to be estimated. Least squares can be used to compute βˆ, the
estimator of β.
Specification, error propagation and Design Space computation
A Critical Quality Attribute (CQA) was selected to assess the quality of a sep-
aration. Lebrun et al. (2008) proposed to use the separation criterion (Scrit or cr2)
defined as the difference between the beginning of the second peak and the end
of the first peak of the critical pair. This separation criterion is easy to compute
and to interpret. If Scrit ≥ 0, the critical pair of peaks is baseline-resolved. An
equivalent quality assessment is given by a critical resolution Rs,crit ≥ 1.5, although
most analysts generally agree that a minimum of Rs,crit = 2 is needed to ensure
baseline-resolved peaks in case of asymmetry.
After the responses modeling, the responses were predicted using Equation (7.2).
Predictions were then back-transformed into the original scale of the responses, i.e.
the retention times.
For a new operating condition defining x˜, included in the experimental domain
χ, the predictive distribution obtained for the responses can be obtained from the
marginalization properties of the multivariate Student’s distribution proposed in
Chapter 3 and Appendix D. Under non-informative priors, it is then defined as:
y˜ | x˜, data ∼ t(x˜βˆ, a
(
1 + x˜′
(
X′X
)−1
x˜
)
, n− p), (7.3)
with a = (y − Xβˆ)′(y − Xβˆ). This is related to the distribution obtained in the
frequentist framework to compute prediction intervals, such as in Neter et al. (1990).
Practically, Monte-Carlo simulations were used to obtain, for a given operating
condition, the predictive distribution of S˜crit from the predictive distributions of
k˜tR,j , w˜l,j or w˜r,j. Finally, using the distribution of S˜crit, the posterior probability
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for S˜crit to be higher than a selected specification was used to determine the DS. In
mathematical terms, the DS can be defined as
Design Space =
{
x˜ ∈ χ | P (S˜crit ≥ 0 | X = x˜, data) ≥ pi
}
. (7.4)
where pi is the quality level. In other words, the DS defines a subspace of the
experimental domain where the posterior probability to obtain baseline-resolved
peaks (i.e. Scrit > 0 min) is higher than a predefined quality level (e.g. pi = 65%).
In practice, it might be difficult to choose a value for pi. No regulatory document
yet provides guidelines on how to compute or estimate the Design Space quality
level. Obviously, in this example, finding a DS with a quality level of 95% would be
desirable to induce the achievement of a robust chromatographic method. A high
pi could only be obtained with a satisfactory mean separation as well as a relatively
small predictive error on the involved responses.
To be able to draw DS even when the optimal pi is not as high, the minimal
quality level has been chosen a percent change of 85% of its optimal value. First,
pi∗ is computed as the optimal value on every point of χ. Then, pi is defined as 0.85
of pi∗. For instance, if pi∗ = 70%, the quality level will be pi = (0.85.pi∗) = 59.5%.
Prediction of optimal separation
The experimental domain was investigated with a grid search method. A multi-
dimensional grid was defined over the experimental domain. Then, the predictive
distribution of the CQA was computed for each of the experimental condition de-
fined by the grid. The optimum was selected as the point x∗ of the grid giving the
highest probability value (pi∗), i.e.
x∗ = max
x˜∈χ
P (S˜crit ≥ 0 | X = x˜, data).
In practice, the number of points was set as high as possible while keeping the
total computing time lower than 12 hours (i.e. one night computation). On each
point of the grid, 2500 Monte-Carlo simulations have been done to estimate the
posterior probability.
7.2.5 Software
An in-house computer program was developed to perform the retention times
modeling with stepwise multiple linear regressions, the Monte-Carlo simulations and
the grid search method. The coding was carried out with R 2.11.1 (R Development
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Core Team, 2010). ICA-based numerical separations were performed using FastICA
algorithm implemented by Marchini et al. (2010).
7.3 Results and Discussions
7.3.1 Peak detection and peak matching
As the compounds from the artemisinin group (i.e. AE, AM, AS and DHA)
present very similar and non-specific UV-signatures, these five molecules were in-
jected individually to identify and match them. Then, for the rest of the compounds,
in case of coelution, ICA was used to determine the times at the beginning (tB),
the apex (tR, the retention time) and the end (tE) of each peak. Finally, for the
non-coeluting peaks, these times were manually read on the chromatograms.
Furthermore, at alkaline pH and high temperature (pH = 10, T = 35°C), DHA
peak was split in two coeluting peaks and several unidentified peaks were also ob-
served. These results suggested that DHA degraded in alkaline conditions at 35°C.
Therefore, the experimental domain was reduced removing all the pH 10 experiments
to avoid problems when recording the retention times.
7.3.2 Retention times modeling
Retention times modeling were achieved by stepwise multiple linear regressions
which selected the terms of Equation (7.2) to maximize R2adj. As three times (tB,
tR and tE) of 19 peaks were modeled, 54 models were obtained. The estimated
model parameters (β0, . . . , β11), their complete chromatographic interpretation and
a summary of the models comprising R2adj were presented in the original publication
(Debrus et al., 2011c) but have been cut here for brevity.
Models adequacy
In order to visualize the models adequacy, Figure 7.3 displays the appropriateness
between predicted and experimental data (a) as well as the corresponding residuals
(b), represented in their original scale. The three rows of the Figure represent
the retention times at the apex, the end and the beginning of the peaks. The m
compounds are confounded and represented by different colors and shapes.
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Figure 7.3: Predicted vs. observed plots and corresponding residuals. (a) Predicted
versus experimental values for tR, tE and tB. (b) Corresponding residuals plots.
Compound assignation: (red square) PPQ, (red circle) CC, (orange head up triangle)
CQ, (yellow diamond) SL, (green head down triangle) AQ, (green square) QN, (green
circle) SD, (green head up triangle) PM, (green diamond) PQ, (blue head down
triangle) PG, (blue square) MQ, (blue circle) ART, (blue head up triangle) DHA,
(blue diamond) AS, (blue head down triangle) AM, (purple square) HF, (purple
circle) AE, (purple head up triangle) LF, (purple diamond) AT
As observed on (b), the residuals are distributed between –2 and 2 min. The
residuals standard deviations (sˆ) computed on the three sets of residuals were 0.36,
0.41 and 0.36 min, respectively. It is thus reasonable to assume that the averaged
error on the retention times is about 0.8 min (i.e. 2 × standard deviation) over the
whole experimental domain. Shapiro-Wilk Normality tests were also carried out on
the residuals. The p-values were all higher than 0.05 which meant that the residuals
are in agreement with a Normal distribution.
pH, Gradient time and temperature effects
The mean predicted tR (back-transformed in their original scale) for the 19 anti-
paludic drugs are shown on Figure 7.4 (top). For each subfigure, one operating
condition is changed while the two others are fixed. As expected, pH is the factor
that had the most significant effect on selectivity (crossing of peaks). The identifi-
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Figure 7.4: Predicted mean retention times (tR) with respect to DoE’s factors. (a)
Predicted tR (min) vs. pH – with tG = 60 min and T = 25 °C. (b) Predicted tR
(min) vs. tG (min) – with pH = 2.5 and T = 25°C. (c) Predicted tR (min) vs. T
(°C) – with pH = 2.5 and tG = 60 min. Compound assignation: (black line) PPQ,
(red line) CC, (green line) CQ, (blue line) SL, (cyan line) AQ, (magenta line) QN,
(yellow line) SD, (grey line) PM, (dashed black line) PQ, (dashed red line) PG,
(dashed green line) MQ, (dashed blue line) ART, (dashed cyan line) DHA, (dashed
magenta line) AS, (dashed yellow line) AM, (dashed grey line) HF, (dotted-dashed
black line) AE, (dotted-dashed red line) LF and (dotted-dashed green line) AT.
(d,e,f) Corresponding predicted Critical Quality Attributes Scrit (blue line, left axis)
and RS,crit (red line, right axis)
cation of neutral, acidic or basic compounds is also easy. Neutral compounds show
no tR variation with respect to pH. Acidic and basic compounds have a respective
decreasing or increasing variation with respect to pH.
The tG also induces changes in the retention time (b). However, the changes in
selectivity is more limited. The temperature has the lowest effect (c). These low tR
variations with respect to T underline the method robustness while changing T as
expected in routine use in Africa.
Notice that mean predicted tB and tE were also computed to predict the CQA at
given operating conditions. (d), (e) and (f) show the behavior of the predicted Scrit
(blue), compared to the more classical criterion of resolution RS,crit (red).
These non-continuous curves clearly illustrate the impossibility to envisage these
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attributes as model responses. This non-continuity is due to the selection of the
critical pair of peaks (by min and max operators, see the Equations (7.1)), that
might be different at each operating condition. The mean predicted CQAs are
without appeal concerning a total separation of the 19 anti-paludic drugs. The best
mean separation is about -0.45, i.e. there is at least two coeluting peaks.
7.3.3 Critical Quality Attributes and Design Space compu-
tation
The CQA separation (Scrit) was computed over the whole experimental domain.
A grid of 42875 points (i.e. 35×35×35) was defined and Scrit was computed for
each operating condition. The predictive distributions of the responses was used to
generate samples whose uncertainty was propagated to Scrit using Monte-Carlo sim-
ulations. Then, the results were presented as probability surfaces (i.e. the posterior
probability for the CQA to to be higher than its specification) rather than response
surfaces.
The very similar chromatographic behavior between ART and DHA prevented
obtaining a separation of the 19 AAIs. Nevertheless, at some operating conditions,
they were the only two coeluting peaks. Thus, two groups were formed. The first
contained 17 AAIs and ART (group 1) and the second contained the same 17 AAIs
and DHA (group 2). These two groups are justified from a therapeutic point of view
because ART and DHA are never present in the same pharmaceutical formulation.
The optimization process was then repeated for each group independently. The
probability surfaces for P (Scrit ≥ 0) for group 1 and group 2 are presented in Figure
7.5 and Figure 7.6, respectively. Low optimal quality levels DS with pi = 28% and
pi = 8% are depicted in red. They represent a better achievement of quality than
in any other zone of the experimental design. It is important to keep in mind that
a chromatogram with slightly coeluted peaks is still relevant when envisaging the
screening of many compounds. Furthermore, these probabilities are representative
of the separation of the critical pair of peaks solely. Then, every other separation
will be at least better.
For a given quality level pi, the DS shape is directly linked to the method robust-
ness against factors variation. Therefore, the DS shapes on Figure 7.5 and Figure 7.6
allowed concluding that the resulting screening methods are still relatively robust
with respect to modifications of tG (from 54 to 60 min for group 1 and from 58 to
60 min for group 2) and T (from 25 to 25.8 °C for group 1 and from 25 to 26 °C for
group 2). Conversely, these screening methods seems far less robust with respect to
pH (from pH 4 to pH 4.1 for both groups). However, the pH measurement vari-
ability is estimated to 0.1%. Consequently, the relatively poor method robustness
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with respect to pH should therefore not be problematic when care is taken during
the buffers preparation and pH measurements.
7.3.4 Prediction of optimal separation
As shown on Figure 7.5 and Figure 7.6, the optimization process gives quite
identical optimal condition. The difference between quality levels for group 1 and
2 came from the shorter DHA retention times compared to ART. DHA slightly
coeluted with MQ (Peak 12 on Figure 7.7) explaining the much lower pi for group
2. Finally, an optimal operating condition was selected, lying inside both DS and
allowing the separation of the 18 AAIs of both groups independently. At operating
condition pH = 4.05, tG = 56.2 min and T = 25 °C, the optimal P (Scrit > 0) = pi∗
was 33% for group 1 and pi∗ = 9.6% for group 2.
Figure 7.5: Posterior probability surfaces (P (Scrit > 0)) for group 1 separation. (a)
Gradient time (min) vs. pH, (b) temperature (°C) vs. pH and (c) temperature (°C)
vs. gradient time (min). The DS (pi = 28%) is encircled by a red line.
Figure 7.6: Posterior probability surfaces (P (Scrit > 0)) for group 2 separation. (a)
Gradient time (min) vs. pH, (b) temperature (°C) vs. pH and (c) temperature (°C)
vs. gradient time (min). The DS (pi= 8%) is encircled by a red line.
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Chromatograms recorded for the group 2 at the optimal operating condition are
very close to those displayed in Figure 7.7 for group 1. Despite the inability to
separate ART and DHA (inducing the creation of 2 groups), it was easy to identify
them even if coeluting because their retention times were slightly different (i.e. tR =
44.5 min for ART and tR = 44.9 min for DHA). Thus, it is still possible to separately
inject a reference solution of each compound in working conditions to confirm their
identification.
Figure 7.7: (a) Experimental chromatogram recorded at pH = 4.05, tG = 56.2 min
and T = 25 °C with group 1. (b) Predicted chromatogram at the same condition.
Peak numbering: 1 = CQ, 2 = SL, 3 = AQ, 4 = SD, 5 = CC, 6 = QN, 7 = PM, 8
= PP, 9 = PQ, 10 = PG, 11 = MQ, 12 = ART, 13 = AS, 14 = AM, 15 = HF, 16
= AE, 17 = LM and 18 = AT.
7.3.5 Sub-mixture
One can observe that the screening method (Figure 7.7) has a quite long analysis
time. It can be also observed that the compounds eluted between 15 and 60 min.
The first 15 min are not “used” to separate the compounds in a shorter time.
Nevertheless, the DoE-DS methodology can also be used to develop methods
aiming at reducing the analysis time while optimizing the separation of specific
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sub-mixtures of compounds. Some compounds (related to a given pharmaceutical
formulation) were therefore selected to test out this opportunity without perform-
ing any additional experiments. Indeed, once models are available to explain the
compound chromatographic behaviors, the optimization process for the separation
of any specific compound combinations can be carried out. The resulting DS would
directly depend on the selected compound involved in the computations. The se-
lected sub-mixture contained AS, PM and SL. This combination is representative
of a pharmaceutical formulation present on the Democratic Republic of the Congo
market (Arte-Plus®).
In order to minimize the time of analysis while simultaneously optimizing the
separation of these 3 compounds, a multi-criteria optimization was carried out. The
selected CQAs were the critical separation Scrit (cr2) and the time of analysis (cr1).
The specification were placed at 0.1 min for Scrit and 20 min for the total run time.
The DS is defined as the subspace where the posterior probability P (c˜r2 ≥
0.1, c˜r1 ≤ 20min | data) is higher than the selected quality level. Here, pi = 97.5%,
as shown on Figure 7.8, and pi∗ ≈ 1.
Figure 7.8: Posterior probability surfaces (i.e. P (Scrit ≥ 0.1min & analysis time ≤
20min)) for sub-mixture separation. (a) Gradient time (min) vs. pH, (b) tempera-
ture (°C) vs. pH and (c) temperature (°C) vs. gradient time (min). The DS (pi =
97.5%) is encircled by a red line.
One can observe that the DS is really small in the gradient time tG space. The
reason behind this observation is the closeness of the last peak with the analysis
time specification (i.e. 20 min). The lowest tG must be selected as it has the highest
effect on compounds retention times. For the other factors, the DS is bigger. The
specific method is then very robust in terms of separation. The optimal operating
condition is pH = 5.4, tG = 20 min and T = 35 °C. The recorded chromatogram at
the optimal condition is displayed in Figure 7.9 (a). Notice that analysis time could
certainly be reduced by decreasing tG. In this case, the operating conditions would
be outside the experimental domain, which is not advised.
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Figure 7.9: (a) Experimental chromatogram recorded at pH 5.4, tG = 20 min and T
= 35 °C with sub-mixture compounds. (b) Corresponding predicted chromatogram.
Peak numbering: 2 = SL, 7 = PM, 13 = AS.
Figure 7.9 presents the adequacy between the predicted (b) and observed (a) chro-
matograms. It is quite obvious that a method development (using already available
commercial softwares or a lighter full factorial design) for the separation of these
three compounds would be able to find operating condition giving a good separation
in a shorter analysis time. However, the present method optimization dedicated to
the pharmaceutical formulation (Arte-Plus®) was carried out from the same data
that those used for the optimization of the screening method. It underlined the fact
that the DoE-DS methodology is generic. Here an innovative methodology was used
to optimize the separation while simultaneously estimating the robustness of either
a general screening method or specific methods.
7.4 Conclusions
In the current trend of being QbD compliant, it is of first importance to develop
methodologies that provide robust optimal separations defined by a DS. With re-
gards to this objective, DoE-ICA-DS allowed obtaining optimal screening methods
for the separation of 19 AAIs. The methods robustness was evaluated thanks to the
DS quality level, DS shape and the assessment of the factors effects. It resulted that
the obtained screening methods were robust against temperature modification. This
result is very important when one of the final aims is a method transfer to African
laboratories where column ovens are not always available.
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Theses screening methods can be considered as a step forward for the fight against
counterfeit medicines. The present work also allowed demonstrating the ability of
the DoE-ICA-DS methodology to encounter optimal separation for complex mix-
tures (i.e. containing compounds with very similar structures and physico-chemicals
properties). This study also demonstrated the ability of fitted mathematical mod-
els to be used to identify and corroborate theoretical chromatographic behaviors of
studied compounds (not presented here). It highlighted the fact that DoE strategy
can be a very useful tool for chromatographists in order to develop or refine the
understanding of some chromatographic behavior.
Furthermore, the separation of a three compound mixture was also carried out
without performing any additional experiments. The resulting method was also
very robust to temperature changes. Finally, the results presented in this manuscript
strengthen the fact that DoE-ICA-DS can be considered as a generic QbD compliant
methodology for the optimization and the robustness assessment of new chromato-
graphic methods for the analysis of pharmaceutical formulations or more complex
matrices such as plant or biological materials.

Chapter 8
Application of an innovative
Design Space optimization
strategy to the development of LC
methods to combat potentially
counterfeit NSAIDS
8.1 Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs) are used against pain, fevers of
various origins and inflammation (Ibrahim et al., 2007; Dinç et al., 2002; McMahon
et al., 1998). Although they are widely prescribed throughout the world, many of
them are associated with side effects. These drugs are often used in self-medication,
as their purchase is also unrestricted over the Internet. The risk of administration
of uncontrolled medicines is thus naturally greater.
Furthermore, NSAIDs are often subject to the practice of counterfeit medicines,
which is gaining increasing momentum in the world and particularly in low-income
populations. This has adverse consequences for public health (Panusa et al., 2007).
The World Health organization (WHO) reported 6% of drugs worldwide are counter-
feit and the Food and Drug Administration (FDA, USA) estimated this proportion
to be 10% (Mazières, 2007). This proportion varies from one country to another. In
some African countries, Marini et al. (2010a) estimated that up to 80% of medical
products are counterfeit (see also Marini et al., 2010b). To ensure the quality of
drugs and to help battle counterfeit medicines, the development of screening meth-
ods that can simultaneously trace many of the most commonly used molecules is
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an important effort. In this context, separation techniques are the usual option
when planning to explore a substantial number of molecules. Conversely, while
techniques such as near infrared or Raman spectroscopy are simpler and quicker
procedures and require no sample preparation, their potential still remains limited
when dealing with the sample analysis of complex mixtures of active ingredients or
their impurities at low concentration levels.
Several liquid chromatographic (LC) methods are described in the literature for
analyzing NSAIDs (Acuña et al., 2004; Ji et al., 2005; Dinç et al., 2002; Boonkerd
et al., 1995; Altun et al., 2001; Franeta et al., 2002; Kartal, 2001; Šafra and Pospíšilová,
2008; Chen and Wu, 2005; Santini et al., 2007; Polásek et al., 2000) However, none
of these includes an exhaustive list of the molecules present in NSAIDs. Thus, they
are of limited use in the context of complex or unknown mixtures screening. For
instance, Iuliani et al. (2010) optimized a LC for separating only seven NSAIDs
regardless of major pharmaceuticals products such as naproxen, diclofenac, etc., or
other major molecules often associated to NSAIDs such as paracetamol, caffeine,
etc.
In the present study, several HPLC separation conditions were optimized for tar-
geted subsets of 27 molecules used alone or in combination. The first objective was
the optimization of the separation conditions for these 27 molecules among which
were 18 NSAIDs: ibuprofen (IBU), diclofenac (DIC), mefenamic acid (MA), keto-
profen (KTO), nimesulide (NIM), dextropropoxyphene (DEX), niflumic acid (NA),
tenoxicam (TE), piroxicam (PI), sulindac (SUL), phenylbutazone (PHE), flurbipro-
fen (FU), suprofen (SUF), naproxen (NAP), tiaprofenic acid (TA), phenoprofen (i.e.
fenoprofen, PF), indomethacin (IDO) and acetylsalicylic acid (AA). Molecules of-
ten associated with NSAIDs were added to the list: chlorzoxazone (CHL), caffeine
(CAF), paracetamol (i.e. acetaminophen, PAR) and salicylic acid (SAL), a degra-
dation product of AA. Finally, five pharmaceutical conservatives found in syrups or
suspensions were concurrently analyzed with the rest: nipagine (i.e. methylparaben,
NIP), nipasol (i.e. propylparaben, NIS), butylated hydroxyanisole (BHA), butylated
hydroxytoluene (BHT) and sodium benzoate (BEN).
To achieve this objective, design of experiments (DoE) was used to establish a
Design Space (DS), extending the works in Lebrun et al., 2008.
According to ICH Q8 (2009) the DS is “the multidimensional combination and
interaction of input variables (e.g. material attributes) and process parameters
that have been demonstrated to provide assurance of quality”. Thus, the DS is a
subspace of the experimental domain where assurance of quality has been proven.
In the present study, the DS defines the space of HPLC operating conditions that
will ensure quality outputs. The minimal expected quality might be described by
acceptance criteria (Λ) that apply on some critical quality attributes (CQAs), i.e.
values or indices that provides some indications about the overall achievement of the
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analytical method. In chromatographic terms, CQAs may be the resolution (Rs,crit)
or the separation (Scrit) of a critical pair of peaks, and the run time of the method
(ttot), while the acceptance criteria may be Scrit > 0 and ttot < 45 min considered
concurrently.
In this context, a result given as a predictive probability that the CQAs will fall
within acceptance criteria allows the quantification of the assurance advocated by
ICH Q8 (R2) (Debrus, Lebrun et al., 2011c). This leads to a risk-based definition
of the DS that may be expressed as:
Design Space = {x˜ ∈ χ | P (CQAs ∈ Λ | x˜, data) ≥ pi} . (8.1)
In other words, the DS is a region of an experimental domain χ (often called
knowledge space) where the posterior probability that the CQAs are within accep-
tance criteria Λ, is higher than a specified quality level pi , conditionally on the
available data. By the use of the posterior predictive distribution of the CQAs,
the posterior probability accounts for the parameter uncertainties and interactions
estimated by the statistical model, as well as residual variability (Peterson, 2008).
Note that if a large and high quality DS is identified within the experimental
HPLC parameter ranges, the corresponding optimized method may be considered
robust, as deliberate changes in the operating conditions (included in the defined
DS) will not negatively impact the quality of the output.
In order to provide faster analysis, a transfer to ultra high performance liquid
chromatography (UHPLC) was the second part of the planned study. This leads
to a shortened run time and reduced solvent consumption, which results in reduced
time and cost to identify substandard or counterfeit medicines in laboratories where
UHPLC systems are available (Sacré et al., 2011). For that purpose, the robust-
ness of the methods firstly developed with conventional HPLC system was found
mandatory to permit the geometric transfer. Indeed, the induced variability when
changing from one LC system to another may lead to small changes in the retention
times of the analytes. Logically, this occurrence could be more pronounced when
moving from a conventional LC system to a UHPLC system. Also, it is noted that
the UHPLC method may suffer from a small loss in peak efficiency due to the drastic
reduction of the analysis time. Consequently, the objective in this context was also
to demonstrate that the knowledge coming from the built DS (i.e., robustness area)
could facilitate the geometric transfer even if several facts might potentially impact
on the separation quality of the transferred analytical methods.
To demonstrate the DS ability, the third objective was to validate one of the
developed HPLC methods, using the accuracy profile as decision tool for the deter-
mination of four compounds (Hubert et al., 2004; Boulanger et al., 2003). A common
NSAIDs combination marketed in some African countries was used. It consisted of
136 8. Design Space strategy to the development of LC methods for NSAIDS
capsules containing paracetamol, ibuprofen, caffeine and potentially 4-aminophenol,
a well known impurity of paracetamol allowing to obtain information on the storage
conditions.
Finally, the quantitative method was applied to analyze five drugs marketed in
the Democratic Republic of Congo (DRC).
8.2 Theory
When CQAs show a highly nonlinear and discontinuous mathematical behavior
with respect to changes of operating conditions, modeling of responses that allow
a satisfactory fit with simple regression models has been recommended (Peterson,
2004; Dewé et al., 2004). This condition is likely to be observed with CQAs such
as the resolution or the separation of a critical pair of peaks due to the inversions
of elution order that may be observed. After their modeling, the selected responses
must be sufficient to derive the CQAs in order to assess the quality of the HPLC
system output.
In this case the retention times at the beginning (tB,j), at the apex (tR,j) and at
the end (tE,j) of every jth peak (j =1,. . . ,m) result in 3m vectors of n data for the
n chromatograms resulting from the designed experiment. Next, the logarithms of
defined retention factors are taken as modeled responses:
kB,j = log
(tB,j − t0
t0
)
, kR,j = log
(tR,j − t0
t0
)
, kE,j = log
(tE,j − t0
t0
)
, (8.2)
where t0 is the dead time of the LC system.
This defines Y = (kB,1,kR,1,kE,1, ...,kB,mkR,mkE,m), the (n × 3m) matrix con-
taining the responses that are modeled jointly using a multivariate regression model:
Y = XB + E, (8.3)
where the vector εi, the ith line of E is assumed independent and identically dis-
tributed as multivariate Normal, i.e., εi ∼ N(0,Σ), i = 1, ..., n. X is the (n × p)
centered and reduced design matrix containing the p effects to be included in the
model (see later) and B is the (p×3m) matrix containing the p parameters for each
of the 3m responses. The modeled effects in X are then similar for every response
and should be chosen according to the particular experimental design. Σ is the
covariance matrix of the residuals.
In order to account for the variability of the parameters B and Σ, a poste-
rior predictive density of new predicted responses can be obtained in the Bayesian
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framework. Considering an informative prior distribution of the parameters p(B,Σ)
= p(B | Σ)p(Σ), with p(Σ) distributed as an inverse-Wishart W−11 and p(B | Σ)
distributed as a (p× 3m) matrix-variate Normal N(B0,Σ,Σ0), the predictive den-
sity of a new predicted set of responses y˜ | x˜, data for a given operating condition
x˜ ∈ χ follows a multivariate Student’s distribution (Minka, 2001; Lebrun et al.,
2012a, Appendix A):
y˜ | x˜, data ∼ Tm
(
x˜MBpost,
(
1 + x˜′(X′X + Σ−10 )−1x˜
)
(Ω + A∗), ν + n0
)
, (8.4)
where MBpost =
(
X′X + Σ−10
)−1 (
X′XBˆ + Σ−10 B0
)
; Bˆ = (X′X)−1 X′Y and A∗ is
as follows:
A∗ = Y′Y + B′0Σ−10 B0 − (X
′XBˆ + Σ−10 B0)
′(X′X + Σ−10 )−1(X
′XBˆ + Σ−10 B0).
(8.5)
Notably, when Σ−10 tends to 0, A∗ is simply the residual sum of squares and
MBpost becomes Bˆ the least square estimate of B. Furthermore, when Ω = 0 and
n0 = 0, the predictive density is similar to that which is obtained using a simpler
form of non-informative prior (see e.g. Press, 2003). The definition of the parameters
of the prior distributions, i.e. the particular values that may be given to Ω, n0,Σ−10
and B0 will be discussed later.
The proposed predictive distribution is of particular interest because it describes
how the HPLC method will perform during future use, given the data and the prior
information. This prior information should be as uninformative as possible when
limited knowledge is available.
For this study, the CQAs computed from the modeled responses are the separation
and the total run time. Using tB,j, tR,j and tE,j (j = 1, . . . ,m) to denote the
retention times of the jth peak of a given chromatogram, and tB,(j), tR,(j) and tE,(j)
to denote the retention times of the jth peak with respect to the time of the apexes
tR, the CQAs are defined as follows:
ttot = Analysis time = max(tR,j), j = 1, ...,m,
Scrit = Critical Separation = min(tB,(j+1) − tE,(j)), j = 1, ...,m− 1.
(8.6)
Both CQAs are expressed in minutes. Actually, the run time ttot is defined as the
retention time of the most retained compound for the different operating conditions.
Both CQAs are determined as the worst value of a calculated characteristic in a
given chromatogram. This ensures that all other computed values, for other peaks
or between other pairs of peaks, are at least as good than these values.
Using Monte-Carlo simulations, one can sample from the predictive distribution
of the responses, obtain tB,j, tR,j and tE,j by back-transforming the responses to
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their original scale, and compute samples from the predictive distribution of the
CQAs. This forms the basis for assessing the quality of the LC method. A Monte-
Carlo estimate of the expected probability (i.e. assurance) of observing CQAs falling
within acceptance criteria in future runs is obtained from the predictive distribution.
For example, in chromatography it may be desirable to obtain a high predictive
probability P (Scrit > 0 | data), or a high joint predictive probability P (Scrit >
0, ttot < 45 | data).
8.3 Experimental section
8.3.1 Materials
Ketoprofen (99.7%), diclofenac (99.7%), naproxen (>98%), piroxicam (>99%),
nimesulide (100.0%), sulindac (98%), suprofen (99.1%), sodium benzoate (99.9%),
4-aminophenol (98%), flurbiprofen (batch F8514-5G), phenoprofen (batch 029K-
1043), tenoxicam (batch T0909-5G) and mefenamic acid (batch 36H0945) were
purchased from Sigma-Aldrich (Antwerp, Belgium). Caffeine (100.1%), paraceta-
mol (99.5%), ibuprofen (99.6%), indomethacin (99.2%), nipagin (100.1%), nipasol
(101.9%), chlorzoxazon (99.1%), acetylsalicylic acid (batch 08G31-B28-232951), sal-
icylic acid (batch 06K14 – B09 – 216351), and butylated hydroxytoluene (batch
05E31-B05) were purchased from Fagron N.V. (Waregem, Belgium). Dextropropo-
xyphen (batch 203100), phenylbutazone (batch 00951QA) and butylated hydrox-
yanisole (batch 511527) were purchased from Federa (Brussels, Belgium). Tiapro-
fenic acid was purchased from Erfa S.A (Brussels, Belgium). Niflumic acid (batch
0411545-2) was purchased from Cayman Chemical Company (Lansing, Michigan,
USA). Lactose (batch 70756355176) was purchased from DMV Fronterra Excipients
(Goch, Germany). Methanol (HPLC gradient grade), hydrochloric acid (37%), am-
monium hydroxide (32%) and ammonium hydrogen carbonate (99%) were purchased
from Merck (Darmstadt, Germany). Ammonium formate (99%) was provided by
Alfa Aesar (Karlsruhe, Germany). Trifluoroacetic acid (batch 1001007) was pur-
chased from Fisher Scientific Bioblock (Tournai, Belgium). Ultrapure water was
obtained from a Milli-Q Plus 185 water purification system (Millipore, Billerica,
MA, USA). For the preparation of validation standards, a matrix formulation of
capsules containing 200 mg of paracetamol, 400 mg of ibuprofen, 40 mg of caffeine
and 10 mg of lactose was kindly provided by Zenufa (Kinshasa, DRC)
The 27 materials were divided into 5 groups as presented in Table 8.1. These
groups were based on the pharmaceutical form of the NSAIDs and were intended to
expedite the determination of the method DS.
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Group Subgroup Molecules
Group 1
(Compounds often
presented in combi-
nation in tablet or
capsule)
- PAR, AA, IBU, DIC, CHL, DEX, NIM,
KTO, MA, SAL, CAF
Group 2
(Compounds
presented in com-
bination in syrup
and suspension)
- PAR, IBU, NIM, MA, NIP, NIS, BEN,
BHA, BHT
Group 3
(NSAIDs found
alone in tablet or
capsule)
- IDO, TE, PI, FU, TA, NAP, SUF,
PHE, PF, NA
Group 4
(Pharmaceutical
combinations
presented in tablet
or capsule)
1 PAR, AA, CAF
2 PAR, IBU
3 PAR, DIC
4 PAR, DIC, CHL
5 PAR, IBU, CAF
6 PAR, MA
7 PAR, DEX
8 PAR, DEX, CAF
Group 5
(Compounds
presented in syrup
and suspension)
1 PAR, NIP, NIS, BEN, BHA, BHT
2 PAR, IBU, NIP, NIS, BEN, BHA, BHT
3 IBU, NIP, NIS, BEN, BHA, BHT
4 NIM, NIP, NIS, BEN, BHA, BHT
5 MA, NIP, NIS, BEN, BHA, BHT
Table 8.1: Groups of compounds studied in this work. (Bold) submixture used for
the validation experiments.
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8.3.2 Standard sample preparation
Mixture preparation groups
1mg/mL stock solutions of each of the 27 studied materials were prepared in
methanol. Mixture solutions were obtained by diluting stock solutions in methanol-
water (50:50, v/v) in such a way as to obtain a working concentration of 50 µg/mL
for HPLC analyses. Solutions injected into the UHPLC were 10 µg/ mL for each
material. Aliquots of these solutions were filtered with 0.20 µm PTFE syringe
filtration disks into vials for injection in the HPLC and UHPLC systems.
Solution used for calibration and validation
A stock solution of PAR, IBU, CAF and 4-aminophenol was prepared by dissolv-
ing 100 mg of each material in 100mL methanol. A stock solution of lactose was
prepared by dissolving 100 mg of lactose in 100 mL of water (1 mg/mL). Heating
and ultrasonic bath were necessary to ensure a complete dissolution.
For the calibration standards (CS), dilutions were performed in methanol-water
(50:50, v/v) in order to obtain solutions at concentration levels of 200 µg/mL, 400
µg/mL and 600 µg/mL, except for 4-aminophenol where a dilution was made to
obtain a concentration of 0.5 µg/mL (i.e. 0.1% of 500 µg/mL of paracetamol, being
the reference concentration of 100%). For PAR, IBU and CAF, three concentra-
tion levels were sufficient to generate different regression models for the calibration,
while for 4-aminophenol, a one-level calibration was made as advised in the Euro-
pean Pharmacopoeia monograph of paracetamol for the determination of impurities
(European Pharmacopoeia, 2011c).
For validation standards (VS), independent stock solutions of PAR, IBU, CAF,
4-aminophenol were prepared in the same way as described for the CS. For the
matrix, the same lactose solution was added into each working solution to obtain
an amount of lactose of 4% relative to the amount of IBU. Subsequent dilutions
in methanol-water (50:50, v/v) were carried out in order to obtain 5 solutions at
different concentration levels (200 µg/mL, 300 µg/mL, 400 µg/mL, 500 µg/mL and
600 µg/mL) of PAR, IBU and CAF. For the 4-aminophenol, only one concentration
level of 0.5 µg/mL was tested as described previously. The VS were independently
prepared in the matrix, simulating as much as possible the formulation and its future
routine analysis.
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8.3.3 Instrumentation and chromatographic conditions
The optimization, validation and routine analysis were performed on a HPLC
system comprised of a Waters 2695 separation module coupled to a Waters selector
valve 7678 and a Waters 996 Photodiode array (PDA) detector (Waters, Eschborn,
Germany). The analytical column was an XBridge C18 (250 mm x 4.6 mm i.d.,
particle size 5 µm), preceded by a guard column XBridge guard C18 (20 mm × 4.6
mm i.d., particle size 5 µm), both from Waters. The HPLC method was transferred
to a UHPLC system Acquity ultra performance liquid chromatography (UPLC™)
system from Waters, comprised of a binary solvent manager, an autosampler with
a 10 µL loop, operating in the partial loop with needle overfill injection mode, and
a PDA detector. The UHPLC system was equipped with an Acquity BEH C18
column (50 mm×2.1 mm i.d., particle size 1.7 µm) from Waters. XBridge and
Acquity BEH columns are made with same stationary phase chemistry, providing
an equivalent selectivity allowing for a geometrical transfer. The analytes were
monitored photometrically at 220 nm while chromatographic data were recorded
from 210 to 400 nm for all the studied conditions. For the HPLC system, the
injection volume was 10 µL and the mobile phase flow rate was 1 mL/min. For the
UHPLC system, the injection volume and the mobile phase flow rate were reduced
geometrically to 2 µL and 613 µL/min, respectively. After each injection, the HPLC
system was reconditioned for 30 min and the UHPLC system for 2 min.
The buffer solutions consisted of 20 mM ammonium formate, except for pH higher
than 5 for which 20 mM ammonium hydrogen carbonate was used. The pH was
adjusted with hydrochloric acid and ammonium hydroxide except for pH 1.85 where
a solution of 0.1
8.3.4 Software
Empower 2.0 for Windows was used to control the HPLC and the Acquity
UPLC™ systems, and to record and interpret the chromatograms.
An algorithm was set up to develop the Bayesian model and to compute the
DS. The algorithm was written in R 2.13, which is available as freeware for most
operating systems (R Development Core Team, 2010).
HPLC calculator v3.0 was used to carry out the necessary computations to iden-
tify the UHPLC conditions from the HPLC conditions using gradient geometric
transfer methodology (Guillarme et al., 2007, 2008).
The accuracy profiles as well as the statistical calculations including the valida-
tion results and uncertainty estimates were obtained using e-noval® V3.0 software
(Arlenda, Belgium).
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8.4 Results and discussions
8.4.1 Design of experiments
For the optimization of HPLC conditions, an augmented central composite design
was generated using the following factors: the pH of the aqueous part of mobile phase
(pH), the gradient time needed to linearly modify the proportion of methanol from
15% to 95% of methanol (TG), and the column temperature (Temp). Experiment at
the center of the experimental domain (i.e. at pH = 4.43, TG = 40 min and Temp
= 27.5°C) was repeated trice, including the preparation of new buffer solutions.
Factors values are presented in Table 8.2. The data augmentation consisted of the
addition of 8 vertices of the cuboid domain and of 4×2 intermediate support points
to obtain better estimates the pH effect (red) at the central levels of TG (green)
and Temp (blue), leading to 32 experimental conditions.
Factors Levels
pH 1.85 2.42 3.14 4.42 5.71 6.42 7
Gradient time (TG, min) - 20 24.5 40 55.5 60 -
Temperature (Temp, °C) - 20 21.7 27.5 33.3 35 -
Table 8.2: Factors and corresponding levels of the augmented central composite
design
An isocratic elution step with 95% methanol for 10 min was applied after the
gradient to ensure the elution of all the tested molecules. For each experimental run,
the three retention times of each peak (apex, begin and end) were recorded. When
coelutions prevented the data treatment to be carried out properly, an independent
component analysis (ICA) was used to accurately determine the retention times of
coeluted peaks (Debrus et al., 2009). Furthermore, individual injections were made
when strong coelutions of many compounds with too similar UV spectra did not
allow peak identification and tracking.
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8.4.2 Model
Responses from the experimental data were modeled using the following multi-
variate linear model,
Y = XB + E,
yj = β0,j + β1,j.pH + β2,j.pH2 + β3,j.pH3 + β4,j.pH4 + β5,j.TG
+ β6,j.TG2 + β7,j.T emp+ β8,j.T emp2 + β9,j.pH.TG+ β10,j.pH.Temp
+ β11,j.T emp.TG+ β12,j.pH.temp.TG+ εj, (8.7)
where yj is the jth column of Y (j = 1, . . . , 3m). As commonly practiced,
quantitative factors were centered and scaled to [−1, 1] before being included in X.
8.4.3 Prior information and model quality
As stated previously, when limited prior information on responses is available a
priori, the parameters of the prior distributions should be as uninformative as pos-
sible. This is the case for the prior parameters B0 and Σ−10 , which are defined as 0
everywhere. However, it is known that the correlations among the three responses
describing one chromatographic peak are high. Indeed, as these responses are mea-
sures of the same compound, a strong dependence could be assumed. The matrix
A∗ might not account for this dependence accurately because data are limited. In
order to induce a stronger correlation, the prior parameter Ω is determined through
a correlation matrix Ωcor, defined as:
Ωcor = Im ⊗
 1 0.95 0.950.95 1 0.95
0.95 0.95 0
 ,
where Im is an identity matrix of size m and ⊗ is the Kronecker product. Finally,
the elements of Ωcor ≡ {ωcor,ij} were rescaled towards the estimated matrix A∗ as
follows:
Ω ≡ {ωij} =
√
a∗ii.ωcor,ij.
√
a∗jj
n0
n
, (8.8)
where a∗ii is the ith element of the diagonal of A∗. Thus, in practice, Ω is scaled to
A∗/n before being multiplied by n0 in order to be properly scaled (i.e. the scale of
a so-called scale matrix with ν0 = n0 − (m + p) + 1 d.f.). Since the experimental
design provided sufficient data to estimate the correlation structure, n0 has been
fixed to 3 to limit the influence of the prior information.
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Goodness of fit is evidenced by the relationship between observed and predicted
responses, and the corresponding residuals in Figure 8.1. As seen on the graph
(bottom), the majority of the residuals are distributed in the [-1, 1] min interval
and the p-values of the Shapiro-Wilk normality test of residuals are all above 0.05
except for the responses of phenylbutazone. Given the satisfactory fit of the model,
it can be used to predict the chromatographic behavior of each compound and to
compute DS.
Figure 8.1: Modeling results. (Top) observed vs. predicted responses. (Bottom)
residuals.
8.4.4 Design Space
As described in Section 8.2, the optimization process was repeated for each of the
five groups of materials. For each group, the model was simplified in order to account
only for the included materials, with the effect of reducing the size of the response
matrix Y (Gupta and Nagar, 1999, Appendix D.6). The computed Monte-Carlo
probability surfaces for P (Scrit > 0) for groups 1, 2, and 3 are presented in Figure
8.2 (top, middle and bottom, respectively). In Figure 8.3 (top), the probability
maps are the product of the probabilities P (Scrit > 0, ttot < 25), for each subgroup
of group 4. In this case, the DS consisted in the intersection of the individual DSs.
The shaded grey zones illustrate the part of the experimental domain where the
quality level was not achieved. Thus a unique optimal condition and an unique DS
was identified for all the subgroups (white area within red contour lines). Similar
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computation is depicted in Figure 8.3 (bottom, group 5) using the joint probability
P (Scrit > 0, ttot < 40min) for optimization, and the DSs intersection of the five
submixtures.
The DS shapes depicted in Figures 8.2 and 8.3 show broad regions with respect
to variations in TG ([40, 60] min for group 1 and 2, [57, 60] min for group 3, [20,
25] min for group 4 and [34, 36] for group 5), in Temp ([20, 35]°C for group 1, 2
and 4, [20, 27]°C for group 3 and from [23, 30]°C for group 5) and pH (from [3.90,
4.30] for group 2 and [1.83, 4] for group 4). These broad regions are key results as
they represent robustness w.r.t. changes of the operating conditions if quality level
is high. Robustness across a wide range of temperature is particularly important in
the case of using these methods in laboratories where the control of temperature is
difficult. This can be the case for some developing countries. Conversely, three of the
developed methods are far less robust with respect to pH ([2.80, 3.10] for group 1,
[6.90, 7.00] for group 3 and [6.05, 6.20] for group 5). Fortunately, the relatively poor
method robustness with respect to pH should not be problematic since this is easier
to control, and care can be taken during the buffer preparation and subsequent pH
measurements.
The results of optimal conditions and operating ranges are summarized in Table
8.3 for each of the 5 groups. For the three factors, the operating range is obtained
as the interval in which the probability to achieve a satisfactory quality is higher
than the specified quality level pi. pi is selected for each method in order to allow the
identification of a risk-based DS. Except for groups 3, this quality level is generally
high, indicating guarantees of quality for future use of the methods.
Optimal
conditions
Optimal
P (S > 0) pi pH TG (min) Temp (°C)
Group 1 67.00% 0.63 3.05 (2.80-3.10) 49.30 (40-60) 34.5 (20-35)
Group 2 ∼100.0% 0.95 4.05 (3.90-4.30) 53.14 (40-60) 23.0 (20-35)
Group 3 23.00% 0.2 7.00 (6.90-7.00) 60.00 (57-60) 21.7 (20-27)
Group 4 ∼100.0% 0.95 3.04 (1.83-4) 20.00 (20-25) 27.5 (20-35)
Group 5 ∼100.0% 0.95 6.14 (6.05-6.20) 35.00 (34-36) 29.4 (23-30)
Table 8.3: Optimal conditions and operating range within DS for the separation of
the 5 groups of tested materials.
To support the ability of the DS to predict analytical conditions that permit
chromatographic separation for the 5 groups, the different optimal conditions were
tested twice (involving the preparation of new buffer solutions) to assess repeatabil-
ity. Results are presented in Figures 8.4–8.6.
The grey area in the predicted chromatograms (top) is generated from 200 Monte-
Carlo simulated chromatograms. This provides information about the uncertainty
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Figure 8.2: (Top) probability surfaces P (Scrit > 0) for group 1. The DS is located
in the white region with minimum quality level of pi = 0.63. (Middle) probability
surfaces P (Scrit > 0) for group 2 with minimum quality level of pi= 0.95. (Bottom)
probability surfaces P (Scrit > 0) for group 3 with minimum quality level of pi =
0.22.
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Figure 8.3: (Top) Design Space identification P (Scrit > 0, ttot < 25) for group 4.
(Bottom) Design Space identification P (Scrit > 0, ttot < 45) for group 5. In both
cases, the DSs consist in the intersection of the DSs (pi = 0.95%) of the proposed
submixtures.
of the prediction. Given uncertainty of prediction, it is easy to visualize prediction
quality while assessing robustness. Figure 8.4 illustrates the quality of the predicted
optimal condition for the screening methods of groups 1 (left) and 3 (right). By the
same way, Figure 8.5 illustrates the prediction quality of a unique method to identify
and quantify eight combinations of NSAIDs in tablet. Figure 8.6 shows the results of
a unique method to analyze five NSAIDs in suspension or syrup, in the presence of
several adjuvants. As can be seen on the Figures 8.4–8.6, the chromatograms gener-
ated from materials tested under optimal conditions (bottom) are in close agreement
with the corresponding predicted chromatograms (top) since the chromatographic
peaks are accurately predicted, as shown by the limited uncertainty (grey). These
results are corroborated in Table 8.4. The difference between the predicted and the
observed critical separation was always negligible (less than one minute). Notably,
this is consistent with the pattern of residuals (Figure 8.1).
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Figure 8.4: (Left) optimal condition for group 1. (Right) optimal condition for group
3. (Top) predicted chromatograms including simulations showing the uncertainty of
predictions (grey). (Bottom) observed chromatograms.
Groups
Predicted
Separation
(min)
Observed
Separation
(min)
Error
(min)Subgroup
1 - 0.259 0.516 -0.257
2 - 0.894 0.317 0.577
3 - 0.115 0.016 0.099
4
1 1.946 2.034 -0.088
2 15.193 15.827 -0.634
3 14.636 14.475 0.161
4 9.168 9.175 -0.007
5 1.946 2.041 -0.095
6 16.35 15.975 0.375
7 1.946 2.033 -0.087
8 10.186 10.483 -0.297
5
1 0.616 0.225 0.391
2 0.616 0.267 0.349
3 0.597 1 -0.403
4 1.558 1.734 -0.176
5 0.923 0.675 0.248
Table 8.4: Predicted and observed critical chromatographic separations.
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Figure 8.5: Optimal condition for the height submixtures of group 4. For each sub-
figure: (top) predicted chromatogram; (grey) simulations showing the uncertainty
of prediction; (bottom) observed chromatogram.
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Figure 8.6: Optimal condition for the five submixtures of group 5. For each subfig-
ure: (top) predicted chromatogram; (grey) simulations showing the uncertainty of
prediction; (bottom) observed chromatogram.
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4-aminophenol was not part of the experimental plan. It always elutes close to the
column dead time. However, it was tested under conditions of optimal separation for
all groups containing paracetamol, and was well separated from other compounds
in every mixture and submixture. For instance, its retention time was 3.4 min at
the optimal condition of group 4.
8.4.5 Transfer
One of the other objectives of the present study was the reduction of analysis
time. This has important implications in the identification of substandard or coun-
terfeit medicines since rapid analytical results provide fast decisions about suspected
medicines. For this reason the screening method using HPLC (Figure 8.7 (a-b)) was
transferred to UHPLC (Figure 8.7 (c)) using geometric transfer methodology (Guil-
larme et al., 2007, 2008). Analytical conditions were similar on HPLC and UHPLC,
except those described in Section 3.3 and the gradient time, which was set to 3.52
min. As illustrated in Figure 8.7, the methods yielded very similar optimal sepa-
ration. This is associated with a 15-fold reduction in analysis time from screening
method, with 25 times less consumption of mobile phase. Because the UHPLC col-
umn geometry has been chosen to maximize the reduction of analysis time, a slight
loss in peak efficiency was observed as predicted by the chromatographic theory.
Detailed results are presented in Table 8.5. Relative retention times were used to
compare elution performance of the two LC systems. This was achieved by dividing
every retention time by the retention time of the last eluting material. Relative
predicted and observed retention times were close. Similar results were obtained
for the other groups of molecules, confirming the adequate geometric transfer of the
methods from HPLC to UHPLC.
Moreover, these results clearly show that the variability induced by the transfer
has not overly degraded the chromatographic separation. Thus, it also permitted
the demonstration of the high robustness of the developed methods by means of the
proposed DS optimization strategy.
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Figure 8.7: Optimal condition for group 2. (a) predicted chromatogram. (Grey) sim-
ulations showing the uncertainty of prediction. (b) observed chromatogram (HPLC).
(c) observed chromatogram resulting of the transfer to UHPLC.
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Pred
tR
Lower
Pred
Int
Upper
Pred
Int
Pred
tR
(rel)
Lower
Pred
Int
(rel)
Upper
Pred
Int
(rel)
Obs
tR
(rel)
Obs
tR
UHPLC
Obs
tR
UHPLC
(rel)
Obs
tRName
PAR 7.79 7.67 7.91 8.01 0.141 0.135 0.139 0.146 0.54 0.15
BEN 20.36 17.91 23.01 22.28 0.369 0.318 0.41 0.406 1.42 0.396
NIP 24.61 24.26 24.98 24.54 0.446 0.434 0.447 0.447 1.57 0.438
NIS 36.39 36.06 36.71 36.36 0.659 0.649 0.661 0.662 2.35 0.657
NIM 37.67 37.15 38.21 37.45 0.682 0.668 0.687 0.682 2.43 0.68
BHA 41.34 40.98 41.7 41.23 0.749 0.737 0.751 0.75 2.66 0.743
IBU 46.95 45.74 48.13 46.92 0.85 0.824 0.867 0.854 3.04 0.849
MA 49.9 48.51 51.11 49.98 0.904 0.876 0.923 0.91 3.25 0.908
BHT 55.21 54.76 55.64 54.95 1 0.988 1.004 1 3.58 1
Table 8.5: Results of the transfer from HPLC to UHPLC. (Columns 2-5) predicted
retention times (Pred tr), predictive intervals (Pred Int) and observed (Obs) re-
tention times for HPLC experiments. (Columns 6-9) relative (rel) predicted and
observed retention times from HPLC experiments. (Columns 10-11) observed and
relative observed retention times for UHPLC experiments. (Bold) comparison of
relative retention times.
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8.4.6 Method validation
After the optimization process, it is necessary to demonstrate that an analyt-
ical method provides accurate quantification results. This is carried out through
a method validation. In this study, a quantitative method for capsules containing
PAR, IBU and CAF (HPLC method for group 4, subgroup 5) was validated by ap-
plying the concept of total error represented by an accuracy profile (Hubert et al.,
2007, 2008). As the capsules contain PAR, a quantitative method for 4-aminophenol
impurity was developed concurrently. According to the European Medicines Agency,
a formulation is declared compliant if its active molecules are within 5% of the nom-
inal content (The European Medicines Agency, 1996). The accuracy profiles were
used to assess the ability of the analytical methods to accurately quantify these
three active ingredients, with acceptance limits that were set at 5% of the targeted
concentration of the analytes (i.e. 5% relative total error is tolerated). The objective
was thus to establish the dosing range in which the method is providing accurate
results. To adequately estimate the total error of the quantitative methods under
investigation and to mimic routine use of the method, three independent replicates
were made for each concentration level. The process was also repeated independently
during three days to estimate intermediate precision.
When a method is validated using the total error approach, and following the ac-
curacy profile methodology, the validation parameters designated in ICH Q2 (pre-
cision, accuracy, linearity) are simultaneously combined to define a concentration
range over which there is high probability to obtain future analytical results within
the predefined acceptance limits (ICH Q2(R1), 2005; Feinberg et al., 2004). Accu-
racy profiles are presented in Figure 8.8. For PAR, IBU and CAF, a simple linear
regression model was determined to be suitable for calibration. For 4-aminophenol,
a one-level calibration was found appropriate. Individual validation parameters are
presented in Table 8.6.
Trueness
Trueness is reported as the mean bias observed between the series of measure-
ments and the targeted concentrations. Using the calibration curve of each material
the concentrations of the VS were back-calculated and expressed in terms of abso-
lute bias (µg/mL) and relative bias (%) (Hubert et al., 2004; ICH Q2(R1), 2005)
The trueness of the developed methods was satisfactory, while the relative biases
were close to 0 and were less than or equal to 1.03%.
Precision
Precision refers to the ability of the method to provide proximate results from
multiple measurements of the same samples, under the same analytical conditions.
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Precision is expressed as relative standard deviation (RSD%), and is reported for
repeatability and intermediate precision at each targeted concentration. As shown
in Table 8.6, precision was acceptable. The RSD% values never exceeded 1.21%.
Accuracy
Accuracy was assessed using the 95% β-expectation tolerance interval in order to
analyze the closeness of agreement of individual measurements (ICH Q2(R1), 2005)
and the assumed true value of the associated measurement. This combines the
uncertainties associated with trueness and precision and is expressed as measured
values and as a percentage of the targeted concentration (Table 8.6). The methods
was found to provide accurate results, as the lower and upper tolerance bounds
are included within the acceptance limits for all the targeted concentration levels
Validation
criteria
Conc.
(µg/mL)
4-
PAR IBU CAF aminophenol
Trueness:
Absolute bias
(µg/mL)
(Relative bias
(%))
50 <0.01 (0.21)
200 1.72 (0.86) 2.06 (1.03) -0.71 (-0.36)
300 1.30 (0.44) -0.29 (-0.09) -3.01 (-1.01)
400 -0.71 (-0.18) -1.15 (-0.29) -3.64 (-0.91)
500 3.10 (0.62) 1.46 (0.29) -0.44 (-0.09)
600 1.27 (0.21) -1.32 (-0.22) -3.65 (-0.61)
Precision:
Repeatability (%)
/
Intermediate
precision (%)
50 1.19 / 1.35
200 0.20 / 0.36 0.18 / 0.67 0.36 / 0.59
300 0.16 / 0.33 0.35 / 0.35 0.75 / 0.75
400 0.17 / 0.40 0.38 / 0.55 1.08 / 1.08
500 0.16 / 0.55 0.32 / 0.63 1.21 /1.21
600 0.26 / 0.48 0.50 / 0.56 1.16 / 1.16
Accuracy:
95% β-exp. tol.
int. (µg/mL)
(Rel. 95% β-exp.
tol. int (%))
50 0.47–0.51
(-3.34–3.75)
200 198.3–203.2 195.0–207.1 194.4–202.2
(-0.37–2.09) (-2.02–4.09) (-2.32–1.62)
300 296.2–303.4 295.7–300.8 290.0–301.0
(-0.77–1.64) (-0.95–0.76) (-2.84–0.83)
400 391.2–403.4 390.1–403.6 383.9–404.8
(-1.72–1.37) (-1.98–1.40) (-3.55–1.72)
500 488.4–512.8 487.2–510.7 482.4–11.8
(-1.83–3.08) (-2.07–2.65) (-3.04–2.87)
600 587.9–608.7 587.1–604.3 576.4–610.3
(-1.53–1.95) (-1.66–1.22) (-3.45–2.22)
Linearity: Slope 1.001 1.001 1.002
Intercept 0.979 -1.555 -4.071
R2 0.998 0.997 0.99
Table 8.6: Summary of the validation criteria for PAR, IBU, CAF and 4-
aminophenol.
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(Figure 8.8), thus assuring that each future result will fall within the acceptance
range with a probability of at least 95% (Boulanger et al., 2003). Moreover, the
relative 95% β-expectation tolerance intervals are generally within a range of [-3,
+3]%.
Figure 8.8: Accuracy profiles for quantitative methods validation
(PAR=paracetamol, IBU=ibuprofen, CAF=Caffeine). (Red) bias (%). (Black)
acceptance limit (±5%). (Blue) 95% β-expectation tolerance interval. (Green)
individual measures. For the 4-aminophenol, a one-level calibration is used.
Linearity
The linearity of the results expresses the ability of the methods to produce results
directly proportional to the concentrations. A simple regression model was adjusted
to the observed vs. targeted concentration results to measure the linearity of the
results. The coefficient of determination (R2) obtained for the three compounds were
all higher than 0.999 thus supporting the adequacy of the linear model adjusted. In
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addition, the linearity of the results was illustrated by the slopes of these regression
models that are close to 1, ranging from 1.001 to 1.002 for PAR, IBU and CAF.
This demonstrates the linearity of the results for the developed method.
Finally, for each concentration level of the VS, the 95% β-expectation tolerance
intervals were all within ±5% of the targeted concentration of the analytes studied.
8.4.7 Application
The validated method was applied to the identification and assay of the three
active ingredients (PAR, IBU, CAF). As an example, five different brands of phar-
maceutical drugs coded A, B, C, D and E were tested. These were purchased in
capsule form in the DRC and are mainly of Indian origin. Dilutions of the drugs
were adapted so that the concentrations fell within the assay ranges.
PAR CAF IBU
Drug Content Content Content
A 325 mg 30 mg 200 mg
98.4 ± 0.41 % 90.7 ± 1.49 % 103.7 ± 0.74 %
B 325 mg 40 mg 200 mg
100.0 ± 0.35 % 94.7 ± 0.63 % 103.0 ± 0.58 %
C 200 mg 40 mg 400 mg
90.4 ± 0.22 % 85.2 ± 0.79 % 91.1 ± 0.73 %
D 325 mg 40 mg 400 mg
78.2 ± 0.39 % 74.5 ± 0.44 % 77.9 ± 0.15 %
E 325 mg 40 mg 400 mg
78.9 ± 0.28 % 75.9 ± 0.31 % 80.6 ± 0.35 %
Table 8.7: Assay results of five pharmaceuticals marketed in DRC. Results consist
in the mean percentage of claimed nominal content and the standard deviation
computed on 3 independent samples. Specifications are set to 95%–105% of the
claimed nominal content (mg). (Bold) non-compliant results for the tested tablets.
The five drugs contained the three active ingredients but, as shown in Table
8.7, most of the products were in one way or another non-compliant. For example,
product A had a declared nominal amount of caffeine equal to 30 mg, while only
90% of this amount was measured. For product B, the measured amount of caffeine
was about 95% of the claimed nominal amount of 40 mg. From the low number of
experiments carried out, this product is however considered non compliant. Finally,
products C, D and E were not compliant since the contents of the 3 active ingredients
were below the acceptance criteria.
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The determination of the impurity of PAR (i.e. 4-aminophenol) was also es-
tablished because of its potential toxicity. The European Pharmacopoeia places a
limit of no more than 0.005% of 4-aminophenol in 100% paracetamol raw material
(European Pharmacopoeia (2011c)). With pharmaceutical formulations, slightly
higher concentrations might be tolerated due to the possible natural degradation
of PAR during the manufacturing process. However, to our knowledge, no precise
specification exists. The method for 4-aminophenol was determined to be valid to
quantify as low as 0.1% of 4-aminophenol (0.5 µg/mL) in 100% paracetamol (500
µg/mL); however further experiments have shown that the limit of detection for 4-
aminophenol is about 0.1 µg/mL. This would represent 0.02% of 4-aminophenol in
100% paracetamol, equivalent to four times the acceptance criterion of the European
Pharmacopoeia.
The presence of 4-aminophenol was investigated in the five tested drugs and was
not detected. Therefore, this seems to show that the low levels of active ingredients
are linked to an insufficient dosing of these medicines rather than poor storage
conditions.
8.5 Conclusions
The main objective of this work was to develop generic methods able to trace,
screen and determine multiple non-steroidal anti-inflammatory molecules and com-
mon associated molecules, in order to help detect the potential counterfeiting of
these drugs.
Using an experimental design based on three analytical factors (temperature,
pH and gradient time), HPLC methods for five groups of NSAIDs and molecules
of interest were developed in an innovative predictive risk-based framework. As
an outcome of this original methodology, DSs were identified. This approach was
then very helpful to optimize the separations of the tested molecules, allowing, for
instance, their further quantification. The experiment showed that only the pH
and gradient time had significant effects on peak separations within the explored
experimental domain. The effect of temperature on quality was assessed and found
to be limited. This may be due to the narrow range of temperatures investigated,
but may suggest that using these methods in laboratories with no or insufficient
temperature control is acceptable.
In order to concurrently support the robustness demonstrated using the com-
puted DSs and to provide faster analytical methods with less solvent consumption,
geometric transfer was used to adapt the optimized HPLC method to a UHPCL
system. Faster methods are critical for laboratories involved in the control of drugs
and counterfeits due to the increasing demands of analysis by legal authorities.
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As an example of validation and application of their use in routine testing, a
selected method was used for the determination of paracetamol, ibuprofen, caffeine
and one impurity of paracetamol (4-aminophenol). The method was successfully
validated using the total error approach and accuracy profile methodology. Finally,
the method was effectively applied to analyze 5 brands pharmaceuticals marketed in
the Democratic Republic of Congo. On the basis of the dramatic results obtained, it
was confirmed that substandard and counterfeit medicines remain a crucial problem
on public health in low-income countries.

Chapter 9
Design Space approach in the
optimization of the spray-drying
process
This chapter has been published in the European Journal of Pharmaceutics and
Biopharmaceutics (Lebrun et al., 2012b).
9.1 Introduction
Nowadays, there is an increasing demand from regulatory authorities calling for
the pharmaceutical industries to gain a comprehensive understanding of their man-
ufacturing processes together with an accurate estimation of their robustness and
reliability. Instead of providing solutions to meet these demands and requirements,
authorities such as the International Conference on Harmonization (ICH) have pub-
lished guidelines establishing the overall methodology to achieve these expectations.
In the ICH Q8 (2009) guideline on pharmaceutical development, the emphasis is
put on the “Quality by Design” (QbD) concept, stating that quality should not be
tested into products, but should be built in (Yu, 2008). The Design Space (DS) con-
cept is also introduced in this guideline, which is “the multidimensional combination
and interaction of input variables (e.g., materials attributes) and process parameters
that have been demonstrated to provide assurance of quality.” Furthermore, ICH
indicates that as long as the process and formulation parameters are kept within
the defined DS, no regulatory post-approval change is needed. Thus, the DS of a
process must also guarantee its reliability and robustness. In the US, the Food and
Drug Administration (2011) has released the manual of policies and procedures for
the effective application of several guidelines including ICH Q8. This is a strong
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indicator that industries must now be fully compliant with these QbD approaches.
Pulmonary delivery is an attractive administration route for the treatment or
prophylaxis of airways diseases. It is also a reliable alternative to the subcutaneous
and intravenous administration routes, especially for proteins and peptides. Indeed,
the large surface area of the alveolar epithelial, the abundance of capillaries, and the
low thickness of the air-blood barrier enable a drug delivery with systemic activity
(Taylor, 2001).
Optimal drug deposition in the lungs requires several criteria to be fulfilled in
terms of morphological aspects and ventilatory parameters. In addition, the par-
ticle’s size and geometry aspects are also crucial (Groneberg et al., 2007). The
optimum aerodynamic particle size for delivery is in the range of 1–5 µm (Hickey,
1996). Among the different particle processing techniques, spray-drying is known
to produce particles that well fulfill the requirements for the pulmonary administra-
tion route. This processing technique offers many advantages, the first one being
that the drying time of a droplet is only a fraction of a second, with a fast evapo-
ration avoiding droplet overheating. The second one is that the final product has
a large surface area and a uniform and controllable particle size (Maltesen et al.,
2008). Furthermore, spray-drying is a continuous drying process consuming less
energy than a freeze-drying process, for example (Masters, 2002). All the previous
advantages make spray-drying (see Figure 9.1) an attractive manufacturing process
for the pharmaceutical industry.
Figure 9.1: Mini spray-drier.
The aerodynamic properties of the powders obtained by spray-drying are deter-
mined by the particle size, density, and shape, which are influenced by spray-drying
process parameters such as the inlet/outlet temperature, the air flow rate, and the
feed flow rate (Cabral-Marques and Almeida, 2009). Facing the previous considera-
tions, it is obvious that a holistic approach is needed to map the process parameters
interactions. In this context, design of experiments is perfectly adapted to gather
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the data and translate how the combination of Critical Process Parameters (CPPs)
affects the product Critical Quality Attributes (CQAs). It will eventually help defin-
ing the combinations of CPPs that will keep the product performance within the
specifications with a quantified guarantee for the future use of the process: the
Design Space.
In this context, the DS being identified is a region of reliable robustness, into
the knowledge space. To provide guarantees of future quality, DS can be defined
in a risk-based framework. The approach would finally be compliant with the QbD
expectations. The results focus on the assessment of quality and on the guarantees
(risks) that this quality could (could not) be achieved. Formally, Design Space is
defined as
DS = {x˜ ∈ χ | P (CQAs ∈ Λ | x˜, data) ≥ pi} (9.1)
In other words, the DS is a region of an experimental domain χ (often called
knowledge space) where the posterior probability that the CQAs are within specifi-
cations Λ, is higher than a specified quality level pi.
Predictive posterior probability is central when dealing with concepts such as De-
sign Space, as it allows quantifying the guarantees and risks that specifications will
(or will not) be met in the future runs of the process, given the today’s information.
Specifications express the minimal satisfying quality that the experimenters want to
obtain.
The optimization of multiple response surfaces usually involves the overlapping
mean responses approach, which can be computed with commercially available soft-
ware packages such as Modde, SAS-JMP, Minitab, Statistica. This approach is
performed as follows: if, for example, a process response is influenced by three
process parameters, then specific pieces of software can generally display the mean
predicted process responses for any combination of the three process parameters
within the defined parameter range. However, such approach does not take into ac-
count the model uncertainty: it will not provide any indication about how well and
how often the process can meet the specifications with respect to the investigated
CQAs, as stated by Peterson (2008). This represents a major drawback since ICH
Q8 is clearly asking for a level of assurance guaranteeing the product specifications
will be met.
In contrast to the overlapped mean response approach, a Bayesian predictive ap-
proach to define the DS takes into account the uncertainty of the process and of the
analytical methods used to determine the CQAs and the uncertainties and corre-
lations between the envisaged responses and the derived CQAs (Castagnoli et al.,
2010). This approach integrates the uncertainty of parameters and the correlations
between CQAs by propagating the multivariate error associated with the responses
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prediction. Consequently, the Bayesian predictive approach will significantly im-
prove the model’s prediction ability. We believe that this is the most efficient way
for “demonstrating assurance of quality” as requested by the ICH Q8 definition of
the DS. Within the pharmaceutical industry, the application of Bayesian statistics
now begins to gain more interest and to be well accepted by authorities, especially
in the field of clinical trials, as advocated by the Food and Drugs Administration
(2010). Among other qualities, the Bayesian approaches allow the incorporation of
prior information into models, if available, and may ease the solutions toward the
predictive risk assessment.
In a previous work, Baldinger et al. (2001) investigated the influence of the pro-
cessing parameters inlet temperature, spray flow rate, and feed rate on the following
Critical Quality Attributes: yield, moisture content, particle size, and flowability by
means of a design of experiment. However, high uncertainty was observed on most
of the model parameters and no DS was identified. In this context, however, the
question is to know to what extend the uncertainty could impact the prediction re-
liability. Within the framework of that previous work, the aim of the present study
was to extend the approach of Baldinger et al. (2001) to define the spray-drying
process DS according to ICH Q8. To our knowledge, this represents the first truly
QbD-compliant approach to a spray-drying manufacturing process.
9.2 Materials and methods
9.2.1 Materials
D (–)-mannitol and D (+)-trehalose dihydrate were purchased from BDH Prolabo
(Leuven, Belgium). Spray-drying was performed using 100 mL of an aqueous solu-
tion containing 10 g of a mixture of mannitol and trehalose in a mass ratio 90/10.
Products were stored in closed vials at 5% relative humidity at room temperature.
9.2.2 Spray-drying
A Büchi Mini Spray-Dryer B-290 (Büchi Labortechnik AG, Flawil, Switzerland)
with a 0.7-mm two-fluid nozzle was used. The solution was sprayed in a co-current
flow with air as drying medium. Relevant spray-drying parameters were varied as
stated in Section 9.3. The spray-dried particles were separated from the drying
air by an improved cyclone (Maury et al. (2005)). Other key parameters were kept
constant: The aspirator rates were set at 100% in all experiments, leading to a drying
air flow of approximately 35 m3/h. Spray-dried powders were collected, weighed,
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and stored in capped glass vials.
9.2.3 Particle size measurement by laser diffraction
The particle size distribution of the dry powders was measured using a laser
diffractometer Mastersizer 2000 connected with a Scirrocco 2000 powder feeder
(both: Malvern Instruments, Malvern, UK). For the measurement of the particles
in air, a dispersion pressure of 1 bar was used.
9.2.4 Thermogravimetric analysis
The residual moisture content of the samples was investigated directly after spray-
drying by using a TGA 7 (Perkin Elmer, Norwalk, CT). Powder samples between 3
and 12 mg were loaded onto a platinum sample pan and heated from 25 to 150 °C
at a rate of 10 °C/min.
9.2.5 Bulk and tapped density
Bulk density and tapped density were obtained by following the European Phar-
macopoeia (2011a) procedure 2.9.34. Due to the small amount of sample, a 10-mL
tarred graduated cylinder was used. The bulk volume used for the calculation of
the bulk density was directly read from the cylinder. Triplicates were made, and
the mean value has been taken to define the bulk density.
Bulk density (g/ml) = (weight of powder) / (bulk powder volume)
The tapped density is obtained by mechanically tapping a graduated measuring
cylinder containing the powder sample. The tapped density is read after 1250 taps
corresponding to 5 min at a tapping height of 3 mm. The mean value of three
replicates is recorded along with the observed variances among the experiments.
Tapped density (g/ml) = (weight of powder) / (tapped powder volume)
9.2.6 Softwares
An in-house computer program was developed to perform the statistical analysis.
The coding was done with R 2.12, freely distributed at http://www.r-project.org
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and available for most operating systems (R Development Core Team, 2010). The
package mvtnorm developed by Genz et al. (2011) has been used in order to sample
from a multivariate Student’s distribution.
9.3 Design of experiments
9.3.1 Critical Process Parameters
Three CPPs have been identified as having an impact on product quality. They
are the inlet temperature, the spray flow rate, and the feed rate. Their range and
unit are presented in Table 9.1.
Critical Process Parameters Abbreviation Low level High level
Inlet temperature (°C) IT 110 220
Spray flow rate (L/h) SFR 439 1744
Feed rate (ml/min) FR 2.5 7.5
Table 9.1: The Critical Process Parameters, their abbreviations and ranges.
For these three factors, a central composite face-centered design has been chosen,
leading to n = 17 experiments comprising a center point in (independent) triplicates
(Montgomery, 2009). Other key process parameters such as the drying air flow, the
aspirator rate, the product variables (raw material characteristics) are kept constant.
9.3.2 Critical Quality Attributes
On every experiment, CQAs are recorded or derived from other attributes. They
are defined in order to allow numerical assessment of the quality of the output. For
every CQA, a specification (Λ) is given that indicates a minimal satisfactory level
of quality. The knowledge about these specifications can be a hard task, but it is
the key toward a thorough and sound understanding of the process. Economical,
efficiency, and safety reasons help in the definition of specifications. The five CQAs
that will be taken into account for further analysis are reviewed hereafter.
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Yield
The yield of the process is taken as a first quality attribute. It is computed as the
percentage of obtained powder to the use of raw material. The experimenter will
naturally look for a high yield. A specification limit can be derived from economical
reason, but also from practical process management, and leads to a yield that must
not be inferior to 80 %. A yield that is lower than this limit means that the use of
the raw material is not optimal. In this case, the proportion of raw material that is
not present in the obtained powder may be lost in the apparatus and more cleaning
would be needed.
Moisture content
The residual moisture content of the obtained powder was analyzed using a ther-
mogravimetric analysis. However, one can be easily convinced that a spray-dried
powder has generally a very low level of moisture. Precision of the thermogravi-
metric apparatus is low in this case. For obvious quality reasons (conservation,
non-aggregation of the powder), residual moisture of no more than 1% must be
observed.
Aerodynamic particle size – inhalable fraction
The optimum aerodynamic particle size distribution for most inhalation aerosols
has generally been recognized to be in the range of 1–5 µm (Hickey (1996)). Aerosols
outside this range generally do not deposit in the lungs. The actual data consist of
a mean of two analyses from the Mastersizer. The specification for this CQA is set
to a minimum proportion of 60% of the particles should have a size between 1 and
5 µm.
Compressibility index and Hausner ratio
Two final CQAs are taken into account, the compressibility index (sometimes
referred as Carr’s index) and the Hausner ratio. They quantify the flowability of
the obtained powder. They are both computed on the basis of the bulk and tapped
density of the obtained powder:
Compressibility index (%) = 100 x (tapped density – bulk density) / tapped density
Hausner ratio = tapped density / bulk density
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Since the compressibility index and the Hausner ratio are the combinations of ran-
dom variables, we do not envisage their direct modeling. Instead, it is preferable to
model the tapped density and the bulk density and to derive the two CQAs from
these two responses. Table 9.2 illustrates some specifications about the compress-
ibility index and the Hausner ratio (European Pharmacopoeia, 2011b):
Flowability Compressibility index (%) Hausner ratio
Excellent 0–10 1.00–1.11
Good 10–15 1.12–1.18
Fair 16–20 1.19–1.25
Passable 21–25 1.26–1.34
Poor 26–31 1.35–1.45
Very poor 32–37 1.46–1.59
Very, very poor > 38 >1.60
Table 9.2: Specification for compressibility index and Hausner ratio.
Specifications for the compressibility index and the Hausner ratio have been cho-
sen such as to have a good flowability, that is, the compressibility index must be
lower 15% and the Hausner ratio lower than 1.18.
The five CQAs are summarized in Table 9.3 together with their specifications Λ.
An optimized process should provide outputs satisfying all the five specifications
simultaneously, with the highest level of quantified guarantee possible.
CQA Specification
Yield ≥ 80
Moisture ≤ 1
Fraction [1-5]µm ≥ 60
Compressibility index ≤ 15
Hausner ratio ≤ 1.18
Table 9.3: The CQAs and their specifications.
9.4 Results and discussion
9.4.1 Model
In this section, the statistical model and the related results are detailed.
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Responses
From the analysis of the CQAs, five model responses are envisaged to allow
analyzing the quality of the output (obtained powder):
• Y ield
• Moisture
• Fraction (Aerodynamic particle size - inhalable fraction)
• Bulk (density)
• Tapped (density)
The yield and the inhalable fraction are percentage values, and should have a
range constrained to a domain [0-100]%. A logit transformation is applied to ensure
that this property will be valid during the predictions:
LY ield = log
(
Y ield
100− Y ield
)
,
LFraction = log
(
Fraction
100− Fraction
)
.
For the 3 other variables, log transformations are applied to ensure positivity.
LMoisture = log(Moisture),
LBulk = log(Bulk),
LTapped = log(Tapped).
Notice also that a good practice is to constrain the value of bulk and tapped
density so that the tapped density is always higher than the bulk density. Otherwise,
the computation of the compressibility index and the Hausner ratio could lead to
a negative value or value smaller than 1, respectively. Constraints can be applied
during a Monte-Carlo simulation step, discarding the samples that do not fulfill
them.
Multivariate multiple linear regression
To account for the correlations that will be observed between the responses, a
multivariate multiple linear regression (MMLR) is adopted. Other statistical models
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are possible but MMLR has the advantage of simplicity for the identification of its
predictive distribution. This model is fitted for every response jointly
Y = (LY ield, LFraction, LMoisture, LBulk, LTapped).
Let the following model be applied on the m = 5 responses (j = 1, ...,m),
yj = β0,j + IT.β1,j + IT2.β2,j + FR.β3,j + FR2.β4,j + SFR.β5,j+
IT.SFR.β6,j + IT.FR .SFR.β7,j + εj,
Y = XB + E, (9.2)
with the lines of E, εi, assumed to be i.i.d. as a multivariate Normal distribution,
εi ∼ N(0,Σ), i = 1, . . . , n, with n the number of experiments. X is then the (n× p)
centered and reduced design matrix and B is the (p ×m) matrix containing the p
effects for each of the m responses. The modeled effects have been chosen so that
the model has the best properties for every response, jointly. Σ is the covariance
matrix of the residuals. In order to account for the variability of the parameters
B and Σ , a predictive density of new predicted responses can be obtained in the
Bayesian framework, considering the non-informative prior distribution p(B,Σ) =
|Σ|−(m+1)/2(see Box and Tiao, 1973; Peterson, 2004). In this context, the predictive
posterior density of a new predicted set of responses (y˜ | X = x˜, data) at a new
operating condition x˜ ∈ χ, is identified as a multivariate Student’s distribution,
defined as follows:
(y˜ | X = x˜, data) ∼ Tm
(
x˜Bˆ,A.
(
1 + x˜(X′X)−1x˜′
)
, ν
)
, (9.3)
where Bˆ is the least squares estimate of B, Bˆ = (X′X)−1X′Y, and A = (Y −
XBˆ)′(Y−XBˆ) is a scale matrix and ν = n− (m+ p)− 1 is the degrees of freedom.
Effects analysis
The analysis of the parameters effects is done using the marginal posterior den-
sity of the parameters B, as in Box and Tiao (1973). This density is centered on
the ordinary least squares estimates Bˆ and provides the credible intervals of the
parameters, as shown on Figure 9.2. It illustrates the high uncertainty observed
on most of the regression parameters. The parameters for which the marginal 95%
credible intervals contain 0 are said to be nonsignificant (red) whereas the others
differ significantly from 0 (green).
Briefly looking at Figure 9.2, one may observe that the increase in feed rate
and spray flow rate have a positive impact on the moisture content of the product.
However, as the moisture remains limited whatever the condition, this may not have
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Figure 9.2: Parameter estimates and 95% credible intervals. (Green) Parameters
significantly different from 0. (Red) Parameters non-significantly different from 0.
a strong impact on the overall quality. The same CPPs show a negative impact on
both bulk and tapped densities. Next, the inlet temperature shows a negative impact
on the yield. It might be due to the fact that more agglomerates are created at higher
temperature, leading to a lower yield (Baldinger et al., 2001). The same observation
is done about the inhalable fraction. These types of results are the first keys toward
a better understanding of the process. Finally, Figure 9.2 clearly emphasis the
necessity in considering the uncertainties of the parameters, when envisaging a risk-
based approach. If checking their mean values and their distributions provide good
insights into the process, it does not provide any direct valuable information on the
quality of the output of the process, nor on the guarantee that this quality would
be achieved.
Predicted vs. observed and residual analysis
Other model checks allow a better understanding of the model’s capabilities.
Firstly, it is advised to visualize the model suitability by plotting the mean (un-
transformed) predicted responses against the observed ones. The residuals have
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been graphically also checked, as illustrated in Figure 9.3.
Figure 9.3: Predicted vs. observed plots (top) and residuals plots (bottom) for every
response.
Figure 9.3 illustrates the low quality of the multivariate model. This has clear
explanations for responses like the moisture content (low precision of the measuring
device for very low concentrations) or the tapped/bulk density (that are experi-
mentally carried on small quantities of powder). Again, taking into account these
residual uncertainties allows giving risk-based results even in the presence of poor
model fit. Finally, Q–Q plots are drawn to see whether the model residuals do not
depart from Normality assumption. This is shown in Figure 9.4. The hypothesis of
Normality of the residuals seems acceptable.
Figure 9.4: Marginal Normal Q-Q plots of the residuals.
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Response correlations
From the model, one can estimate the correlations that exist between the re-
sponses by rescaling the matrix A into an estimated correlation matrix, by dividing
its elements with the appropriate row and column standard deviations (Draper and
Smith, 1998). The correlations are given in Table 9.4.
LY ield LTapped LMoisture LBulk LFraction
LY ield 1
Ltapped -0.05 1
Lmoisture 0.16 0.04 1
LBulk 0.30 0.90 0.31 1
LFraction 0.83 0.32 0.28 0.60 1
Table 9.4: Estimated residuals correlations between the responses.
A strong correlation (0.90) is observed between the bulk and the tapped densities
meaning that these two values generally have a similar behavior. These similarities
might be a result of the tapping process carried out on small quantities of powder.
The observation is as follows: if the bulk density is low (high), this will give a
proportionally low (high) tapped density. From a statistical point of view, not
taking this correlation into account when deriving the compressibility index and the
Hausner ratio would be harmful. Next, there is an agreement between the yield and
the inhalable fraction. In the present process, the higher the yield, the higher the
inhalable fraction will be. In addition, a correlation of 0.60 between the inhalable
fraction and the bulk density can be observed. From a physical point of view,
this can be explained by the fact that the lower the particle size is, the higher the
bulk density will be. Moreover, the tapped density being correlated with the bulk
density, the tapped density is also slightly correlated with the inhalable fraction.
Nevertheless, this correlation is lower than the one between the inhalable fraction
and bulk density because the inhalable fraction determination is based on the bulk
powder and not on the tapped one
Design Space computation
Basically, the way to compute the DS is to use the joint predictive distribu-
tion of the CQAs, derived from Equation (9.3) in every point of the experimental
domain. When CQAs are transformations and/or combinations of the responses,
Monte-Carlo simulations are envisaged to propagate the predictive uncertainty and
interactions/correlations of the responses to the CQAs. Randomly looking at a point
xsub of the knowledge space, for instance, Inlet Temperature = 180 °C, Feed Rate
= 2.5 ml/min, Spray Flow Rate = 1744 L/h, one can analyze the sampled CQAs
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derived from the responses drawn from the multivariate Student’s t distributions,
as shown on Figure 9.5.
Figure 9.5: Marginal predictive kernel density estimations of the Critical Quality
Attributes on a point xsub of the experimental domain. The red lines are the spec-
ification limits and the red regions are the estimated probabilities of achieving the
specifications. The black lines are the medians (plain) and the means (dashed) of
the distributions.
The red lines indicate the specifications for each CQA, while the red regions of the
predictive densities illustrate the proportion of simulated points (i.e., the estimated
predictive probability) that are within specifications. For instance, at operating
condition xsub and for the CQA Y ield, the proportion is about 30%, meaning that
there is a probability of about 0.3 to have, in the future, a yield higher than 80%
(P (Y ield ≥ 80%) = 0.3).1 This represents a high risk of 1 − 0.3 = 0.7 of being
outside the specification. Taking into account the yield alone, this condition may
thus be considered outside of the DS with a satisfying quality level. Regarding the
Moisture content, the probability to have this CQA within the specification is 0.8,
so there is a risk of 0.2 of being outside specifications. Envisaging this CQA alone,
xsub could belong to the “design space” with a specified minimal quality level pi of,
say, 0.6. However, going multivariate deteriorate the results. The joint probability
to accept all the specifications is lower than 0.001. The xsub input condition is then
clearly not within any DS.
Next, the same computations are done, on every point x˜ of the experimental
domain χ. To do so, a grid search is applied. For each operating condition, the
1i.e., P (Y ield ≥ 80% | data) = 0.3. The conditioning on data is removed to simplify the
notations.
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Figure 9.6: Posterior probability map that the CQAs satisfy the five specifications
presented in Table 9.3. Inner black lines define the DS for the minimal quality level
pi=0.437 The black point is the sub-optimal condition xsub presented in Figure 9.5.
estimated expected probability that the 5 CQAs are jointly within specifications
is recorded. A probability map is then drawn, as shown in Figure 9.6. A clear
similarity with response surface is seen, but the interpretation of such maps is quite
different. In each operating condition represented, the map gives the joint expected
probability (i.e., the guarantees) to observe the process within specifications, on
a future run. On the cuboid knowledge space, only three slices that include the
optimal condition are represented.
The black-contoured region is the DS, i.e., the operating conditions where the
joint probability to achieve all specifications on the CQAs is the highest over the
experimental domain. A cuboid can be extracted, and the limit values for its vertices
are given in Table 9.5.
Critical Process Parameters DS range
Feed Rate (ml/min) [4.2–4.8]
Spray Flow Rate (L/h) [1614–1744]
Inlet temperature (°C) [118–125]
Table 9.5: Design Space of the process.
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Figure 9.7: Marginal predictive kernel density estimations of the Critical Quality
Attributes on at the optimum. See Figure 9.5 for colors and legend.
In this application, a DS is found, for a specified minimal quality level of pi=0.437,
chosen as 95% of the quality level of the optimal solution. However, one can be
suspicious about the quality of the results. Indeed, the optimal expected probability
is only about 0.45. Thus, within the DS, there is a risk of 0.55 not to be within all
the specifications concurrently. A good insight for a better comprehension of what
happens is to have a look at the marginal predictive distributions at the optimal
point, which is: Inlet Temperature = 123.75 °C, Feed Rate = 4.69 ml/min and Spray
Flow Rate = 1744 L/h, as shown in Figure 9.7.
Regarding Figure 9.7, it is obvious that, marginally, the estimated expected prob-
abilities for every CQA are quite satisfactory. The acceptance probability is higher
than 0.7 for the yield (P (Y ield ≥ 80%) = 0.71), 0.78 for the moisture content
(≤ 1%), 0.62 for the inhalable fraction (≥ 60%), and 0.85 for both the compress-
ibility index (≤ 15) and the Hausner ratio (≤ 1.18). Then, except for the inhalable
fraction, the model provides us a satisfying confidence toward the future performance
of the process.
From a probabilistic perspective, the addition of univariate specifications in a
multivariate analysis logically leads to a decrease of the joint predictive probability
of acceptance (Ekins et al., 2002). At optimal condition, the following decreasing
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probabilities illustrate this situation.
P (Y ield ≥ 80%) = 0.71,
P (Y ield ≥ 80% and Moisture ≤ 1%) = 0.56,
P (Y ield ≥ 80% and Moisture ≤ 1% and Fraction ≥ 60%) = 0.48,
P (Y ield ≥ 80% and Moisture ≤ 1% and Fraction ≥ 60% and Hausner ≤ 1.18) = 0.45
The definition of multivariate specifications may be seen as a remedy to this.
In this context, desirability functions can be envisaged to aggregate the values of
every individual predicted CQA into a single value, namely the desirability index,
representing the desirability of the solution (Harrington, 1965; Derringer and Suich,
1980; see also Chapter 5). Steuer (2000) has shown how Monte-Carlo simulations
can be used to propagate the predictive uncertainty and the correlations of the CQAs
(or the responses) to the desirability index. This index allows for certain trade-offs
between the CQAs. A slightly bad result for one CQA could be compensated by a
very satisfactory result for another.
In this 5-CQAs study with univariate specifications, it may not be surprising to
observe the optimal joint estimated expected probability of acceptance being about
0.45. Of course, finding a DS with a higher minimal quality level and even stronger
specifications would be an even more desirable situation.
Some estimates for each CQA are provided in Table 9.6, computed from the
distribution presented in Figure 9.7. The mean values (dashed lines) or the medians
(plain line) are the values expressing the central tendency one can expect to observe.
Additionally, the 75% and 95% Bayesian predictive intervals are also provided as
valuable information about the uncertainty of prediction.
CQA Lower 95% Lower 75% Median Mean Upper 75% Upper 95%
Yield (%) 42 75 88 81 94 100
Moisture content (%) 0.26 0.57 0.71 0.76 0.89 1.31
Inhalable fraction (%) 17 49 70 65 85 100
Compressibility index 0.4 6.2 8.8 9 11.5 16.1
Hausner ratio 1 1.07 1.09 1.1 1.13 1.19
Table 9.6: Statistics on the CQAs at the optimal input condition.
For instance, the 75% predictive interval around the CQA Inhalable fraction is
very large ([49–85]%). Then, the model is poorly informative regarding this CQA. A
similar conclusion was reached when looking at the marginal acceptance probability
for this CQA at the optimum, which was only 0.62.
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9.4.2 Validation
The optimal solution has been carried out three times independently on the same
apparatus to observe how the process performs within its 0.45 quality level DS. Table
9.7 summarizes the experimental results. They reinforce the statistics observed
during the optimization process.
Compressibility Hausner
Batches Yield (%) Moisture (%) Fraction (%) index ratio
1 88 < 0.2 63 11.6 1.13
2 89 < 0.2 62 12 1.14
3 88 < 0.2 59 11.5 1.13
Mean 88.7 < 0.2 61.18 11.76 1.13
Standard Deviation 0.61 NA 1.82 0.22 0.01
Table 9.7: Results of the validation experiments.
As expected, the process performs according to the predictions. Most batches
are within specifications. The inhalable fraction is seen as acceptable (higher than
60%) except in the third batch (red). However, on average (bold), the process
corroborates the results of the joint expected probability, which was about 0.45.
Obviously, a longer-term study would be necessary to plainly assess the routine
performance of the process.
Finally, Table 9.7 provides the indication of the variability observed in the three
independent batches. This variability is low compared to the predictive uncertainty
that was observed (see Figure 9.7 and Table 9.6). This indicates that the residuals
predictive uncertainty is not only due to the noise of the process. The poor model
fit is also a concern. A possible explanation is that more complex interactions and
higher order or non-linear effects are present. Unfortunately, the central composite
face-centered design used in the experimental part is too light to detect such effects.
Indeed, the design allows only the estimation of the main and quadratic effects
and the principal interactions. This underlines the need to define more informative
designs when little is known about the process, even if the price that must be paid
is the carrying out of more experiments.
9.5 Conclusions
When setting up a QbD-compliant ICH Q8 Design Space for a process such as
spray-drying, the use of the mean response surface optimization methodology is
not recommended due to the inevitable uncertainties and interactions that are en-
countered. Accordingly, the data gathered through an experimental plan have been
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analyzed using a risk-based Bayesian predictive approach allowing the uncertainties
and interactions to be integrated into a multivariate statistical model.
These variabilities result in a minimal quality level that has been kept relatively
low in order to be able to define a Design Space, i.e., the guarantee of jointly observ-
ing the Critical Quality Attributes within their acceptance limits is low. Even with
this situation, these guarantees are quantified along with the risks of not observing
such quality, jointly or marginally. The specifications have been designed such as to
provide a minimal satisfying quality for whole process. In this way, the quality of the
resulting product is built in by the design and controlled setup of the spray-drying
equipment.
Validation of the optimal condition within the Design Space has been carried out,
and these experiments provided a product compliant with the predicted quality. To
better assess how the guarantees of quality prediction perform, one would consider
analyzing longer-term process data.
In addition, the validation experiments carried out independently provided sup-
plementary information concerning the statistical model. Indeed, the good repeata-
bility of the process seems to indicate that the causes of the poor model fit were
not solely due to the noise present in the data. Instead, more complex interactions
or non-linearity of the responses can be present. In cases where nothing or little is
known about a specific process, defining a more informative though labor-intensive
design of experiments should be envisaged.
Finally, the definition of a low guarantee Design Space could be seen as the
very first step toward a Quality by Design methodology. The results presented are
of great interest for the spray-drying manufacturers and experimenters in order to
improve quality. For instance, the causes of variation could be identified, such as
poorly controlled factors. Furthermore, the effect of the key process parameters that
have been kept constant during this study could be analyzed in a more detailed way
through a new experimental plan.

Chapter 10
Automated validation of a
quantitative chromatographic
method
10.1 Introduction
In the pharmaceutical field, the need to develop analytical methods able to quan-
tify accurately compounds of interest is high. For instance, the determination of the
conformity of samples before clinical trials or during the phases of a drug develop-
ment is crucial. Drugs quality issues were also discussed in Chapters 7 and 8, where
the screening and complete analysis of drugs were detailed, in order to detect and
potentially fight against the poor quality medicines.
An analytical method such as the high performance liquid chromatography (HPLC)
is a flexible tools to obtain these types of results. In order to become quantitative,
the method needs first to be calibrated. This calibration links the results of inter-
est (the concentration or amount of a compound) to the responses of the method,
that are extracted from the chromatograms recorded with a diode array detector
(DAD-chromatograms). Typically, the area under the curve (AUC) of the observed
peaks can be recorded if the corresponding compounds are separated. For a given
wavelength of observation, an AUC is proportional to the real concentration of
a compound, following the Beer-Lambert law (1852). For HPLC system with an
ultra-violet detector, the relation between the responses and the concentrations is
generally well explained by a simple linear regression.
To prove that a method is able to provide accurate results for its future runs,
the method must go through a process called validation. Following ICH Q2(R1)
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Figure 10.1: Example of chromatogram. For this study, suboptimal chromatograms
were used, with the first peak being the sums of two peaks of sulfinpyrazone (1) and
granisetron (2).
(2005), “the objective of validation of an analytical procedure is to demonstrate that
it is suitable for its intended purpose”. See also ISO/CEI 17025 (2005). However,
validation is a non productive process from an industrial point of view, with many
experiments that must be carried out. One bottleneck remains the analysis of the
chromatograms, comprising the identification, the integration of the peaks, and
the reporting of the analytical responses comprising the AUC. In the best cases,
softwares can help in this data processing, but it is far to be automated. Besides,
even when it is made with great care, data manipulation problems or integration
errors can also occur, as it will be shown.
In this chapter, a totally automated validation of quantitative method is pre-
sented based on real data obtained on a mixture of sulfinpyrazone, granisetron and
phenytoine. In the proposed example, a suboptimal chromatographic condition was
purposely chosen, resulting in non fully separated peaks. This type of results de-
parts from the best case scenario, and generally, the method validation can not be
envisaged with these poor separation properties. An example of data is provided
in Figure 10.1. The two first peaks (sulfinpyrazone and granisetron) are coeluted
and observed at 1.3 min. A third peak (phenytoine, at 2.5 min) is well separated
from the others. During the experiments, the position of the peaks will not vary as
the HPLC method is always the same. However, their heights, widths and resulting
AUC will change because different concentrations of the compounds are injected
into the HPLC system.
This chapter is an application of the independent component analysis (ICA) and
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of the clustering methodologies presented in Chapter 6. It also makes use of the
predictive models presented in Chapter 4, illustrating an example of automated
calibration and validation of quantitative methods.
Structure of the chapter
Section 10.2 describes the data. In Section 10.3, the independent component
analysis (ICA) is used to process the original chromatograms and identify sources
that contain the peak information. Next, Section 10.4 illustrates the method valida-
tion using firstly the distribution of the inverse prediction from the calibration, and
secondly, the accuracy profile strategy. Both validation methodologies are intended
to assess the quality of the quantitative methods for each of the three involved
compounds.
10.2 Materials and methods
10.2.1 Instrumentation and chromatographic conditions
All experiments were carried out on a conventional HPLC system Alliance from
Waters (Eschborn, Germany) equipped with an ultra-violet diode-array detector
(UV-DAD), similar to the one presented in Chapter 7. The analytical column was
an Xbridge C18 (100 mm x 4.6 mm i.d., particle size 5 µm) from Waters and was
kept at 20°C during the experiments. An isocratic elution was envisaged. The
mobile phase used for the analysis was a 38:62 (v/v) mixture of acetonitrile and
ammonium hydrogen carbonate buffer (10 mM) with aqueous part adjusted to pH
7 with hydrochloric acid and ammonium hydroxide.
10.2.2 Samples preparation
Two sets of data were generated for the calibration of the quantitative method
for the three compounds, and for its validation. They are referred as the calibration
set and the validation set. Each set consisted in 45 DAD-chromatograms recorded
during 3 days of 15 runs, as explained in the two next subsections.
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Calibration set
From stock solutions of phenytoine, granisetron and sulfinpyrazone, dilutions were
carried out in methanol-water (20:80, v/v) in order to obtain working solutions
at three concentration levels of 30 µg/mL, 150 µg/mL and 300 µg/mL for each
compound. For the calibration set, the three compounds were then present at the
same concentration (either 30, 150 or 300 µg/mL) in the working solutions. Aliquots
of the working solutions were filtered with 0.20 µm PTFE syringe filtration disks
into vials for injection in the HPLC system. The injection volume was 10 µL and
the flow of the mobile phase was 1 ml/min.
Three independent series of data were generated, including new preparation of
the solutions on 3 different days. Each day, five replicates were carried out, for each
of the three concentration levels. This provided 3× 5× 3 = 45 chromatograms.
Validation set
From stock solutions of phenytoine, granisetron and sulfinpyrazone, dilutions were
carried out in methanol-water (20:80, v/v) to obtain working solutions at three con-
centration levels of 30 µg/mL, 150 µg/mL and 300 µg/mL for each compound.
However, for the validation set, each sample has been created with different con-
centrations of the compounds. In order to design the way these concentrations are
mixed in the samples, an incomplete latin-square design was used (Cox and Cochran,
1957). The design is presented on Table 10.1 and was also replicated during three
days, leading to 45 chromatograms. Filtration and injections of the solutions were
made as mentioned for the calibration set.
Experiments
Compounds 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Sulfinpyrazone 2 1 3 1 3 1 3 2 1 2 1 3 2 3 2
Granisetron 1 2 2 3 3 1 1 2 3 3 1 1 2 2 3
Phenytoine 1 1 1 1 1 2 2 2 2 2 3 3 3 3 3
Table 10.1: Incomplete latin square design for the concentration levels in the valida-
tion samples. 1: 30 µg/mL; 2: 150 µg/mL; 3: 300 µg/mL. Validation data resulted
of three application of this design.
The latin square was used to create arduous and worst-case data. In this way,
the coeluted compounds are often observed as a tall and a small peak. In some
experiments where the concentrations have a ratio 1/10, the smaller peak is nearly
non detectable when looking at the original chromatograms, as the peaks 1-2 in
Figure 10.1.
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10.2.3 Softwares
Empower V2.0 for Windows was used to control the HPLC system and to record
the chromatograms. The R environment was used for all the analysis, including
ICA, for which the package fastICA was used (R Development Core Team, 2010;
Marchini et al., 2010).
10.3 Independent component analysis
The aim of the ICA algorithm is to estimate the independent components that
are mixed in the observed signal, and to estimate the way they are mixed. Here,
the relevant components should correspond to peaks of interest. Eventually, after of
a successful ICA, it is possible to compute the AUC of each numerically separated
peak by integrating the peaks observed in the relevant components.
In Chapter 6, the ICA was briefly described. On the basis of a DAD-chromatogram
X consisting of m observed wavelengths (or signals) at ttot recorded time points, the
idea is to estimate a (m × f) mixing matrix Aˆ and the f sources in Sˆ (f × ttot) as
independent as possible, such that:
AS = X.
After the estimation, f components Xˆg and a reconstructed DAD-chromatogram
Xˆ are obtained by computing:
Aˆ,gSˆg, = Xˆg and
f∑
g=1
Xˆg = AˆSˆ = Xˆ, (10.1)
where Aˆ,g is the gth column of Aˆ and Sˆg, is the gth line of Sˆ. Notice that ICA is
applied on each DAD-chromatogram separately.
In Section 6.4.2, a methodology to find the optimal number of sources f ∗ was
proposed, based on the fact that a mixture containing the same compounds is
injected several times. This methodology was then applied on the 45+45 DAD-
chromatograms from the calibration and validation sets. For both sets of this exam-
ple, a value of f ∗ = 4 for every DAD-chromatograms was identified to numerically
separate the three peaks. For simple cases, in general, ICA performs well when
the number of sources allows the separation of the components of interest (here, 3),
plus one or more sources for the noise and other artifacts. f ∗ = 4 is then not a
surprising result. On more complex cases, it was also shown in Chapter 6 how f ∗
can be adapted for each chromatogram.
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10.3.1 ICA results
On the (45+45)*3=270 peaks, the percentage of correct peak picking is 100%.
Furthermore, no irrelevant artifact was found. Figure 10.2 illustrates the components
(observed at 220 nm) of two numerically separated DAD-chromatograms, with the
apexes of the peaks marked in red. It is observed that the components from the
validation set (B) seem more affected by disturbances. Indeed, some small artifacts
generally remain in the relevant components (lines 2-3). For instance, an artifact is
found in the second source (line 2, insert at 2.4 min). It was found that it might
correspond to an impurity of granisetron, that has appeared in the samples of the
validation set. This small impurity elutes at the same time than the compound
phenytoine, which is referred as a specificity problem (see for instance ICH Q2(R1),
2005) that can cause some difficulties if care is not taken.
The very similar UV-signature of granisetron and of this impurity is the reason
why they appear in the same ICA component. Finally, in the third source, a peak
at 4 min. is also clearly visible, and it might be an impurity of phenytoine.
Thus, ICA successfully achieved the automated peak detection process. It also
improved the identification of some impurities that were not detected manually.
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Figure 10.2: Numerical separation with ICA observed at 220 nm. (A) components
from the calibration set. (B) components from the validation set. (Red) position of
the apexes.
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10.3.2 Peak tracking
Continuing the application of the methodology of Chapter 6, some dissimilarities
computed on the sources and the components are derived to track the peaks among
the DAD-chromatograms. In the present example, the process was simplified as all
the similar peaks had similar retention times (times of the apexes). Assuming that
stot relevant components Xˆs(s = 1, ..., stot) were identified in all the chromatograms,
and using these components as in Equations 6.5–6.10 (page 101), let t(s)R be defined
as the time of the apex of the peak contained in the component Xˆs. An appropriate
distance is then
dt(s1, s2) = |t(s1)R − t(s2)R |, (∀s1, s2 = 1, ..., stot) (10.2)
with |a| being the absolute value of a. The penalty distance dart was used as a
second metric to avoid matching together the components coming from the same
DAD-chromatogram (see page 103). The Ward’s algorithm was then applied on the
dissimilarity matrix D ≡ {ds1,s2} = dart(s1, s2) + dt(s1, s2), for the calibration set
and the validation set separately.
The dendrograms for both the calibration and validation data are presented in
Figure 10.3. The number of clusters was set to 3, the number of compounds. Every
peak was matched accurately by the clustering algorithm with 100% of hit.
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Figure 10.3: Dendrograms of the matching of peaks. (A) calibration set. (B) vali-
dation set. Red rectangles are the clusters for the 3 compounds.
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10.3.3 Integration
As previously explained, the analytical results of the methods are the AUC of
each peak in each chromatogram. To compute AUC, each of the (45+45)*3 numer-
ically separated peaks was integrated individually. To make simple, the integration
was done at one selected wavelength (here, 220 nm), i.e., one column of Xˆs. The
wavelength was manually chosen so that all the compounds under investigation have
an acceptable absorbance and a high signal-to-noise ratio.
For each component, the time of the apex t(s)R was recorded, as shown in Figure
10.4. Next, locally around t(s)R , the beginning t
(s)
B and the end t
(s)
E of the peak
were defined as the time where the absolute value of the first derivative of the
chromatogram (red line) was close to 0. Simply summing the values of absorbance
of the chromatogram between t(s)B and t
(s)
E would allow a first approximation of the
AUC. However, an improvement was added because the baseline was not always
perfectly horizontal. The integral of the linear baseline estimated from t(s)B to t
(s)
E
(blue line) was simply removed from the previous estimation of AUC.
2 3
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t
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Figure 10.4: Example of peak integration. (Black) component observed at 220 nm.
(Red) first derivative. (Blue) baseline estimation.
For both the calibration and the validation sets, the concentrations are known
from the dilutions carried out when preparing the samples. At this stage, the data
consists of the known concentrations and of the AUC computed on the ICA com-
ponents observed at 220nm, for each of the 3 series, 5 replicates and 3 compounds,
that were identified using Ward’s algorithm.
10.4 Method validation
Results quality is a strongly regulated topic about which several guidances have
been published by authorities (see ICH Q2(R1) (2005); Food and Drug Administra-
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tion (2001); ISO/CEI 17025 (2005)). Indeed, authorities as well as the experimenter
want to be confident about the method quality for its intended purpose.
To provide evidences of quality results for the future runs of the methods, two op-
tions to analyze their performances are presented using Bayesian predictive method-
ology and distributions. First, based solely on the calibration data, predictive pre-
cision and (posterior) probability profiles are derived from the distribution of the
inverse predictions. Second, the strategy of accuracy profiles is applied using the
data from both the calibration and the validation sets. In both options, series were
made in such way to represent as close as possible the conditions that will be met
during the routine analysis (change of operator or device). See Hubert et al. (2006).
10.4.1 Calibration model
The following hierarchical calibration model was applied separately for the three
compounds using the data of the calibration set:
yij = (β0 + α0j) + (β1 + α1j)xi + εij, (10.3)
with yij being the logarithm of the observed response (AUC) for the ith repetition and
the jth serie, and xi is the logarithm of the results (concentrations). Logarithmic
transformation is applied to ensure positivity of the results and of the responses
and to provide an homogenous variance over the concentration range. β0 and β1
correspond to fixed effects. α0j and α1j represent the additional variability induced
by the serie j and are random parameters. The Bayesian model and the related non-
informative priors were presented in Chapter 4, page 61. The advantage of using
such model is the ability to easily obtain the distributions of the predictions and of
the inverse predictions, accounting for the effect of the series, and potentially using
prior information if available. The generic use of prior information is unfortunately
far from being adopted in the method validation context, although numerous data
sets and analysis reports are available.
Using Monte-Carlo simulations from the joint posterior distribution of the param-
eters, the predictive distribution of the back-calculated concentrations (x˜ | y˜, data)
given a new response y˜ was thus computed, as presented in Figure 10.5 (blue,
y˜ = 3.8).
10.4.2 Validation of the method
Method quality can be analyzed using different tools. Among other, the precision
profile and the probability profiles are interesting plots constructed using the cali-
bration data set only. They can then be available without a validation set. Another
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Figure 10.5: Inverse prediction using the hierarchical linear calibration model.
tool is the accuracy profile, that is computed using both the calibration set to create
several calibration curves, and the validation set to assess the inverse prediction of
new samples.
Precision profile
The precision profile is a graph of the (predictive) coefficient-of-variation (CV)
of new concentrations versus the assumed true or mean concentrations (Dmitrienko
et al., 2007). The predictive CV is calculated as follows:
CVx˜ =
100× sd(x˜ | y˜, data)
Eˆ(x˜ | y˜, data) ,
where sd(x˜) is the estimated standard deviation of x˜ and Eˆ(x˜) can be taken as
the mean of the distribution of x˜. Both sd and Eˆ are computed from the Monte-
Carlo samples of the predictive distribution of the inverse prediction (back-calculated
results). In this example, y˜ is the log-AUC of a new sample.
The precision profile for the phenytoine is illustrated on Figure 10.6. A spec-
ification was set up as follows: the CVx˜ must be lower or equals to 10%. When
the specification is achieved, the method quality is assumed sufficiently high. As
observed on the precision profile, the range of concentrations between 29.95 (∼ 30)
and 298.85 (∼ 300) µg/mL fulfill the specification and is then defined as the dosing
range of the assay, i.e., the range of concentration for which the new measures will
be satisfactory w.r.t. the specification.
Similar profiles were obtained for granisetron and sulfinpyrazone, but are not
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Figure 10.6: Precision profile of phenytoine. A specification is fixed as CVx˜ ≤ 10%
(horizontal dashed line). Concentrations satisfying the specifications are in the
dosing range of the method (vertical red lines).
presented here.
Probability profile
Another way to assess the performance of the method is to represent the guar-
antees that future runs will be within predefined specifications with regards to their
uncertainty. These specifications also apply on the back-calculated concentrations
x˜. Let the following specification by applied: the experimenter want to know the
guarantee and the risk for the method to have a predictive uncertainty constrained
into λ% of the mean predicted concentrations (λ = 10). Monte-Carlo simulations
were used to compute the probability that the specifications will be satisfied:
Px˜ = P (x˜ ∈ Λ | y˜, data) with Λ : Eˆ(x˜ | y˜, data)[100%± λ]. (10.4)
Repeating the computation for every concentration level, a probability profile was
plotted and compared to a minimal quality level pi (here, pi = 90%), as shown on
Figure 10.7 for the phenytoine. The dosing range computed from the probability
profile is then the concentration values for which Px˜ ≥ pi. On the basis of the cali-
bration data, the dosing range is [29.95, 234.57] µg/mL. Similar probability profiles
were computed from the two other compounds but are not presented here.
A similar profile can be obtained using 1− Px˜ instead of Px˜. This defines a risk
profile expressing the risk not being within specifications. The main interest of both
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Figure 10.7: Probability profile to observe the measure within 10% of the mean
concentration of phenytoine. Minimal quality level is set to 90% (horizontal dashed
line). Vertical red lines identify the dosing range.
profiles is the ability to control the risk to make wrong decision by adapting pi and
λ with respect to the situation.
In this manuscript, there is a clear similarity between the computations of the
dosing range in the present chapter, and the Design Space approach presented in
the previous chapters. Indeed, for the quantitative analytical method, the dosing
range is its univariate Design Space, i.e. the range where quality is demonstrated.
Accuracy profile
The two previous profiles were computed using the predictive uncertainty (i.e.
the intermediate precision) of the analytical method, including two sources of vari-
ation, but lacked the inclusion of a bias estimation. To account for this bias, a
possibility is to compute difference between the found and the true concentrations
of the validation set.
For a given serie j, the concentration of a compound from the validation set xj,val
is back-calculated from the response yj,val (log-AUC) using the mean calibration
curves fitted with the calibration data of the same serie (Hubert et al., 2006). xj,val
is then compared to the true results µj,val, obtained using a reference method. In
this way, the precision and bias of several xval,11, ..., xval,ij, ..., xval,nm = xval are both
included in the validation process, when compared to the corresponding references
µval.
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According to Hubert et al. (2007) and Rozet et al. (2011), β-expectation tol-
erance intervals computed on the results in relative scale, (xval − µval)/µval, are
one of the most suitable solutions to simultaneously combine the systematic error
(bias) and the random influences encountered in the data (spread or precision). The
β-expectation tolerance interval allows predicting where, on average, a stated pro-
portion β of future results will be found. From a Bayesian predictive perspective,
tolerance intervals are simply computed from the posterior predictive distribution
new results as demonstrated by Guttman (1970).
β-expectation tolerance intervals are then computed on the (relative) back-calculated
results for each concentration level found in the validation set (here: 30, 150, 300
µg/ml). For this purpose, the data were modeled with a random one-way ANOVA
to estimate the effect of the series, as introduced in Chapter 4.2.
For the following results, the frequentist and the Bayesian tolerance intervals
were computed. These relative tolerance intervals were compared to acceptance
limits that defines minimal quality (i.e. specifications). This allows drawing the
accuracy profile. Acceptance limits must generally be defined following regulation
requirements but might also be driven by the objectives of the quantitative method.
For the following results, the acceptance limits were arbitrary set at ±15% of the
true concentrations, given the complexity of the validation standards preparation.
The first result that concerns phenytoine is shown on Figure 10.8. For this com-
pound, the results from the ICA computations (A) were compared to the results
obtained when processing the chromatograms manually (B). Notice this compar-
ison is only possible because phenytoine was completely separated from the two
others compounds (see Section 10.3.1). The obtained Frequentist and Bayesian
β-expectation tolerance intervals (n∗ = 20000) are drawn in dark and light blue,
respectively, and look equivalent.
Focusing on the levels of 150 and 300 µg/mL, the data from the automated
and the manual peak integration showed similar uncertainty, with a total relative
error (i.e., the relative β-expectation tolerance intervals) below 5%. However, at the
lowest concentration level (30 µg/mL), the profiles were different. On one hand, the
manually integrated data (B) seemed to concede a sufficient quality (i.e. accuracy)
for the quantitative method, with a small bias. On the other hand, the automatically
treated data (A) showed a higher negative bias, although the intermediate precision
(i.e., the total uncertainty) looks similar in both profiles.
The reasons of this difference can be identified using the original data or the
sources given by ICA. On the sources (see Figure 10.2 (B)), a specificity problem
was identified for phenytoine, which elutes at the same time than an impurity of
granisetron. Moreover, phenytoine degradation might have begun during the vali-
dation experiments. First, the degradation certainly induces a loss of precision for
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Figure 10.8: Accuracy profiles for phenytoine. (Dots) results in relative scale (colors
identify series). Frequentist (dashed dark blue line) and Bayesian (dashed light blue
line) β-expectation tolerance intervals expressed in relative scale. (Red) relative
bias. (Dotted black) Acceptance limits. (A) data obtained using the ICA automated
methodology. (B) data obtained by integrating peaks manually.
the manual and the automated methods, as these degradations might not be similar
in every samples. Second, when envisaging the manual treatment, the impurity of
granisetron was integrated with phenytoine, then (un-)fortunately reducing the bias
on this peak, with a higher effect when the concentration of granisetron is high (in-
ducing an higher concentration of the impurity) and the concentration of phenytoine
is low.
A manual check allowed confirming these results: with the help of ICA to detect
the position of the impurities, it was possible to identify them in the original chro-
matograms. The purity of the solutions were not tested because it was not expected
to observe degradation during the short total run time of the experiments. As con-
clusion, the experimenter should choose the profile from ICA-treated data because
specificity of the original data is not good, even if the peak was thought to be well
separated. In summary, ICA permitted improving the specificity and, in the same
time, showed that the results were biased at the lowest concentration level. This
was probably due to a lower concentration of phenytoine than the expected one,
caused by the apparition of the impurity during the validation experiments.
Finally, accuracy profiles for the two coeluted peaks were computed and drawn.
They are illustrated on Figure 10.9 for sulfinpyrazone (A) and granisetron (B). As no
sufficiently good manual technique to unmix these peaks was found, no comparison
is done with manually treated data.
10. Automated validation of a quantitative chromatographic method 195
(A)
50 100 150 200 250 300
-2
0
-1
0
0
10
20
Concentration
R
el
at
iv
e 
er
ro
r
Accuracy profile
(B)
50 100 150 200 250 300
-2
0
-1
0
0
10
20
Concentration
R
el
at
iv
e 
er
ro
r
Accuracy profile
Figure 10.9: Accuracy profiles for coeluted sulfinpyrazone (A) and granisetron (B)
automatically treated using ICA. Frequentist (dashed dark blue line) and bayesian
(dashed light blue line) β-expectation tolerance intervals expressed in relative scale.
(Red) relative bias. (Dotted black) Acceptance limits.
For both compounds, the specification was kept at 15% of the nominal concen-
trations. Both profiles were found acceptable for a dosing range covering all the
concentrations used during the experiments. As previously, ICA was able to numer-
ically separate the peaks in order to recover the specificity of both analytes. The
detected impurity of granisetron does not seem to affect its profile, except on the
lowest concentration level where the precision is close to the specifications.
Notice that to be fully compliant with ICH Q2, several other validation results
must be given, such as the linearity of the calibration curve, the trueness, the de-
tection and quantitation limits, the precision, etc. These results are cut here, for
brevity.
10.5 Conclusion
An example of method validation for several compounds was presented. The
proposed analytical method was a high-performance liquid chromatography with a
diode-array detector, resulting in matrix-like signal. The input factors were chosen
so that the method was suboptimal, with two strongly coeluting peaks. In this case,
the method validation can generally not been carried out as method specificity is
one of the first method quality to demonstrate following ICH Q2.
Independent component analysis was shown helpful in this case to simply locate
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all the peaks in the chromatograms while numerically separating them. From this
first identification, an automated peak matching procedure was possible using the
retention times at the apex of the ICA-recovered peaks, to discriminate them. This
procedure was simple because the HPLC operating condition was always similar.
For each of the compounds, different quality profiles were used to analyze the
quantitative results of the method. First, based solely on the calibration data, a
precision profile and a probability profile have been computed. They allowed a
first assessment of the results precision based on hierarchical Bayesian predictive
models to account for a series effect. Second, the strategy of accuracy profile was
used, allowing the inclusion of the observed bias in the results. Each profile allowed
deriving critical quality attributes such as the dosing range of the method.
ICA definitively opens new perspectives toward the fully automated treatment
of chromatograms. In this validation study, some of the results obtained after ICA
were at least as good as the results obtained manually, while other results could not
be obtained without an appropriate numerical separation.
The first analysis focused on a single peak. Comparing manual and automated in-
tegration after ICA, the superiority of the automated process using ICA was shown.
Indeed, it permitted detecting and isolating some impurities, thus improving the
specificity of the method. Second, the successful application of ICA shown that
strong coelutions are not a barrier against method validation. Indeed, the results
obtained for the two coeluted peaks also fully met the expectations. It would be
difficult to reproduce such results without the help of ICA.
ICA and the proposed automated treatments could then be used to drastically
solve the time-consuming problem of quantitative methods validation while increas-
ing the quality of information extracted from the chromatograms. However, the
approval of such methodology by the authorities and regulatory bodies might be
doubtful given its complexity.
10.6 Further works
In this study, the integration of the peaks were made at one wavelength of interest
(220 nm). This wavelength was chosen to obtain a one-dimensional signal on which
it is easy to work. It is a usual analytical practice to have an acceptable absorbance
for all the compounds under investigation, to improve the signal-to-noise ratio. With
manual integration, it must clearly be chosen prior to further analysis.
The automated treatment opens the perspective to compute the profiles for every
wavelengths. After this intensive computation, it is rather obvious to select the
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wavelength(s) providing the best profiles. This can allow the automated selection of
a wavelength that shows i) acceptable absorbance, ii) no influence from solvent or
other artifacts, iii) no influence of ICA estimation, and iiii), the best results given
the purpose of the method.
For the point iii), it was observed that in some cases, ICA can have difficulties to
properly unmix UV-signatures, mainly when they are too similar in some ranges of
the UV spectra (see e.g. Figure 6.10 (Bottom), page 108). Improvements might be
obtained by using more specific implementation of ICA, such as the non-negative
ICA (see Yuan and Oja, 2004; Zheng et al., 2006).

Chapter 11
Validation and routine of the
ligand-binding assay
This chapter has been written using materials from three talks made in interna-
tional conferences (Lebrun and Boulanger, 2010; Lebrun et al., 2010; and Lebrun
et al., 2011).
11.1 Introduction
Ligand-binding assays (LBA), such as the Enzyme-Linked Immuno-Sorbent As-
say (ELISA), are widely used in life sciences. They allow the quantification of
endogenous analytes such as proteins or peptides in biological samples. The biologi-
cal properties of the analyte of interest are used to capture them by means of plates
pre-coated with a specific antibody, that is able to link the analyte. The process
is followed by an immunological detection of the specifically captured analyte by a
conjugate enzyme. With the addition of a substrate, the enzyme provides a reaction
resulting in some coloration. The coloration is related to the amount of enzymes
and the amount of analyte. It can be detected through measurement of the optical
density (signal) of the product within the plates.
Generally, the plates are some sets of wells that allows to make different measure-
ments simultaneously, possibly with some operating conditions that may be changed.
Figure 11.1 illustrates one plate with its wells having different optical densities.
The general purpose of LBA is to provide results that are used to make decisions
such as the release of a production batch, stability studies, the PK of a drug (e.g.
that might interact with some proteins used as biomarkers), the optimization of
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Figure 11.1: Plate for ELISA test.
the dose of a drug, the optimization of a process, etc. Therefore, the quantitative
results given by the LBA must be as accurate as possible, otherwise the risk to
make wrong decision or to provide low quality drugs to patients would be high.
In practice, an assay should first be validated and then used during routine. The
objective of validation is to prove the quality of the results for the future use of
the LBA (Khan and Findley, 2010, chapter 5).
11.1.1 Data
To make a LBA quantitative, calibration standards are prepared in appropri-
ate matrices (e.g. blood sample, urine) from known stock solutions of the analyte.
Various concentrations can be obtained using serial dilution of the initial solutions.
François et al. (2004) analyzed the optimal design for different calibration models
and with the inverse prediction problem. As conclusion, equidistant data points (on
the log-concentrations scale) around the EC50 are close to optimal when envisaging
a four-parameter logistic regression, as frequently occuring with LBA. Example of
calibration data are given in Figure 11.2 (simulated data). For different concentra-
tions, different signals would be obtained, and a calibration model is envisaged to
describe the data.
11.2 Validation, setting of critical quality attributes
Assay quality is defined by the results quality. Several values that reflect the
quality of the results may be defined as critical quality attributes (CQAs).
The CQAs should be set up to reflect the use of the LBA. When new experiments
are carried out, new signals are obtained. Inverse prediction is done to provide an
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Figure 11.2: Example of data for the calibration of LBA.
estimation of the real concentrations of the analytes in the samples. Thus, the
distribution of these back-calculated concentration seems appropriate when defining
the CQAs.
11.2.1 Model
A four-parameter logistic (4PL) regression is generally well adapted to fit data
of LBA assay (Findlay and Dillard, 2007). Often, a heteroskedastic variance is
observed. The simulated data have been generated to have this property, as il-
lustrated on Figure 11.2. To account for this particular variability, Davidian and
Giltinan (1995) proposed that the model includes a variance (or a precision) that is
modeled as a power of the expected values (POM). Thus, if yi is an observed signal
and xi is the known analyte concentration, a simple fixed effects model for the 4PL
regression is given by:
yi = β1 +
β2 − β1
1 + ( xi
β4
)β3 + εi, and εi ∼ N(0, τY ), (11.1)
with τY = τE[yi]θ .
If different batches are used, it is possible to account for the induced variability
using the model presented in Chapter 4.4, page 65. In this example, four batches
(m = 4) were used with 3 replicates (nj = 3), so the mixed-effects model holds.
200000 simulations using vague a priori were done and the chains were thinned to
keep one sample out of ten in order to reduce autocorrelation. The chain for each
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Figure 11.3: Bivariate joint distributions of the model parameters.
parameters then contained n∗ =20000 samples. Figure 11.3 presents the bivariate
joint distributions of the parameters. No special correlation structure are observed
from the simulated data. The marginal posterior distributions of the top asymptote
and of the slope are rather peaked. Due to the mixed-effects modeling, they certainly
depart from the log-normality assumption of the prior.
From the parameter chains, Chapter 4.4 presented how to produce samples from
the predictive distribution of an inverse prediction x˜ given a new observed signal y˜,
i.e., samples following the density p(x˜ | y˜, data). Monte-Carlo simulations were used
to propagate the uncertainty of the joint posterior distribution of the parameters to
the distribution of the inverse prediction.
Figure 11.4 illustrates the fit of the mixed model with POM variance. The
95% Bayesian predictive interval is represented in red and is equivalent to the β-
expectation tolerance interval for a new signal Guttman (1970). The mean predic-
tion over the 4 series is drawn in black.
Assume a first new signal is observed at y˜1 = 1.0. In this case, the inverse
prediction is close to the inflection point (C50) of the 4PL curve. The uncertainty
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of the distribution (blue densities) is rather limited. On the other hand, when a
second signal is observed at y˜2 = 2.7, the inverse prediction is closer to an asymptote.
In that case, the uncertainty is logically higher. It is common to loose quality of
prediction when an observed signal is close to the limits of the system.
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Figure 11.4: Inverse prediction using the Bayesian 4PL model.
11.2.2 Derivation of critical quality attributes
The objective of the validation of the assay is to give guarantee that each new
measure will be close enough to the unknown true amount. CQAs are developed
to summarize the quality of the assay. They must provide an appreciation of the
original data and of the calibration curve. To do so, it is first envisaged to develop
two predictive profiles, on which CQAs can be directly computed : the precision
profile and the probability profile.
Precision profile
The precision profile is a characterization of the precision of the inverse predicted
concentrations of new samples, using the calibration curve. It may be drawn by
plotting the coefficient-of-variation (CV) of new predicted concentration versus the
assumed true concentration on a log scale (Dmitrienko et al., 2007). As the true
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concentrations are generally unknown with the serial dilution assay, the expected
predicted concentration may be used instead. The predictive CV is then calculated
as follows,
CVx˜ =
100× sd(x˜ | y˜, data)
Eˆ(x˜ | y˜, data) ,
where sd(x˜) is the estimated standard deviation of x˜ and Eˆ(x˜) can be taken as the
mean (or possibly the median or the mode) of the distribution of x˜. Both sd and Eˆ
have been computed using Monte-Carlo simulations.
Figure 11.5 illustrates the precision profile computed from the data of Figure
11.4. A specification was fixed so that the CV must not be higher than 20%. The
range of concentrations between 1.76 and 228.15 mg/ml is the dosing range of the
assay, i.e. the range of concentration for which the new measures will be acceptable
given the specification.
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Figure 11.5: Precision profile. A specification is fixed as CV≤20% (horizontal dashed
line). Concentrations satisfying the specifications are in the dosing range of the
method (vertical red lines).
Probability profile
Monte-Carlo simulations can also be used to compute different risk-based results
from the predictive distribution of the inverse prediction. For instance, Assume
some specifications holds on the predicted concentrations. Next, simply compute
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the probability that the specifications will be satisfied (i.e. the guarantee), or the
probability that the specifications will not be satisfied (i.e. the risk).
In the example, the specification was set so that the uncertainty around Eˆ(x˜ |
y˜, data) must not be greater than λ%.E(x˜ | y˜, data), with λ = 20. It is then possible
to compute the probability Px˜ to achieve the specification:
Px˜ = P (x˜ ∈ Λ | y˜, data) with Λ : Eˆ(x˜ | y˜, data)[100%± λ]. (11.2)
Repeating the operation for every signal in the range of interest, a probability
profile can be plotted, as shown on Figure 11.6. In this example, a minimal quality
level of pi = 90% was defined. The dosing range is defined as the concentration
range for which Px˜ ≥ 0.9.
A similar profile can be obtained using 1 − Px˜ instead of Px˜. This is a risk
profile expressing the risk not being within specifications. The main interest of the
probability or risk profiles is the ability to control the risk to make wrong decision by
adapting λ with respect to regulations, if any, and pi with respect to the situation.
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Figure 11.6: Probability profile to observe the measure within 20% of the mean
concentration. Minimal quality level is set to 90%. Vertical red lines are the dosing
range.
Example of CQAs
The profiles are good tools to control the assay quality. Different CQAs can be
extracted from them:
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• The size of dosing range,
• the area under the probability curve,
• the area under the precision curve,
• the lower limit of quantification,
• the average precision over the concentration range,
• etc.
The two first CQAs are values to be maximized while the three last are intended
to be minimized. For each, various specifications can be given, driven by econom-
ical, efficiency or regulatory reasons. As they are based and/or represent similar
information, each CQA might be strongly dependent on each other.
The assay will remain valid for operating conditions and concentration for which
the envisaged CQAs are within specification. For instance, the dosing range was
computed from the probability profile as the concentrations for which the uncertainty
on the future results was limited with high guarantee. Furthermore, if the dosing
range (i.e., the CQA) covers the actual values of concentration for which the assay
is intended to be used (i.e., the specification), the assay is declared valid. The
parallelism between the dosing range and the Design Space as presented in the
previous chapters is direct.
With this in mind, CQAs might be used as responses for the screening or the
optimization of the operating conditions of the LBA (Lebrun et al. (2010)). Obvi-
ously, it is necessary to estimate one calibration curve for each operating condition of
the experimental plan. With such approach, the experimenter may want to reduce
the cost. Fortunately, in an optimization context, it is generally less important to
estimate random effects and it is often possible to use one LBA plates for several
well-chosen operating conditions.
The model presented in the next section simplify the mixed-effects model pre-
sented in Chapter 4 to a simpler fixed-effects models. It may be used with non-
informative prior distributions in optimization context, and can be used with infor-
mative prior in routine.
11.3 Routine of LBA
During routine, new calibration experiments are done for each new run. Some
wells on the plates are often reserved for this purpose. As only one “series” of data
is analyzed each time, calibration curves do not include random effects.
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The costly data gathered during the validation experiments represents an oppor-
tunity to improve the models used in routine. Indeed, using the information from
the posterior distributions of the parameters obtained during validation, it is possi-
ble to help the definition of prior distributions for the routine. The inclusion of prior
knowledge may then lead to decrease the uncertainty of the parameters and then
to improve the calibration models, while also decreasing the number of experiments
for the new calibration curves that will be made.
Without the estimation of random effects, the model presented in Section 4.4 can
be simplified and is defined as in Equation 11.1. Prior distributions are defined as
follows:
p(β1) = lN(b1, τ1) p(β2) = lN(b2, τ2)
p(β3) = N(b3, τ3) p(β4) = lN(b4, τ4)
p(τ) = Gamma(a, b) p(θ) = Gamma(c, d) (11.3)
11.3.1 Update of prior from validation experiments
Assuming the prior and posterior distribution are approximately similar and the
correlation structure between the parameters is limited. It is then possible to use
the information gathered during the validation experiments. Table 11.1 references
the update rules to compute the prior parameters b1−4, τ1−4, a, b, c, d for the routine,
from the posterior distributions obtained during validation. The first column is the
assumption on the prior distribution of the parameters, while the second column is
the way to compute the prior parameters from available information in the posterior
distributions obtained in the validation step.
Prior distribution Parameters update
β ∼ N(µ, τ) µ = E(β | data)
τ = V (β | data)−1
β ∼ lN(µ, τ) µ = log (E(β | data))− 0.5 log
(
1 + V (β|data)
E(β|data,I)2
)
τ = log
(
1 + V (β|data)
E(β|data)2
)−1
τ ∼ Gamma(s, r) s = E(τ | data)2/ V (τ | data)
r = E(τ | data) / V (τ | data)
Table 11.1: Update of the prior parameters from the posterior distributions of the
parameters.
With the proposed 4PL mixed-effects model of the validation step, the prior
distributions were not conjugate with the likelihood. Furthermore, the model for
the routine is not identical to the one used for the validation. Thus, the marginal
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Figure 11.7: Comparison of the posterior distribution from validation (black) and
the new informative prior distributions (blue).
posterior distributions are certainly not from the same distribution families. The
proposed prior distributions in Equation (11.3) could however be considered as an
approximation of the posteriors. Of course, dependencies that might exists between
the parameters are lost during the update. However, this dependencies have been
shown limited for this simple example, when observing the bivariate joint distribu-
tions of the parameters.
In this case, a careful comparison of the posterior densities (obtained via MCMC
simulations) and of the updated prior distribution is advised. As shown on Figure
11.7, the agreement of the distributions for τ, θ and β2 is satisfactory, while the three
effects considered as random during validation experiments (β1, β3 and β4) are not
perfectly fitted by the updated prior.
Limited knowledge on the posterior, poor mixing of the chains, and small number
of d.f. might be of concern. In this case, the d.f should be analyzed because, from the
linear regression framework, it is assumed that the marginal posterior distribution
of regression parameters follows some Student’s distributions. However, it is not
straightforward to obtain approximations of these d.f. for mixed-effects nonlinear
models (Fong et al., 2010).
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Figure 11.8: New calibration curve fitted using prior information from the validation
experiments and four new data points.
11.3.2 New routine data
New data and updated prior distributions can be combined using Bayes’ theorem
and sampling methodologies to obtain the posterior distribution of the parameters
for the routine. Thanks to the strong prior information coming from validation,
it is possible to rely on very few data points. In this example, only one new data
point was taken for each of the following concentration levels: 1, 10, 100 and 1000
mg/ml. 1 This is then a very light design for 4PL calibration and the model can
not be adjusted without the prior knowledge. For instance, there is no support for
the estimation of the additional parameters for POM variance.
The new calibration curve is presented in Figure 11.8 (thick black line) and is
close to the mean regression line observed during the validation (grey line), while
still appropriately adjusted to the 4 new data points. The 95% predictive interval
of this new calibration (red) is included with the one computed during validation
(light red). About 95% of future data of this particular new batch will be included
in the new interval. Also, at least 95% of future data of this particular new batch
will be included in the validation predictive interval. It is noted that the increased
variance due to the series effect during validation has then a more limited effect for
1Notice also that if the validation data allowed getting a better idea of the EC50, the experi-
mental design could be adapted accordingly.
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the routine (although it is present in the updated prior distributions).
Regarding the uncertainty, The POM variance has a clear effect, although the
new data points did not allow its identification.
Finally, depending on the number of new data points and of the prior precision,
the new calibration curve might be biased towards the regression obtained during
validation. This is not necessarily a problem if the validation was made in order to
mimic the true routine of the assay. Small simulation studies might be carried out
in order to assess the sensitivity of the updated prior and to help powering the new
calibration with enough data points.
11.4 Conclusion
In the Bayesian setting, samples from the predictive distribution of the inverse
prediction are simple to obtain using simulations, even with the (unbalanced) non-
linear mixed-effects model and the addition of a heteroskedastic variance. It is then
an appropriate way to gather the right information about the assay and its future
performance.
The Bayesian analysis was then used for the validation of a ligand-binding assay
and for new calibrations during its routine use. It allowed to predict the future
behavior of the methods to ensure the predictive probability of accurate results is
high. Information from validation was transferred to routine through the update of
prior distributions.
Another use of the statistical models and the Critical Quality Attributes, men-
tioned in this chapter, is the optimization of the ligand-binding assay with regards
to various operating conditions. This was the topic of two presentations focusing
on a risk-based Design Space approach to simultaneously optimize and assess the
robustness of the developed assay (Lebrun and Boulanger, 2010; Lebrun et al., 2010).
General conclusions
Given the guidelines and regulatory documents making authority for the Phar-
maceutical Development, their is a pressing need from the pharmaceutical industry
to obtain precise methodologies to apply the Quality by Design paradigm for their
processes and methods. Indeed, documents such ICH Q8 explain the principles for
drug developments in a quality environment, and the expectations of the regula-
tory authorities, but no precise methodology is proposed given the broadness of the
application domain.
A first step was to understand the flaws of the classical optimization strategies,
including Design of Experiments and Multi-Criteria Optimization techniques. Chap-
ter 1 explained why the classical use of these tools is generally not sufficient, even if
they aim at improving the quality and the understanding of processes or methods.
The main reason is that the most of the softwares and toolboxes that address this
problematic make use of the mean responses predicted by statistical models only,
without taking into account the uncertainty and responses dependencies. If qual-
ity can be improved using classical methodologies, there is limited possibilities to
provide assurance of quality in a predictive risk-based framework.
To integrate the uncertainty of the response predictions for the future use of
the method or process under development, fully predictive statistical models were
developed. In this context, the Bayesian statistical framework has been helpful to
obtain the (posterior) predictive distribution of new predictions using simulations
or mathematical derivation. This was made for various classes of statistical models
that were presented in Chapters 2–4.
The proposed methodology was then not intended to provide optimal solutions
based on mean predictions. Instead, it was developed to define the settings of the op-
erating conditions where high quality can be guaranteed. The minimal required qual-
ity was expressed with specifications defined on Critical Quality Attributes (CQAs).
It was illustrated that, when these high guarantee-settings allowed variations in the
operating conditions, robustness of the methods and process can be easily demon-
strated, which is the direct application of the Design Space defined by ICH Q8.
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Finally, a last general topic was addressed: as the Critical Quality Attributes are
multivariate by nature, the Multi-Criteria Optimization problematic was reviewed
and extended in Chapter 5, to obtain risk-based results based on the predictive
distribution. The classical approach of computing the joint probability of accep-
tance was shown to be easily carried out using Monte-Carlo simulations form the
predictive distribution. This simulation approach was then extended to compute
the probability to have specifications flexibly accepted using desirability methodolo-
gies. It was shown how the classical approach is a particular case of the desirability
approach, when desirability functions are properly parametrized.
Analytical method development. High performance liquid chromatography is
one of the most widespread analytical methods in the laboratories of the pharma-
ceutical industry. In this work, the first example of application of a Quality by
Design compliant methodology was made on this particular process: the analytical
separation methods (Chapters 7 and 8).
Considering the complex nature of the Critical Quality Attributes, it was decided
to model simpler responses – the chromatographic retention times – that eventually
allows the computation of the CQAs, i.e. the separation or the resolution of the
critical pair of peaks, the total run time, etc. As no closed-form can be found for
the predictive distribution of the future observations of CQAs, it was decided to
use Monte-Carlo simulations to propagate the predictive error from the retention
times to the CQAs. Monte-Carlo simulations were found powerful as the correlation
structures of the multivariate error is preserved.
The Design Spaces computed with this methodology allowed an efficient sepa-
ration for the screening and precise analysis of several sets of possibly unknown
molecules, showing the way to a systematic development of robust analytical meth-
ods. This robustness allowed the methods to be simply transferred to high-end
equipment and also eased the validation of their results.
In addition, to thematic of automatic development was addressed, using an au-
tomated reading of the chromatograms using the Independent Component Analysis
(ICA, Chapter 6). The aim was to automatically separate from the noise the peaks,
and track them among a set of chromatograms from the same experimental design.
This was helpful as it allowed to achieve automation in most of the real case studies
presented in this manuscript and references. When complete automation was not
achieve, it permitted easing the data treatment, which was too difficult to be carried
out manually with precision.
Manufacturing process. In order to evaluate the generic character of the ap-
proach, a transposition of the Design Space methodology to a small-scale manufac-
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turing process was envisaged as a feasibility study (Chapter 9). The joint prediction
of future outputs of the process was also the key to answer the objective dictated
by ICH Q8: to provide assurance of quality.
For this application, the variabilities resulted in a minimal quality level that
was kept relatively low in order to be able to define a Design Space. The risks
of being out of specifications were identified higher than acceptable, while a mean
response surface optimization might have wrongly stated that the process would run
accordingly to its specifications.
One of the identified reasons was the inability of the multivariate linear model to
fit part of the data properly. However, the experimental plan available was poorly
designed to allow better modeling properties.
Analytical method validation. Finally, the Bayesian framework was used to
derive in a simulation perspective the predictive distribution of univariate random
and mixed-effect models. The choice of these models was made because they were
useful for the calibration problem of assay with both linear and non-linear behaviors,
and for the validation of the results provided by the analytical methods.
In Chapter 10, the validation of a chromatographic method to quantify three
compounds was illustrated, in a completely automated way, using predictive models
and the ICA as a deconvolution technique. Furthermore, the analytical conditions
were set in such way this method validation would have been erroneous and even
impossible with data treated manually.
With the proposed tools, several steps of the method life cycle were explored,
including the development of robust separation methods and their validation, aim-
ing at demonstrating the quality of their quantitative results. It was also noted
that demonstrating the quality of the results of analytical methods is an important
objective as these results are used to take the important decision during the drug
development process, the batch releases, and also for post-marketing analysis.
In Chapter 11, a last insight was made on another type of method: the bio-
analytical ligand-binding assay. The most noticeable difference with the classical
analytical methods is that the calibration curves are non-linear. They follow a
logistic form that must be use to take advantage of all the data. The Bayesian
predictive framework also allowed providing Critical Quality Attributes about the
assay future performance. It was also illustrated how to account for past experiments
to set up informative prior distributions that result in very light experimental designs
to collect data during routine.
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Further works
The successful application of the methodologies proposed in the work leads to
envisage new applications as further works. It might include other analytical sep-
aration methods such as particular liquid chromatography modes (chiral, ion ex-
change, HILIC, supercritical fluid, etc.), gas chromatography, capillary electrophore-
sis. Other manufacturing processes will also be considered in a near future, consid-
ering the very promising preliminary results obtained.
Next, it is recognized that, during the statistical process control (SPC) operated
on a manufacturing process or the use if an analytical method, the use of prior
information gathered during the experiments and modeling steps can improve the
quality of the decision to accept or reject production batches. However, no SPC
have been set up and carried out after the presented optimization processes, which
could be the subject of future studies.
The methodology proposed in this work showed good results in terms of efficiency
and flexibility. However, for each of the various applications, it was mandatory to
code several new functions and to adapt the scripts in order to provide the Design
Space and solutions.
One obvious further work is to propose the methodology as one or several tool-
box(es). Fortunately, all the steps of the methodology are modular, from the model
definition to the Critical Quality Attributes and Design Space computations. Spe-
cific modules can thus be coded once for every new applications.
Finally, a computer-based system can provide a way for the industry to retrieve
and make use of its previous results easily, using a database system. Three advan-
tages can be highlighted. First, if the data and the experimental design are sufficient,
it can allow new optimizations without any additional experiments. For instance,
the development of robust and specific methods for molecule screening and determi-
nation can then be made in a snap, as shown in Chapter 8. A second advantage is
to ease the definition of informative priors that are based on previous experiments,
including prior covariance structures. Finally, if changes of formulation cause new
materials to be added in a drug, the number of experiences to analyze the new for-
mulation might be drastically reduced as the experimental domain can readily be
restrained to the Design Space of the previous formulations. Indeed, outside this
Design Space, it was already demonstrated that the analytical method will not have
a good quality, with several compounds that might be not fully separated.
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Appendix A
Use of informative prior with the
multivariate linear regression
A.1 Description of the problem
The problem is a multivariate response surface model with m responses and k
factors for each responses, using a common derivative matrix X. The inference using
non-informative priors distribution have been well discussed in Box and Tiao (1973),
in Geisser and Cornfield (1963), and in Geisser (1965).
In this problem, n observations of the m-variate response vector are available.
The multivariate model can then be written as
Y = XB + E, (A.1)
where Y and E are (n×m) matrices for the m-variate responses and for the corre-
sponding errors, respectively. X is the (n× p) design matrix (p > k, generally) and
B is the (p×m) matrix containing the predictors of the model. One observation of
the responses is described as yi = (yi1, . . . , yij, . . . , yim) and the expectation of its
elements is
E(yij) =
p∑
l=1
xilβlj, i = 1, ..., n; j = 1, ...,m. (A.2)
This equation can be written in matrix form for the m-variate response as
E(yi) = xiB (A.3)
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with
xi =
(
xi1, . . . , xil, . . . , xip
)
and B =

β11 · · · β1j · · · β1m
...
. . .
...
βl1 βlj βlm
...
. . .
...
βp1 · · · βpl · · · βpm
 . (A.4)
Thus, xi is the ith line of X. Finally, it is assumed that each m-variate response
follows a multivariate Normal distribution. Furthermore response vectors are inde-
pendent and identically distributed (i.i.d.). That is,
yi ∼ Nm (xiB,Σ) , i = 1, ..., n. (A.5)
A.2 Bayesian framework
Introduction. Bayesian methods are used to derive the posterior density of model
parameters. Using Bayesian rule, the posterior density is the product of the likeli-
hood and the prior densities for the parameters:
p(B,Σ | data) ∝ L(B,Σ | Y) . p(B,Σ)
∝ L(B,Σ | Y) . p(B | Σ) . p(Σ). (A.6)
Prior assumptions are the following: the density p(B | Σ) is assumed to be
Normally distributed, and p(Σ) follows an inverse-Wishart distribution. These are
natural assumptions when inferring using proper informative prior distributions.
Moreover, they are conjugate (Press, 1972, §8.6.2). Some results concerning these
prior distributions have been derived in a note by Minka (2001). Alternatively, it is
possible to use the Normal-Wishart prior distribution for the joint prior p(B,Σ−1)
as shown in Guttman (1970).
Likelihood. Following Equation A.5 and the i.i.d. assumptions on n observations,
the likelihood for this model is given by:
L (B,Σ | Y) = (2pi)−mn2 |Σ|−n2 . exp
(
−12
n∑
i=1
[
(yi − xiB) Σ−1 (yi − xiB)′
])
with −∞ < εij = yij − xiβj <∞, i = 1, . . . , n, j = 1, . . . ,m. (A.7)
Or, more conveniently,
L (B,Σ | Y) = (2pi)−mn2 |Σ|−n2 . exp
(
−12tr
[
Σ−1 (Y −XB)′ (Y −XB)
])
(A.8)
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Prior distribution of B | Σ. Assume that the prior distribution of B given Σ is a
matrix-variate Normal distribution of mean B0 and covariance matrices Σ (columns
of B) and Σ0 (rows of B). The matrix-variate Normal distribution extends the
classical multivariate Normal distribution to matrices of random values (instead of
vectors).
B | Σ ∼ Np×m (B0,Σ,Σ0) . (A.9)
B0 is then of the same size than B, Σ is (m×m) and Σ0 is (p× p). By definition,
the the matrix-variate Normal can be compute from a classical multivariate Normal
using the following indentity (See Appendix D):
vec (B | Σ) ∼ Npm (vec (B0) ,Σ⊗Σ0) , (A.10)
where ⊗ is the Kronecker product. In this case, vectorized forms of B and B0 are
used. This is rather useful for implementation purpose as the matrix-variate Normal
is usually not available in softwares. The operator vec, applied on any matrix B of
size (p×m), stacks its columns into a vector of length p.m:
vec(B) = (β11, β21, . . . , βp1, β12, β22, . . . , . . . , βpm)′ . (A.11)
Notice that Σ⊗Σ0 is the (pm×pm) matrix defining the covariances between the pm
parameters in B. This covariance matrix is highly structured due to the Kronecker
product. Note that, conditional to Σ, the definition of the prior covariance matrix
is only depending on Σ0. It follows that the prior information in Σ0 will be similar
for each response.
The density of B | Σ is:
p (B | Σ) = (2pi)−pm2 |Σ0|
−m
2 |Σ|−p2
. exp
(
−12tr
[
Σ−1(B−B0)′Σ−10 (B−B0)
])
. (A.12)
Prior distribution of Σ. Σ is the (m × m) unknown covariance matrix that
describes the multivariate residual error between the m column of E. Σ is assumed
to follow an inverse-Wishart distribution W−11 with a scale matrix Ω and ν0 degrees
of freedom (See Appendix D):
Σ ∼ W−11 (Ω, ν0), ν0 > 0. (A.13)
The density of Σ is:
p(Σ) = 2
m(ν0+m−1)
2 Γm
(
ν0 +m− 1
2
)−1
|Ω| ν0+m−12 |Σ|− ν0+2m2
. exp
(
−12tr[Σ
−1Ω]
)
, (A.14)
where Γm(.) is the multivariate gamma function. This is the definition used in Box
and Tiao (1973). ν0 has to be understood as the number of degrees of freedom of
the prior distribution. It could be defined as follows: ν0 = n0 − (m + p) + 1, with
n0 being the number of prior observations.
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Complete joint posterior distribution of the parameters. Combining the
likelihood and the proposed prior distributions as in Equation (A.6), the posterior
density of the parameters can be written, by regrouping first, normalizing constants;
second, terms comprising Σ alone; and finally, terms with Σ and B:
p (B,Σ | data) = (2pi)−mn2 (2pi)−pm2 |Σ0|
−m
2 2
m(ν0+m−1)
2 Γm( ν0+m−12 )−1 |Ω|
ν0+m−1
2
. |Σ|−n2 |Σ|−p2 |Σ|− ν0+2m2 . exp
(
−12tr[Σ
−1Ω]
)
. exp
(
−12tr
[
Σ−1 (Y −XB)′ (Y −XB)
])
. exp
(
−12tr
[
Σ−1(B−B0)′Σ−10 (B−B0)
])
. (A.15)
Simplification of the posterior density. Equation (A.15) is unpractical as the
regression parameters are present in both third and fourth lines. The idea is to
regroup those two exponents in one single term. The last two lines can be recognized
to be proportional to the posterior distribution of B conditional to Σ. They can be
combined using exponential and trace properties:
p (B | Σ, data) ∝
exp
(
−12tr
[
Σ−1
(
(Y −XB)′ (Y −XB) + (B−B0)′Σ−10 (B−B0)
)])
.
(A.16)
The quadratic terms are developed and isolated as follows:
p (B | Σ, data)
∝ exp
(
−12tr
[
Σ−1
(
Y′Y − 2B′X′Y + B′X′XB + B′Σ−10 B− 2B
′Σ−10 B0 + B
′
0Σ−10 B0
)])
∝ exp
(
−12tr
[
Σ−1
(
B′(X′X + Σ−10 )B− 2B
′(X′Y + Σ−10 B0) + (Y
′Y + B′0Σ−10 B0)
)])
.
(A.17)
Noticing first that X′Y = X′XBˆ, where Bˆ = (X′X)−1X′Y is the OLS estimation of
B; and second, the a posteriori covariance matrix for the rows of B is (X′X+Σ−10 )−1
and the covariance matrix for the columns of B is Σ, thus the quadratic form in B
need to be completed (see Equation (A.18)). In the next steps, it is shown how the
terms that do not influence this quadratic form, conditional to Σ, are isolated (see
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Equations (A.20)):
p (B | Σ, data)
∝ exp
(
− 12tr
[
Σ−1
(
B′(X′X + Σ−10 )B
−2B′(X′X + Σ−10 )(X
′X + Σ−10 )−1(X
′XBˆ + Σ−10 B0)
+(X′XBˆ + Σ−10 B0)
′(X′X + Σ−10 )−1(X
′XBˆ + Σ−10 B0)
)])
. exp
(
− 12tr
[
Σ−1
(
(Y′Y + B′0Σ−10 B0)
−(X′XBˆ + Σ−10 B0)
′(X′X + Σ−10 )−1(X
′XBˆ + Σ−10 B0)
)])
(A.18)
∝ exp
(
− 12tr
[
Σ−1(B−MBpost)′(X′X + Σ−10 )(B−MBpost)
])
(A.19)
. exp
(
− 12tr
[
Σ−1A∗
])
, (A.20)
with
MBpost = (X
′X + Σ−10 )−1(X
′XBˆ + Σ−10 B0), and,
A∗ = Y′Y + B′0Σ−10 B0 − (X
′XBˆ + Σ−10 B0)
′(X′X + Σ−10 )−1(X
′XBˆ + Σ−10 B0).
MBpost is a linear combination of the OLS estimation of B and its prior mean B0,
weighted by their respective variances. The terms A∗ is simply a constant. When
using uniform prior distributions, A∗ is equal to the A matrix presented by Geisser
(1965) or Box and Tiao (1973) (See later). A∗ is also the sum of squares of the
multivariate residual error, though it is not easy to visualize it due to the prior
incorporation.
Naturally, given Σ, Equation (A.20) is also a constant, and the density of Equa-
tion A.19 alone is proportional to p (B | Σ, data). It can readily be identified as a
matrix-variate Normal distribution with mean MBpost and covariance matrices Σ
(for the columns) and (X′X + Σ−10 )−1 (for the rows):
B | Σ, data ∼ Np×m
(
MBpost,Σ,
(
X′X + Σ−10
)−1)
(A.21)
Or, more conveniently,
vec(B) | Σ, data ∼ Npm
(
vec(MBpost),Σ⊗
(
X′X + Σ−10
)−1)
(A.22)
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Notice that the posterior row covariance is simply the (inverse of the) sum of the
likelihood precision matrix (X′X) and of the prior row precision matrix (Σ−10 ).
Now that the two last lines of Equation (A.15) have been simplified, the joint
posterior distribution can be restated as:
p
(
B,Σ | data
)
= (2pi)−mn2 (2pi)
−pm
2 |Σ0|
−m
2 2
m(ν0+m−1)
2 Γm( ν0+m−12 )−1 |Ω|
ν0+m−1
2
. |Σ|−n2 |Σ|−p2 |Σ|− ν0+2m2
. exp
(
−12tr
[
Σ−1Ω
])
exp
(
−12tr
[
Σ−1A∗
])
. exp
(
−12tr
[
Σ−1(B−MBpost)′(X′X + Σ−10 )(B−MBpost)
])
. (A.23)
Marginal posterior density of Σ. The posterior distribution of Σ is computed
as
p (Σ | data) ∝
∫
B
p (B,Σ | data) dB.
(A.24)
This integral is fortunately simple to resolve as only the last line of Equation (A.23)
has terms including B. All the other terms are then putted out of the integral.
Noticing that, as in Geisser (1965) (Equation 4.6), the terms in B can be integrated
out as: ∫
B
exp
(
−12tr
[
Σ−1
(
B−MBpost
) (
X′X + Σ−10
)(
B−MBpost
)])
dB
= (2pi)
pm
2 |Σ| p2
∣∣∣X′X + Σ−10 ∣∣∣−m2 , (A.25)
the marginal posterior density of Σ can be written as
p (Σ | data) ∝ |Σ|− ν0+n+p+2m2 exp
(
−12tr
[
Σ−1(Ω + A∗)
])
.
∫
B
exp
(
−12tr
[
Σ−1
(
B−MBpost
) (
X′X + Σ−10
) (
B−MBpost
)])
dB
∝ |Σ|−
ν0+n+p+2m2 exp
(
−12tr
[
Σ−1(Ω + A∗)
])
.(
√
2pi)mp 
|Σ| p2
∣∣∣X′X + Σ−10 ∣∣∣−m2
∝ |Σ|− (ν0+n)+2m2 exp
(
−12tr
[
Σ−1(Ω + A∗)
])
(A.26)
This density can then be identified as the inverse-Wishart W−11 (Ω + A∗, ν0 + n).
Note that if ν = n− (m+ p) + 1 and ν0 = n0 − (m+ p) + 1, then ν0 + n = ν + n0,
and
Σ | data ∼ W−11 (Ω + A∗, ν + n0) . (A.27)
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The scale matrix is then the sum of the prior scale matrix Ω and A∗. There is
ν + n0 degrees of freedom (d.f.), i.e., the number of d.f. from the likelihood (ν)
added by the number of virtual observations n0 injected from the informative prior
distribution of Σ.
Here follows some results derived from the properties of the Wishart and inverse-
Wishart distribution. First, the distribution of Σ−1 is a classical Wishart distribu-
tion (Box and Tiao, 1973) :
Σ−1 | data ∼ W1
(
(Ω + A∗)−1, ν + n0
)
. (A.28)
This is straightforward as the only difference between the inverse-Wishart and the
Wishart distributions is the transformation from Σ to Σ−1, whose Jacobian is
|Σ|m+1. This equivalence may be helpful for several purposes, such as the sam-
pling using computer softwares, or the identification of the predictive distribution
of the responses.
Second, great care should be taken when sampling or using statistics derived
from other implementations of the Wishart or inverse-Wishart distributions that
exist (referred as W 12 and W−12 respectively). Indeed, the distributions included in
softwares such as R or WinBUGS may have a different definition of the d.f. than
the ones proposed here. As discussed in Appendix D, if W 11 and W−11 both have ν1
d.f. (ν1 > 0), then, W 12 and W−12 must have ν2 d.f. (ν2 > m− 1) with the following
relation: ν1 +M − 1 = ν2.
Marginal posterior density of B. The posterior distribution of B is computed
as
p (B | data) ∝
∫
Σ
p (B,Σ | data) dΣ.
(A.29)
As in the previous section, this integral is not hard to resolve if the terms in Σ are
on the “right place”. From Dickey (1967), the following relation is available:∫
U
|U|λ−m+12 . exp
(
tr
[
−UM
])
dU = Γm(λ) |M|−λ , (A.30)
where U and M are symmetric and definite positive (m × m) matrices and λ >
1
2(m−1). The idea is to transform the joint posterior density so that this relationship
can be applied.
Thus, the joint posterior of Equation A.23 is simplified using trace and exponen-
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tial properties, and only the relevant terms are selected:
p
(
B,Σ | data
)
∝ |Σ|− ν0+n+p+2m2 . exp
(
−12tr
[
Σ−1Ω
])
. exp
(
−12tr
[
Σ−1A∗
])
. exp
(
−12tr
[
Σ−1(B−MBpost)′(X′X + Σ−10 )(B−MBpost)
])
∝ |Σ|− ν0+n+p+2m2
. exp
(
−12tr
[
Σ−1
(
(Ω + A∗) + (B−MBpost)′(X′X + Σ−10 )(B−MBpost)
) ])
(A.31)
To use Equation (A.30), the posterior must be restated. Using the Jacobian of
the transformation of Σ to Σ−1, equal to |Σ|m+1 (Box and Tiao, 1973), the posterior
is:
p
(
B, Σ−1 | data
)
∝
∣∣∣Σ−1∣∣∣ ν0+n+p+m−12 −m+12
. exp
(
tr
[
−Σ−1 (Ω + A
∗) + (B−MBpost)′(X′X + Σ−10 )(B−MBpost)
2
])
.
(A.32)
With this arrangement, the posterior density now has a form compatible with the
formula of Dickey in Equation (A.30). Assuming that U = Σ−1, p(B,Σ−1 | data)
is integrated with respect to Σ−1, and gives:
p (B | data) = 12Γm(
(ν0+n)+p+m−1
2 )
.
∣∣∣(Ω + A∗) + (B−MBpost)′(X′X + Σ−10 )(B−MBpost)∣∣∣− (ν0+n)+p+m−12
(A.33)
This last density is identified as the following (p × m) matrix-variate Student’s
distribution:
B | data ∼ Tp×m(MBpost,Ω + A∗, (X′X + Σ−10 )−1, ν0 + n). (A.34)
Notice that the use of the Jacobian is similar to assume a Wishart distribution
for Σ−1 instead of an inverse-Wishart distribution for Σ.
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A.3 Using non-informative prior distributions
Without being a justification of the previous calculation, it is interesting to see
if the use of uniform priors leads to the same solutions than the classical non-
informative distributions (Box and Tiao, 1973).
For B | Σ, a vague prior is given by any values of B0 (e.g. a 0−matrix), and a
precision matrix Σ−10 being non significant with 0 everywhere. Clearly, the posterior
variance for vec(B) will be
Σ⊗
(
X′X + Σ−10
)−1
= Σ⊗
(
X′X
)−1
(A.35)
which is the solution proposed by Box and Tiao. The simplification of the posterior
mean in a non-informative case is as follows:
MBpost =
(
X′X + Σ−10
)−1 (
X′XBˆ + Σ−10 B0
)
=
(
X′X
)−1 (
X′XBˆ
)
=
(
X′X
)−1 (
X′X
)
Bˆ
= Bˆ, (A.36)
which is the ordinary least-squares estimation of B.
Similarly, the scale parameter of the posterior distribution of Σ is similar to the
one proposed in the non-informative case in the literature. Let n0 = 0 and Ω be 0
everywhere, the posterior distribution becomes:
Σ ∼ W−11 (Ω + A∗, ν + n0) = W−11 (A∗, ν) (A.37)
Below are listed the details to simplify A∗ in the non-informative case:
A∗ =
(
Y′Y + B′0Σ−10 B0
)
−
(
X′XBˆ + Σ−10 B0
)′ (
X′X + Σ−10
)−1 (
X′XBˆ + Σ−10 B0
)
=
(
Y′Y
)
−
(
X′XBˆ
)′ (
X′X
)−1 (
X′XBˆ
)
=
(
Y′Y
)
−
(
Bˆ′X′XBˆ
)
=
(
Y′Y
)
− 2
(
Bˆ′X′XBˆ
)
+
(
Bˆ′X′XBˆ
)
=
(
Y′Y
)
− 2
(
Bˆ′X′Y
)
+
(
Bˆ′X′XBˆ
)
=
(
Y −XBˆ
)′ (
Y −XBˆ
)
= A, (A.38)
to compare with A in Geisser (1965) and Box and Tiao (1973), i.e., the sum of
squares of the multivariate residual error. The simplification of the marginal poste-
rior distribution of B under non-informative prior also leads to the same Student’s
distribution as in Box and Tiao (1973).
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A.4 Simultaneous Predictions
Known Σ. Assume that n˜ vectors of m responses create a (n˜ × m) matrix Y˜.
These vectors are predicted simultaneously at different operating conditions X˜ =
(x˜1, ..., x˜n˜)′. Mean responses are obviously obtained using the regression model
E(Y˜ | X˜, data) = X˜MBpost, where X˜ is a (n˜ × p) containing the design vector
effects. Each line of X˜ may be estimated in the experimental domain. The interest
is to obtain the distribution of several independent new response vectors. To keep
the text simple, the first results are presented conditionally to Σ. All constant terms
(terms that does not depend upon B) can then be dropped.
p(Y˜ | X˜,Σ, data) =
∫
B
p(Y˜ | X˜,B,Σ).p(B | Σ, data)dB (A.39)
∝
∫
B
|Σ|−n˜2 . exp
(
−12tr
[
Σ−1(Y˜ − X˜B)(Y˜ − X˜B)′
])
. exp
(
−12tr
[
Σ−1(B−MBpost)′(X′X + Σ−10 )(B−MBpost)
])
dB. (A.40)
Grouping the two exponential within the integral (using trace and exponential prop-
erties) gives:
p(Y˜ | X˜,Σ, data) ∝
∫
B
exp
(
− 12tr
[
Σ−1
(
(Y˜ − X˜B)(Y˜ − X˜B)′
+ (B−MBpost)′(X′X + Σ−10 )(B−MBpost)
)])
dB
∝
∫
B
exp
(
−12tr
[
Σ−1
(
Q
)])
dB. (A.41)
The quadratic form Q is developed hereafter,
Q = Y˜′Y˜ − 2B′X˜′Y˜ + B′X˜′X˜B
+ B′(X′X + Σ−10 )B− 2B
′(X′X + Σ−10 )MBpost + M
′
Bpost(X
′X + Σ−10 )MBpost.
(A.42)
To solve the integral in B, it is enviable to group the terms that include B to simplify
the equation:
Q = B′
(
X˜′X˜ + (X′X + Σ−10 )
)
B− 2B′
[
(X′X + Σ−10 )MBpost + X˜
′Y˜
]
+ Y˜′Y˜ + M′Bpost(X
′X + Σ−10 )MBpost. (A.43)
Analyzing the first line of Equation A.43 a quadratic form in B might be found. The
variance term would be the inverse of (X˜′X˜+(X′X+Σ−10 )). Let V = (X˜
′X˜+(X′X+
Σ−10 )) to shorten equations. Pre-multiplicating the crossed term (i.e. −2B′ [...]) by
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I = VV−1 and completing the square form gives
Q = B′VB− 2B′(VV−1)
[
(X′X + Σ−10 )MBpost + X˜
′Y˜
]
+
[
(X′X + Σ−10 )MBpost + X˜
′Y˜
]′
V−1VV−1
[
(X′X + Σ−10 )MBpost + X˜
′Y˜
]
+ Y˜′Y˜ + M′Bpost(X
′X + Σ−10 )MBpost
−
[
(X′X + Σ−10 )MBpost + X˜
′Y˜
]′
V−1VV−1
[
(X′X + Σ−10 )MBpost + X˜
′Y˜
]
.
(A.44)
Although this is barely visible, the three first terms of Q are now a quadratic form
in B. Letting L =
[
(X′X + Σ−10 )MBpost + X˜
′Y˜
]
, Q is simplified as follows:
Q =
(
B−V−1L
)′
V
(
B−V−1L
)
+ Y˜′Y˜ + M′Bpost(X
′X + Σ−10 )MBpost − L
′V−1L. (A.45)
Thus, the terms in B have been isolated. Returning back to Equation A.41, Q
and L are kept as in Equation A.45. The constant values are putted out from the
integral using trace and exponential properties:
p(Y˜ | X˜,Σ,data) ∝
∫
B
exp
(
− 12tr
[
Σ−1
(
Q
)])
dB
∝
∫
B
exp
(
− 12tr
[
Σ−1
(
(B−V−1L)′V(B−V−1L)
+ Y˜′Y˜ + M′Bpost(X
′X + Σ−10 )MBpost − L
′V−1L
)])
dB
∝
∫
B
exp
(
− 12tr
[
Σ−1
(
(B−V−1L)′V(B−V−1L)
)])
.dB
. exp
(
− 12tr
[
Σ−1
(
Y˜′Y˜ + M′Bpost(X
′X + Σ−10 )MBpost − L
′V−1L
)])
∝ (2pi) pm2 |Σ| p2 |V|m2
. exp
(
− 12tr
[
Σ−1
(
Y˜′Y˜ + M′Bpost(X
′X + Σ−10 )MBpost − L
′V−1L
)])
.
(A.46)
The integration of B has been done as in Geisser (1965), Equation 4.6. These
constants are dropped for the moments.
Next, the objective is to simplify and identify the form of the density for Y˜. Let
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work on Q∗, defined as:
p(Y˜ | X˜,Σ, data) ∝ exp
(
− 12tr
[
Σ−1
(
Y˜′Y˜ + M′Bpost(X
′X + Σ−10 )MBpost
− L′V−1L
)])
∝ exp
(
− 12tr
[
Σ−1
(
Q∗
)])
, (A.47)
A quadratic form in Y˜ would look similar to Q∗ = (Y˜−µy)′C(Y˜−µy) = Y˜′CY˜−
2µ′yCY˜ + µ
′
yCµy. Basically, the idea is, again, to develop quadratic forms, to
isolate relevant terms, and to identify variance and mean terms by completing the
quadratic form with the necessary values. First, developing L′V−1L gives:
Q∗ = Y˜′Y˜ + M′Bpost(X
′X + Σ−10 )MBpost
−
[
(X′X + Σ−10 )MBpost + X˜
′Y˜
]′
V−1
[
(X′X + Σ−10 )MBpost + X˜
′Y˜
]
= Y˜′Y˜ + M′Bpost(X
′X + Σ−10 )MBpost
−
[
M′Bpost(X
′X + Σ−10 )V−1(X
′X + Σ−10 )MBpost
]
− 2
[
M′Bpost(X
′X + Σ−10 )V−1X˜
′Y˜
]
−
[
Y˜′X˜V−1X˜′Y˜
]
. (A.48)
Regrouping the squared terms in Y˜ (first and last terms of Equation (A.48)), and
removing the two squared terms in MBpost (second and third terms; note they will
simplify to 0 later on) provides:
Y˜′(I− X˜V−1X˜′)Y˜ − 2
[
M′Bpost(X
′X + Σ−10 )V−1X˜
′Y˜
]
. (A.49)
Let C = (I − X˜V−1X˜′). Notably, it is the inverse of the (predictive) variance.
Pre-multiplying Y˜ in the crossed term (−2[...]) by I = (C−1C) and completing the
quadratic form allow obtaining:
Y˜′CY˜ − 2
[
M′Bpost(X
′X + Σ−10 )V−1X˜
′(C−1C)Y˜
]
+
[
M′Bpost(X
′X + Σ−10 )V−1X˜
′C−1CC−1X˜V−1(X′X + Σ−10 )MBpost
]
−
[
M′Bpost(X
′X + Σ−10 )V−1X˜
′
 C−1 CC−1X˜V−1(X
′X + Σ−10 )MBpost
]
=
[
Y˜ −C−1X˜V−1(X′X + Σ−10 )MBpost
]′
C
[
Y˜ −C−1X˜V−1(X′X + Σ−10 )MBpost
]
−
[
M′Bpost(X
′X + Σ−10 )V−1X˜
′C−1X˜V−1(X′X + Σ−10 )MBpost
]
. (A.50)
Assuming µy = C−1X˜V−1(X
′X + Σ−10 )MBpost, this last equation simplifies to:[
Y˜ − µy
]′
C
[
Y˜ − µy
]
−
[
µ
′
yCµy
]
,
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which is the desired quadratic form in Y˜. Considering the constant terms w.r.t Y˜
are dropped, and that the density is conditional to Σ, the density of Equation A.40
may then be simplified in
p(Y˜ | X˜,Σ, data) ∝ exp
(
− 12tr
[
Σ−1
(
(Y˜ − µy)
′C(Y˜ − µy)
)])
. (A.51)
Conditional to Σ, this joint predictive distribution for n˜ new samples is identified
as a matrix-variate Normal distribution:
Y˜ | X˜,Σ, data ∼ Nn˜×m
(
µy,Σ,C−1
)
. (A.52)
Some simplifications can be easily made. First, noticing that C−1 = (I +
X˜(X′X + Σ−10 )−1X˜
′) (see e.g. Marriott and Spencer, 2001), µy directly simplifies
into X˜MBpost, which was expected.
Second, regrouping all the terms in MBpost, which were removed during the com-
putations (from Equations (A.48) and (A.51)), these lasts can be shown to be equal
to 0:
M′Bpost(X
′X + Σ−10 )MBpost −
[
M′Bpost(X
′X + Σ−10 )V−1(X
′X + Σ−10 )MBpost
]
− µ′yCµy. (A.53)
As µy as been defined as C−1X˜V−1(X
′X + Σ−10 )MBpost = X˜MBpost, the following
relation holds:
µ
′
yCµy =
[
M′Bpost(X
′X + Σ−10 )V−1X˜
′X˜MBpost
]
.
Finally, replacing µ′yCµy in Equation (A.53) gives:
M′Bpost(X
′X + Σ−10 )MBpost −
[
M′Bpost(X
′X + Σ−10 )V−1(X
′X + Σ−10 )MBpost
]
−
[
M′Bpost(X
′X + Σ−10 )V−1X˜
′X˜MBpost
]
= M′Bpost(X
′X + Σ−10 )
[
I−V−1
(
(X′X + Σ−10 ) + X˜
′X˜
)]
MBpost
= M′Bpost(X
′X + Σ−10 )
[
I−V−1
(
V
)]
MBpost
= M′Bpost(X
′X + Σ−10 ) [I− I] MBpost
= 0. (A.54)
Notice that, conditional to Σ, the joint predictive distribution for n˜ new samples
can be better expressed as:
Y˜ | X˜,Σ, data ∼ Nn˜×m
(
X˜MBpost,Σ, I + X˜(X
′X + Σ−10 )−1X˜
′)
. (A.55)
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The non-zero constants are |Σ|−n˜2 from Equation (A.40) and (2pi) pm2 . |Σ| p2 . |V|m2
from Equation (A.46). These constants given Σ will be important in the next
section.
Adding the uncertainty of Σ. Until now, Σ has been assumed known when
identifying the predictive distribution of new response vectors. With Σ unknown,
its uncertainty is added by multiplicating the predictive density of the previous
section by the posterior density of Σ, and integrate everything over Σ:
p(Y˜ | X˜, data) ∝
∫
Σ
p(Y˜ | X˜,Σ, data).p(Σ | data).dΣ (A.56)
In Equation (A.40), p(Y˜ | X˜,Σ, data) was computed using only the last line of
the joint posterior in Equation (A.31). Retrieving all the constants, the predictive
density could be written as:
p(Y˜ | X˜, data) ∝
∫
Σ
|Σ|−n˜2 (2pi) pm2 |Σ| p2 |V|m2
. exp
(
− 12tr
[
Σ−1
(
(Y˜ − X˜MBpost)′C(Y˜ − X˜MBpost)
)])
.(2pi)−mn2 (2pi)
−pm
2 |Σ0|
−m
2 2
m(ν0+m−1)
2 Γm( ν0+m−12 )−1 |Ω|
ν0+m−1
2
. |Σ|−n2 |Σ|−p2 |Σ|− ν0+2m2
. exp
(
−12tr
[
Σ−1Ω
])
. exp
(
−12tr
[
Σ−1A∗
])
dΣ. (A.57)
This last equation can be considerably simplified by dropping every term that does
not comprise Σ or Y˜. In this case, it looks as:
p(Y˜ | X˜, data) ∝
∫
Σ
|Σ|−n˜2 |Σ| p2 |Σ|−n2 |Σ|−p2 |Σ|− ν0+2m2
. exp
(
− 12tr
[
Σ−1
(
(Y˜ − X˜MBpost)′C(Y˜ − X˜MBpost)
)])
. exp
(
−12tr
[
Σ−1Ω
])
. exp
(
−12tr
[
Σ−1A∗
])
dΣ.
∝
∫
Σ
|Σ|− n˜+n+ν0+2m2
exp
(
−12tr
[
Σ−1
(
Ω + A∗ + (Y˜ − X˜MBpost)′C(Y˜ − X˜MBpost)
)])
dΣ.
(A.58)
To solve this integral (see Equation (A.30)), the transformation of Σ to Σ−1 is
necessary, with Jacobian equals to |Σ|m+1. Again, this is similar to assume that
Σ−1 follows a Wishart distribution. Indeed, the Wishart distribution is part of the
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generative process of a matrix-variate Student’s distribution, as in Gupta and Nagar
(1999). Multiplying by the Jacobian, the predictive density is expressed:
p(Y˜ | X˜, data) ∝
∫
Σ−1
p(Y˜ | X˜,Σ−1, data).p(Σ−1 | data).dΣ−1
∝
∫
Σ−1
∣∣∣Σ−1∣∣∣ (n+ν0)+n˜+2m2 |Σ|m+1
exp
(
−12tr
[
Σ−1
(
Ω + A∗ + (Y˜ − X˜MBpost)′C(Y˜ − X˜MBpost)
)])
dΣ−1
∝
∫
Σ−1
∣∣∣Σ−1∣∣∣ (n+ν0)+n˜+m−12 −m−12
exp
(
−12tr
[
Σ−1
(
Ω + A∗ + (Y˜ − X˜MBpost)′C(Y˜ − X˜MBpost)
)])
dΣ−1.
(A.59)
The integrals in Σ−1 is performed (Equation (A.30) with U = Σ−1) to obtain
p(Y˜ | X˜, data) ∝
∣∣∣Ω + A∗ + (Y˜ − X˜MBpost)′C(Y˜ − X˜MBpost)∣∣∣− (n+ν0)+n˜+m−12 ,
(A.60)
which is recognized as a matrix-variate Student’s distribution of size (n˜ ×m) with
mean X˜MBpost, scale matrices (Ω + A∗) and C−1, and n+ ν0 d.f.
As classical implementations of matrix-variate Student’s distribution make use of
spread matrices (often wrongly referred as covariance matrices) instead of scale ma-
trices, the a posteriori spread matrix can be computed as the scale matrix divided
by the total d.f.: (A∗ + Ω)/(n+ ν0) (See for instance Press, 2003, p 294). Particu-
larly, this spread matrix corresponds to the covariance matrix of the matrix-variate
Normal distribution that is used in the generative process of the matrix-variate
Student’s distribution. Finally, this covariance matrix of the Student’s distribution
is:
(A∗ + Ω)/(n+ ν0 − 2).
The predictive distribution for n˜ new samples Y˜ can then be written as
Y˜ | X˜, data ∼ Tn˜×m
(
X˜MBpost,Ω + A∗,C−1, n+ ν0
)
, (A.61)
or, more conveniently
vec(Y˜) | X˜, data ∼ Tn˜m
(
(Ω + A∗)⊗C−1, n+ ν0
)
. (A.62)
This result is related to the ones of Zellner and Chetty (1965) and Kibria (2006).
Finally, the marginalization property of the matrix-variate Student’s distribution
can be used to retrieve the predictive distribution for the prediction of only one new
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response vector y˜. y˜ is then a vector of size m (i.e., a (1×m) matrix) and, in this
case, it has the form of a multivariate Student’s distribution (See Appendix D.6).
vec(y˜) | X˜, data ∼ Tm
(
(Ω + A∗).C−1, n+ ν0
)
, (A.63)
where C−1 is a scalar (i.e., a (1× 1) matrix).
A.5 Matrix operations
Here are presented the basic matrix operations that are used in this text. Most
equations are referenced in Petersen and Pedersen (2008).
(AB)′ = B′A′ , ..., (ABCD)′ = D′C′B′A′, etc. (A.64)
(AB)−1 = B−1A−1 , ..., (ABCD)−1 = D−1C−1B−1A−1, etc. (A.65)
tr(ABC) = tr(CAB) = tr(BCA) cyclic property (A.66)
tr(c.A) = c.tr(A) (A.67)
A(BC) = (AB)C associativity (A.68)
A(B + C) = AB + AC distributivity (A.69)
(A + B)C = AC + BC (A.70)
ABA + ACA = A(B + C)A (A.71)
c(AB) = (cA)B = A(cB) = (Ac)B = (AB)c = A(Bc) (A.72)
r(A + B) = rA + rB (A.73)
IN×NA = AIM×M = A size of A : (N ×M) (A.74)
Another useful property:
m∑
j=1
(aj)′(aj) = (A′A) , (A.75)
with aj being the jth column of the A matrix.
A.6 Kronecker product and vec operator
Let A be an (n× k) matrix and B be a (m× l) matrix. The Kronecker product
⊗ of both matrices is the following (nm× kl) matrix:
A⊗B =

a11B · · · a1kB
...
. . .
...
an1B · · · ankB
 (A.76)
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It is also referred as the direct product or the tensor product. Here are some prop-
erties of the Kronecker product:
(A⊗B) , (B⊗A) most of times (A.77)
(A⊗B)(C⊗D) = AC⊗BD (A.78)
(A⊗B)′ = A′ ⊗B′ (A.79)
(A⊗B)−1 = A−1 ⊗B−1 (A.80)
Intensive usage of vec operator is used in this text. The vec operator applied on
a matrix A stacks the columns into a vector, as shown below for a 2× 2 matrix:
A =
(
a11 a12
a21 a22
)
⇔ vec(A) = (a11 a21 a12 a22)′ (A.81)
The following properties link the vec operator to the Kronecker product or trace.
(B′ ⊗A)vec(X) = vec(AXB) (A.82)
tr(A′B) = vec(A)′vec(B) (A.83)
tr(A′BCD′) = vec(A)′(D⊗B)vec(C) (A.84)

Appendix B
Monte-Carlo simulation methods
The Bayesian statistical analysis has been confronted to strong limitations during
many years. Indeed, before the discovery of computer based simulation methods,
the Bayesian statistician had to be able to produce a posterior distribution of some
variables in a closed-form and to identify a well-known distribution to allow a prac-
tical work on their results. If this identification is possible with some simple sets of
problems, in many others, this analysis is not tractable.
When deriving Critical Quality Attributes (CQAs) that are rather complex func-
tions of several variables that may contain ratios or non-linear operators (such as
min or max), the situation becomes even more intricate, and the use of approxi-
mations is of limited help. In this context, Monte-Carlo simulations are a popular
strategy to propagate the uncertainty of some modeled responses (the variables) to
the CQAs.
Assume the interest is the posterior density p(θ | data). θ is either a variable,
a set of variables or a set of responses with various distribution assumptions and
possible correlations. Even if available in closed-form, p(θ | data) is rather complex
and highly dimensional.
In this case, statistics and moments such as the mean, the variance, the quantiles
of the distributions and the probabilities used to make risk-based decision, etc.
remains unfortunately unavailable for the responses, and a fortiori, for the critical
quality attributes of interest. The Monte-Carlo method provides a simple way to
obtain estimates of such statistics by drawing samples that follow the posterior
distribution.
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B.1 Monte-Carlo estimates
Metropolis and Ulam (1949) proposed to learn from a distribution by sampling
elements from it. Obviously, the only limitation of their approach is to be able to
draw samples from the distribution. When this is not possible directly, a solution is
to use the Markov-chain Monte-Carlo method, presented in Appendix C.
To make simple, the following results are made on a univariate posterior distribu-
tion of a random variable θ. Let θ(1), θ(2), ..., θ(n∗) be some samples from p(θ | data).
The different statistics of interests can be estimated from these samples with a rel-
ative accuracy, depending on how many samples are drawn and the way they are
drawn.
From the samples, one can easily compute the following Monte-Carlo estimates
of the properties of p(θ | data):
1. Eˆ(θ | data) = θ¯ = 1
n∗
n∗∑
s=1
θ(s).
2. ˆV ar(θ | data) = s2θ = 1n∗−1
n∗∑
s=1
(θ(s) − θ¯)2.
3. pˆi = p(θ ≤ λ | data) = 1
n∗
n∗∑
s=1
I(θ(s) ≤ λ), I(A) being an indicator function
being 1 if A is true, 0 otherwise.
4. λˆ such that p(θ ≤ λˆ | data) = pi. In this case, one will look after the value
of λ such that the proportion of sampled θ(s) lower or equal to λ is pi, (s =
1, 2, ..., n∗).
5. The shape of the density curve can be visualized using a histogram or a ker-
nel/splines density estimate on θ(1), θ(2), ..., θ(n∗).
6. etc.
For multivariate problem, the generalization of such method is direct. For in-
stance, the computation of pˆi for m variables θ = (θ1, θ2, ..., θm) that must achieve
different quantiles Λ (acceptation limits or criteria), i.e., that must lie within a region
defined by some specifications, is done as follows:
pˆi = p(θ ∈ Λ | data) = 1
n∗
n∗∑
s=1
I(θ(s) ∈ Λ).
For instance, let Λ = {λ1 ≤ θ1 ≤ λ2, θ2 ≤ λ3, θ3 ≥ λ4, ...}.
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When there is interest in several CQAs that are combinations of several variables
θ, i.e. CQAj = Oj(θ), the uncertainty of θ may be propagated to the function Oj.
For each sampled value θ(s), one basically computes the critical quality attribute
of interest CQA(s)j = Oj(θ(s)), (s = 1, 2, ..., n∗). Doing so, the uncertainties and
interactions present in θ will be propagated in the newly sampled distribution of
the CQA. The different Monte-Carlo estimates can then be computed on the sampled
values of the CQA(s).
B.2 Monte-Carlo error
Following the law of large numbers, and assuming the sampling is I.I.D, it is
possible to estimate the accuracy of the Monte-Carlo simulated statistics, conditional
to n∗. For instance, if θ¯ = 1
n∗
∑n∗
s=1 θ
(s) is our statistics of interest, its variance
computed from repeated Monte-Carlo simulations is V ar(θ¯) = σ
2
θ
n∗ , with σ
2
θ being
the true variance of p(θ | data). A Monte-Carlo standard error (MCSE) estimator
is then:
M̂CSE(θ¯) = sθ√
n∗
, (B.1)
where sθ is the standard deviation computed on the sampled values. This results can
be used to find the value of n∗ that must be chosen to get an MCSE of a particular
value δ. Assume a first set of 1000 samples has been drawn, providing a sθ of (say)
0.8, and assume a MCSE about δ =0.01 is envisaged. Inverting equation B.1 to
have n∗ in function of the other quantities gives:
M̂CSE(θ¯) = δ = sθ√
n∗
⇐⇒ n∗ = s
2
θ
δ2
, (B.2)
providing n∗ = 0.82/0.012 = 6400. Notice that, for the same problem, reaching
δ = 0.001 would require 640000 samples ! Generally speaking, the reduction of
the error by a factor 10 (one additional accurate decimal) requires the sample size
to be increased by a factor 100 (Bauer, 1958; Hammersley and Handscomb, 1964).
However, the magnitude of the error on θ¯ remains of order 1/
√
n∗, whatever the
dimension of the problem (Robert, 2007). The increasing speed of computing devices
allows today the creation of millions of samples, and the computation of useful
statistics takes less than a second. Nevertheless, simply increasing the sample size
to decrease simulation error might still lead to high computational burden.
In the risk-based approach presented along the manuscript, intensive use is done
of the estimate of the probability of acceptance pˆi. Similar computations can be
done on the binary vector I(θ(s) ∈ Λ), (s = 1, ..., n∗) to estimate its MCSE and the
corresponding n∗.
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Finally, in the proposal of Metropolis and Ulam, nothing indicates that Monte-
Carlo simulation methods must be carried out on i.i.d. samples. Indeed, the Monte-
Carlo estimates of the statistics are also obtainable if the samples are dependent,
such as the ones that can be obtained using Markov-chains (Appendix C). In this
case, the samples are autocorrelated. Then, they do not provide as much information
about p(θ | data) than i.i.d. samples would. As a consequence, more dependent
samples are needed to have a similar accuracy than with i.i.d. samples. If there is a
significative first-order auto-correlation ρ in the Markov-chain of sampled (θ | data)
(i.e. the chain is assumed AR1), the following adapted formula can be used to
compute the MCSE or the desired n∗:
M̂CSEAR1(θ¯) =
sθ√
n∗
.
√
1− ρ
1 + ρ, (B.3)
where ρ can be estimated as ρˆ = 1
sθ.(n∗−1)
∑n∗
s=2(θ(s) − θ¯)(θ(s−1) − θ¯).
Other methods to estimate the Monte-Carlo error exist, for instance to take into
account the autocorrelations at lag of order higher than 1. See for instance Ntzoufras
(2009).
Appendix C
Markov-chains Monte-Carlo
methods
C.1 Introduction
Markov chains Monte-Carlo methods (or Monte-Carlo simulation from Markov
chains, MCMC) are a practical tool to generate samples from a distribution of
interest. Particularly, the joint posterior distribution of random variables obtained
using Bayes’ theorem is of great interest.
Under the name MCMC, different methodologies have been proposed to create,
from a predefined starting value θ(0), a chain of correlated elements θ(s), (s =
1, 2, 3, ...). This takes the form of a random walk as each θ(s) is a drawn from a
transition distribution, conditionally to the previous element of the chain, θ(s) ∼
gs(θ(s),θ(s−1)). The transition distribution is chosen accordingly so that the chain
has a stationary distribution equivalent to the posterior distribution of interest.
Then, for a sufficiently large number of iterations B, θ(s∗>B) (s∗ = B+ 1, ..., B+n∗)
may be viewed as random samples from the distribution, presenting more or less
autocorrelations.
The elements θ(s) with s < B are called the burn-in elements (or period) of the
sampled chains and are generally discarded. B should be cautiously specified to
make sure the chains have converged around their stationary point. At the end,
useful statistics can be computes from the draws B + 1 to B + n∗. For instance,
the means, the posterior modes, the variances, some probabilities of acceptance,
etc. can be computed with Monte-Carlo estimates (see Appendix B). As MCMC
techniques provide dependent samples, this generally leads to a slower learning, i.e.,
more iterations are necessary to obtain the same information about the distribution
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than with a i.i.d. sampling. The advantage of MCMC methods is to allow the
sampling from nearly any distribution, even when it is non-identified and highly
dimensioned.
The following sections present three classical MCMC algorithm, in their chrono-
logical order of appearance: the Metropolis algorithm, the Metropolis-Hasting algo-
rithm and the Gibbs sampler.
C.2 Metropolis algorithm
The Metropolis algorithm, due to Metropolis et al. (1953), is the foundation
of MCMC, and still one of the most popular methodology, because it is simple
but practical. Whatever the dimensionality or complexity of the distribution, the
Metropolis algorithm is able to generate samples from it. Furthermore, the related
density may only be known up to constant. This simplifies the analytical task as
normalizing constants must not be computed.
Metropolis works with a transition function based on a symmetric proposal dis-
tribution
q(θ(s) | θ(s−1)) = q(θ(s−1) | θ(s)),
those draws are either accepted or rejected following a simple decision rule. Some
restrictions must be observed on the proposal : q and p must have the same support,
and there is a constant φ such as p(θ)/q(θ) ≤ φ, ∀ θ.
The process goes as follows: first, an initial value θ(0) is chosen. From this value,
the Metropolis algorithm is used to generate the elements of the chain θ(1),θ(2),θ(...),
by successively repeating the following steps :
For s = 1 to n∗
1. From a symmetric proposal distribution q(θ(s) | θ(s−1)), draw a new
candidate vector θt,
2. compute the acceptance probability: Pa = min
(
1, p(θ
(s)|data)
p(θ(s−1)|data)
)
,
3. keep θ(s) with probability Pa or assign the old value θ(s) = θ(s−1) other-
wise.
End
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In step 1, the proposal distribution can be a Normal distribution θ(s) ∼ N(θ(s−1), v).
It is a good practice to choose a distribution that well reflects the (posterior) distri-
bution of interest. In step 2, one just need to evaluate the value of the (posterior)
density at the particular values of the variable θ(s) and θ(s−1). The ratio of the
densities at iteration s and s − 1 makes clear that the posterior density may only
be known up to a multiplicative constant. Indeed, both constants of the numerator
and denominator always simplify to 1 in the fraction. In step 3, the probability Pa
can simply be compared with a draw from an Uniform distribution U(0, 1).
The variance of the proposal distribution (here, v) plays an important role in the
sampling algorithm. In the Normal case, it is defined byv. If this variance is too
small, the proposed set of parameters will be very close from the previous one, and
will be accepted very often. Unfortunately, this would lead to high autocorrelations
in the chain, and a poor visit of the distribution. Indeed, the chain will stay in small
region of the variable space for long period. Notice that a large autocorrelation is
symptomatic and allows identifying this problem.
At opposite, if the variance is too large, incongruous values of the variable would
be drawn from the proposal. These values will be rejected too frequently and the
parameters will then stay at the same place possibly for many iterations. Thus, this
may also lead to a slow visit of the distribution. The monitoring of the sampled
chains generally reveals such problems by the (excessive) succession of similar values
for the parameters.
There exist some golden rules about the selection of the variance of the proposal.
For instance, in an univariate problem with approximately Normal posterior dis-
tribution, an acceptance rate (the number of accepted θ(s) over the total number
of iterations) should be between 0.15 to 0.4 to yield at least 80% of the maximum
efficiency obtainable (see Gelman et al., 1996). Then, the variance of the proposal
could be chosen accordingly to reach such acceptance rate.
It has also been proposed to update the variance parameter v at each iteration to
automatically attain the target acceptance rate Ptarget (Haario et al., 2001). After
each iteration, let
√
vs+1 = h(
√
vs +
1
s.(Pa(s)− Ptarget)) (C.1)
with
h(x) =

c if x < c
x if x ∈ (c, A);
A if x > A;
(C.2)
where c is a very small positive value (e.g. 10−5) and A is larger (e.g. 1). Both A
and c constrain the variance of the proposal distribution. They must be chosen in
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accordance with the problem, and are subject to fine tuning. Pa(s) is the acceptance
rate after iteration s.
Finally, this type of procedure is extendable for multivariate sampling. In this
case, not only the variances may be adapted, but also the covariances between the
variables.
C.3 Metropolis-Hasting algorithm
In 1970, Hasting generalized the work of Metropolis et al. to use a proposal distri-
bution that is not symmetric. More flexibility is left to use any proposal distribution.
The only difference with the Metropolis algorithm is the acceptance probability that
is computed as
Pa = min
(
1, p(θ
(s) | data) . q(θ(s−1) | θ(s))
p(θ(s−1) | data) . q(θ(s) | θ(s−1))
)
The adaptative variance parameters of Haario et al. (2001) can be used as well.
C.4 Gibbs sampler
When the conditional distributions of some subsets θ = (θ1,θ2, ...,θm) are ex-
actly known, one can use these distributions as the proposal distribution (Geman
and Geman, 1984; Gelfand and Smith, 1990; Casella and George, 1992). As a con-
sequence, every draws from the (conditional) proposal distributions are accepted
(Pa = 1). The algorithm is then simplified as follows, for each iteration s:
For j = 1 to m
Draw a sample from θ(s)j ∼ p(θj | θ(s−1)1 , θ(s−1)2 , ..., θ(s−1)j−1 , θ(s−1)j+1 , ..., θ(s−1)m , data),
End
C.5 Concluding remarks
Some basic MCMC methods have been presented in this Appendix. They allow
drawing samples from a (posterior) distribution of interest. When no direct sam-
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pling is possible, the use of Gibbs sampling algorithm is of course the most desired
situation as it remains computationally efficient.
Assuming θ = (θ1,θ2), it is sometimes possible to identify the conditional pos-
terior distribution for one subset of variables (θ1 | data), but not for an other set
(θ2 | data). In this case, it is also possible to combine the different MCMC algo-
rithms. For instance, in the iterative scheme, one will make a first Gibbs step to
draw θ1, followed by a Metropolis-Hasting step to generate a sample from θ2.
To avoid the trouble to code complex MCMC sampler in the Bayesian context
of learning from posterior distributions, it is possible to use softwares such as Win-
BUGS, OpenBUGS or JAGS, that allow easily dealing with MCMC techniques
(Lunn et al., 2000, 2009; Plummer, 2011). Using the structured language BUGS
(Spiegelhalter et al., 1996), it is easy to describe a likelihood and the related prior
distributions of the variables of interest. Fed with some data, these samplers draw
samples from the posterior distribution. Under the hood, different sampling al-
gorithms are used, that include direct sampling from known distributions when
possible, Gibbs sampling when the conditional posterior distributions are avail-
able in closed-form, or, when non available, using other MCMC techniques such
as derivative-free adaptive rejection sampling, slice sampling (both not presented
here, see Gilks, 1992; Neal, 1997), and the Metropolis-Hasting algorithm, which is
one of the most polyvalent, but also one of the most inefficient.
The force of these automated sampler is to automatically select the most suitable
sampling algorithm. Another great advantage is their ability to automatically tune
the sampling parameters (such as the variance of the proposal distributions), which
allows the user not being bothered with such considerations. The drawback related
to these advantages is that this process is generally hidden within the softwares, and
most often, the user does not know what has been chosen for him.
Recently, the SAS Institute Inc. has developed a MCMC sampler for the SAS
system, under the MCMC procedure, which is certainly a major advance towards
the massive adoption of simulation-based Bayesian statistics in the industry (SAS/-
STAT® 9.2.1 User’s Guide, SAS Institute Inc., 2010).

Appendix D
Multivariate densities
In this Appendix, several multivariate distributions that are used throughout this
manuscript are detailed.
D.1 Wishart distribution
The Wishart distribution is a multivariate generalization of the gamma distribu-
tion. Suppose that Σ is a (m × m) positive definite symmetric matrix of random
variables. The structure and the variances of Σ are defined by an (m×m) positive
definite scale matrix A (related to a sum of squares of multivariate error) and ν
degrees of freedom (d.f.).
Under classical Normality assumptions, the Wishart distribution is the conjugate
prior distribution of the inverse of a covariance matrix, namely Σ (i.e. a precision
matrix Σ−1).
Reviewing the literature, slightly different definitions of the Wishart density can
be found. They differ in the way the d.f. are defined (Dawid, 1981). Two definitions
are proposed hereafter.
The first one, that is widely used in the Bayesian multivariate regression domain
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(see Box and Tiao, 1973; Dawid, 1981), is defined as
Σ−1 ∼ W1(A−1, ν1)
p(Σ−1) = 2
m(ν1+m−1)
2 Γm
(
ν1 +m− 1
2
)−1 ∣∣∣A−1∣∣∣ ν1+m−12 ∣∣∣Σ−1∣∣∣ ν1−22
. exp
(
−12tr[AΣ
−1]
)
(D.1)
with d.f. = ν1 > 0 and Γm(b) is the m-dimensional generalized gamma function
Γm(b) = (pi)
m(m−1)
4
m∏
j=1
Γ
(
b+ j −m2
)
, b > (m− 1)/2. (D.2)
Γ(c) is the classical gamma function, with c a positive real or a complex number
with a positive real part.
The second one, that tends to be more used these last decades (see Aitchison and
Dunsmore, 1975; Gupta and Nagar, 1999; Gelman et al., 2004; Ntzoufras, 2009), is
defined as
Σ−1 ∼ W2(A−1, ν2)
p(Σ−1) =
2mν22 pim(m−1)4 m∏
j=1
Γ
(
ν2 + 1− j
2
)−1 ∣∣∣A−1∣∣∣−ν22 ∣∣∣Σ−1∣∣∣ ν2−m−12
. exp
(
−12tr[AΣ
−1]
)
, (D.3)
with d.f. = ν2 > m− 1.
This density has several interesting advantages, such as to be invariant under
marginalization. This means that a submatrix Σ−1∗ of Σ−1, of size m∗ ×m∗, will
simply follows a Wishart distribution Σ−1∗ ∼ W (A−1∗, ν), with the degrees of free-
dom kept unchanged, and A−1∗ being a similar submatrix of A−1.
Notice W2 is also the Wishart that is implemented in some R packages (Martin
et al., 2010; Rossi, 2010) and in Winbugs (Lunn et al., 2000). This makes it very
convenient to work with.
The obvious equivalence between W1 and W2 is easily obtain observing that
ν1 +m− 1 = ν2. In other words, to implement the results presented for instance in
Box and Tiao (1973), it is possible to useW2(A−1, ν1+m−1) instead ofW1(A−1, ν1).
D.2 Inverse-Wishart distribution
The inverse-Wishart distribution is used as a natural conjugate prior for the
(m × m) covariance matrix Σ in the context of multivariate Normal distribution
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(Anderson, 1984). The structure and scale of the random variables in Σ are also
described by an (m×m) positive definite scale matrix A and ν d.f.
Again, different forms of the inverse-Wishart density can be found in the liter-
ature, with various uses of the d.f. To be consistent with the presentation of the
Wishart distribution, the inverse-Wishart found in Box and Tiao (1973) and Dawid
(1981) is first presented:
Σ ∼ W−11 (A, ν1)
p(Σ) = 2
m(ν1+m−1)
2 Γm
(
ν1 +m− 1
2
)−1
|A| ν1+m−12 |Σ|− ν1+2m2
. exp
(
−12tr[AΣ
−1]
)
(D.4)
with d.f. = ν1 > 0. This time, this density has the advantage to be invariant under
marginalization.
As it is the case with the Wishart distribution, the second definition seems to
make consensus in the recent literature, such as Gelman et al. (2004), and is also the
one that can be found implemented in the R language (Martin et al., 2010; Rossi,
2010) and in the proc IML of SAS (SAS/STAT® 9.2.1 User’s Guide, SAS Institute
Inc., 2011). It is defined as
Σ ∼ W−12 (A, ν2)
p(Σ) =
2mν22 pim(m−1)4 m∏
j=1
Γ
(
ν2 + 1− i
2
)−1 |A| ν22 |Σ|− ν2+m+12
. exp
[
−12tr(AΣ
−1)
]
, (D.5)
with ν2 > m−1. Note again the clear relationW−12 (A, ν1+m−1) = W−11 (A−1, ν1).
There exists at least one other form of the inverse-Wishart density, that can be
found in Gupta and Nagar (1999) or Tiao and Zellner (1964). This rare form is
the one that is used by SAS in proc MCMC (SAS/STAT® 9.2.1 User’s Guide, SAS
Institute Inc. (2010)).
D.2.1 Relation between Wishart and Inverse-Wishart dis-
tributions
A very convenient relation is expressed as follows:
Σ−1 ∼ W1(A−1, ν1) iff Σ ∼ W−11 (A, ν1) (D.6)
Σ−1 ∼ W2(A−1, ν2) iff Σ ∼ W−12 (A, ν2) (D.7)
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To be convinced of the previous relationships, it is possible to account for the
transformation of Σ (inverse-Wishart) to Σ−1 (Wishart), using the Jacobian of the
transformation that is equal to |Σ|m+1 (Box and Tiao, 1973).
D.3 Multivariate Normal distribution
The multivariate Normal distribution is of much importance as it is a classical
regression model assumption, and a typical prior distribution for the model param-
eters of a multiple linear regression. It is described by many textbook. In the
Bayesian framework, two classical references are Box and Tiao (1973) and Gelman
et al. (2004).
Let θ be a vector of m random variables with mean location µ and symmetric
positive definite (m × m) covariance matrix Σ. Then, if the distribution of θ is
multivariate Normal, it is defined as
θ ∼ Nm(µ,Σ)
p(θ) = (2pi)−
m
2 |Σ|− 12 . exp
[
−12(θ − µ)
′Σ−1(θ − µ)
]
. (D.8)
In this case, E(θ) = mean(θ) = mode(θ) = µ and var(θ) = Σ.
D.4 Matrix-variate Normal distribution
A generalization of the multivariate Normal distribution for a matrix of random
variables is the matrix-variate Normal distribution. It commonly occurs as a proper
prior distribution for the parameters of a multivariate linear regression, when ex-
pressed in matrix form, and conditionally to the variance Σ. It can also be retrieved
to be the posterior predictive distribution of several jointly predicted vector of re-
sponses of a multivariate linear regression, still assuming the variance Σ known.
Let Θ be a (p × m) matrix of random variables with mean location M and
two symmetric positive definite (m ×m) and (p × p) covariance matrix Σ (for the
columns of Θ) and Ω (for the rows of Θ), respectively. Then the matrix-variate
Normal density of Θ is
Θ ∼ Np×m(M,Σ,Ω),
p(Θ) = (2pi)−
pm
2 |Ω|−m2 |Σ|− p2 . exp
[
−12tr
(
Σ−1(Θ−M)′Ω−1(Θ−M)
)]
. (D.9)
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D.4.1 Link between the Multivariate and Matrix-Variate
Normal distributions
When using the matrix-variate Normal distribution, it is generally easier to apply
the following identity:
Θ ∼ Np×m(M,Σ,Ω) ⇔ vec(Θ) ∼ Npm(M,Σ⊗Ω), (D.10)
where ⊗ is the Kronecker product and the vec(X) operator stacks the column of
the (p ×m) matrix X into a (column) vector of size pm. In other word, to draw a
sample from a matrix-variate Normal distribution, it is possible to draw a sample
from a multivariate Normal and unstack the resulting vector into the desired matrix,
following the previous relation.
Proof. The proof is direct considering the three following relations applied on the
density of Equation D.9, that allow to retrieve the density of Equation D.8 :
|A|−1 = |A−1| (D.11)
|A⊗B| = |A|m |B|p , if rank(A) = p and rank(B) = m (D.12)
tr(A′B′CD) = vec(B)′(C⊗A)vec(D). (D.13)
D.5 Multivariate Student’s distribution
When working on limited samples (when d.f. is small), normality is often a too
strong hypothesis. The Student’s distribution (or t-distribution) is more adapted
in this case. More specifically, it extends the univariate Student’s distribution in
the same way the univariate Normal distribution is generalized by the multivariate
Normal.
Notice that different types of multivariate Student’s distributions exist as dif-
ferent generalization of the univariate Student’s distributions are used. Hereafter
is presented one of the most common distribution, that is found and discussed in
Johnson and Kotz (1972); Sutradhar (2006). This form allows for non-centrality
(i.e., when the mean may be different from 0) and scaling. Notice this definition
uses a scale matrix instead of a correlation matrix, as in Kotz and Nadarajah (2004),
Equation (1.1)).
Let θ be a vector of m random variables with mean location µ and symmetric
positive definite (m×m) scale matrix A. Let also be ν d.f. If the distribution of θ
is a noncentral multivariate Student, it is generated by two variables y ∼ N(0,Σ)
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and w ∼ χ2(ν) such that θ = y
√
ν/w+µ. In this case, θ has the following density:
θ ∼ Tm(µ,A, ν)
p(θ) =
Γ(ν+m2 )
Γ(ν2 )
(piν)−m2 |A|− 12
(
1 + (θ − µ)′A(θ − µ)
)− ν+m2 (D.14)
if m = 1, the probability density function reduces to a noncentral scaled univariate
Student’s distribution. Further, if A = 1 and µ = µ = 0, the distribution of the
univariate θ reduces to the classical univariate Student’s distribution.
To clarify a common confusion, note that A/ν is the covariance matrix of the
multivariate Normal distribution that is in the generative process of the multivari-
ate Student’s distribution. However it is not the covariance matrix of the Stu-
dent’s distribution. The covariance matrix of the multivariate Students is defined as
(A/ν).ν/(ν − 2) = A/(ν − 2), if ν > 2. It is why, in the context of the multivariate
Student’s distribution, A/ν is often called a scale or spread matrix, as in Sutradhar
(2006) and Gupta and Nagar (1999). To avoid confusion with the scale matrices of
the Wishart and inverse-Wishart distributions (i.e., A), the terms spread matrix is
preferably employed for A/ν. In summary,
- A is a scale matrix,
- E(Σ) = A/ν is a covariance matrix for Normal distribution, and a spread
matrix for Student’s distribution,
- A/(ν − 2) is a covariance matrix for a Student’s distribution.
The covariance matrix of the multivariate Student’s distribution is then undefined
for ν ≤ 2. Some degenerative or generalized forms of the multivariate Student’s
distribution exist when 0 ≤ ν ≤ 2 and when ν ∈ R. In the context of drawing
samples from a multivariate Student’s distribution, as presented in Appendix E,
the classical χ2 distribution allows for positive and non integer degrees of freedom,
ν ∈ R+0 (Johnson et al. (1995)).
D.6 Matrix-variate Student’s distribution
As the matrix-variate Normal extends the multivariate Normal for matrix of
random values instead of vector of random values, the matrix-variate Student’s
distribution extends the multivariate Student’s distribution presented in the previous
section. The matrix-variate Student’s distribution is a very convenient form for the
posterior distribution of regression parameters in multivariate multiple regression.
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It is also the distribution of the joint prediction of several new responses in the same
context.
Again, different forms exists, that differ for instance in the choice of the degrees
of freedom (Dawid (1981)). The focus is kept on the definition proposed first by
Kshirsagar (1961), discussed by Dickey (1967) and used by Box and Tiao (1973),
as it directly generalizes Equation D.14. A complete discussion about the matrix-
variate Student’s distribution and its properties can be found in Gupta and Nagar
(1999).
Let Θ be an (p×m) matrix of random variables with mean location M and two
symmetric positive definite (m×m) and (p× p) scale matrices A (for the columns
of Θ) and Ω (for the rows of Θ), respectively. Finally, Θ has ν d.f. (ν > 0). Then
Θ follows a matrix-variate Student’s distribution if
Θ ∼ Tp×m(M,A,Ω, ν),
p(Θ) =
(
Γ( 12)pm
Γm(12ν +m− 1)
Γm(12ν +m+ p− 1)
)−1
|Ω|−m2 |A|− p2
.
∣∣∣Im + A−1(Θ−M)′Ω−1(Θ−M)∣∣∣− 12 (v+m+p−1) . (D.15)
Notice that, in the exponent, (v + M + F − 1) may simply be the number of ob-
servations n in regression context. When m = 1 or p = 1, the density reduces to a
multivariate Student’s distribution.
D.6.1 Marginal distribution
Assume that Θ ∼ Tp×m(M,A,Ω, ν) and that the interest lies in solely a partition
of the values in Θ. Partitioning Θ and M in columns, and A accordingly as
Θ = (Θ1,Θ2), M = (M1,M2), and A =
(
A11 A12
A21 A22
)
(D.16)
with Θ1 and M1 being (p×m1) matrices (1 ≤ m1 ≤ m) and A is (m1×m1), yields
Θ1 ∼ Tp×m1(M1,A11,Ω, ν). This results is proven in Gupta and Nagar (1999).
The same partitioning apply also when splitting Θ in lines. In this case, taking
the corresponding part of Ω allows retrieving a similar matrix-variate Student’s
distribution. This means that the matrix-variate Student’s distribution is invariant
under marginalization. At the limit, when only one line or one column (in this case,
m1 = 1) is taken from Θ, the multivariate Student’s distribution holds.
This marginalization property is important as the sampling from a matrix-variate
Student’s might be intricate. Indeed, many different ways to sample random vari-
ables already exist only for the multivariate Student’s distribution (see previous
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section), and the task is clearly harder in this matrix-variate case. The marginaliza-
tion then allows obtaining marginal quantities easily (e.g., the marginal distribution
of the regression parameters of the multivariate regression).
Appendix E
Sampling from a Student’s
distribution
The Student’s distribution, or “t” distribution, has been introduced by Gosset
(1908), under the pseudonym of Student. The Student’s distribution is well adapted
in the context of hypothesis testing for small samples, when Normality is difficult to
prove. Indeed, Normal distribution fits well when the sample size from a population
is very large, so that its parameters (mean and variance) can be accurately esti-
mated. They can then be assumed known. When departing from this large sample
hypothesis, the Student’s distribution allows, thanks to its heavier tails, to better
model the parameters uncertainty.
Logically, the Bayesian statistical framework often lead to Student’s distribution,
because uncertainty of the parameters is prominent in the analysis.
Here several methods are presented to draw samples from the univariate Student,
the multivariate Student and the linear constrained multivariate Student’s distribu-
tions. These results are finally extended to the matrix-variate Student’s distribution.
These samples can then be used in Monte-Carlo simulations.
E.1 Univariate Student’s distribution
The univariate Student’s distribution is defined as the probability distribution of
the variable
X = Z√
V/ν
(E.1)
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where Z is Normally distributed as N(0, 1), V is chi-square distributed, with ν
degrees of freedom (d.f.), and Z and V are independent. The ratio is said to follow
the Student’s distribution with ν d.f, and this distribution is noted T (ν).
If Z is distributed as N(µ, σ2), this gives the more general case of the non-central,
scaled, Student’s distribution (also known as three-parameters Student distribution),
T (µ, a, ν), with a/ν being en estimator of σ2.
To draw a sample from a Student’s distribution, the previous explanations simply
suggest to draw a sample from a Normal distribution and divide this sample by a
square-rooted draw from a chi-square distributed variable with ν d.f., divided by ν:
• For s = 1 to n∗
• 1. Sample z(s) from N(µ, a/ν)
• 2. Sample v(s) from χ2(ν)
• 3. The Student’s sample x(s) equals z(s)/
√
v(s)/ν
• End.
Normal samples can be obtained by inverse transform sampling or rejection sampling
while chi-square samples may be obtained using rejection sampling.
E.2 Multivariate Student’s distribution
The distribution of the multivariate data X of sizem, that follow the multivariate
(non-central, scaled) Student’s distribution Tm(µ,A, ν) is obtained by the ratio of a
multivariate normal N(µ,Σ) to an independent chi-square variable
√
χ2(ν)/ν. An
estimator of Σ is assumed to be A/ν.
Then, this simply extends the previous univariate example :
• For s = 1 to n∗
• 1. Sample z(s) from N(µ,A/ν)
• 2. Sample v(s) from χ2(ν)
• 3. The Student’s sample x(s) equals z(s)/
√
v(s)/ν
• End.
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E.3 Truncated sampling
Let’s assume that several constraints apply on the distribution of the m-sized
vectors x ∼ T (µ,A, ν). Geweke (1991) proposed a method to sample x subject to
the constraints a ≤ Cx ≤ b, where C is a full-rank (m×m) matrix and the elements
of a and b can be any real to −∞ (for a), and to +∞ (for b). Then, maximum m
linear restrictions can be applied on x.
A naive rejection procedure could be applied, deleting each sample that does
not fulfill one of the constraints. Doing so could be dramatic ! As the number of
constraints can be high, and they can sometimes be hard to achieve, the massive
number of samples (potentially all, almost surely) that would be deleted invalidates
this naive solution for many applications.
The first subsection shows how to proceed with the (simpler) problem of trun-
cated multivariate Normal distribution. Next, it is explained how to use the same
methodology for the truncated multivariate Student’s distribution in the second
subsections.
E.3.1 Truncated multivariate Normal distribution
Geweke showed that the problem of constructing samples from x ∼ Nm(µ,Σ)
w.r.t a ≤ Cx ≤ b is equivalent to the sampling of
z ∼ Nm(0,ΣC), α ≤ z ≤ β, (E.2)
with
ΣC = CΣC′, α = a −Cµ, β = b−Cµ,
x being equals to µ+ C−1z.
The method relies on the fact that each element of z is a truncated univariate
Normal, conditional to all the other elements of z. A Gibbs sampler can then be
used to sample from these sub-distributions.
Suppose that, using the non-truncated (classical) Normal distribution N(0,ΣC),
we have
E[zi | z−i] =
∑
j,i
cijzj.
Now, using the truncated Normal distribution of (E.2), the distribution of zi | z−i
(z−i is the vector z with deleted element i) can be constructed as
zi | z−i =
∑
j,i
cijzj + hii, i ∼ TN
(
αi −∑j,i cijzj
hi
,
βi −∑j,i cijzj
hi
)
,
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where TN(a, b) is the standardized univariate normal restricted to (a, b), that can
be easily simulated with an inverse transform sampling where the limit of the
uniform distribution are φ(a) and φ(b), φ(.) being the probability density func-
tion of a N(0, 1). The vector of coefficients in the conditional means ci,−i =
(ci,1, ..., ci,i−1, ci,i+1, ..., ci,m)′, i = 1, ...,m is defined as:
ci,−i = −
Σ−1C;i,−i
(Σ−1C;ii)
,
where Σ−1C;ii is the ith diagonal element of Σ−1C , and Σ−1C;i,−i is the ith row of Σ−1C with
the ith diagonal elements deleted. Finally, let define
h2i = 1/Σ−1C;ii
In a Gibbs sampling scheme, one will construct at each iteration, the successive
values z(s)i | (z(s)1 , ..., z(s)i−1, z(s−1)i+1 , ..., z(s−1)m ), and finally one get the samples of the
truncated distribution doing x(s) = µ+ C−1z(s).
A burn-in period should be envisaged, and a comparison with a classical mul-
tivariate Normal sampling can be interesting, particularly if the variables in x are
strongly correlated. In this case, it is advised to draw more samples. Indeed, as the
zi variables are sampled conditionally to the other variables in z, but without ac-
counting for any correlation structure, a slow exploration of the distribution will be
observed, as well as high auto-correlations. The sample size for correlated samples
is discussed in Appendix B.
Notice that other methods exist to generate samples from a constrained multivari-
ate Normal distribution. Among other, the sampler presented by Rodriguez-Yam
et al. (2004) seems to be much more efficient than the sampler of Geweke, as it
provides nearly i.i.d. samples, even in presence of strong correlations between the
variables. It also allows for any number of constraints.
E.3.2 Truncated multivariate Student’s distribution
Now, if the samples are assumed to follow a multivariate Student’s distribution
with ν d.f., x ∼ Tm(µ,Σ, ν), w.r.t to the linear constraints a ≤ Cx ≤ b, the same
idea is used. The Student construction is made by the ratio of a multivariate Normal
and an independent chi-square w ∼
√
χ2(ν)/ν. This leads to the Gibbs sampling
algorithm for the vector of parameters (w, z1, ..., zM). The elements x are retrieved
computing x = µ+ C−1zw−1.
At iteration s, (w(s−1), z(s−1)1 , ..., z(s−1)m ) are available. First, Geweke proposes to
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draw w(s) ∼
√
χ2(ν)/ν, subject to the constraints
αjw
(s) ≤ z(s−1)j ≤ βjw(s) (j = 1, ...,m)
with an acceptance/rejection procedure. Second, z can be drawn from the truncated
multivariate Normal conditional to w(s), with the restrictions
αjw
(s) ≤ z(s)j ≤ βjw(s)
doing
zi | z−i =
∑
j,i
cijzj + hii,
i ∼ TN
(
αiw
(s) −∑j,i cijzj
hi
,
βiw
(s) −∑j,i cijzj
hi
)
.
At the end, one can compute x(s) = µ+ C−1z(s)(w(s))−1.
The acceptance/rejection procedure for the sampling of w is fortunately very
efficient and a low number of samples are generally rejected.
We developed the truncated multivariate Normal and Student algorithms with
the R language (R Development Core Team, 2010), with intensive Gibbs sub-routine
programmed in C language for efficiency. The C code, although not directly portable,
has been successfully compiled for Windows XP (32 bits) and Mac OS 10.6 (64 bits).
No problems should be noted for a Unix/Linux version.
E.4 Matrix-variate Student’s t-distribution
In several application, the matrix-variate Student distribution might be used to
draw samples for a set of n˜ new response vectors. As the rows of the generated matrix
are independent, it is possible use the marginalization properties of the matrix-
variate Student distribution. In this case, each row is distributed as a simpler
multivariate Student.
However, for computational efficacy purpose, it may be practical to draw first
a matrix-variate Normal (with lines that are independent) and, second, to add an
independent chi-square draw for every line/prediction.
For the variable X following this matrix-variate Student Tn˜×m(M,A,Ω, ν), this
scheme can be used to obtain samples X(s):
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• For s = 1 to n∗
• 1. Draw Z(s) ∼ Nn˜×m(M, Aν ,Ω), i.e. vec(Z(s)) ∼ Nn˜m(vec(M), Aν ⊗Ω),
• 2. Draw n˜ samples v(s)
i˜
from χ2(ν), i˜ = 1, ..., n˜,
• 3. Divide each line of Z(s), z(s)
i˜
, by
√
v
(s)
i˜
/ν, to obtain X(s).
• End.
If n˜ is large (with m potentially large as well), the size of the covariance matrix
(A/ν)⊗Ω might be huge. In this case, a large amount of memory is necessary and
computational overheads might be encountered. A proper number of simultaneous
prediction n˜ might be chosen to optimize the computations.
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